20-F

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from                      to

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number: 001-39005

Sundial Growers Inc.

(Exact name of Registrant as specified in its charter)

#300, 919 - 11 Avenue SW

Calgary, AB, Canada, T2R 1P3

Tel.: (403) 948-5227

James Keough, Chief Financial Officer

#300, 919 – 11 Avenue SW

Calgary, AB, Canada, T2R 1P3

Tel.: (403) 948-5227

investors@sundialgrowers.com

(Name, Telephone, E-mail and/or facsimile number and Address of Company Contact Person)

Securities registered or to be registered, pursuant to Section 12(b) of the Act

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Shares SNDL Nasdaq Capital Market

Securities registered or to be registered pursuant to Section 12(g) of the Act.

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of business covered by the annual report. As at December 31, 2021, 2,060,408,357 common shares were issued and outstanding.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒    

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    Yes  ☐    No  ☒    

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ☒ Accelerated filer  ☐ Non-accelerated filer  ☐ Emerging growth company  ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP  ☐ International Financial Reporting Standards as issued by the International Accounting Standards Board  ☒ Other  ☐

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.    Item 17  ☐    Item 18  ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐    No  ☒

TABLE OF CONTENTS

		Page
Introduction		5
Cautionary Statement Regarding Forward-Looking Statements		5
PART I
ITEM 1.	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS	7
ITEM 2.	OFFER STATISTICS AND EXPECTED TIMETABLE	7
ITEM 3.	KEY INFORMATION	7
	B. Capitalization and indebtedness	7
	C. Reasons for the offer and use of proceeds	7
	D. Risk factors	7
ITEM 4.	INFORMATION ON THE COMPANY	38
	A. History and development of the company	38
	B. Business overview	40
	C. Organizational structure	50
	D. Property, plant and equipment	51
ITEM 4A.	UNRESOLVED STAFF COMMENTS	51
ITEM 5.	OPERATING AND FINANCIAL REVIEW AND PROSPECTS	51
	A. Operating results	51
	B. Liquidity and capital resources	51
	C. Research and development, patents and licences, etc.	52
	D. Trend information	52
	E. Off-balance sheet arrangements	52
	F. Tabular disclosure of contractual obligations	52
ITEM 6.	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	53
	A. Directors and senior management	53
	B. Compensation	54
	C. Board practices	60
	D. Employees	65
	E. Share ownership	65
ITEM 7.	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	65
	A. Major shareholders	65
	B. Related party transactions	66
	C. Interests of experts and counsel	68
ITEM 8.	FINANCIAL INFORMATION	68
	A. Consolidated statements and other financial information	68
	B. Significant Changes	70
ITEM 9.	THE OFFER AND LISTING	70
	A. Offer and listing details	70
	B. Plan of distribution	70
	C. Markets	70
	D. Selling shareholders	70
	E. Dilution	70
	F. Expense of the issue	70
ITEM 10.	ADDITIONAL INFORMATION	70
	A. Share capital	70

3

	B. Memorandum and articles of association	71
	C. Material contracts	71
	D. Exchange controls	71
	E. Taxation	71
	F. Dividends and paying agents	78
	G. Statement by experts	79
	H. Documents on display	79
	I. Subsidiary information	79
ITEM 11.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	79
ITEM 12.	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	79
PART II
ITEM 13.	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	80
ITEM 14.	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	80
	A-D. Material Modifications to the Rights of Security Holders	80
	E. Use of Proceeds	80
ITEM 15.	CONTROLS AND PROCEDURES	80
ITEM 16		80
	A. Audit committee financial expert	80
	B. Code of Ethics	80
	C. Principal Accountant Fees and Services	80
	D. Exemptions from the Listing Standards for Audit Committees	81
	E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers	81
	F. Changes in Registrant’s Certifying Accountant	81
	G. Corporate Governance	81
	H. Mine Safety Disclosure	81
PART III
ITEM 17.	FINANCIAL STATEMENTS	82
ITEM 18.	FINANCIAL STATEMENTS	82
ITEM 19.	EXHIBITS	82

4

INTRODUCTION

Unless otherwise indicated, all references in this annual report on Form 20-F (the “Annual Report”) to “Sundial,” “we,” “our,” “us,” “the Company” or similar terms refer to Sundial Growers Inc. and its consolidated subsidiaries. We publish our consolidated financial statements in Canadian dollars. In this Annual Report, unless otherwise specified, all monetary amounts are in Canadian dollars, all references to “$,” “C$,” “CDN$,” “CAD$,” and “dollars” mean Canadian dollars and all references to “US$” or “USD”, mean United States dollars.

This Annual Report contains our audited consolidated financial statements and related notes for the year ended December 31, 2021, the year ended December 31, 2020, and the year ended December 31, 2019 (“Annual Financial Statements”). Our Annual Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”).

In addition to our financial results presented in accordance with IFRS as issued by the IASB, we believe certain non-IFRS measures provide useful information both to management and investors in measuring the financial performance and financial condition of the Company. These measures do not have a standardized meaning prescribed by IFRS (or U.S. generally accepted accounting principles (“U.S. GAAP”)); and, therefore, they may not be comparable to similarly titled measures presented by other companies, and they should not be construed as an alternative to other financial measures determined in accordance with IFRS.

All references to “shares” or “common shares” in this Annual Report refer to the common shares of Sundial Growers Inc., no par value.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

• the uncertainties associated with the COVID-19 pandemic, including our ability to continue operations, the ability of our suppliers and distribution channels to continue to operate, and the use of our products by consumers, and disruptions to the global and local economies due to related stay-at-home orders, quarantine policies and restrictions on travel, trade and business operations and a reduction in discretionary consumer spending;

• our ability to raise future capital through debt or equity financing transactions, and our ability to efficiently deploy the capital raised through such transactions;

• our ability to successfully implement our cost and asset optimization initiatives;

• the continued development and growth of the demand and markets for medical and adult-use cannabis;

• the competitive conditions of the industry and the expected number of customers using our products;

• the maintenance of our existing licences and the ability to obtain additional licences as required;

• our ability to establish and market our cannabis and retail brands within our targeted markets and compete successfully;

• our ability to produce and market additional products as regulations permit;

• our growth strategies;

• the timing and the amount of capital expenditures related to maintenance of our facilities;

• our ability to attract and retain key employees and franchisees;

• our ability to generate and manage growth in our business, including expanding our cultivation operations and retail network;

• our ability to identify and successfully execute and manage strategic partnerships, joint ventures (including SunStream (as defined below)), strategic alliances, debt and equity investments as well as the costs and benefits associated with such initiatives, including the expected return on any investments;

• our ability to find suitable acquisition opportunities, as well as finance and integrate any acquisitions; and

• the volatility in the price of our common shares.

5

Although we base the forward-looking statements contained in this Annual Report on assumptions that we believe are reasonable, we caution you that actual results and developments (including our results of operations, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this Annual Report. In addition, even if results and developments are consistent with the forward-looking statements contained in this Annual Report, those results and developments may not be indicative of results or developments in subsequent periods. Certain assumptions made in preparing the forward-looking statements contained in this Annual Report include:

• our ability to implement our operational and liquidity strategies as well as our strategic initiatives;

• our competitive advantages;

• the impact of competition;

• the changes and trends in the cannabis cultivation and retail industry;

• changes in laws, rules and regulations;

• our ability to maintain and renew required licences;

• our ability to maintain good business relationships with our customers, distributors and other strategic partners;

• our ability to keep pace with changing consumer preferences;

• our ability to protect our intellectual property;

• our ability to manage and integrate acquisitions;

• our ability to retain key personnel;

• our ability to efficiently deploy capital and achieve our expected and desired returns on such investments;

• our ability to open new retail locations and attract a sufficient number of qualified franchisees; and

• the absence of material adverse changes in our industry or the global economy, including as a result of COVID-19.

These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Item 3D—Risk Factors”, and elsewhere in this Annual Report. Readers of this Annual Report are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the U.S. Securities and Exchange Commission (the “SEC”) after the date of this Annual Report.

This Annual Report contains estimates, projections and other information concerning our industry, our business, and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this Annual Report titled “Item 3D—Risk Factors”. These and other factors could cause our future performance to differ materially from our assumptions and estimates.

6

PART I

Item 1. Identity of Directors, Senior Management and Advisers

Not applicable.

Item 2. Offer Statistics and Expected Timetable

Not applicable.

Item 3. Key Information

B. Capitalization and indebtedness.

Not applicable.

C. Reasons for the offer and use of proceeds.

Not applicable.

D. Risk factors.

Risk Factors Summary

Investing in our common shares involves a high degree of risk. You should carefully consider the risks described in this item before making a decision to invest in our common shares. If any of these risks actually occur, our business, financial condition and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline, and you may lose part or all of your investment. Below is a summary of some of the principal risks we face:

• We have a history of net losses, and we may not achieve or maintain profitability in the future.

• The industry in which we operate and the regulations governing it continue to develop, and if they develop or change in ways that differ from our expectations or ways that are adverse to us, our business and results of operations may be adversely impacted.

• We are dependent upon regulatory approvals and licences for our ability to grow, process, package, store and sell cannabis and other products derived therefrom as well as to own and operate cannabis retail stores through which we and our franchisees sell cannabis products, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal.

• Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.

• We are, and may become, subject to litigation, regulatory or agency proceedings, investigations and audits.

• We face competition from the illegal cannabis market.

• We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.

• We experience significant customer concentration, with a limited number of customers accounting for a significant portion of our revenues.

• We face risks associated with our franchise business model.

• Our success in the cannabis retail market is dependent, in part, on our ability to attract and retain an adequate retail consumer base.

• We are dependent upon a limited number of facilities that are integral to our cannabis cultivation and production business.

• We currently rely on a limited number of suppliers for our extraction requirements.

• We are subject to risks inherent in an agricultural business, including the risk of crop failure.

• Natural disasters, unusual weather, pandemic outbreaks such as COVID-19, boycotts and geo-political events or acts of terrorism could adversely affect our operations and financial results.

7

• Significant interruptions in our access to certain key inputs such as labor, raw materials, electricity, water and other utilities may impair our growing operations and materially affect our business.

• Failure in our quality control systems may adversely impact our sales volume, market share and profitability.

• We intend to continue to focus primarily on the premium segment of the adult-use cannabis market, which may not be sustainable, or in which we may not be able to develop or maintain a brand that attracts or retains customers.

• The adult-use cannabis market in Canada has experienced, and may in the future experience, supply and demand fluctuations.

• We may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada.

• We may make investments into equity or debt securities of other companies, or provide credit to other companies, and we may not obtain the anticipated level of return on such investments, or any return at all.

• Our joint venture interest in SunStream is subject to certain risks associated with the conduct of joint ventures.

• We may not realize all or any of the anticipated returns on our joint venture interest in SunStream, or any return at all.

• Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis would likely result in SunStream’s inability to execute its business plan, and may subject us to significant civil or criminal liability and other adverse consequences.

• We are subject to the risk of possibly becoming an investment company under the Investment Company Act of 1940.

• A decline in the consumption of alcoholic beverage products could adversely affect our business, financial condition and results of operations.

• Unfavourable publicity or poor consumer perception of the Company’s liquor retail brands could have an adverse effect on the Company’s business, financial condition and results of operations.

• If a significant number of the Company’s licences were revoked or not renewed, or if the Company failed to secure new licences, there could be a material adverse effect on its business, financial condition, liquidity and results of operations.

• We may not be able to successfully identify and execute future acquisitions or dispositions or to successfully manage the impacts of such transactions on our operations.

• We face integration risks in connection with our acquisition strategy.

• The price of our common shares in public markets has experienced and may in the future experience extreme volatility and you may lose some or all of your investment in our common shares as a result.

• We may sell a substantial number of our common shares in the public market at any time. Such sales or the perception that they may occur could cause the market price of our common shares to drop significantly, even if our business is doing well.

• If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.

Risks Related to Our Financial Position and Accounting

We have a history of net losses, and we may not achieve or maintain profitability in the future.

We were incorporated in 2006, began cultivating cannabis in 2012, and started selling cannabis in 2018 after the federal legalization of adult-use cannabis in Canada. In 2021, we expanded into corporate-owned and franchised cannabis retail with the acquisition of Inner Spirit, as well as created a new investments segment focused on our activities in the deployment of capital to strategic initiatives. We have yet to generate an annual profit. We generated a net loss from continuing operations before income tax of $232.5 million and $206.3 million, for the fiscal years ended December 31, 2021 and 2020, respectively, and had negative operating cash flows for each of these periods. Our accumulated deficit as of December 31, 2021 was $788.5 million. Although we have implemented business optimization initiatives and suspended construction of certain facilities, we will continue to expend significant funds to maintain our growing and production capacity, fund capital investments, expand our marketing and sales operations, expand our retail network and fund strategic investments. We may not achieve or maintain profitability.

Our efforts to grow our business may be more costly than we expect and we may not generate enough revenue to offset our operating expenses. We have incurred, and may in the future incur, significant losses for a number of reasons, including as a result of unforeseen expenses, difficulties, complications and delays in obtaining governmental licences, failure to secure and profitably operate corporate-owned retail stores, failure to expand our franchised store network, failure to realize expected benefits of strategic investments and the other factors and risks described in this Annual Report. The amount of any future losses will depend, in part, on our ability to generate revenue on the one hand and any increases in our expenses on the other hand. If we continue to incur losses in the future, the net losses and negative cash flows incurred to date, together with any such future losses, will have an adverse effect on our shareholders’ equity and working capital. Because of the numerous risks and uncertainties associated with our business and industry, we are unable to accurately predict when, or if, we will be able to achieve profitability. Even if we achieve profitability at some point in the future, we may not be able to sustain profitability in subsequent periods. If we are unable to achieve and sustain profitability, the market price of

8

our common shares may significantly decrease and our ability to raise capital, expand our business or continue our operations may be impaired. A decline in the value of our common shares may also cause you to lose all or part of your investment.

Unless and until we achieve profitability, we will be required to finance our losses with issuances of equity or debt. Recently, we financed our liquidity needs primarily with issuances of equity and equity-linked securities, but our ability to do so in the future will depend on future market conditions, which are beyond our control and may be adversely affected by factors which include, but are not limited to, macroeconomic conditions, volatility, wars and other armed conflicts, geopolitical tensions, pandemics, and other factors.

We have in the past, and may in the future, record significant impairments or write-downs of our assets.

Our cannabis inventory in our cannabis operations and cannabis retail segments has a finite shelf life and is subject to obsolescence, expiration, spoilage, shrinkage, unacceptable quality, contamination or other declines in value prior to wholesale or retail sale. We have in the past, and may in the future, be required to record substantial write-downs or impairments related to loss of value in our cannabis inventory.

In addition, our facilities may be subject to obsolescence, damage, loss of fair market value or other declines in value. For example, in the year ended December 31, 2020, we recorded significant write-downs with respect to our facility in Olds, Alberta (the “Olds Facility”) as a result of the carrying value of our total net assets significantly exceeding our market capitalization, due to reductions in capacity usage in response to decreasing estimates for the size of the potential Canadian cannabis market. In the same year, we recorded an impairment in connection with our facility in Rocky View, Alberta (the “Rocky View Facility”). Pursuant to a non-binding purchase agreement to sell the facility for $5.0 million, the recoverable amount of the Rocky View facility was determined to be its fair value less costs of disposal, leading to recording of a write-down of the asset to its recoverable amount.

Lastly, we may also record impairments to goodwill related to our acquisitions, intellectual property, investments or similar assets. In the year ended December 31, 2020, we recorded an impairment with respect to the intellectual property assets of Pathway Rx (“Pathway”) due to our decision to reduce our focus on medical cannabis research. In the year ended December 31, 2019, we recorded a substantial goodwill impairment related to Bridge Farm (of which we have since disposed).

There can be no assurance that we will not be required to record inventory, facility, goodwill, intellectual property, investment or other write-downs in the future. Such write-downs could be substantial and result in a material adverse effect on our business, financial condition and results of operations.

We have material weaknesses in our internal control over financial reporting and our management may not be able to successfully implement adequate internal control over financial reporting or disclosure controls and procedures.

In connection with the audit of our consolidated financial statements for the fiscal period ended December 31, 2021, our management and independent auditors concluded that there were material weaknesses in our internal control over financial reporting as at December 31, 2021. A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

The material weaknesses identified were (i) an ineffective control environment resulting from an insufficient number of financial reporting and accounting, and information technology (IT) personnel with the appropriate knowledge, experience or training commensurate with the Company’s financial reporting requirements, (ii) the insufficient number of personnel described above contributed to an ineffective risk assessment process necessary to identify changes to its operations and to identify all relevant risks of material misstatement and to evaluate the implications of relevant risks on its internal control over financial reporting (iii) an ineffective information and communication process resulting from a combination of deficiencies within its information technology general and application controls (“ITGCs”) across the systems supporting the Company’s financial reporting process, including access controls and administrator-level access resulting in a lack of segregation of duties, resulting in insufficient controls to ensure the relevance, timeliness and quality of information used in control activities, and (iv) as a consequence of the above and as a result of inadequate segregation of duties and secondary review, the Company had ineffective control activities related to the design, implementation and operating effectiveness of process level and financial reporting controls which had a pervasive impact on the Company's internal control over financial reporting.

These material weaknesses resulted in material misstatements, which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021, and also in immaterial misstatements, some of which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021. These material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.

Management has implemented and continues to implement measures designed to ensure that control deficiencies are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

• developing and maintaining documentation underlying ITGCs to promote knowledge transfer upon personnel and function changes;

• developing enhanced procedures and controls related to administrator and privileged-level access to IT systems;

9

• implementing an IT management review, documentation and testing plan to enhance implementation and monitoring of software updates and changes with a specific focus on systems supporting our financial reporting processes;

• adding personnel with an appropriate level of knowledge, experience and training commensurate with the Company’s financial reporting requirements; and

• working with our advisors to develop a plan to improve our risk assessment process and to assist with process improvements and control remediation efforts.

The Company is pursuing remediation of all of the above material weaknesses during the 2022 fiscal year.

If we fail to establish and maintain adequate internal controls, including by remediating the aforementioned material weaknesses, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. As a result, we may be subject to costly litigation and shareholder actions, our access to the capital markets may be limited or adversely affected, our results of operations may be adversely affected and the trading price of our common shares may decline. Additionally, ineffective internal controls could expose us to an increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchanges on which we list or to other regulatory investigations and civil or criminal sanctions. Furthermore, we may be the subject of negative publicity focusing on the restatement of our previously issued financial results and related matters and may be adversely impacted by negative reactions from our shareholders, creditors, or others with whom we do business. This negative publicity may impact our ability to attract and retain customers, employees and suppliers.

Proper systems of internal control over financial reporting and disclosure controls and procedures are critical to the operation of a public company. However, we do not expect that our internal control over financial reporting or disclosure controls and procedures will prevent all errors and remove all risk of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

The valuation of our biological assets is subject to certain assumptions and estimates.

Pursuant to IFRS, we measure the value of our biological assets (consisting of plants in various stages of vegetation) at fair value less costs to sell up to the point of harvest. As market prices are generally not available for biological assets while they are growing, we are required to make assumptions and estimates relating to, among other things, expected harvest yields, selling prices and costs to sell. The assumptions and estimates used to determine the fair value of biological assets, and any changes to such prior estimates, directly affect our reported results of operations. If actual yields, prices, costs, market conditions or other results differ from our estimates and assumptions, there could be material adjustments to our results of operations. In addition, the use of these future estimated metrics differs from US GAAP. As a result, our financial statements and reported earnings are not directly comparable to those of similar companies in the United States.

We may be subject to credit risk.

Credit risk is the risk that the counterparty to a financial instrument fails to meet its contractual obligations, resulting in a financial loss to us. We have credit risk exposure based on the balance of our cash, accounts receivable, investments, and taxes recoverable. There are no assurances that our counterparties, including parties to whom we extended credit, or customers will meet their contractual obligations to us.

We have implemented, and continue to implement, business optimization initiatives, which may negatively impact our control environment and distract from our operation of the business and may not be successful.

In response to slower than expected regulatory approvals of new retail stores and delays in some cannabis derivative products, in 2020 and 2021, we implemented several cost savings and business optimization initiatives, including the enhancement of facility workflows and processes, realignment of product lines and product formats to areas of stronger demand, workforce optimization and a heightened discipline in cost management. The Company continues to pursue additional business optimization initiatives, including optimization of power usage, streamlining the workforce and improving supply chain efficiency. As part of the leadership team's focus on improved efficiency, cost management and long-term sustainability, the Company continues to monitor operations to ensure it remains responsive in the current environment.

A variety of factors could cause us not to realize some or all of the expected cost savings, including, among others, delays in the anticipated timing of activities related to our cost savings programs, lack of sustainability in cost savings over time, unexpected costs associated with operating our business, our ability to reduce headcount and our ability to achieve the efficiencies contemplated by the business optimization initiatives. We may be unable to realize all of these cost savings within the expected timeframe, or at all, and we may incur additional or unexpected costs in order to realize them. The magnitude of expected cost savings is based upon a number of assumptions and estimates that are in turn based on our analysis of the various factors which currently, and could in the future, impact our business. These assumptions and estimates are inherently uncertain and subject to significant business, operational, economic and competitive uncertainties and contingencies. Certain of the assumptions relate to business decisions that are subject to change, including, among others, our anticipated business strategies, our marketing strategies, our product development and licensing strategies and our ability to anticipate and react to business trends. Other assumptions relate to risks and uncertainties beyond our

10

control, including, among others, the economic environment in which we operate, cannabis regulation and licensing and other developments in our industry as well as capital markets conditions from time to time. The actual results of implementing the various cost savings initiatives may differ materially from our estimates if any of these assumptions prove incorrect. Moreover, our continued efforts to implement these cost savings may divert management attention from the rest of our business and may preclude us from seeking attractive new product and other opportunities. Additionally, former employees may file lawsuits against us, which may be expensive to defend and could potentially result in adverse judgements against us. Any of the foregoing may materially and adversely affect our business, results of operations and liquidity.

Fluctuations in the exchange rate of the Canadian dollar against the U.S. dollar could harm our results of operations.

We may be exposed to fluctuations of the Canadian dollar against the U.S. dollar because we publish our financial statements in Canadian dollars, while a portion of our assets, liabilities, revenues and costs, including, in particular, assets, liabilities, revenues and costs recorded in connection with our joint venture with SunStream Bancorp Inc. (“SunStream”), are denominated in U.S. dollars. Fluctuations in the exchange rate of the Canadian dollar against the U.S. dollar may have a material adverse effect on our earnings or assets when translating U.S. dollars into Canadian dollars.

Risks Related to Regulation and Legal Proceedings

The industry in which we operate and the regulations governing it continue to develop, and if they develop or change in ways that differ from our expectations or ways that are adverse to us, our business and results of operations may be adversely impacted.

Regulations are continuing to be developed for different aspects of the adult-use cannabis industry in Canada. The regulations and market for adult-use cannabis, various cannabis formats and cannabis retail may not develop as we expect or on the timeline that we expect, which could have a material adverse effect on our business and results of operations.

Any adverse changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities or a revocation of our licences and other permits and authorizations. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely impact our ongoing regulatory compliance costs. There is no assurance that we will be able to comply or continue to comply with applicable regulations.

We are dependent upon regulatory approvals and licences for our ability to grow, process, package, store and sell cannabis and other products derived therefrom as well as to own and operate cannabis retail stores through which we and our franchisees sell cannabis products, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal.

Our Canadian business operations are dependent on licences issued by Health Canada as well as those issued by the various provincial regulators having jurisdiction over the provinces in which we operate licensed cannabis retail stores. Our federal licence for our Olds Facility expires on February 23, 2027, and our licence for our Rocky View Facility, expires on June 11, 2023. Each of these licences was issued for a period of three years. A holder of a cannabis licence under the Cannabis Act (Canada) (the “Cannabis Act”) and the Cannabis Regulations (Canada) (the “Cannabis Regulations”) must apply to renew its licence on or before the licence expiry date. Following receipt of the renewal application, Health Canada will (i) confirm the security clearance status of all relevant individuals; (ii) confirm the status of fees paid (if applicable) and (iii) confirm the status of licences issued by the Canada Revenue Agency under the Excise Act, 2001 (if applicable). Health Canada may also conduct an inspection to verify compliance or ask the licence holder to provide additional information. A renewed licence with a new expiry date will be issued once Health Canada confirms that all requirements have been met. Cannabis licence holders can apply to renew their licence up to four months before the licence expires. Failure to comply with the requirements of the licences or any failure to renew the licences would have a material adverse impact on us. There can be no guarantee that Health Canada will renew our licences, or that such renewals will occur in a timely fashion or on terms similar to our existing licences or otherwise acceptable to us. Any new facilities or the expansion of our business at existing facilities requires the approval of Health Canada, and there is no guarantee that Health Canada will grant such approvals. Health Canada requires new applicants for cannabis licences under the Cannabis Act to have a fully built site that meets all the requirements of the Cannabis Regulations at the time of their application, as well as satisfying other application criteria. Further, according to Health Canada, it will not substantively review our licence applications until the facilities associated with such licence applications are fully constructed and meet all the requirements of the Cannabis Regulations. Any delay in renewing or granting a licence, revocation of an existing licence, refusal to grant a licence or change in the terms of licence could materially adversely impact our expected future operations.

Our ability to continue operating our cannabis cultivation and retail cannabis business is dependent on the good standing of various licences, permits and authorizations from time to time possessed by us and adherence to all regulatory requirements related to such activities. We will incur ongoing costs and obligations related to regulatory compliance, and any failure to comply with the terms of such licences, permits or authorizations, or to renew the licences, permits and authorizations after their expiry dates, could have a material adverse effect on our business, financial results and operations. There can be no assurance that applicable regulators will extend or renew the applicable licences, permits and authorizations, or if extended or renewed, that they will be extended or renewed on the same or similar terms. In the event that the applicable regulators do not extend or renew the applicable licences, permits and authorizations, or should they renew the applicable licences, permits or authorizations on different terms, any such event or occurrence could have a material adverse effect on our business, financial results and operations.

11

In our retail cannabis segment, our retail licences, permits and authorizations are specific to individual cannabis retail store locations. As our retail business continues to grow, any expansion to or update of our currently operating cannabis retail stores, or the introduction of new cannabis retail stores, will require the approval of the applicable cannabis regulator. There can be no guarantee that the applicable regulator will approve any such expansions and/or renovations, which could have a material adverse effect on our business, results of operations and financial results.

Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.

Our business activities are heavily regulated in all jurisdictions where we do business. Our operations are subject to various laws, regulations and guidelines by governmental authorities, including Health Canada, relating to the cultivation, processing, manufacture, marketing, management, distribution, transportation, storage, wholesale and retail sale, packaging, labelling, pricing and disposal of cannabis and cannabis products. In addition, we are subject to laws and regulations relating to employee health and safety, insurance coverage and the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services.

Health Canada inspectors routinely assess our production facilities for compliance with applicable regulatory requirements. In addition, we have in the past, and in the future may, self-report violations of regulatory requirements to Health Canada and other regulators. Any failure by us to comply with the applicable regulatory requirements could:

• require extensive changes to our operations;

• result in regulatory or agency proceedings or investigations;

• result in the revocation of our licences, permits and authorizations and increased compliance costs;

• result in damage awards, civil or criminal fines or penalties;

• result in restrictions on our operations;

• result in Health Canada or other regulators destroying, seizing or placing a hold on our inventory;

• harm our reputation; or

• give rise to material liabilities.

Further, our employees or other agents may, without our knowledge and despite our efforts, policies and procedures, engage in prohibited conduct under applicable regulatory requirements for which we may be held responsible.

There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management’s attention and resources or other adverse consequences to our business.

Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all necessary regulatory approvals for the cultivation, processing, production, storage, distribution, transportation, wholesale and retail sale, import and export, as applicable, of our products. Any failure to comply with the regulatory requirements applicable to our operations may lead to possible sanctions, including:

• the revocation or imposition of additional conditions on licences, permits and authorizations to operate our business;

• the suspension or expulsion from a particular market or jurisdiction or of our key personnel;

• the imposition of additional or more stringent inspection, testing and reporting requirements;

• product recalls or seizures; and

• the imposition of fines and censures.

Trade of cannabis for non-medical purposes within Canada may be restricted by the Canadian Free Trade Agreement.

We have entered into supply agreements with the Provincial Buyers for the supply of adult-use cannabis and cannabis derivative products. We have also been cleared by the SLGA to supply cannabis to retail and wholesale permit holders in Saskatchewan. The Canadian Free Trade Agreement, which generally reduces or eliminates the barriers to the free movement of persons, goods, services, and investments within Canada, specifically excludes cannabis for non-medical purposes from its scope and instead leaves the intra-Canadian movement of non-medical cannabis to future negotiations among the provinces and territories. There is a risk that the outcome of the negotiations will result in the interprovincial and interterritorial trade of cannabis for non-medical purposes in Canada being entirely restricted or subject to conditions that will negatively impact our ability to sell cannabis in provinces and territories in which we do not have cultivation and production facilities, including those in which we have already executed agreements or been approved to supply cannabis to retailers.

12

Our business is or may become subject to a variety of laws related to controlled substances and money laundering, the application of which to our business is unsettled and still developing and which could subject us to claims or otherwise harm our business.

In the United States, despite cannabis having been legalized for medical use or adult use in a number of states, cannabis and cannabis products, other than hemp and certain hemp-derived products, such as CBD, continue to be categorized at the federal level as a Schedule I controlled substance under the Controlled Substances Act (“CSA”), and subject to the Controlled Substances Import and Export Act, as amended (“CSIEA”). We are or may become subject to various other U.S. federal laws and regulations, including as result of the listing of our common shares on the Nasdaq Capital Market (“Nasdaq”) and lending and providing other financial services to cannabis companies engaging in the adult-use cannabis business in the United States (whether directly or through SunStream). Violations of any U.S. federal laws or regulations, including the CSA and CSIEA, to which we may be found to be subject, whether intentionally or inadvertently, could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by either the U.S. federal government or private citizens or criminal charges, including disgorgement of profits, cessation of business activities or divestitures. Further, the status of cannabis as a Schedule I controlled substance may cause us, and our business, to be negatively perceived by prospective U.S. investors or other parties, or who may have reputational or other concerns about dealings with a cannabis grower even if it is not distributing any products in the United States, which may limit our ability to access capital in private or public capital markets. For further information about the risks related to U.S. federal laws and regulations with respect to SunStream’s operations, see “—Risks related to our investments—Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis would likely result in SunStream’s inability to execute its business plan and may subject us to significant civil or criminal liability and other adverse consequences.”

We also are, or may become, subject to a variety of laws and regulations in Canada, the United States and elsewhere that prohibit money laundering, including the Proceeds of Crime and Terrorist Financing Act (Canada), the U.S. Money Laundering Control Act, as amended, and the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by governmental authorities in Canada, the United States or any other jurisdiction in which we may in the future have business operations or to which we may in the future export. Although we believe that none of our activities implicate any applicable money laundering statutes, in the event that any of our business activities, any dividends or distributions therefrom, or any profits or revenue accruing thereby are found to be proceeds of crime under one or more of the statutes described above or any other applicable legislation, any persons, including investors, found to be aiding and abetting us in such violations could be subject to criminal or civil liability. Any violations of these laws, or allegations of such violations, could disrupt our operations, significantly distract management and involve significant costs and expenses, including legal fees. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.

If we are not able to comply with all safety, health and environmental regulations applicable to our operations and industry, we may be held liable for any breaches of those regulations.

Safety, health and environmental laws and regulations affect nearly all aspects of our operations, including product development, working conditions, waste disposal, emission controls, the maintenance of air and water quality standards and land reclamation, and, with respect to environmental laws and regulations, impose limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Compliance with safety, health and environmental laws and regulations can require significant expenditures, and failure to comply with such safety, health and environmental laws and regulations may result in the imposition of fines and penalties, the temporary or permanent suspension of operations, the imposition of clean-up costs resulting from contaminated properties, the imposition of damages and the loss of or refusal of governmental authorities to issue permits or licences to us. Exposure to these liabilities may arise in connection with our existing operations, our historical operations and operations that may in the future be closed or sold to third parties. We could also be held liable for worker exposure to hazardous substances and for accidents causing injury or death. There can be no assurance that we will at all times be in compliance with all safety, health and environmental laws and regulations notwithstanding our attempts to comply with such laws and regulations.

Changes in applicable safety, health and environmental standards may impose stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. We are not able to determine the specific impact that future changes in safety, health and environmental laws and regulations may have on our industry, operations or activities and our resulting financial position; however, we anticipate that capital expenditures and operating expenses will increase in the future as a result of the implementation of new and increasingly stringent safety, health and environmental laws and regulations. Further changes in safety, health and environmental laws and regulations, new information on existing safety, health and environmental conditions or other events, including legal proceedings based upon such conditions or an inability to obtain necessary permits in relation thereto, may require increased compliance expenditures by us.

We are, and may become, subject to litigation, regulatory or agency proceedings, investigations and audits.

We are, and may in the future become, subject to litigation, regulatory or agency proceedings, investigations and audits from time to time, some of which may adversely affect our business. Should any litigation, regulatory or agency proceeding, investigation or audit in which we become involved be determined against us, such a decision could, among other impacts, adversely affect our ability to continue operating without more onerous restrictions or at all, adversely affect our financial condition and results of operations, harm our reputation, or reduce the value or market price for the common shares. Even if we are involved in litigation, regulatory or agency proceedings, investigations and audits and are ultimately successful, they can require the redirection of significant resources and may also create a negative perception of our brand.

13

For example, we have received notice of a legal proceeding commenced against us in the province of Quebec by another licensed cannabis producer alleging breach of a supply agreement and have filed a statement of defense. We have recorded a reserve in the amount of $2.6 million at December 31, 2021 in respect of this matter. All litigation steps have been completed, including discoveries and our filing of a defense, and the parties are awaiting to be called by the court to schedule the trial.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several actions that alleged violations of securities laws. For further detail in respect of ongoing legal proceedings, please see the section of this Annual Report entitled “Legal Proceedings and Regulatory Actions.”

While we intend to defend ourselves vigorously in all pending and future legal proceedings, we may settle certain matters for strategic reasons, as a part of a resolution of other matters or in order to avoid potentially worse consequences arising from inherently uncertain judicial or administrative processes. Moreover, regardless of the merits of our defenses, if we are unable to resolve certain legal proceedings or regulatory actions, indirect consequences arising from unproven allegations or appealable regulatory findings may have adverse consequences to us. The outcome of any litigation, regulatory or agency proceedings investigations and audits is inherently uncertain. Unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business, liquidity and results of operations.

We are subject to various laws relating to the use of customer information and other personal and confidential information and any non-compliance may result in material adverse consequences to our business.

We collect, process, maintain and use data, including sensitive personal information on individuals, available to us through online activities and other customer interactions with our business. Our current and future marketing programs may depend on our ability to collect, maintain and use this information, and our ability to do so is subject to evolving laws and enforcement trends in Canada and other jurisdictions. There are a number of laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the Personal Information Protection and Electronic Documents Act (Canada) (“PIPEDA”), and similar laws in other jurisdictions, protect medical records and other personal health information by limiting their use and the disclosure of health information to the minimum level reasonably necessary to accomplish the intended purpose. We collect and store personal information about our patients and are responsible for protecting that information from privacy breaches. A privacy breach may occur through a procedural or process failure, an IT malfunction or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated through employee collusion or negligence or through deliberate cyberattack. Moreover, if we are found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of patient health information, including as a result of data theft and privacy breaches, we could be subject to sanctions and civil or criminal penalties, which could increase our liabilities and harm our reputation.

Certain of our marketing practices rely upon e-mail, social media and other means of digital communication to communicate with consumers on our behalf. We may face risk if our use of e-mail, social media or other means of digital communication is found to violate applicable laws. We post our privacy policy and practices concerning the use and disclosure of user data on our website. Any failure by us to comply with our posted privacy policy, anti-spam legislation or other privacy-related laws and regulations could result in proceedings which could potentially harm our business. In addition, as data privacy and marketing laws change, we may incur additional costs to ensure we remain in compliance. If applicable data privacy and marketing laws become more restrictive at the international, federal, provincial or state levels, our compliance costs may increase, our ability to effectively engage customers via personalized marketing may decrease, our investment in our e-commerce platform may not be fully realized, our opportunities for growth may be curtailed by our compliance burden and our potential reputational harm or liability for security breaches may increase.

The Canadian excise duty framework may affect profitability.

The federal and provincial or territorial legislation and regulatory regimes for cannabis products include excise duties payable by licensed cannabis producers on adult-use cannabis products, in addition to goods and services tax or harmonized sales tax in certain provinces and territories. We currently hold licences issued by the Canada Revenue Agency (“CRA”) required to comply with this excise framework. The rate of the excise duties for cannabis products varies by province and territory. Any significant increase in the rate of excise duties on cannabis products in the future and any restrictive interpretations by the CRA or the courts of the regulatory-like restrictions contained in the Excise Act, 2001 (Canada) (which may be different than those contained in the Cannabis Act) could reduce consumer demands for cannabis products and adversely impact the adult-use cannabis industry and market in general. In addition, any increase in the rate of excise duties on cannabis products in the future could reduce our margins and profitability in the event that we could not or chose not to pass along such increases to consumers.

We are constrained by law in our ability to market our products in Canada.

The development of our business and operating results may be hindered by applicable restrictions on production, sales and marketing activities imposed on us and other licensed producers and cannabis retailers. All products we distribute into the Canadian adult-use market are subject to restrictions with respect to product formats, product packaging and labelling. In addition, the Cannabis Act regulates our marketing activities, including prohibitions on testimonials and endorsements, lifestyle branding, and promotion that is appealing to young persons. Each Canadian province and territory has also enacted regulatory regimes for the distribution and sale of cannabis for adult-use purposes within its jurisdiction. As such, our portfolio of brands, products and services must be specifically tailored, and our marketing activities carefully structured, to comply with individual provincial and territorial rules and regulations.

14

These restrictions may preclude us from establishing our branding, achieving pricing differentiation, effectively marketing our cannabis products or competing for market share, and may impose costs on us that cannot be absorbed through increased selling prices for our cannabis products.

Risks Related to Cannabis Operations Segment

We face competition from the illegal cannabis market.

We face competition from the illegal dispensaries that are unlicensed and unregulated, and otherwise from illegal market participants, who sell cannabis and cannabis products, including products with higher concentrations of active ingredients, use flavors or other additives that we are prohibited from using, or engage in distribution, advertising and promotion activities in which we are not permitted to engage, use delivery methods that we are prohibited from offering to individuals in Canada, sell products at lower prices, brand products more explicitly, or sell at lower prices. As these illegal market participants do not comply with the regulations governing the cannabis industry, their operations may also have significantly lower costs. The perpetuation of the illegal market for cannabis may have a material adverse effect on our business, results of operations, as well as the perception of cannabis use.

We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.

Under the terms of our production licences issued pursuant to the Cannabis Act, we are restricted as to whom we can sell our cannabis products. We currently derive, and expect to continue to derive a significant portion of our revenues from supply agreements with Canadian provincial and territorial governments, including AGLC, the Ontario Cannabis Store (the “OCS”), the BC Liquor Distribution Branch (the “BCLDB”), Manitoba Liquor and Lotteries (the “MLL”), Saskatchewan Liquor and Gaming Authority (the “SLGA”), New Brunswick Liquor Corporation (the “ANBL”), Nova Scotia Liquor Corporation (the “NSLC”), PEI Cannabis Management Corporation (the “PEICMC”) and Quebec SQDC (the “SQDC”). We also intend to expand our offerings to other provincial and territorial governments across Canada.

Our provincial or territorial supply agreements do not contain purchase commitments or otherwise obligate the purchaser to buy a minimum or fixed volume of products from us and allow the purchaser broad latitude to return product to us. As a result, the amount of cannabis that the AGLC, the OCS, the BCLDB, MLL, SLGA, ANBL, NSLC, PEICMC or SQDC, (collectively, the “Provincial Buyers”) may purchase under our supply agreements, or its price, may deviate significantly from our expectations. In addition, our results of operations could fluctuate materially in the future and could be materially and disproportionately impacted by the purchasing decisions of the Provincial Buyers and any other future government purchasers as well as the return of unsold products. If any of the Provincial Buyers decides to purchase lower volumes of products from us (or return more products) than we expect, charges “slotting fees” in connection with carrying our products, charges additional taxes, insists on a price that is lower than we expect, alters its purchasing patterns at any time with no or limited notice, decides not to continue or begin to purchase our cannabis products at all or does not renew its agreement with us on similar terms or other terms acceptable to us, our results of operations could be materially adversely affected. We have in the past, and may in the future, offer price discounts and other promotions to the Provincial Buyers to promote the movement of slower selling products or as the result of price compression in the market. We also record return provisions in our financial statements based on the estimated likelihood of having additional slow-moving and aged product returned. If we underestimate the magnitude of such return provisions, our results of operation would be negatively affected. In addition, if the legal distributions channels in Canada for cannabis do not continue to develop in accordance with our expectations, either because of delays in the opening of dispensaries or otherwise, our results of operations would be materially adversely affected.

We experience significant customer concentration, with a limited number of customers accounting for a significant portion of our revenues.

Our top five customers in the cannabis operations segment accounted for 78% for the year ended December 31, 2021. Of these customers, three customers have each accounted for more than 10% of our revenues for such period. Inherent risks exist when a large percentage of total revenues is concentrated with a limited number of customers.

It is not possible for us to predict the future level of demand for our products that will be generated by these customers or the future demand for the products of these customers in the consumer marketplace. In addition, revenues from these large customers may fluctuate from time to time based on market demand for our products among consumers, the level which may be affected by market conditions or other factors, some of which may be outside of our control. Further, our contracts with these large customers do not contain purchase commitments or otherwise obligate the purchasers to buy a minimum or fixed volume of products from us (and allow these customers to return product to us for a variety of reasons). If any of our major customers experience declining or delayed sales of our products to consumers due to market, economic or competitive conditions, we could be pressured to reduce the prices we charge for our products, reduce the volume of products we supply to such customers, we could lose the customer or have a substantial amount of product returned to us. Additionally, if any of our large customers were to suffer financial instability, they could refuse or delay payment of outstanding receivables. Any such development may have a material adverse effect on our business, results of operations and financial condition.

15

Any failure on our or our retail store suppliers’ part to comply with supplier standards established by provincial or territorial distributors could prevent us from accessing certain markets in Canada.

Government-run provincial and territorial distributors in Canada require suppliers to meet certain service and business standards, and routinely assess their suppliers for compliance with these standards. For example, our current supply agreement with the AGLC permits the AGLC to inspect and test our products for compliance with a rigorous set of criteria, including packaging, labelling, timing and stated quality test results. We use third parties to extract delta-9-tetrahydrocannabinol (“THC”) and hemp-derived cannabidiol (“CBD”) for use in various product offerings, including for use in our vape products. Any failure by us or our third-party suppliers to comply with such standards could result in our being disqualified as a supplier and could lead to the termination or cessation of orders under existing or future supply contracts. If any of the foregoing events were to occur, our business, financial condition and results of operations could be materially adversely impacted.

We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception.

We believe that the cannabis industry is highly dependent upon positive consumer and investor perception regarding the benefits, safety, efficacy and quality of cannabis and cannabis products. Such categories of products having previously been commonly associated with various other narcotics, violence and criminal activities, and there is a risk that our business might attract negative publicity. Perception of the cannabis industry and cannabis products, currently and in the future, may be significantly influenced by scientific research or findings, regulatory investigations or proceedings, litigation, political statements, media attention and other publicity (whether or not accurate or with merit) both in Canada and in other countries relating to the benefits and risks of consuming cannabis or cannabis products, including unexpected safety or efficacy concerns or the activities of industry participants. There can be no assurance that future scientific research, findings, regulatory investigations or proceedings, litigation, political statements, media attention or other research findings or publicity will be favorable to cannabis or cannabis products. Adverse future scientific research reports, findings, regulatory investigations or proceedings, and political statements, that are, or litigation, media attention or other publicity that is, perceived as less favorable than, or that questions, earlier research reports, findings or publicity (whether or not accurate or with merit) could result in a significant reduction in the demand for cannabis or cannabis products. Further, adverse publicity reports or other media attention regarding consumption of cannabis being associated with physical or mental illness or other negative effects or events, the safety, efficacy and quality of cannabis or cannabis products generally, as well as our current or future products and facilities, specifically could adversely affect us. Adverse publicity could arise even if the adverse effects associated with cannabis-use resulted from consumers’ failure to use such products legally, appropriately or as directed.

There is also a risk that the actions of other companies and service providers in the cannabis industry may negatively affect the reputation of the industry as a whole and, thereby, negatively impact our reputation. The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share negative opinions and views in Canada and elsewhere in regard to our activities and the cannabis industry in general, whether true or not. The legal restrictions with respect to labelling and marketing cannabis may exacerbate these risks by increasing the influence of social media users and prohibiting us from effectively responding to negative publicity.

We do not ultimately have direct control over how we or the cannabis industry is perceived by others. Reputational issues may result in decreased investor confidence, declines in our stock price, litigation, difficulty in obtaining financing, increased challenges in developing and maintaining community relations and may otherwise present an impediment to our overall ability to advance our business strategy and grow our business.

We may be subject to additional risks if we expand our cannabis operations internationally.

We may in the future expand our cannabis operations internationally, including to the United States, by importing or exporting cannabis products, establishing cultivation operations in other jurisdictions or otherwise. Pursuant to the Cannabis Act, only industrial hemp or cannabis used for medical or scientific purposes may currently be imported into or exported from Canada. Any such import or export requires a permit. In the future, we may seek permits to import or export cannabis and cannabis products. If we do not receive the required permits or receive licences with limitations that we do not expect, our ability to import and export cannabis and cannabis products could be materially adversely affected.

If we expand outside of Canada, our ability to operate and sell in foreign jurisdictions will be dependent on our ability to obtain and comply with the necessary regulatory licences and requirements. Additional government licences may be required in the future in connection with our operations, in addition to other known and unknown permits and approvals which may be required, including with respect to our Canadian and other foreign operations. To the extent such permits and approvals are required and not obtained, we may be prevented from operating or expanding our business.

As a result of any international expansion, we may become exposed to various levels of political, economic, legal, regulatory and other risks and uncertainties associated with operating in or exporting to foreign jurisdictions. These risks and uncertainties include changes in the laws, regulations and policies governing the production, sale, branding, marketing, and use of cannabis and cannabis-based products; political instability; currency controls; fluctuations in currency exchange rates and rates of inflation; price, export and import controls; land and water restrictions; government policies awarding contracts to local competitors or requiring domestic producers or vendors to purchase supplies from a particular jurisdiction; changes in taxation laws, regulations and policies; restrictions

16

on foreign exchange and repatriation; changing political conditions and governmental regulations relating to foreign investment and the cannabis business more generally.

Failure to comply strictly with applicable laws, regulations and local practices could result in additional taxes, costs, civil or criminal fines or penalties or other expenses being levied on our international operations, as well as other potential adverse consequences such as the loss of necessary permits or governmental approvals or the inability to grow our business in these jurisdictions. Complying with the varying laws of the jurisdictions in which we may choose to expand can be time consuming, expensive and divert management attention from the rest of our business.

Risks Related to Retail Operations Segment and Franchise Operations

We face risks associated with our franchise business model.

We receive a significant portion of our cannabis retail revenue in the form of franchise royalty payments. Failure to collect payments due to us from our franchisees, due to their inability to make timely payments, dispute with us or otherwise, could have a material adverse effect on our results of operations and financial condition. Our franchisees operate franchised retail locations independently, and as such are subject to many factors beyond our control, all of which could adversely affect such franchisees’ ability to make timely royalty payments to us.

As a result, the success of our retail business and results of operations is significantly dependent upon the success of our franchisees' retail cannabis stores and their cooperation with us. Our franchisees' stores may be adversely affected by: declining economic conditions; increased competition in the retail cannabis market; changes in consumer preferences; demographic trends; changes in consumer sentiments towards the use of cannabis products; decreases in consumers’ discretionary income; consumers' willingness to accept product price increases; adverse weather conditions; our reputation, the strength of the Spiritleaf brand and consumer perception of our market position and offerings in terms of quality, price, value and service; consumers' experiences in our retail cannabis stores; and other risk factors related to operation of cannabis retail stores discussed in this Annual Report, to the extent they apply to such franchisees.

Our franchisees may also be susceptible to increases in certain key operating expenses that are either wholly or partially beyond our control, including: labour costs, including wages, workers' compensation, minimum wage requirements, health care and other benefits expenses; rent expenses and construction, remodeling, maintenance and other costs under leases; compliance costs as a result of changes in legal, regulatory or industry standards; energy, water and other utility costs; insurance costs; information technology and other logistical costs; and expenses associated with legal proceedings, if any.

Our success also relies on the willingness and ability of our independent franchisees to implement major initiatives, which may include financial investment, and to remain aligned with us on operating, value/promotional and capital-intensive reinvestment plans. The ability of franchisees to contribute to the achievement of our plans is dependent in large part on the availability to them of funding at reasonable interest rates and may be negatively impacted by the financial markets in general, by their or our creditworthiness or by banks’ lending practices. If our franchisees are unwilling or unable to invest in major initiatives or are unable to obtain financing at commercially reasonable rates, or at all, our future growth and results of operations could be adversely affected.

In addition, franchise retail cannabis stores are subject to various laws, regulations and guidelines relating to the management, packaging/labelling, advertising, sale, transportation, storage and disposal of cannabis, and our franchisees may not comply with such laws, regulations and guidelines, which may adversely affect the franchisee’s ability to operate profitably, without incrementally onerous restrictions or at all, and which may therefore limit the franchisee’s ability to make timely and full payments to us. In addition, franchisees’ failure to comply, which we may be unable to prevent, may harm our brand, which could have a material adverse effect on the reputation, profitability and operations of our entire corporate-owned and franchised cannabis retail network.

Our ownership mix also affects our results and financial condition. The decision to own or to operate under franchise agreements is driven by many factors whose interrelationship is complex. The benefits of a franchised structure depend on various factors including whether we have effectively selected franchisees, licensees and/or affiliates that meet our rigorous standards, whether we are able to successfully integrate them into our structure and whether their performance and the resulting ownership mix supports our brand and financial objectives.

Our success in the cannabis retail market is dependent, in part, on our ability to attract and retain an adequate retail consumer base.

Our success in the cannabis retail market depends, in part, on our ability to attract and retain consumers and to establish an adequate consumer base. There are many factors which could impact our ability to attract and retain retail consumers, including but not limited to the ability to continually source a sufficient selection of desirable products, the successful implementation of consumer-acquisition plans, the ability to profitably maintain price points attractive to consumers, the ability to secure leases and open retail stores in locations convenient to consumers, the ability to select a sufficient number of qualified franchisees and such franchisees’ ability effectively manage retail locations, and the continued growth in the aggregate number of consumers. The failure to acquire and retain consumers would have a material adverse effect on our business, operating results and financial condition.

17

We may lease unlicensed premises for potential cannabis retail stores with no guarantee of generating earnings.

We may enter into lease agreements for locations which are not subject to permit or licence to sell cannabis products at the time of entry into the lease. In the event we are unable to obtain applicable licences, permits and authorizations to sell cannabis products at such locations in compliance with applicable law, but are unable to terminate the lease or sub-lease the premises, we will be liable for payments on the lease, but may have no or limited revenues from which to make such payments, which could have a material adverse effect on our business, financial conditions and operating results.

Our retail business is dependent on the supply of cannabis products from third-party licensed producers.

Cannabis retailers are dependent on the supply of cannabis products from licensed producers. There can be no assurance that there will be a sufficient supply of cannabis of acceptable quality and at an acceptable price available to us to purchase in order to operate our cannabis retail business or satisfy all of consumers’ demand. Licensed producers’ growing operations are dependent on a number of key inputs and their related costs, including raw materials and supplies. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact licensed producers and, in turn, could have a material adverse effect on our business, results of operations and financial results. Any inability of licensed producers to provide us with sufficient supply of cannabis at acceptable prices as a result of factors that include, but are not limited to, the risks described in this Annual Report that are applicable to our cannabis operations, could have a material adverse effect on our business, financial condition and results of operations.

We may not be able to find additional franchisees who meet our desired criteria, and even if we do, they may ultimately be unable to open franchise locations.

The opening of additional franchise retail cannabis stores depends, in part, upon the availability of prospective franchisees who meet our desired criteria. We may not be able to identify, recruit or contract with suitable franchisees in our target markets on a timely basis or at all. In addition, our potential franchisees may not ultimately be able to access or effectively utilize the financial or management resources that they need to open the stores contemplated by their agreements with us, they may elect to cease store development for personal or other reasons beyond our control, or they may ultimately not be permitted to open a store due to limits on the number of licences available for retail locations in a particular province or municipality or other regulatory or business reasons. If we are unable to recruit suitable franchisees or if franchisees are unable or unwilling to open new stores as planned, our growth may be slower than anticipated, or cease, which could materially adversely affect our ability to increase our revenue and materially adversely affect our business, financial condition and results of operations.

We face risks imposed by franchise regulation.

Our cannabis retail franchise business is subject, in part, to provincial franchise requirements, provincial laws regulating the offer and sale of franchises in Canada through the provision of franchise disclosure documents to potential franchisees containing certain mandatory disclosures, and various provincial laws regulating the franchise relationship. There can be no assurance that we will maintain compliance with such laws at all times, and non-compliance could adversely impact our fundraising activities and thereby reduce anticipated royalty income, which in turn could materially adversely affect our business, financial condition and results of operations.

Certain provinces of Canada in which we have granted or may grant franchises have franchise statutes and regulations. These franchise laws require a disclosure document or statement of a material change to be issued to prospective franchisees containing prescribed information. Failure to comply with these statutes can result in a prospective franchisee having the right to rescind the associated franchise agreement, without penalty or obligation, for up to 60 days after receipt of the disclosure document, if the franchisor failed to provide the disclosure document or statement of material change within the time period prescribed or if the contents did not meet the requirements set out in the relevant legislation, or for a period of up to two years after entering into the associated franchise agreement if the franchisor failed to provide the disclosure document. In addition, if a franchisee suffers a loss because of a misrepresentation contained in the disclosure document or in a statement of a material change or as a result of the franchisor failing to comply with the disclosure requirements, a franchisee has a right of action for damages. These rights are in addition to any other rights a franchisee may have at law.

Risks Related to Our Cannabis Cultivation Operations

We are dependent upon a limited number of facilities that are integral to our cannabis cultivation and production business.

As of the date of this Annual Report, all our cultivation and production activities are conducted at our Olds Facility and Rocky View Facility, and our licences issued under the Cannabis Act are specific to those facilities. Disruptions at, or adverse changes or developments affecting, our Olds Facility or Rocky View Facility, including municipal rezoning, facility design errors, environmental pollution, equipment or process failures, production errors, disease or infestation of our crops, fires, breakdowns of our sewage system, explosions, power failures, natural disasters or security failures, have had and could in the future have negative impacts on our production, the quality of our products, our reputation in the market and our financial results – any one of which could materially adversely impact our business. For example, a fire at our Olds Facility in December 2018 damaged a portion of our crops and caused some delays in our production cycle. In addition, any failure to comply with regulatory requirements under the Cannabis Act could result in the suspension or termination of our Health Canada licences and could have an adverse impact on our ability to renew such licences.

18

We currently rely on a limited number of suppliers for our extraction requirements.

Although we have recently commenced extraction activities at our facility at Olds, we currently depend, and may continue to depend on a limited number of suppliers for extracting THC and CBD for use in certain of our cannabis products. We cannot ensure that these suppliers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. Our current vendors may be unable or unwilling to meet our future demands for our supply needs. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions, which would damage our business, financial condition, prospects and results of operations.

If we were to have to switch to a replacement supplier, the manufacture and delivery of our products could be interrupted for an extended period, which could adversely affect our business. Furthermore, although we are developing our own extraction capabilities, there is no guarantee that we will be successful in doing so or that we will have sufficient capacity to meet our supply needs. We may not be able to quickly establish additional or replacement suppliers for our extraction needs, if required. If we are able to find a replacement supplier, the replacement supplier would need to be licensed by Health Canada, which might require additional regulatory authority approval, which could result in further delay. Any interruption or delay in the supply of components or materials for our products or our inability to obtain components or materials from alternate sources at acceptable prices, or at all, in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders.

Our reliance on these suppliers, service providers and manufacturers subjects us to a number of risks that could harm our reputation, business, financial condition, prospects and results of operations, including, among other things:

• delays to the development timelines for our products;

• interruption of supply resulting from modifications to or discontinuation of a supplier’s operations;

• delays in product shipments resulting from uncorrected defects, reliability issues or a supplier’s variation in a component;

• a lack of long-term supply arrangements for key components with our suppliers;

• inability to obtain adequate supply in a timely manner or to obtain adequate supply on commercially reasonable terms;

• difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;

• production delays related to the evaluation and testing of products from alternative suppliers and corresponding regulatory qualifications;

• delay in delivery due to our suppliers prioritizing other customer orders over ours;

• damage to our reputation caused by defective components produced by our suppliers; and

• fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.

If any of these risks materialize, our costs could significantly increase and our ability to meet demand for our products could be impacted.

We are subject to risks inherent in an agricultural business, including the risk of crop failure.

The cultivation of cannabis is an agricultural process. As such, our business is subject to the risks inherent in the agricultural business, including risks of crop failure presented by weather, insects, fire, plant diseases and similar agricultural risks. Although we currently grow our products indoors under climate-controlled conditions, there can be no assurance that natural elements, such as extreme weather, insects and plant diseases, will not partially or completely disrupt our production activities or have an adverse effect on our business. Cannabis plants can be vulnerable to various pathogens including bacteria, fungi, viruses and other miscellaneous pathogens. We have had to dispose of crops in the past due to pathogens. Such instances often lead to reduced crop quality, stunted growth or death of the plant. Moreover, cannabis, including hemp, is “phytoremediative”, meaning that it may extract toxins or other undesirable chemicals or compounds from the ground in which it is planted. Various regulatory agencies have established maximum limits for pathogens, toxins, chemicals and other compounds that may be present in agricultural materials. In addition, we have experienced, and may in the future experience, production issues at our facilities, including poor crop yields, harvests of product with THC concentration that is too low to meet product specifications, fires, floods and contamination of our product from foreign objects. As a result of the foregoing, our products may not be suitable for commercial sale or may be returned to us by our customers, and we may have to destroy the affected portions of our crops.

Natural disasters, unusual weather, pandemic outbreaks such as COVID-19, boycotts and geo-political events or acts of terrorism could adversely affect our operations and financial results.

The occurrence of one or more natural disasters, such as hurricanes, floods and earthquakes, unusually adverse weather, pandemic outbreaks of influenza and other highly communicable diseases or viruses, such as the COVID-19 virus, boycotts and geo-political events, such as civil unrest in countries in which our operations are located and acts of terrorism, or similar disruptions could

19

adversely affect our business, financial condition, liquidity and results of operations. These events could result in physical damage to one or more of our properties, increases in fuel or other energy prices, the temporary or permanent closure of one or more of our facilities (production or retail) or our customers, the temporary lack of an adequate workforce in a market, the temporary or long-term disruption in the supply of products from suppliers, the temporary disruption in the transport of goods, delay in the delivery of goods to and from our facilities, and the disruption to our information systems.

In March 2020, as a result of the COVID-19 pandemic, Alberta declared a state of emergency and ordered the closure of schools and certain other public facilities. Alberta also amended its rules around paid sick leave to allow full and part-time employees to take 14 days of job-protected leave if they are required to self-isolate or caring for a dependent that is required to self-isolate. In addition, we announced enhanced safety protocols at our Canadian facilities, staffing measure changes and implemented remote work procedures for its corporate staff. Such measures and government mandates may not be effective and one or more of our employees may get sick and may come to work infected, necessitating a short or long-term closure of the affected facilities, disrupting production. Such measures and mandates may also increase our expenses and otherwise impair our production levels or cause us to close or severely limit production at our facilities. Further, licensed cannabis retail stores in Canada may close voluntarily or be forced to close by the provincial governments, reducing our ability to distribute cannabis and otherwise potentially materially adversely affecting our business and results of operations. Consumer demand for cannabis and our other products may be reduced as a result of reductions in consumers’ disposable income associated with lay-offs and work or pay limitations due to mandatory social distancing and lockdown measures implemented by governments in the geographies where we operate. Production limitations, delays or stoppages, social distancing measures and other impediments affecting our suppliers, partners, producers of goods (such as vape hardware) and retail operations should they materialize, may make it difficult, more costly, or impossible for Sundial to produce or distribute cannabis, conduct quality testing, extract cannabis oils, or otherwise market and sell products. For example, we have experienced delays in shipment of vape cartridge hardware for our products from China. Limitations on the function of Health Canada and other regulators as a result of remote work of its employees or redeployment of its resources to addressing the pandemic may delay our communications with the regulatory authorities and delay renewal of our existing licences or the receipt of additional licences, permits and approvals required for our operations, should such licences, permits and approvals be sought. If macroeconomic conditions continue to worsen in Canada and the rest of the world, demand for cannabis and our other products may significantly decline and industry participants, including our customers and suppliers, may face financial hardship. In addition, the increased market volatility resulting from global business and economic disruption related to the pandemic and measures to contain it has made it more difficult for companies to access capital markets. Such volatility has hampered, and may in the future hamper, Sundial’s efforts to secure additional financing.

The future impact of the COVID-19 pandemic, including as a result of the introduction of more infectious or severe variants, on the Canadian cannabis market is uncertain. Even after the pandemic subsides, our businesses could also be negatively impacted should the effects of COVID-19 lead to changes in consumer behavior, including as a result of a decline in discretionary spending due to the adverse impact that the COVID-19 pandemic has had on the Canadian economy, financial markets and employment levels. During the past year, financial conditions for the cannabis industry have faced increased volatility. If such volatility continues, or there is a prolonged recession resulting from the COVID-19 pandemic, resulting in declines of cannabis purchases by consumers, our business, financial condition, results of operations and cash flows would be materially adversely affected.

Significant interruptions in our access to certain key inputs such as labor, raw materials, electricity, water and other utilities may impair our growing operations and materially affect our business.

Our production business is dependent on a number of key inputs and their related costs, including raw materials, supplies and equipment related to our operations, as well as electricity, water and other utilities. Any significant interruption, price increase or negative change in the availability or economics of the supply chain for key inputs and, in particular, rising or volatile energy costs could curtail or preclude our ability to continue production and may have a material adverse impact on our business and results of operations. While we believe we have met all milestones and have made application for all subsidies, there is no assurance that subsidies will continue or that our outstanding applications will be approved. In addition, our operations could be significantly affected by a prolonged power outage. Furthermore, our cultivation operations require a significant amount of electricity as a result it may be difficult for us to locate areas to construct additional cultivation operations as we grow.

Our ability to compete and grow cannabis is dependent on us having access, at a reasonable cost and in a timely manner, to skilled labor, equipment, parts and components. No assurances can be given that we will be successful in maintaining our required supply of labor, equipment, parts and components.

Our headquarters, Olds Facility and Rocky View Facility, are in Alberta, a province whose economy has historically relied heavily on the oil and gas industry. During periods of strong oil and gas industry conditions, we may face increased competition for employees, which could harm our ability to attract and retain employees or increase our compensation costs.

Failure in our quality control systems may adversely impact our sales volume, market share and profitability.

The quality and safety of our products are critical to the success of our business and operations. As such, it is imperative that our (and our service providers’) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training program, and adherence by employees to quality control guidelines, among other factors. Although we strive to ensure that we and all of our service providers have implemented and adhere to high caliber quality control systems, we or our service providers could experience a significant failure or deterioration of such quality

20

control systems. If, as a result of a failure in our (or our service providers’) quality control systems, contamination of, or damage to, our inventory or packaged products occurs, we may incur significant costs in replacing, destroying or repurposing such inventory, providing replacement products to our customers or recalling such products. We may be unable to meet customer demand and may lose customers who have to purchase alternative brands or products. In addition, consumers may lose confidence in our products whether affected or not and our brand may be materially damaged. A loss of sales volume from a contamination event may occur, and such a loss may affect our ability to supply our current customers and to recapture their business in the event they are forced to switch products or brands, even if on a temporary basis. We may also be subject to legal action as a result of a contamination, which could result in negative publicity and negatively impact our results of operations. During this time, our competitors may benefit from an increased market share that could be difficult and costly to regain.

We may not be able to store or transport our cannabis products to customers in a safe, timely and cost-efficient manner, and we may experience breaches of security at our facilities or loss as a result of theft of our products.

Because of the nature of our products and the limited legal channels for distribution, as well as the concentration of inventory in our facilities (including our licensed cannabis retail stores), we are subject to a heightened risk of theft of our product and other security breaches.

Canadian adult-use distribution rules take various forms on a jurisdiction-by-jurisdiction basis and often require us to employ third parties to deliver our products to central government sites and from such sites to our cannabis retail stores. Any prolonged disruption of third-party transportation services could have a material adverse effect on our sales volumes or our end users’ satisfaction with our products. Rising costs associated with third-party transportation services used by us to ship our products may also adversely impact our profitability.

The security of our products during transportation to and from our facilities is of the utmost concern. A breach of security at one of our facilities, or during transport or delivery, could result in the significant loss of product as well as customers and reputational damage and may expose us to additional liability, including regulatory fines, litigation or increased expenses relating to the resolution and future prevention of similar events. Any failure to take steps necessary to ensure the safekeeping of our cannabis could also have an impact on our ability to continue operating under our existing licences, to renew or receive amendments to our existing licences or to receive required new licences.

Risks Related to Our Liquor Retail Business

A decline in the consumption of alcoholic beverage products could materially adversely affect our business, financial condition and results of operations.

Our Company relies on consumers' demand for the alcoholic beverage products it sells in its Alcanna stores. Consumer preferences may shift due to a variety of factors, including changes in demographic or social trends, public health policies, and changes in leisure, dining and beverage consumption patterns. Even if overall liquor consumption does not decline, shifts in consumer preferences from alcoholic beverage products that are more profitable (for example, high-end wine or the Company's preferred label products) to those that are less profitable (for example, domestic beer), could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

A decline in consumption of alcohol generally or of one or more alcoholic beverage product categories could occur in the future due to a variety of factors, including:

• a general decline in economic or geopolitical conditions and/or decline in discretionary consumer income;

• increased public concern about the health consequences of consuming alcoholic beverage products;

• a decline in the consumption of alcoholic beverage products in on-premise establishments, resulting in a decline in alcohol beverage products purchased by such establishments on a “cash and carry” basis;

• consumers favoring alcohol consumption at bars and restaurants instead of purchasing liquor for consumption at home;

• consumer dietary preferences favouring lighter, lower calorie beverages such as diet soft drinks, sports drinks and water products;

• consumer shopping preferences favouring online shopping, resulting in less foot traffic in shopping centres where the Company's retail liquor stores are located;

• the increased activity of anti-alcohol consumption groups;

• a decline in the consumption of alcoholic beverage products as a result of consumers substituting legalized recreational cannabis or other similar products in lieu of alcoholic beverage products;

• increased federal, provincial and/or foreign excise or other taxes on alcoholic beverage products that increase product prices for the consumer and possible restrictions on alcoholic beverage advertising and marketing;

• increased regulation placing restrictions on the purchase or consumption of alcoholic beverage products or increasing prices due to the imposition of duties or excise tax or changes to international trade agreements or tariffs;

21

• inflation; and

• wars, pandemics (including COVID-19), weather and natural or man-made disasters.

Changes in government regulations, in particular changes which decrease the cost of competition, could have a material adverse effect on the Company’s business, financial condition and results of operations.

The Company operates in the highly regulated retail liquor industry in the Provinces of Alberta and British Columbia. The business, operations or licensing of liquor stores may be adversely affected by: (i) new legislation, regulations, rules or bylaws; (ii) changes and court challenges to existing legislation, regulations, rules or bylaws; (iii) new interpretations of existing legislation, regulations, rules or bylaws; or (iv) decisions of the AGLC, the Liquor Control and Licensing Branch of the Province of British Columbia (the "LCRB"), or other governmental authorities (including federal, provincial, municipal, or other local governments or agencies) or applicable courts. Such regulatory changes, interpretations or decisions could increase the cost of operating the Company’s liquor retail business, limit the marketing, sales and other activities in which the Company is permitted to engage, limit the number and types of retail locations the Company can operate, or require the Company to cease operations altogether.

In addition to the foregoing, as a result of the Province of British Columbia's 2021 renewal of the moratorium on granting new liquor licences for the next ten years, new liquor stores cannot be opened in the province except pursuant to an existing license purchased from another liquor retailer. Growing the Company’s liquor retail network in the Province of British Columbia would, accordingly, require the purchase of existing licenses from other retailers, which may not be available on acceptable terms or at all, which may limit the Company’s ability to profitably expand in this market, resulting a material adverse effect on the Company’s business, financial condition, liquidity, results of operations and prospects.

The private retail distribution of alcoholic beverages in the Provinces of Alberta and British Columbia is both competitive and fragmented. Competition exists mainly on a local basis with the main competitive factors being location, convenience, price and service. Changes in the regulatory regime in a particular jurisdiction, for example to allow the licensing of more retail locations or reduce costs for new entrants in the industry, may increase competition that could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

In the Province of Alberta, the Company competes with local single store operators, other local and regional chain operators, and liquor stores associated with national and regional grocery store chains. The current regulatory regime in Alberta limits certain of the potential competitive advantages of large-scale retailers by, among other things, requiring liquor stores to be operated as a separate business, prohibiting the sale of liquor in stores selling other goods and by requiring all retailers to pay the same wholesale price and a uniform "postage stamp" delivery charge. Some municipalities have enacted zoning restrictions that limit the number of liquor store locations by establishing minimum distances of liquor stores to schools, religious establishments, playgrounds, and other areas. The Cities of Edmonton and Calgary have also enacted a "mature neighborhood overlay", requiring a minimum distance separation between two liquor stores of 500 meters (subject to certain "grandfathering" exceptions) in certain areas of the city. These zoning requirements limit the amount of competitors and competition in general in these municipalities and if they were to be relaxed or eliminated, this could adversely affect the Company’s business, financial condition, liquidity and results of operations.

In the Province of British Columbia, Alcanna competes with government owned and operated liquor stores, local independent stores and wine stores. A retail liquor store is not permitted to be relocated anywhere within 1.0 kilometers of an existing retail liquor store, or the site of an application to licence a new retail liquor store (subject to certain "grandfathering" exceptions). This arrangement limits the number of competitors who are able to enter into the market. Wine is permitted to be sold inside retail grocery stores in British Columbia as long as the grocery store obtains or owns a licence and complies with the current licensing requirements (including the 1.0 km separation requirements to another liquor store). Prior to July 8, 2019, only BC VQA wines were permitted to be sold; however, in order to comply with the United-States-Mexico-Canada Agreement, the Province of British Columbia now allows imported wine to be sold on grocery store shelves.

In addition, competition with new entrants in the liquor retail industry in the Province of British Columbia is reduced as a result of the above-described moratorium on granting new liquor retail licenses. Should such moratorium be lifted, competition in the British Columbian liquor retail industry could increase. If the moratorium remains and the Company’s competitors are able to purchase existing liquor retail licenses on acceptable terms while the Company is not able to do so, the Company may face increased competition, lower market share or similar adverse competitive consequences, all of which could result in a material adverse effect on its business, financial condition, liquidity, results of operations and prospects.

Any future changes to the British Columbia or Alberta regulatory regimes may have a significant impact on the level of competition and the value of licences in such provinces, and therefore could materially adversely affect business, financial condition, liquidity and results of operations.

Unfavourable publicity or poor consumer perception of the Company’s liquor retail brands could have a material adverse effect on the Company’s business, financial condition and results of operations.

Success in the highly competitive retail liquor industry is dependent upon consumer perception of a number of factors, including the accessibility, affordability and safety of a company's retail liquor stores. The Company's reputation, and consequently its brands, may be negatively affected by various factors, several of which may be outside of the Company's control, including, but not limited to, the Company’s ability to maintain prices for its products despite any increases in costs, the quality and safety of alcohol products supplied

22

to the Company and the success of the Company’s branding, marketing and advertising efforts. In addition, thefts and robberies of retail liquor stores in Alberta have become a publicized issue that may deter customers from shopping at the Company's stores. There can be no assurance that the Company's efforts to maintain the physical security and safety of its retail locations will be successful, or that future media attention or publicity regarding this issue, and other consumer perceptions, will be favourable to the Company's retail liquor business. Any unfavourable publicity or consumer perceptions could materially adversely affect the Company's business, financial condition, liquidity and results of operations.

If a significant number of the Company’s retail liquor licences were revoked or not renewed, or if the Company failed to secure new retail liquor licences, there could be a material adverse effect on its business, financial condition, liquidity and results of operations.

All of the Company’s Alberta liquor retail stores are operated pursuant to licences issued by the AGLC, which must be renewed annually. Similar to the process in Alberta, the Company’s liquor retail store in British Columbia is operated pursuant to a licence issued by the LCRB, which must be renewed annually. The AGLC and the LCRB have discretion in the granting or revocation of a licence to operate a liquor store. If a significant number of the Company's licences were revoked or not reissued, if their terms were modified in a manner materially adverse to the Company, or if new licences for any network expansion are not granted in a timely manner, on favorable terms or at all, it could materially adversely affect the Company's business, financial condition, liquidity and results of operations.

Delays or interruptions in the supply of liquor to the Company’s retail locations, or spoilage or shrinkage of the Company’s inventory, could have a material adverse effect on the Company’s business, financial condition and results of operations.

The Company is dependent upon a limited number of distributors for a substantial majority of its products. Specifically, liquor store operators in Alberta are dependent on the Connect Logistics Service warehouse and Brewers Distributor Ltd. for the substantial majority of their products. In British Columbia, liquor store operators are dependent on the British Columbia Liquor Distribution Branch (the "BCLDB") for the majority of their products. Any significant disruptions in the operations of these distributors, as a result of, for example, a labour disturbance, lack of product supply, pandemics or epidemics (including COVID-19), natural disasters or severe weather events, road or other transportation link closures, acts of crime, war or terrorism, or for any other reason,   and a resulting interruption, delay or reduction in supply could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

In addition, once the Company’s supply enters its inventory, it may be subject to spoilage, breakage or shrinkage. Spoilage, breakage or shrinkage of inventory at levels materially greater than what the Company’s plans or budgets for could have a material adverse effect on the Company’s business, financial condition, liquidity and results of operations.

Risks Related to our Markets and Industry

We intend to continue to focus primarily on the premium segment of the adult-use cannabis market, which may not be sustainable, or in which we may not be able to develop or maintain a brand that attracts or retains customers.

We focus primarily on users of cannabis in the Canadian adult-use cannabis market who are looking for premium products; however, such a market may not be sustainable. We may not be able to achieve or maintain attractive margins and our ability to achieve our near term or long-term business objectives would be materially adversely affected. Further, we may not be successful in creating and maintaining consumer perceptions of the value of our premium products. The promotion of cannabis is strictly regulated in Canada. For example, promotion is largely restricted to the place of sale and subject to prescribed conditions set out in the Cannabis Act and the Cannabis Regulations. Among other restrictions, the Cannabis Act prohibits testimonials and endorsements, lifestyle branding and promotion that is appealing to minors. Such restrictions on advertising, marketing and the use of logos and brand names, and other restrictions on advertising imposed by Canadian federal or provincial laws or regulations, or similar regulations imposed in other jurisdictions, may prevent us from creating and maintaining consumer perceptions in the value of our premium products and establishing ourselves as premium producers. If we cannot successfully enter into or compete in the premium market, we may face significant challenges in gaining or maintaining a market share in Canada or in other cannabis markets in which we intend to operate, or we may be forced to sell our products at a lower price, which may materially adversely affect our results of operations.

Our success depends, in part, on our ability to attract and retain customers who in turn sell to ultimate consumers of cannabis and cannabis-related products. To do this, we are dependent upon, among other things, continually producing desirable and effective products and the continued growth in the aggregate number of adult-use cannabis consumers. We have made significant investments in enhancing our brand to attract consumers. Subject to the applicable legal restrictions, we expect to continue to make significant investments to promote our current products to new consumers and new products to current and new consumers. Such campaigns can be expensive and may not result in increased sales. If we are unable to attract new consumers or retain existing consumers and customers, we may not be able to increase our sales or sustain our business.

Our business model, including our ability to successfully target the premium segment of the adult-use cannabis market and maintain our brand, is also dependent on being able to grow at scale different strains of cannabis with consistent yields and THC-levels by strain. To the extent we are unable to do so, or we are unable to achieve desired THC-levels, our ability to achieve our near term or long-term business objectives would be materially adversely affected.

23

The legal cannabis market is a relatively new industry. As a result, the size of our target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.

Because the cannabis industry is in a nascent stage, there is a lack of information about the total addressable market as well as comparable companies available for potential investors to review in deciding about whether to invest in us. In addition, the development of the legal cannabis market is dependent on Health Canada and other regulators approving licences for retail stores and other distribution channels in a timely fashion. Any delays in such approvals or other regulatory developments may impact our market and price estimates, which may make it difficult to develop reliable expectations and assumptions. Accordingly, investors should rely on their own estimates regarding the potential size, economics and risks of the cannabis market in deciding whether to invest in our common shares. We have not generated net earnings since our inception and there can be no assurance that we will do so in the future. There can be no assurance that our growth estimates are accurate or that the cannabis market will be large enough for our business to be profitable or to grow as projected.

Although we are committed to researching and developing new markets and products and improving existing products, there can be no assurances that such research and market development activities will prove profitable or that the resulting markets or products, if any, will be commercially viable or successfully produced and marketed. We must rely largely on our own market research to forecast sales and design products as detailed forecasts and consumer research are not generally obtainable from reliable third-party sources in Canada and in other international jurisdictions.

In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management’s expectations and assumptions. We could also be subject to other events or circumstances that that adversely affect the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets.

The adult-use cannabis market in Canada has experienced, and may in the future experience, supply and demand fluctuations.

Following legalization, there was a shortfall in supply in the Canadian adult-use cannabis market leading to increased prices, increases in out-of-stocks and the consumers opting to buy cannabis on the illicit market. We and other licensed producers responded by increasing capacity. The increase in production combined with slower than expected retail store growth has resulted in over-supply in 2020, a trend that has continued into 2021. As inventory levels become greater than consumer demand, we have had to, and may in the future have to, engage in sale of excess inventory at discounted prices or offer promotional pricing to move older product, which could significantly impair operating results and our brand image. Conversely, if we underestimate demand for our products, we may experience inventory shortages, which might delay shipments to customers, reduce revenue, negatively impact customer relationships and diminish brand loyalty. For example, we have experienced shortages and out-of-stocks in our vape products due to supply constraints. In addition, demand for cannabis and cannabis products is dependent on a number of social, political and economic factors that are beyond our control, including the novelty of legalization, which may wear off. A material decline in the economic conditions affecting consumers can cause a reduction in disposable income for the average consumer (as a result of the continuing impact of the COVID-19 pandemic or otherwise), change consumption patterns and result in a reduction in spending on cannabis products or a switch to other products obtained through illicit channels. There can be no assurance that market demand for cannabis will continue to be sufficient to support our current or future production levels or that we will be able to generate sufficient revenue to be profitable.

We may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada.

Our Canadian adult-use business faces enhanced competition from others who are licensed under the Cannabis Act and the various provincial and territorial regulatory regimes to participate in the adult-use cannabis industry. The Cannabis Act and the various provincial and territorial legislation have established licensing regimes for the cultivation, production, processing, testing, packaging, labelling, delivery, transportation, distribution, sale, possession and disposal of cannabis for adult use.

Subject to certain restrictions set out in the Cannabis Act, adults are permitted to cultivate, propagate, harvest and distribute up to four cannabis plants per household. If a significant number of individuals take advantage of the ability to cultivate and use their own cannabis, our success in the adult-use business may be limited and may not fulfill our expectations.

As of April 1, 2022, approximately 838 licences were issued under the Cannabis Act by Health Canada. Certain of these competitors have longer operating histories and significantly greater financial, production, marketing, research and development and technical and human resources than we do. Some of these competitors have become public companies in the United States or Canada, giving them the ability to raise significant amount of capital quickly or use their publicly traded equity securities to conduct acquisitions. In addition, like us, many other competitors have established retail locations. As a result, our competitors may be able to bring more and better products to market more quickly than us. Our commercial opportunity in the adult-use market could be reduced or eliminated if our competitors produce and commercialize products for the adult-use market that, among other things, are safer, more effective, more convenient, better quality or less expensive than the products that we produce, have greater sales, marketing and distribution support than our products, enjoy enhanced timing of market introduction and perceived effectiveness advantages over our products and receive more favorable publicity than our products. If our adult-use cannabis products do not achieve an adequate level of acceptance by the adult-use cannabis market, or if our retail stores do not achieve and sustain adequate customer bases, we may not generate sufficient revenue from these operations, and our adult-use cannabis business may not become profitable. We expect that competition in the adult-use cannabis market will become more intense as current and future competitors begin to offer an increasing number of diversified products. As competition increases, we may experience additional downward price pressure on our cannabis products, loss

24

of market share and increased marketing costs. To remain competitive, we will require a continued high level of investment in marketing, sales and client support, and we may not have sufficient resources to maintain such efforts.

We also face competition from the illicit cannabis market. Illegal dispensaries and ‘black market’ operations and participants, despite not having a valid licence under the Cannabis Regulations, command a significant percentage of the total market for cannabis and cannabis products in Canada and may be able to (i) offer products with higher concentrations of active ingredients, including THC, than permitted by the Cannabis Act and Cannabis Regulations or offered in the legal market, (ii) use delivery methods, that licensed producers are prohibited from offering to individuals in Canada, (iii) brand products more explicitly, (iv) sell products at lower prices and (v) market and distribute products in ways not permissible by law. As these illicit market participants do not comply with the regulations governing the cannabis industry in Canada, their operations may also have significantly lower costs.

In addition, the legal landscape for medical and adult-use cannabis is changing internationally. An increasing number of jurisdictions globally are passing laws that allow for the production and distribution of medical or adult-use cannabis. Increased international competition, including competition from suppliers in other countries who may be able to produce at lower cost, and limitations placed on us by Canadian or other regulations, might lower the demand for our products on a global scale.

Consumer preferences may change, and we may be unsuccessful in acquiring or retaining consumers and keeping pace with changing market developments.

As a result of changing consumer preferences, many consumer products attain financial success for a limited period of time. Even if our products find success at retail, there can be no assurance that such products will continue to be profitable. Our success will be significantly dependent upon our ability to develop and carry new and improved product lines and adapt to consumer preferences. Even if we are successful in introducing new products or developing our current product offerings, a failure to gain consumer acceptance or to update products and our product offerings could cause a decline in our products’ or our retail stores’ popularity and impair our brand. In addition, we may be required to invest significant capital in the creation of new product lines, strains, brands, marketing campaigns, packaging and other product features — none of which are guaranteed to be successful. Failure to introduce new features and product lines and to achieve and sustain market acceptance could result in us being unable to satisfy consumer preferences and generate revenue.

The legal cannabis industry is in its early stages of development, and it is likely that we, and our competitors, will seek to introduce new products in the future. In attempting to keep pace with any new market developments, we may need to spend significant amounts of capital in order to successfully develop and generate revenues from new products we introduce. As well, we may be required to obtain additional regulatory approvals from Health Canada and any other applicable regulatory authorities, which may take significant amounts of time. We may not be successful in developing effective and safe new products, anticipating shifts in social trends and consumer demands, bringing such products to market in time to be effectively commercialized, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of such product development and regulatory approval processes, may have a material adverse effect on our business and results of operations.

In addition, the patterns of cannabis consumption in Canada may shift over time due to a variety of factors, including changes in demographics, social trends, public health polices and other leisure or consumption behaviors. If consumer preferences for our products or cannabis products move away from our products or cannabis products in general, or if we are unable to anticipate and respond effectively to shifts in consumer behaviors, we may be adversely affected.

We may not be successful in maintaining consumers’ brand recognition and loyalty to our products or retail stores.

Our continued success depends in part on our ability and our ability to continue to differentiate our brand names and maintain similarly high levels of recognition with target consumers.

Our ability to build and maintain brand recognition and loyalty is limited by current and potential future regulations that restrict our packaging, advertising and other branding efforts, making it more difficult to appeal to consumers or to leverage our brands. For example, the Canadian federal regulatory regime requires plain packaging on cannabis products and prohibits testimonials, lifestyle branding and packaging that is appealing to youth. These and similar limitations could have a material adverse impact on our business, financial condition and results of operations, as they make it more difficult to establish and retain brand recognition and customer loyalty.

Furthermore, even if we are able to continue to distinguish our products and retail stores, there can be no assurance that the sales, marketing, retail and distribution efforts of our competitors will not be successful in persuading consumers of our products and retail stores to switch to their products or retail stores. Some of our competitors have greater access to resources than we do, which better positions them to conduct market research in relation to branding strategies or costly marketing campaigns. Any loss of consumer brand recognition or loyalty to our products and offerings or our inability to effectively brand our products and offerings in a recognizable way, whether as a result of regulation or otherwise, will have a material effect on our ability to continue to sell products and maintain our market share, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

25

The vape market is a new market that is still evolving and is subject to significant uncertainty, including as a result of recent negative press and regulatory scrutiny of vape products in the United States.

We sell vape products in Canada. In Canada, vape products are regulated under the Cannabis Act and associated regulations, and such regulations were drafted prior to the recent reports of vaping-related deaths and illnesses in the United States. As a result, Health Canada or the individual provinces may amend or further review the rules governing vape products and restrict or prohibit sales of such products. For example, the AGLC delayed the legalization of vaping products in Alberta and, currently, vaping products are illegal in Quebec and Newfoundland. There can be no assurance that we will be able to meet any additional compliance requirements or regulatory restrictions or remain competitive in the face of unexpected changes in market conditions.

There is a limited history and volume of research on the health effects of vaping, electronic cigarettes and other similar products. If the medical community were to determine that vaping or use of any of related products caused or posed a risk of long-term health risks, market demand for these products and their use could materially decline. Such a determination could expose us to litigation and result in increased regulation. Furthermore, vaping products sold on the illicit market that contain harmful chemicals or other ingredients may adversely impact the demand for such products in the legal market and create the perception that such products were dangerous. In addition, regulators may prohibit the sale of vaping products all together or severely restrict their use. A decline in the market demand for our vaping products, product liability claims, and increased regulation could have a material adverse effect on our business.

Risks Related to Our Products

There has been limited study on the health effects of cannabis and cannabis products, including vaping products, and future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the benefits, viability, safety, efficacy, dosing and social acceptance of such products.

Research in Canada, the United States and internationally regarding the benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids, such as CBD and THC, remains in relatively early stages. Few clinical trials on the benefits and risks of cannabis or isolated cannabinoids have been conducted.

Future research and clinical trials may draw opposing conclusions to statements contained in the articles, reports and studies currently favored, or could reach different or negative conclusions regarding the benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical or adult-use cannabis, which could adversely affect social acceptance of cannabis and the demand for our cannabis products.

Our products may be subject to recalls or returns for a variety of reasons, which could require us to expend significant management and capital resources.

Manufacturers and distributors of consumer goods products are sometimes subject to the recall or return of their products for a variety of reasons, including public health and public safety risks, product defects, such as contamination, adulteration, unintended harmful side effects or interactions with other substances, packaging safety, inadequate or inaccurate labelling disclosure or expiry. Although we have detailed procedures in place for testing our finished products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid product returns, recalls, regulatory action or lawsuits, whether frivolous or otherwise. While we have not been subject to a recall to date, if any of the products produced by us are recalled in the future due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. In addition, from time to time, we have had customers return our products alleging, among other things, contamination and failure to meet designated specifications as well as a result of the age of slow-moving product. As a result of any such recall or return, we may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall or return may require significant management attention, expose us to liabilities or damage our reputation and goodwill or that of our products or brands.

Additionally, product recalls and returns may lead to increased scrutiny of our operations by Health Canada or other regulatory agencies, requiring further management attention, increased compliance costs and potential legal fees, fines, penalties and other expenses. Any product recall affecting the cannabis industry more broadly, whether or not involving us, could also lead consumers to lose confidence in the safety and security of such products, including products sold by us.

We may be subject to product liability claims or regulatory action if our products are alleged to have caused significant loss, injury or death, which is exacerbated by the fact that cannabis use may increase the risk of certain serious health conditions.

As a manufacturer and distributor of products which are ingested or otherwise consumed by humans, we face the risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused loss, injury or death. We may be subject to these types of claims due to allegations that our products or the products we have sold caused or contributed to injury, illness or death, made false, misleading or impermissible claims, failed to include adequate labelling and instructions for use or failed to include adequate warnings concerning possible side effects or interactions with other substances. This risk is exacerbated by the fact that cannabis use may increase the risk of developing schizophrenia and other psychoses, symptoms for individuals with bipolar disorder, and other side effects. Previously unknown adverse reactions resulting from human consumption of cannabis products alone or in combination with other medications or substances could also occur. In addition, the manufacture, sale and distribution of cannabis products, like the manufacture, sale and distribution of any ingested or consumable product, involves a risk of injury to

26

consumers due to tampering by unauthorized third parties or product contamination. We may in the future have to recall certain of our cannabis products as a result of potential contamination and quality assurance concerns. A product liability claim or regulatory action against us could result in increased costs and could adversely affect our reputation and goodwill with our consumers. There can be no assurance that we will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could result in us becoming subject to significant liabilities that are uninsured and also could adversely affect our commercial arrangements with third parties.

Risks Related to Our Employees, Partners and Third Parties

We may seek to enter into extraction agreements, co-packing agreements, joint ventures, licensing arrangements or other relationships, or expand the scope of currently existing relationships, with third parties that we believe will have a beneficial impact on us, and there are risks that such strategic alliances or expansions of our currently existing relationships may not enhance our business in the desired manner.

We currently have, and may expand the scope of, and may in the future enter into, extraction agreements, co-packing agreements, tolling services, joint ventures, licensing arrangements or other relationships with third parties that we believe will complement or augment our existing business and create additional revenue streams, including leasing any unused or excess facility space to other licensed producers. Our ability to complete additional arrangements is dependent upon, and may be limited by, among other things, the availability of suitable candidates and capital. In addition, such third-party arrangements could present unforeseen integration obstacles or costs, may not enhance our business and may involve risks that could adversely affect us, including the investment of significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such relationships. Future third-party arrangements could result in the incurrence of debt, costs and contingent liabilities, cross-contamination, damage to our products or facilities and harm to our brand, and there can be no assurance that future such arrangements will achieve, or that our existing arrangements will continue to achieve, the expected benefits to our business or that we will be able to consummate future arrangements on satisfactory terms, or at all.

Our contracts with other licensed producers may expose us to additional costs and negatively impact our results of operations.

We derive a portion of our revenue from sales of cannabis flower and trim to other licensed producers in Canada. Our supply contracts with these other licensed producers contain provisions governing, among other things, the quality and THC-content of the cannabis supplied and the manner, time and place of such delivery. We have in the past experienced issues with such supply agreements, including a legal dispute with one of our customers resulting from our failure to timely deliver product and the provision of additional product at no cost to another customer due to a disagreement over the THC content of product supplied. Issues with our contracts, including disagreements with our counterparties and any resulting publicity, and failure to comply with such agreements may have a material adverse impact on our results of operation and business. In addition, we are exposed to the credit risk of the licensed producers to which we sell. If any of our licensed producer-customers were to suffer financial difficulty, including bankruptcy, our business and liquidity may be materially adversely affected.

Directors and certain key employees of a licensed producer must obtain and maintain a security clearance from Health Canada. There is no assurance that any of our existing directors or employees who presently or may in the future require a security clearance will be able to obtain or renew such clearances in a timely manner or at all, or that new personnel who require a security clearance will be able to obtain one.

Each director and certain key employees of a company that holds a licence for cultivation, processing or sale under the Cannabis Regulations is subject to the requirement to obtain and maintain a security clearance from Health Canada. Certain additional key personnel are also required to obtain and maintain a security clearance. Under the Cannabis Regulations, a security clearance cannot be valid for more than five years and must be renewed before the expiry of a current security clearance. All of our directors and executive officers have obtained security clearance from Health Canada. There is no assurance that any of our existing personnel who presently or may in the future require a security clearance will be able to obtain or renew such clearances in a timely manner or at all, or that new personnel who require a security clearance will be able to obtain one. A failure by an individual in a key operational position to maintain or renew his or her security clearance could result in a reduction or complete suspension of our operations or loss of our licences. In addition, if an individual in a key operational position leaves us, and we are unable to find a suitable replacement who is able to obtain a security clearance required by the Cannabis Act in a timely manner, or at all, we may not be able to conduct our operations at planned production volume levels or at all. Furthermore, the Cannabis Regulations require us to designate a qualified individual in charge who is responsible for supervising transactions with cannabis, which individual must meet certain educational and security clearance requirements. Moreover, depending on the activity, under current regulations a qualified person in charge or an individual with security clearance must be physically present in a space where other individuals are conducting activities with cannabis. If our current designated qualified person in charge fails to maintain his security clearance, or if our current designated qualified person in charge leaves us and we are unable to find a suitable replacement who meets these requirements, we may no longer be able to conduct activities with respect to the cultivation, production or sale of cannabis.

27

We rely on third-party distributors to distribute our products, and those distributors may not perform their obligations.

We rely on third-party distributors, including provincial regulatory boards and private retailers to distribute our products, other than through our retail stores, and may in the future rely on other third parties, to distribute and sell our products to consumers. If these distributors do not successfully carry out their contractual duties, if there is a delay or interruption in the distribution of our products or if these third parties damage our products, it could negatively impact our revenue from product sales. Furthermore, any damage to our products, such as product spoilage, could expose us to potential product liability, damage our reputation and the reputation of our brands or otherwise harm our business and results of operations.

Third parties with whom we do business may perceive themselves as being exposed to reputational risk as a result of their relationship with us.

The parties with whom we do business, or would like to do business with, may perceive that they are exposed to reputational risk as a result of our business activities relating to cannabis, which could hinder our ability to establish or maintain business relationships or raise capital. These perceptions relating to the cannabis industry may interfere with our relationship with service providers in Canada and other countries.

Risks Related to Our Investments

We may make investments into equity or debt securities of other companies, or provide credit to other companies, and we may not obtain the anticipated level of return on such investments, or any return at all.

We have made in the past, and intend in the future, to make investments into the equity or debt securities of other companies, including by subscribing for such companies’ common shares, preferred shares, convertible debt or other securities. We may also provide revolving or non-revolving credit facilities or other types of loans to other companies.

Any such investment will be subject to liquidity, market value, credit, interest rate, reinvestment and certain other risks, which will be increased if we invest in securities or instruments which are not investment grade assets. The companies that we invested into in the past have had, and companies we may invest into in the future may have, poor financial performance, liquidity and results of operations and high levels of leverage. These risks may be further increased to the extent that we invest into companies that are distressed or bankrupt, or into new, small companies with limited operating histories. Liquidity risks will be especially high if we invest in companies that are not publicly traded, the shares of which would be subject to legal and other restrictions on resale and which would otherwise be less liquid than publicly traded securities.

Non-investment grade assets are considered speculative in nature and, if such assets represent debt securities or credit instruments, they may become a defaulted obligation for a variety of reasons. If such debt securities or credit instruments become subject to either substantial workout negotiations or restructuring, this may entail, among other things, a substantial reduction in the interest rate, a substantial write-down of principal, and a substantial change in the terms, conditions and covenants of such instruments. Such negotiations or restructuring may be quite extensive and protracted over time, which may detract the attention of our management from other matters and result in substantial uncertainty with respect to the ultimate recovery on the instrument. In the event of default, the liquidity of our investments may be limited, and to the extent that they are sold, it is highly unlikely that the proceeds from such sale will be equal to the amount of unpaid principal and interest thereon.

The fact that any debt securities or credit instruments may be secured does not guarantee that we will receive principal and interest payments according to their terms, or that we will be able to collect on such securities or instruments should we be forced to enforce our remedies. There is also a risk that the assets securing the securities or instruments may decrease in value over time, carry liabilities for which we may be responsible should we take possession of collateral, be impossible to transfer to us as a result of applicable laws and regulations (particularly in the case of cannabis-related assets), be difficult to appraise or liquidate and may fluctuate in value based upon the success of the borrowers’ business and market conditions, including as a result of the inability of such borrowers to raise additional capital or otherwise as a result of deterioration of its financial condition and prospects.

Credit we extend to other companies may contain provisions that allow loans we have made to be prepaid. In some cases, the prepayment of a loan may reduce our achievable yield if the capital returned cannot be invested in transactions with equal or greater expected yields, which could have a material adverse effect on our business, financial condition and results of operations.

If we invest in equity securities of other companies, such companies may never declare dividends, or may declare dividends in amounts insufficient to generate a return on our investment. As such, our only means to earn a return on our investment may be to sell the securities for a greater price than we paid for them, and there can be no assurance that we would be able to do so. The price of such securities may be volatile, and will be dependent on the business, financial position, results of operations and prospects of the company in which we invested, which would be beyond our control as we do not anticipate becoming a controlling shareholder in any such company, as well as factors beyond our control or the control of the company in which we invested, including, but not limited to, performance of the financial markets generally, investor perception of the company and its industry, and speculation about such company in the media, investor community or on the internet. The price of such securities will in all cases be subject to the risks similar to those facing our common shares and risks applicable to the business and securities of the company in which we may invest. Recent developments and volatility throughout the North American cannabis industry, including declines in prices of shares of cannabis companies, challenging access to capital, and mergers and acquisitions activity has in the past, and may in the future, adversely impact the value of our direct cannabis-related investments, as well as SunStream’s credit portfolio. In the event of

28

liquidation of a company in which we invested, any interest we have in the company’s equity will be subordinate to the interests of holders of debt and preferred shares of the company, if any, and as a result, we may lose our entire investment in the event of liquidation. If the company in whose equity securities we invest is private or ceases to trade on a stock exchange by virtue of de-listing following inability to comply with requirements of such stock exchange or otherwise, the liquidity of our investment in equity securities may become limited or cease to exist, causing the value of our investment to decline or be eliminated. All the foregoing could cause us to fail to realize the expected or any return on our investment in equity securities of another company.

If any of our investments provide for the payment of a royalty to us, then part of the value of our investment will be dependent on the ability of the company in which we invested to effectively maintain and grow sales of the products subject to such royalty. Such company’s ability to do so will be subject to the risks applicable to its business and there can be no assurance that such company will achieve the revenue targets required to trigger royalty payments in the near-term or at all. Should the company be unable to maintain or grow sales of its products, we may not be able to realize all or any anticipated revenues from any royalty arrangements.

Any investment we make will be subject to the risks applicable to the business, securities and operations of the company in which we invested, which, if such company is public, will be disclosed in the company’s filings with securities regulators in the applicable jurisdiction. You should read disclosure of any such risks in the company’s filings to assess the risk profile to which our investments may be subject.

In some circumstances, particularly in connection with investment in distressed or bankrupt companies, we may be required to bear certain extraordinary expenses, including legal, accounting, valuation and transaction expenses, in order to protect or recover our investments.

Any of the foregoing could cause us not to realize all or any of the anticipated benefits of our investments and may result in our taking an impairment charge related to such investments, which may materially adversely affect our financial position, results of operations and prospects. All of our investment decisions will be subject to our discretion, and you will not be able to influence investment decisions with which you might disagree.

Our joint venture interest in SunStream is subject to certain risks associated with the conduct of joint ventures.

Our joint venture interest in SunStream is subject to the risks normally associated with the conduct of joint ventures, including: (i) disagreement with SAF Group about the strategy, financing or operations of SunStream; (ii) that SAF Group may not comply with the underlying agreements governing the joint venture and may fail to meet its obligations thereunder; (iii) that SAF Group may at any time have economic or business interests or goals that are, or become, inconsistent with our interests or goals; (iv) the possibility that SAF Group may become insolvent; and (v) the possibility of litigation with SAF Group.

We may not realize all or any of the anticipated returns on our joint venture interest in SunStream, or any return at all.

SunStream is intended to leverage our strategic, financial and operational partnership with SAF Group to target asymmetrically enhanced risk-return opportunities in the cannabis industry to provide exposure to a portfolio of financial services and instruments. The profitability of SunStream, and, therefore, the return we realize on our investment in it, is dependent on SunStream’s ability to effectively execute its business strategy, which is subject to risks affecting its planned business, which include, but are not limited to: economic recessions or downturns and global economic, political and market conditions (including as a result of the COVID-19 pandemic and the Russia-Ukraine conflict); volatility, disruption and instability of the capital markets generally and the cannabis industry in particular; changes in interest rates; competition for business opportunities; the qualities of SunStream’s investment advisor’s investment expertise and the ability of such advisor to deploy its expertise in the financial services process and maintain referral and other relationships that generate business opportunities; regulations applicable to SunStream (and any adverse changes therein) and the regulations applicable to SunStream’s portfolio; and the ability of SunStream to generate returns on its business ventures, which include, but are not limited to, such other risks as are described under this section entitled “Item 3D—Risk Factors”.

Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis would likely result in SunStream’s inability to execute its business plan, and may subject us to significant civil or criminal liability and other adverse consequences.

In the United States, despite cannabis having been legalized for medical use or adult use in a number of states, cannabis and cannabis products, other than hemp and certain hemp-derived products, such as CBD, continue to be categorized at the federal level as a Schedule I controlled substance under the CSA. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law. The U.S. government has not enforced the CSA or related federal laws related to cannabis against companies complying with state cannabis law and their vendors for over seven years, but there can be no assurance that this will continue. Accordingly, there can be no assurance that the portfolio companies to which SunStream provided financial services will not be prosecuted under the CSA or other federal laws for their cannabis-related activities. If SunStream’s portfolio companies were so prosecuted, it would have a material adverse effect on our business, financial condition and operations as a result of our interest in SunStream. There is also no assurance that third party service providers with whom we work could suspend or withdraw services due to SunStream’s involvement in the U.S. cannabis industry, which could have a material adverse effect on our business, financial condition and operations.

Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA, or conspire with another to violate the law, and violating the CSA is a predicate for certain other crimes, including money laundering laws and the Racketeer

29

Influenced and Corrupt Organizations Act. To the extent that any of SunStream’s portfolio companies are found to violate the CSA, there can be no assurance that SunStream and/or Sundial would not be found to be in violation of the CSA, money laundering, racketeering or similar laws for financing such companies. If SunStream and/or Sundial are found to violate such laws, it could lead to arrests, criminal charges, forfeiture of property, significant fines and penalties, disgorgement of profits, administrative sanctions, criminal convictions and cessation of business activities, as well as civil liabilities arising from proceedings initiated by either the U.S. government or private citizens, all of which would materially adversely affect our business, financial condition, results of operations and reputation.

We may not realize all or any of the anticipated benefits of our investment in Zenabis.

On December 30, 2020, we completed an investment into Zenabis Investments Ltd. (“Zenabis”), a subsidiary of Zenabis Global Inc., whereby we acquired $58.9 million of aggregate principal amount of senior secured debt of Zenabis (the “Senior Loan”). The Senior Loan bears interest at a rate of 14% per annum and has a maturity date of March 31, 2025, with principal repayments due under certain circumstances over time. As of December 31, 2021, $51.9 million is outstanding under the Senior Loan. Due to the credit risk associated with Zenabis and its parent, and uncertainty of the completion of their proposed restructuring, the Company has adjusted the fair value of the Zenabis Senior Loan downward by $3.3 million in accordance with the requirements of IFRS. In the event that facts and circumstances change the fair value will be adjusted accordingly. The fair value determination does not attribute value to the associated royalty due to its inherent uncertainty, or monitoring fee.

The Senior Loan is subject to liquidity, market value, credit, interest rate, reinvestment and certain other risks, which is increased because the Senior Loan is a below investment grade asset. As a non-investment grade loan, the Senior Loan is considered speculative in nature and may become a defaulted obligation for a variety of reasons. On December 31, 2020, pursuant to the terms of the Senior Loan, we delivered a notice of default to Zenabis with respect to certain defaults not related to principal non-payment, which Zenabis is disputing. Should the Senior Loan become a defaulted obligation as a result of the foregoing notice of default or otherwise in the future, it may become subject to either substantial workout negotiations or restructuring, which may entail, among other things, a substantial reduction in the interest rate, a substantial write-down of principal, and a substantial change in the terms, conditions and covenants of the Senior Loan. Such negotiations or restructuring may be quite extensive and protracted over time, which may detract the attention of our management from other matters and result in substantial uncertainty with respect to the ultimate recovery on the Senior Loan. In the event of default, the liquidity for the Senior Loan may be limited, and to the extent that it is sold, it is highly unlikely that the proceeds from such sale will be equal to the amount of unpaid principal and interest thereon.

The fact that the Senior Loan is secured does not guarantee that we will receive principal and interest payments according to its terms, or that we will be able to collect on the Senior Loan should we be forced to enforce our remedies. There is also a risk that the assets securing the Senior Loan may decrease in value over time, carry liabilities for which we may be responsible should we take possession of collateral, be difficult to appraise or liquidate and may fluctuate in value based upon the success of Zenabis’ business and market conditions, including as a result of the inability of Zenabis to raise additional capital or otherwise as a result of deterioration of its financial condition and prospects.

Furthermore, pursuant to the terms of the Senior Loan, Zenabis will, on a quarterly basis for 32 quarters, also pay us a royalty (the “Royalty”) based on quarterly sales revenue from its medical, recreational and wholesale cannabis lines, net of value added or sales taxes (“Net Cannabis Revenue”), at a rate that will vary from 2.0% to 3.5% based on the volume of such Net Cannabis Revenue in the quarter. The payment of the Royalty is subject to certain Net Cannabis Revenue targets and the maintenance by Zenabis of certain debt service ratios. If the Royalty is not payable in a given fiscal quarter because of failure to meet such targets, the term of the Royalty is extended for another quarter.

As a result, part of the value of our investment is dependent on Zenabis’ ability to effectively maintain and grow sales of the products subject to the Royalty. Zenabis’ ability to do so is subject to the risks applicable to its business and there can be no assurance that it will achieve the revenue targets required to trigger Royalty payments in the near-term or at all. Should Zenabis be unable to maintain or grow sales of its products, we may not be able to realize all or any anticipated revenues from the Royalty. In addition, Zenabis filed a petition with the Supreme Court of British Columbia for a determination of the amount required to repay and terminate the Royalty. The court subsequently dismissed the petition and did not decide the merits of the case. Zenabis had 30 days from December 17, 2021 to file a notice of appeal in respect of the court’s findings, but they did not do so.

Any of the foregoing could cause us not to realize all or any of the anticipated benefits of our investment in Zenabis and may result in our taking an impairment charge related to such investment, which may materially adversely affect our financial position, results of operations and prospects.

We are subject to the risk of possibly becoming an investment company under the Investment Company Act of 1940.

To the extent we continue to make investments in the equity or debt securities of other companies, we run the risk of inadvertently becoming an “investment company” under Investment Company Act of 1940, as amended (the “Investment Company Act”), which may require us to register as an investment company under the Investment Company Act. Registered investment companies are subject to extensive, restrictive and potentially adverse regulations relating to, among other things, operating methods, management, capital structure, dividends and transactions with affiliates. Registered investment companies are not permitted to operate their business in the manner in which we operate our business, nor are registered investment companies permitted to have many of the relationships that we have with our affiliated companies.

30

To avoid becoming and registering as an investment company under the Investment Company Act, we operate as an ongoing enterprise, along with an asset base from which to pursue investments. Because we monitor the value of our investments and structure transactions accordingly, we may structure transactions in a less advantageous manner than if we did not have Investment Company Act concerns, or we may avoid otherwise economically desirable transactions due to those concerns. In addition, adverse developments with respect to our ownership of certain of current or future investments, including significant appreciation or depreciation in the market value of certain publicly traded holdings, could result in our inadvertently becoming an investment company. If it were established that we were an investment company, there would be a risk, among other material adverse consequences, that we could become subject to monetary penalties or injunctive relief, or both, in an action brought by the SEC, that we would be unable to enforce contracts with third parties or that third parties could seek to obtain rescission of transactions with us undertaken during the period it was established that we were an unregistered investment company.

Risks Related to our Acquisitions

We may not be able to successfully identify and execute future acquisitions or dispositions or to successfully manage the impacts of such transactions on our operations.

We have in the past, and may in the future, seek strategic acquisitions. Our ability to identify and consummate any future potential acquisitions on terms that are favorable to us may be limited by the number of attractive acquisition targets, internal demands on our resources and, to the extent necessary, our ability to obtain financing on satisfactory terms, if at all. Any such activities may require, among other things, various regulatory approvals, licences and permits and there is no guarantee that all required approvals, licences and permits will be obtained in a timely fashion or at all. Acquisitions may expose us to additional risks including: difficulties in integrating administrative, financial reporting, operational and information systems; difficulties in managing newly acquired operations and improving their operating efficiency; difficulties in maintaining uniform standards, controls, procedures and policies through all our operations; difficulties entering into markets in which we have little or no direct experience; difficulties in retaining key employees of the acquired operations; and disruptions to our ongoing business. In addition, future acquisitions could result in the incurrence of additional debt, costs, and contingent liabilities. In the past, we have incurred substantial goodwill impairments related to prior acquisitions. We may also incur costs for and divert management attention to potential acquisitions that are never consummated. For acquisitions that are consummated, expected synergies may not materialize.

We face integration and liability risks in connection with our acquisition strategy, some of which may be unforeseen by us.

Our acquisitions are completed with the expectation that the successful completion of such acquisition will result in increased earnings and cost savings by taking advantage of operating and other synergies to be realized from the integration of the acquired entity. These anticipated benefits will depend in part on whether the acquired entity’s operations can be integrated in an efficient and effective manner. Management may face challenges incorporating the systems and personnel of an acquired entity, including possible unanticipated liabilities, unanticipated costs, the loss of key employees and commercial relationships, the need to revisit assumptions about future revenues, capital expenditures and operating costs, including synergies, and the need to address unanticipated liabilities. As a result of these factors, it is possible that the synergies expected from the combination of our business and that of an acquired entity will not be realized. In addition, integration efforts require substantial management attention and could detract attention from our day-to-day business.

Despite any diligence we may perform on an acquisition target, we may not fully appreciate, understand or fully anticipate the extent of the risks associated with a target business and the acquisition and integration. Even if we have the benefit of indemnification provisions, escrow funds and/or insurance policies in connection with an acquisition agreement, our exercise of due diligence and risk mitigation strategies may not anticipate or mitigate the full risks of the acquisition and the associated costs. As a result of an acquisition, we will incur the liabilities of the target, including, but not limited to, matters related to litigation, regulation, the environment or otherwise, some or all of which may be unforeseen by us. We may not be able to contain or control the costs associated with unanticipated risks or liabilities, which could materially and adversely affect our business, liquidity, capital resources or results of operations.

The foregoing risks could be exacerbated, and new risks to our company, some or all of which we may be unable to foresee, may arise, if we acquire businesses engaged in other business lines, such as alcohol retail, even if the new business lines are ancillary or related to our current business.

Risks Related to Our Jurisdiction of Incorporation

We are incorporated in the Province of Alberta and enforcement of actions may be difficult.

We are incorporated under the laws of the Province of Alberta and our head office is located in the Province of Alberta. All of our directors and officers and some of the experts named in this Annual Report are residents of Canada or otherwise reside outside of the United States, and a substantial portion of their assets and our assets are located outside the United States. Consequently, it may be difficult for investors in the United States to bring an action against such directors, officers or experts or to enforce against those persons or us a judgement obtained in a United States court predicated upon the civil liability provisions of U.S. federal securities laws or other laws of the United States.

31

We are a foreign private issuer and intend to take advantage of less frequent and detailed reporting obligations.

We are a “foreign private issuer”, as such term is defined in Rule 405 under the Securities Act, and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the U.S. Exchange Act of 1934, as amended (the “Exchange Act”), we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we are not required to file the same reports that a U.S. domestic issuer would file with the SEC, although we are required to file or furnish to the SEC the continuous disclosure documents that we are required to file in Canada under Canadian securities laws. In addition, our officers, directors, and principal shareholders are exempt from the reporting and “short swing” profit recovery provisions of Section 16 of the Exchange Act. Therefore, our shareholders may not know on as timely a basis when our officers, directors and principal shareholders purchase or sell shares, as the reporting deadlines under the corresponding Canadian insider reporting requirements are longer.

As a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements. We are exempt from Regulation FD, which prohibits issuers from making selective disclosures of material non-public information. While we will comply with the corresponding requirements relating to proxy statements and disclosure of material non-public information under Canadian securities laws, these requirements differ from those under the Exchange Act and Regulation FD and shareholders should not expect to receive the same information at the same time as such information is provided by U.S. domestic companies. In addition, we will have more time than U.S. domestic companies after the end of each fiscal year to file our annual report with the SEC and will not be required under the Exchange Act to file quarterly reports with the SEC.

In addition, as a foreign private issuer, we have the option to follow certain Canadian corporate governance practices, except to the extent that such laws would be contrary to U.S. securities laws, and provided that we disclose the requirements we are not following and describe the Canadian practices we follow instead. We have elected to follow Canadian practices with regard to certain corporate governance matters. As a result, our shareholders may not have the same protections afforded to shareholders of U.S. domestic companies that are subject to all corporate governance requirements.

We may in the future lose our foreign private issuer status.

We may in the future lose our foreign private issuer status if a majority of our shares are held in the United States and if: (i) a majority of either our directors or executive officers, considered as separate groups, are either U.S. citizens or residents; (ii) a majority of our assets are located in the United States; or (iii) our business is administered principally in the United States. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. If we are not a foreign private issuer, we would not be eligible to use foreign issuer forms and would be required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the SEC, which are generally more detailed and extensive than the forms available to a foreign private issuer. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on the Nasdaq that are available to foreign private issuers. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer will be significantly more than the costs incurred as a Canadian foreign private issuer.

General Risks

We may not be able to obtain adequate insurance coverage in respect of the risks we and our business face, the premiums for such insurance may not continue to be commercially justifiable or there may be coverage limitations and other exclusions which may result in such insurance not being sufficient to cover potential liabilities that we face.

We currently have insurance coverage, including product liability, business interruption and property insurance, protecting many, but not all, of our assets and operations. Our insurance coverage is subject to coverage limits and exclusions and may not be available for the risks and hazards to which we are exposed. In addition, no assurance can be given that such insurance will be adequate to cover our liabilities, including potential litigation and product liability claims, or will be generally available in the future or, if available, that premiums will be commercially justifiable. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, we may be exposed to material uninsured liabilities that could impede our liquidity, profitability or solvency.

We may be subject to risks related to the protection and enforcement of our intellectual property rights, or intellectual property we licence from others, and may become subject to allegations that we or our licensors are in violation of intellectual property rights of third parties.

The ownership, licensing and protection of trademarks and other intellectual property rights are significant aspects of our future success.

It is possible that we will not be able to make non-provisional applications, register, maintain registration for or enforce all of our intellectual property, including trademarks, in all key jurisdictions. The intellectual property registration process can be expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable intellectual property applications at a reasonable cost or in a timely manner or may obtain intellectual property registrations which are invalid. Further, changes in either intellectual property laws or interpretation of intellectual property laws in Canada, and other countries may diminish the value of our intellectual property rights or narrow the scope of our intellectual property protection. As a result, our current or future intellectual property portfolio may not provide us with sufficient rights to protect our business, including our products, processes and brands.

32

Termination or limitation of the scope of any intellectual property licence may restrict or delay or eliminate our ability to develop and commercialize our products, which could adversely affect our business. We cannot guarantee that any third-party technology we licence will not be unenforceable or licensed to our competitors or used by others. In the future, we may need to obtain licences, renew existing licence agreements in place at such time or otherwise replace existing technology. We are unable to predict whether these licence agreements can be obtained or renewed, or the technology can be replaced on acceptable terms, or at all.

Unauthorized parties may attempt to replicate or otherwise obtain and use our products, brands and technology. Policing the unauthorized use of our current or future trademarks, patents or other intellectual property rights could be difficult, expensive, time consuming and unpredictable, as may be enforcing these rights against unauthorized use by others. Identifying the unauthorized use of intellectual property rights is difficult as we may be unable to effectively monitor and evaluate the products being distributed by our competitors, including parties such as unlicensed dispensaries and black-market participants, and the processes used to produce such products. In addition, in any infringement proceeding, some or all of our trademarks or other intellectual property rights or other proprietary know-how, or those we licence from others, or arrangements or agreements seeking to protect the same for our benefit, may be found invalid, unenforceable, anti-competitive or not infringed; may be interpreted narrowly; or could put existing intellectual property applications at risk of not being issued.

In addition, other parties may claim that our products, or those we licence from others, infringe on their intellectual property, including their proprietary or patent protected rights. Such claims, whether or not meritorious, may result in the expenditure of significant financial and managerial resources and legal fees, result in injunctions or temporary restraining orders or require the payment of damages. As well, we may need to obtain licences from third parties who allege that we have infringed on their lawful rights. Such licences may not be available on terms acceptable to us, or at all. In addition, we may not be able to obtain or utilize on terms that are favorable to us, or at all, licences or other rights with respect to intellectual property that we do not own. In the event that we licence our intellectual property to a third party, including a third-party manufacturer, such third party could misappropriate our intellectual property or otherwise violate the terms of our licence. If any of the foregoing events were to occur, it could have a material adverse effect on our business, results of operations and financial condition.

We also rely on certain trade secrets, technical know-how and proprietary information that are not protected by patents to maintain our competitive position. Our trade secrets, technical know-how and proprietary information, which are not protected by patents, may become known to or be independently developed by competitors.

We may be subject to risks related to our information technology systems, including the risk that we may be the subject of a cyberattack.

We have entered into agreements with third parties for hardware, software, telecommunications and other information technology (“IT”), services in connection with our operations. Our operations depend, in part, on how well we and our vendors protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism or theft. Our operations also depend on the timely maintenance, upgrade and replacement of networks, equipment and IT systems and software, as well as preemptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays or increases in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact us.

We may be subject to cyber security risks or other breaches of IT security intended to obtain unauthorized access to our proprietary information or the information of our customers and consumers, destroy data or disable, degrade, hold for ransom, or sabotage these systems through the introduction of computer viruses, fraudulent emails, cyber-attacks and other means, and such breaches could originate from a variety of sources including our own employees or unknown third parties. There can be no assurance that measures implemented to protect the integrity of these systems will provide adequate protection, and any such breach of our IT could go undetected for an extended period of time. A breach of our cyber security measures or the failure or malfunction of any of our computerized business systems, associated backup or data storage systems could cause us to suffer a disruption in one or more parts of our business and experience, including the shut-down of certain of our facilities or retail stores among other things, financial loss, a loss of business opportunities, misappropriation or unauthorized release of confidential or personal information, damage to our systems and those with whom we do business, violations of privacy and other laws, litigation, regulatory enforcement actions and penalties, indemnity obligations, remediation and restoration costs, increased costs to maintain our systems and other possible liabilities. Cyber-security breaches, ransomware attacks, or failures of our information technology systems could have a material adverse effect on our business operations, financial reporting, financial condition and results of operations, and result in reputational damage.

Risks Related to Our Common Shares

The price of our common shares in public markets has experienced and may in the future experience extreme volatility and you may lose some or all of your investment in our common shares as a result.

The price of our common shares has experienced significant volatility since the time of our listing on the Nasdaq Global Select Market, sometimes in the absence of a recent change in our financial condition or results of operations, such as our earnings, revenues, or other measure of company value, such that increases in our share price have at times been significantly inconsistent with improvement in the actual or expected indicators of the value of the Company.

33

The market price for our common shares has been and may in the future continue to be extremely volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following: (i) actual or anticipated fluctuations in our quarterly results of operations; (ii) recommendations by securities research analysts; (iii) changes in the economic performance or market valuations of other issuers that investors deem comparable to us; (iv) the addition or departure of our executive officers and other key personnel; (v) the release or expiration of lock-up or other transfer restrictions on our common shares; (vi) sales or perceived sales, or expectation of future sales, of our common shares or instruments convertible or exercisable for our common shares; (vii) significant dispositions, acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving us or our competitors; (viii) news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in our industry or target markets; (ix) trading activity by investors which is not motivated by or commensurate with changes in the actual or expected indicators of the value of our Company; (x) speculation in the press, in the investment community, or on the internet, including on online forums and social media, about our Company, our industry or our securities; (xi) anticipated or pending investigations, proceedings, or litigation that involve or affect us, other companies in our industry, or other companies that investors deem comparable to us; and (xii) the occurrence of any other risk identified in the risk factors included in our filings with the Securities and Exchange Commission or the Canadian securities regulators.

Financial markets have experienced significant price and volume fluctuations which have affected the market prices of equity securities of public entities. Companies in the cannabis sector have also experienced extreme volatility in their trading prices. In many cases, these fluctuations, and the effect that they have on market prices, have been unrelated to the operating performance, underlying asset values or prospects of such entities. For example, certain companies, including ours, have recently experienced extreme volatility and increases in share price due to trading activity by retail investors which was motivated primarily by a desire to influence the financial performance of hedge funds, rather than changes in actual or expected value of the companies subject to trading activity. Accordingly, the market price of our common shares may decline rapidly and substantially even if our operating results or prospects have not changed.

Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed not to be temporary, which may result in impairment losses to us. Furthermore, certain investors may base their investment decisions on considerations of our environmental, governance and social practices of our industry as a whole, and our performance in these areas against such institutions’ respective investment guidelines and criteria. The failure to satisfy such criteria may result in limited or no investment in our common shares by those institutions, which could materially adversely affect the trading price of our common shares. There can be no assurance that continuing fluctuations in the price and volume of equity securities will not occur and affect the trading price of our common shares.

Since we have never paid, and, for the foreseeable future, do not anticipate paying, dividends to holders of our common shares, your only means of receiving any return on an investment in our common shares may be to sell our shares for a price greater than that which you paid for them. Any of the foregoing risks may prevent you from doing so in the foreseeable future or at all, and you may lose some or all of your investment. In addition, while the daily trading volume in our common shares has recently been significant, there can be no assurance that such volume will not decline, perhaps rapidly and substantially, limiting your ability to sell our common shares and make a return on your investment on your desired timeline or at all.

The risk that you fail to resell our common shares at a price greater than you paid for them and lose some or all of your investment as a result will be further exacerbated if our shares experience a “short squeeze” and you purchase shares during a short squeeze.

Investors may purchase our common shares to hedge existing exposure in our common shares or to speculate on the price of our common shares. Speculation on the price of our common shares may involve long and short exposures. To the extent aggregate short exposure exceeds the number of our common shares available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our common shares for delivery to lenders of such common shares. Those repurchases may, in turn, dramatically increase the price of our common shares until investors with short exposure are able to purchase additional common shares to cover their short position. This phenomenon is often referred to as a “short squeeze”. A short squeeze could lead to or exacerbate volatile price movements in our common shares that are not directly correlated to the performance or prospects of our Company. Once investors purchase the shares necessary to cover their short position, our share price will likely decline rapidly and substantially relative to its levels during the short squeeze, and may not return to levels at or above those during the short squeeze for a long time or at all. As a result, if you purchase our shares during a short squeeze, you will be at an increased risk of failing to sell our shares at a price greater than what you paid for them and losing some or all of your investment. While we currently have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that we will not in the future be a target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares at a price that is significantly disconnected from the underlying value of our Company.

We may sell a substantial number of our common shares in the public market at any time. Such sales or the perception that they may occur could cause the market price of our common shares to drop significantly, even if our business is doing well.

We have in the past, and may in the future, sell a substantial number of our common shares, or securities convertible or exercisable into our common shares, in the public market at any time, without approval of existing shareholders, which we are not required to obtain under our articles of incorporation. Such sales, or the perception in the market that they may occur, could reduce the market price of our common shares rapidly and substantially. Accordingly, you may become unable to resell our shares at a price greater than

34

you paid for them for a long time or at all, and may lose some or all of your investment. The foregoing could also impair our ability to raise capital through the sale of additional equity securities.

Holders of our common shares may be subject to dilution resulting from future offerings of securities, the conversion or exercise, as applicable, of our outstanding warrants and the issuance of equity-based compensation by us.

We may raise additional funds in the future pursuant to a registration statement or otherwise, by issuing common shares, or securities exercisable or convertible into common shares, including preferred shares, warrants, rights or units comprising two or more of the foregoing securities. Holders of our common shares do not have preemptive rights in connection with such further issuances. Our board of directors has the discretion to determine if an issuance of securities is warranted, the price at which such issuance is effected and the other terms of any such future issuance. In addition, additional common shares may be issued by us in connection with the exercise of options and exchange of restricted share units (“RSUs”) and deferred share units (“DSUs”) granted by us or as part of an employee compensation plan or agreement, as well as in connection with warrants we previously issued to certain investors, which are subject to customary anti-dilution protections and certain other adjustments contained in such instruments. Such additional equity issuances have in the past, and could in the future, depending on the price at which such securities are issued, substantially dilute the interests of the holders of our common shares.

If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.

Our common shares are listed on the Nasdaq. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least US$1.00 per share. We were first notified by the Listing Qualifications Department of the Nasdaq that the closing bid price of our common shares did not meet the minimum bid price of US$1.00 per share on May 12, 2020. Subsequent to this notification, we transferred our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market in order to take advantage of an additional period of time to comply with the minimum bid price requirement, and regained compliance with the requirement on February 12, 2021.

On August 9, 2021, we were again notified by the Listing Qualifications Department of the Nasdaq that the closing bid price of our common shares for the last 30 consecutive business days from June 25, 2021 to August 6, 2021 did not meet the minimum bid price of US$1.00 per share as set forth in the minimum bid requirement. At that time, we had until February 7, 2022, to regain compliance with the minimum bid requirement. On February 8, 2022, we received a 180-day extension to regain compliance with the minimum bid requirement. As a result, we have until August 8, 2022 to regain compliance with the minimum bid requirement. If at any time prior to August 8, 2022, the closing bid price of our common stock is at least US$1.00 for a minimum of ten consecutive business days, we will be considered by Nasdaq to have regained compliance with the minimum bid requirement. There can be no assurance that this will be the case.

If we fail to regain compliance with the minimum bid price rule or fail to maintain compliance with any other applicable Nasdaq continued listing requirements, Nasdaq may determine to delist our common stock, at which time our common stock would be quoted on the over-the-counter markets. If we fail to comply with the applicable listing standards and Nasdaq delists our common shares, we and our shareholders could face significant material adverse consequences, including:

• a limited availability of market quotations for our common shares;

• reduced liquidity for our common shares;

• a determination that our common shares are “penny stock”, which would require brokers trading in our common shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common shares;

• a limited amount of news about us and analyst coverage of us; and

• a decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.

We cannot assure you that we will be able to maintain compliance with the continued listing standards of Nasdaq in the future.

Any equity securities we issue will be subordinate to our future indebtedness, if any, and any common shares we issue will be subordinate to any preferred shares we issue.

Common shares are equity interests in our Company and do not constitute indebtedness. As such, our common shares will rank junior to our future indebtedness, if any, and other non-equity claims on our Company with respect to assets available to satisfy claims on our Company, including in a liquidation of our Company. Additionally, our board of directors is authorized to issue series of preferred shares without any action on the part of shareholders of our common shares. Holders of our common shares are subject to the prior dividend, liquidation preferences, terms of redemption, conversion rights and voting rights, if any, of any holders of our preferred shares or depositary shares representing such preferred shares then outstanding.

Ownership of our common shares may be considered unlawful in some jurisdictions and holders of our common shares may consequently be subject to liability in such jurisdictions.

Cannabis-related financial transactions, including investment in the securities of cannabis companies and receipt of any associated benefits, such as dividends, are currently subject to anti-money laundering and a variety of other laws that vary by jurisdiction, many

35

of which are unsettled and still developing. While the interpretations of these laws are unclear, in some jurisdictions, financial benefit directly or indirectly arising from conduct that would be considered unlawful in such jurisdiction may be viewed to be within the purview of these laws, and persons receiving any such benefit, including investors in an applicable jurisdiction, may be subject to liability under such laws. Each prospective investor should therefore contact his, her or its own legal advisor regarding the ownership of our common shares and any related potential liability.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our share price and trading volume could decline.

The trading market for our common shares depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about our business, our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.

Our articles permit us to issue an unlimited number of common shares without additional shareholder approval.

Our articles permit the issuance of an unlimited number of common shares, and shareholders will have no pre-emptive rights in connection with such further issuance. Additional issuances of our securities may involve the issuance of a significant number of common shares at prices less than the current market price for the common shares. Issuances of substantial numbers of common shares, or the perception that such issuances could occur, may adversely affect prevailing market prices of our common shares. Any transaction involving the issuance of previously authorized but unissued common shares, or securities convertible into common shares, would result in dilution, possibly substantial, to security holders.

It is not anticipated that any dividends will be paid to holders of our common shares for the foreseeable future.

No dividends on our common shares have been paid to date. We anticipate that, for the foreseeable future, we will retain future earnings and other cash resources for the operation and development of our business. Payment of any future dividends will be at the discretion of our board of directors after taking into account many factors, including our earnings, operating results, financial condition and current and anticipated cash needs. In addition, our ability to pay cash dividends on our common shares is limited by the terms of our financing arrangements. As a result, investors may not receive any return on an investment in our common shares unless they are able to sell their shares for a price greater than that which such investors paid for them.

Our by-laws, and certain Canadian legislation, contain provisions that may have the effect of delaying or preventing a change in control.

Certain provisions of our by-laws, together or separately, could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that certain investors may be willing to pay for our common shares. For instance, our by-laws contain provisions that establish certain advance notice procedures for nomination of candidates for election as directors at shareholders’ meetings. A non-Canadian must file an application for review with the minister responsible for the Investment Canada Act (Canada) and obtain approval of the minister prior to acquiring control of a “Canadian business” within the meaning of the Investment Canada Act (Canada), where prescribed financial thresholds are exceeded. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. Otherwise, there are no limitations either under the laws of Canada or Alberta, or in our articles on the rights of non-Canadians to hold or vote our common shares. Any of these provisions may discourage a potential acquirer from proposing or completing a transaction that may have otherwise presented a premium to our shareholders.

Our by-laws provide that any derivative actions, actions relating to breach of fiduciary duties and other matters relating to our internal affairs will be required to be litigated in Canada, which could limit investors’ ability to obtain a favorable judicial forum for disputes with us.

We have adopted a forum selection by-law that provides that, unless we consent in writing to the selection of an alternative forum, the Alberta Court of Queen’s Bench of the Province of Alberta, Canada and appellate Courts therefrom (or, failing such Court, any other “court” as defined in the ABCA, having jurisdiction, and the appellate Courts therefrom), will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf; (2) any action or proceeding asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us; (3) any action or proceeding asserting a claim arising pursuant to any provision of the ABCA or our restated articles or by-laws; or (4) any action or proceeding asserting a claim otherwise related to our “affairs” (as defined in the ABCA), provided that the by-law does not apply to any action brought to enforce any liability or duty created by the Exchange Act or the Securities Act, including the respective rules and regulations promulgated thereunder, or any other claim under U.S. securities law for which the United States federal or state courts have exclusive jurisdiction. Our forum selection by-law also provides that our securityholders are deemed to have consented to personal jurisdiction in the Province of Alberta and to service of process on their counsel in any foreign action initiated in violation of our by-law. Therefore, it may not be possible for securityholders to litigate any action relating to the foregoing matters outside of the Province of Alberta.

Our forum selection by-law seeks to reduce litigation costs and increase outcome predictability by requiring derivative actions and other matters relating to our affairs to be litigated in a single forum. While forum selection clauses in corporate charters and by-laws

36

are becoming more commonplace for public companies in the United States and have been upheld by courts in certain states, they are untested in Canada. It is possible that the validity of our forum selection by-law could be challenged and that a court could rule that such by-law is inapplicable or unenforceable. If a court were to find our forum selection by-law inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions and we may not obtain the benefits of limiting jurisdiction to the courts selected.

The regulated nature of our business may impede or discourage a takeover, which could reduce the market price of our common shares.

We require and hold various government licences to operate our business, which would not necessarily continue to apply to an acquiror of our business following a change of control. In addition, our directors, officers and certain other personnel are required to obtain, and maintain, security clearances from Health Canada. These licensing and security clearance requirements could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer for our common shares, which, under certain circumstances, could reduce the market price of our common shares.

There is a significant risk that we may be treated as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. investors.

Based on the past and projected composition of our income and assets, and the valuation of our assets, including goodwill, there is a significant risk that we may be treated as a passive foreign investment company (“PFIC”), for the taxable year ending December 31, 2021, and we can make no assurances in this regard with respect to the current taxable year or any future taxable years. The determination of whether or not we are a PFIC is made on an annual basis and will depend on the composition of our income and assets, from time to time. Specifically, for any taxable year, we will be classified as a PFIC for U.S. federal income tax purposes if either: (i) 75% or more of our gross income in that taxable year is passive income, or (ii) the average percentage of our assets by value in that taxable year which produce or are held for the production of passive income is at least 50%. The calculation of the value of our assets is expected to be based, in part, on the quarterly market value of our shares, which is subject to change.

If we are or were to become a PFIC, such characterization could result in adverse U.S. federal income tax consequences to U.S. investors. For example, if we are a PFIC, U.S. investors may become subject to increased tax liabilities under U.S. federal income tax laws and regulations and will become subject to burdensome reporting requirements. U.S. Holders should consult their tax advisor concerning the U.S. federal income tax consequences of holding and disposing shares of a PFIC, including the possibility of making any election that may be available under the PFIC rules (including a mark-to-market election) which may mitigate the adverse U.S. federal income tax consequences of holding shares of a PFIC. See “Item 10E—Taxation—Certain U.S. Federal Income Tax Considerations for U.S. Persons” for more information.

The New Warrants, the 2020 Series A Warrants and the New Investor Warrants have certain terms which may impede a takeover or similar transaction, which, under certain circumstances, could reduce the market price of our common shares.

The outstanding warrants issued pursuant to a securities purchase agreement, dated June 5, 2020 (the “New Investor Warrants”), the Series A warrants issued in connection with a unit offering on August 18, 2020 (the “2020 Series A Warrants”) and the warrants issued pursuant to the warrant exercise agreement dated February 19, 2021 (the “New Warrants”) prohibit us from engaging in Fundamental Transactions (as defined in such instruments), including specified transactions related to Change of Control (as defined in such instruments), unless the successor entity assumes all of our obligations under such instruments under a written agreement in form and substance satisfactory to, and approved by, the holder thereof. These restrictions could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer for our common shares, which, under certain circumstances, could reduce the market price of our common shares.

37

Item 4. Information on the Company

A. History and development of the company.

Sundial was incorporated under the Business Corporations Act (Alberta) (the “ABCA”) on August 19, 2006. On July 22, 2019, we filed articles of amendment to effect a 1 to 1.6 share split. We have eight direct and indirect subsidiaries, all of which are wholly-owned. On August 1, 2019, our common shares commenced trading on the Nasdaq under the symbol “SNDL”.

Our headquarters, principal executive and registered offices are located at #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3. Our phone number is +1 (403) 948-5227. Our website is www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this Annual Report, and the inclusion of our website address in this Annual Report is only for reference.

We are subject to the informational requirements of the Exchange Act and are required to file reports and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that make electronic filings with the SEC using its EDGAR system.

Over the three most recently completed fiscal years and for the current fiscal year, we have undertaken and/or completed a business disposition, several business acquisitions and capital expenditures, including, among others, the following:

Business dispositions

Bridge Farm

On February 22, 2019, the Company, through its wholly owned subsidiary, Sundial UK Limited, signed a Sale and Purchase Agreement to acquire all the issued and outstanding shares of Project Seed Topco (together with its subsidiaries, “Bridge Farm”). The acquisition closed on July 2, 2019. Bridge Farm was acquired to expand the Company’s business to CBD extraction and production, subject to certain regulatory, licensing and other restrictions, to launch CBD sales in the United Kingdom. At December 31, 2019, the Company recorded a goodwill impairment based on significant delays and uncertainties in the licensing and regulatory framework in the United Kingdom. As part of the negotiations with the Company’s senior lenders regarding a December 31, 2019 covenant breach and restructuring of its credit agreements, the Company was required to enter into a definitive sale and purchase agreement related to the sale of Bridge Farm.

On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Bridge Farm to a company affiliated with the former management sellers that were parties to the original acquisition (the “Bridge Farm Purchaser”) in exchange for (i) the assumption by the Bridge Farm Purchaser of $45 million of the total $115 million principal amount outstanding under the secured credit agreement (the “Term Debt Facility”) (thereby reducing the Company’s obligations thereunder to $70 million), (ii) the assumption by the Bridge Farm Purchaser of contingent consideration liabilities related to the additional share obligation and remaining earn out obligation under the original Bridge Farm acquisition agreement dated July 2, 2019, and (iii) the cancellation of approximately 2.7 million Sundial common shares (value of $3.0 million), representing all of the shares currently held by the management sellers of Bridge Farm issued in connection with the original acquisition of Bridge Farm by the Company in 2019 (collectively, the “Bridge Farm Disposition”). The sale of Bridge Farm closed on June 5, 2020.

The Bridge Farm operations comprised the Company’s entire Ornamental Flower segment located in the United Kingdom. The Ornamental Flower segment was not previously classified as held-for-sale or as a discontinued operation as it was not highly probable that the carrying amount of the disposal group would be recovered through a sale transaction rather than through continuing use. The comparative statement of loss and comprehensive loss and statement of cash flows has been re-presented to show the discontinued operation separately from continuing operations. With the disposition of the Ornamental Flower segment, the Company no longer has multiple segments. Accordingly, the Cannabis operations in Canada comprise the entire operations of the Company.

Pathway Rx

On March 23, 2021, the Company’s equity interest in its subsidiary, Pathway, decreased from 50% to 25%, resulting in a loss of control. The Company decreased its equity interest in connection with amending the licence agreement that provides for use of Pathway’s intellectual property. The licence agreement was amended to terminate the quarterly fixed payments.

Business acquisitions

Pathway Rx

On March 13, 2019, the Company signed a share purchase agreement with Darryl Hudson, Olga Kovalchuk and Igor Kovalchuk, who was our non-executive employee, to acquire 50% of the issued and outstanding shares of Pathway Rx in consideration for an aggregate of 296,800 of our common shares. The Company subsequently reduced its interest in Pathway Rx as discussed above under “—Business Dispositions.”

38

Concurrently with the acquisition of our interest in Pathway Rx, we entered into a licence agreement (the “Pathway Rx Licence Agreement”), which granted us an exclusive right to use Pathway Rx’s intellectual property in exchange for:

• a royalty of 3% of gross revenues derived from activities which use the intellectual property that is the subject matter of the licence agreement (the “Pathway Royalty Activities”), which royalty percentage is increased to 5% of gross revenues derived from Pathway Royalty Activities upon the achievement of certain gross revenue milestones in one calendar year;

• the grant of up to 280,000 of warrants to purchase our common shares at an exercise price of $1.81 per share, subject to achievement of certain milestone gross revenues derived from the Pathway Royalty Activities;

• 50% of net revenues received by the Company from the sale of certain of the licensed products or the use of certain of the licensed intellectual property; and

• a fixed payment of $1.4 million, payable in quarterly installments of $87,500 over the first four years of the term of the Pathway Rx Licence Agreement.

The initial term of the Pathway Rx Licence Agreement is ten years, and it is automatically renewable for consecutive one year terms unless we notify Pathway Rx of the intention not to renew the agreement at least 30 days prior to the expiration of the initial term or the applicable renewal term.

Inner Spirit

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021.

The Inner Spirit Transaction consideration was comprised of:

(i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share);

(ii) an aggregate 24.4 million Sundial common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.0835 of a Sundial common share for each Inner Spirit common share); and

(iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

The acquisition of Inner Spirit has led to the establishment of a retail operations segment that comprises the sale of recreational cannabis through wholly owned and franchise retail cannabis stores. Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

Alcanna

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company will acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximately 63% equity interest in Nova Cannabis Inc. (“Nova”), a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 320.6 million Sundial common shares valued at $280.4 million based on the fair value of each common share of the Company on the closing date (8.85 of a Sundial common share for each Alcanna common share).

Due to the proximity of the closing of the Alcanna Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Capital expenditures

Olds Facility

Capital expenditures in 2021 totaled $1.4 million and mainly related to infrastructure.

Capital expenditures in 2020 totaled $2.3 million and mainly related to buildings and infrastructure. The Olds Facility is complete and fully licensed for cannabis cultivation, processing and sale by Health Canada. In addition, the Company completed and operates a 20,000 square foot processing facility.

Capital expenditures in 2019 totaled $138.1 million of which $98.8 million was spent continuing the construction and expansion of our facility in Olds, Alberta.

39

Merritt Facility

Construction of our facility in Merritt, British Columbia (the “Merritt Facility”) began in March 2019 with capital spending totaling approximately $10 million in 2019; however, has been suspended pending increases in market demand. The Merritt Facility was intended to serve as the primary production facility of the Company’s BC Weed Co. brand. Management is committed to a plan to sell the Merritt Facility and the asset is available for immediate sale, resulting in the reclassification to assets held for sale on the consolidated statement of financial position.

Capital expenditures in 2020 were a recovery of $1.2 million relating to refunds of provincial hydro and utility deposits.

There were no capital expenditures with respect to the Merritt Facility in 2021.

The amount of remaining capital expenditures at the Merritt Facility will vary depending on the scale of the facility that will be constructed. A mini-pod is expected to cost $15 million to construct, while a larger facility with extraction capabilities is expected to cost up to $30 million to complete.

Clay Lake Facilities

Following the acquisition of Bridge Farm on July 2, 2019, we incurred $27.8 million of capital expenditures primarily related to the construction and development of the second phase of the facility in Clay Lake, UK (the “Clay Lake Phase 2 Facility”).

Capital expenditures in 2020 totaled $4.4 million mainly related to the construction and development of the Clay Lake Phase 2 Facility, prior to the disposition.

The entire facility in Clay Lake, UK, was disposed of as part of the Bridge Farm Disposition (see “Business dispositions—Bridge Farm” above).

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed herewith as Exhibit 15.1 for information about significant financing transactions.

B. Business overview.

Our Company

The principal activities of the Company are (i) the production, distribution and sale of cannabis in Canada pursuant to the Cannabis Act, which regulates the production, distribution, and possession of cannabis for medical and adult recreational access in Canada, (ii) the operation and support of corporate owned and franchised retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted and (iii) the deployment of capital to investment opportunities in the global cannabis industry.

The Company’s reportable segments are organized by business line and are comprised of three reportable segments: cannabis operations, retail operations and investments. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada. Retail operations include the private sale of recreational cannabis through corporate-owned and franchised retail cannabis stores. Investments include the deployment of capital to investment opportunities in the global cannabis industry. Certain overhead expenses not directly attributable to any reportable segment are reported as “Corporate”.

Sundial is a licensed producer that grows cannabis using state-of-the-art indoor facilities with retail operations focused on the retail sale of cannabis products and accessories, and investments targeting the global cannabis industry.

Our Industry

Adult-use Cannabis

We are currently serving the adult-use cannabis industry in Canada. In October 2018, Canada became the first major industrialized nation to legalize adult-use cannabis at the federal level. On October 17, 2019, the Canadian government has amended the Cannabis Regulations and Schedules to the Cannabis Act, to permit the production and sale of cannabis edibles, extracts and topicals by holders of federal licences specific for these product classes. Products in the new classes were made available for sale to provincially or territorially authorized distributors beginning in December 2019. We expect that additional countries will also legalize adult-use cannabis, creating the opportunity for us to serve the adult-use market in those other countries in the future, although we cannot predict whether and when this will occur.

CBD

In Canada, the updated Industrial Hemp Regulations (Canada) (the “IHR”) under the Cannabis Act replaced the previous form of the Industrial Hemp Regulations (Canada) under the Controlled Drugs and Substances Act (Canada) on October 17, 2018. The regulatory scheme for industrial hemp largely remains the same; however, the IHR permits the sale of hemp to federally licensed cannabis processors under certain circumstances, and licensing requirements were softened in accordance with the perceived lower risk posed by industrial hemp. The IHR defines industrial hemp as a cannabis plant, or any part of that plant, in which the concentration of THC

40

is 0.3% by weight or less in the flowering heads and leaves. In Canada, cannabis products containing CBD are subject to the Cannabis Act and the Cannabis Regulations. Not every activity involving industrial hemp falls within the scope of the IHR. For example, the extraction of CBD or another phytocannabinoid from the flowering heads, leaves and branches of the plant falls under the Cannabis Regulations and requires a cannabis processing licence.

Furthermore, although we do not currently have plans to address the U.S. CBD market in the near term, recently adopted U.S. federal legislation has legalized hemp-derived CBD products, subject to certain conditions, including compliance with state and federal regulations.

Our Cannabis Operations

Sundial currently produces and markets cannabis products for the Canadian adult-use market. The Cannabis Act provides provincial, territorial and municipal governments with the authority to prescribe regulations regarding retail and distribution of recreational cannabis. As such, the distribution model for recreational cannabis differs from province to province. Some provinces have government-run retailers, while others have government-licensed private retailers, and some have a combination of the two. All of the Company’s sales are conducted according to the applicable provincial and territorial legislation and through applicable local agencies. The Company has established supply agreements with nine Canadian provinces and has a distribution network that covers 98% of the national recreational cannabis industry.

The Company’s primary focus in the cannabis operations segment has been on producing and distributing premium inhalable products and brands (flower, pre-rolls and vapes). Upon receiving a licence from Health Canada to sell cannabis oil products, the Company began the sale and distribution of cannabis vape products in December 2019.

The Company is currently marketing its adult-use products under its Top Leaf (Premium), Sundial Cannabis (Premium Core), Palmetto (Core) and Grasslands (Value) brands and intends to introduce new products under these brands as it expands its brand portfolio.

Sundial’s operations cultivate cannabis using an individualized “room” approach, in approximately 448,000 square feet of total available space. Sundial is headquartered in Calgary, Alberta, with operations in Olds, Alberta, and Rocky View County, Alberta.

Production and Services

Our purpose-built indoor modular grow rooms enable us to produce large volumes of cannabis in small batches. Our individual room-based cultivation format affords us several advantages compared to other growing methods, including optimized and customizable environments for each one of our strains, efficient scaling of our production capacity, higher and more predictable yields and real-time collection of cultivation data and multiple harvests per day. Different strains may have different harvest cycles and different harvest yields. Our modular cultivation rooms have been designed with the objective of improving our ability to learn, experiment and improve our cultivation process and end products. This approach also helps mitigate the risk of crop loss.

Specialized Skill and Knowledge

All aspects of the Company’s business require specialized skills and knowledge. The Company’s management is comprised of individuals with extensive experience and expertise in areas including, but not limited to, cultivation of cannabis, consumer packaged goods, product development, strategy, analytical testing and legal and regulatory compliance.

Specialized skills and knowledge are important to the Company’s success as it continues to evolve with the industry and grow its brands, and we continue to build on the skills and knowledge required within our organization to meet our goals.

Competitive conditions

The Company’s cannabis operations face enhanced competition from others who are licensed under the Cannabis Act and the various provincial and territorial regulatory regimes to participate in the adult-use cannabis industry. The Cannabis Act and the various provincial and territorial legislation have established licensing regimes for the cultivation, production, processing, testing, packaging, labelling, delivery, transportation, distribution, sale, possession and disposal of cannabis for adult use.

Pursuant to transitional provisions in the Cannabis Act, existing holders of medical cannabis licences under the Access to Cannabis for Medical Purposes Regulations have, subject to satisfying certain requirements, automatically been deemed licensed under the Cannabis Act for corresponding activities, and other individuals and corporations are now able to apply for such licences.

Subject to certain restrictions set out in the Cannabis Act, adults are permitted to cultivate, propagate, harvest and distribute up to four cannabis plants per household.

We expect that competition in the adult-use cannabis market and other cannabis markets in which we expect to participate will become more intense as current and future competitors begin to offer an increasing number of diversified products. To remain competitive, we will require a continued high level of investment in research and development, marketing, sales and client support.

41

We also face competition from the illicit cannabis market. Illegal dispensaries and ‘black market’ operations and participants, despite not having a valid licence under the Cannabis Regulations, command a significant percentage of the total market for cannabis and cannabis products in Canada.

As well, the legal landscape for medical and adult-use cannabis is changing internationally. An increasing number of jurisdictions globally are passing laws that allow for the production and distribution of medical or adult-use cannabis. Increased international competition, including competition from suppliers in other countries who may be able to produce at lower cost, and limitations placed on us by Canadian or other regulations, might lower the demand for our products on a global scale.

Components

In the cultivation process, obtaining seeds for growing cannabis must be done in accordance with the Cannabis Act. Seeds can be obtained from Health Canada, imported from a jurisdiction for medical purposes, or acquired from another Licence Holder. An authorization from Health Canada may be required to conduct such a transaction depending on its nature.

Intangible Properties

The ownership, licensing and protection of trademarks and other intellectual property rights are significant aspects of our future success. Currently we rely on trade secrets, technical know-how and proprietary information. We protect our intellectual property by seeking and obtaining registered protection where possible, developing and implementing standard operating procedures to protect trade secrets, technical know-how and proprietary information and entering into agreements with parties that have access to our inventions, trade secrets, technical know-how and proprietary information, such as our partners, collaborators, employees and consultants, to protect confidentiality and ownership. We also seek to preserve the integrity and confidentiality of our inventions, trade secrets, trademarks, technical know-how and proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems.

Economic Dependence

The Company’s supply contracts with the various Canadian provinces are a critical element of the Company’s current revenues. If any larger Canadian provinces change the material terms of such agreement or otherwise alter the supply arrangement with the Company, such a change may have a material adverse effect on the Company’s revenue. See “Risk Factors — Risks Related to Our Business — We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.”

Lending

The Company’s lending operations, including the investment policies and lending and investment restrictions are discussed in the section “Business overview — Our Investments — Lending”.

Our Retail Operations

Retail operations comprise the private sale of recreational cannabis through corporate-owned and franchised retail cannabis stores under the “Spiritleaf” retail banner. Spiritleaf aims to be the most knowledgeable and trusted source of recreational cannabis by offering a premium consumer experience and quality curated cannabis products.

Since the legalization of recreational cannabis on October 17, 2018, Inner Spirit has built a strategic portfolio of 105 corporate-owned and franchised Spiritleaf retail cannabis stores in five provinces across Canada. Sundial acquired Inner Spirit on July 20, 2021.

Spirit Leaf Corporate

The Company, through Spirit Leaf Corporate Inc. (“Spirit Leaf Corporate”), opens and operates corporate-owned Spiritleaf retail cannabis stores in strategic locations across Canada in jurisdictions where permitted.

The Company intends to continue to seek and secure leases of real estate locations for potential corporate Spiritleaf retail cannabis stores in jurisdictions where permitted.

Spirit Leaf operations

The Company, through Spirit Leaf Inc. (“Spirit Leaf”), supports a chain of franchised Spiritleaf branded retail cannabis stores in jurisdictions where permitted. The Company also intends to create house brands under the Spiritleaf banner, brand white-label cannabis products with such house brands in jurisdictions where doing so is permitted, and to sell such white-label cannabis products through its own vertical distribution network, which, if and where permitted, may include online, corporate-owned and franchised retail cannabis stores.

42

In addition, Spiritleaf operates an online business through which it sells non-cannabis products (cannabis accessories and apparel) and allows consumers to arrange for pick-up of their orders in-store and through which it plans to, in the future, sell cannabis products, where permitted. A franchise partner of Spiritleaf operates an online store in the province of Saskatchewan, through which it sells cannabis products and accessories.

Production and Services

As a retailer, the Company, through Spirit Leaf Corporate, sells cannabis products, cannabis accessories and other products permitted to be sold in accordance with applicable regulatory frameworks. As a franchisor, the Company, through Spirit Leaf, sells fixtures to franchise partners prior to them opening their Spiritleaf retail cannabis stores, and once such stores open, its sells Spiritleaf cannabis accessories to them.

In general, the Company is only authorized to sell cannabis products purchased from an authorized provincial distributor and cannabis accessories and other items prescribed by the applicable provincial regulator.

Specialized Skill and Knowledge

All aspects of the Company’s retail operations, whether it is the operation of retail cannabis stores, the sale of cannabis and cannabis accessories, the sale of franchises, the ongoing support of franchisees or otherwise, require specialized skills and knowledge. Such skills and knowledge include, among other things, knowledge on franchising, cannabis, cannabis products and accessories, retail, real estate, consumer goods, customer service and the sale of recreational cannabis in Canada.

Competitive Conditions

The private retail cannabis industry in Canada is very competitive, and the Company anticipates increased levels of competition in the industry as new participants enter the market and established retails consolidate. In anticipation of the Cannabis Act coming into effect on October 17, 2018, numerous parties sought and applied for licences to operate retail cannabis stores in jurisdictions where the private retail of cannabis was permitted. As certain jurisdictions moved to a private or semi-private market system for the retail of cannabis, and as regulators increased the aggregate number of licences available for issuance to private cannabis retailers and the pace at which such licences are issued, competition in the private retail cannabis industry continued to increase.

The principal aspects of competition include, among other things, obtaining retail cannabis store licences and regulatory approvals, the availability of cannabis products and cannabis accessories, securing optimal real estate locations and the ability to attract and retain key personnel and customers. The Company believes that its significant competitors are other entities seeking multiple retail cannabis store licences in multiple jurisdictions. It is also important to note that competition between retail cannabis stores is significantly geographical in nature, and the main competition Spiritleaf retail cannabis faces is from other retail cannabis outlets that are located in the same local geographical area and that serve the same consumer demographic.

The Company also faces competition from vertically integrated cannabis companies, existing retailers, government retailers, and the illegal market. The recent consolidation of retail companies in the market is also anticipated to increase competition in the industry, as larger consolidated companies generally have better access to capital and other necessary resources. Increased competition by numerous independent retail cannabis stores and larger competitors could materially and adversely affect the business, financial condition, and results of the Company.

In light of the strong competition in the industry, cannabis retailers are attempting to differentiate themselves from their competitors through retail cannabis store locations, their brands and their product offerings (through perceived quality, product variety and price). Retailers are using a variety of communication strategies to draw attention to these differentiators, including through social media, experiential marketing and traditional print and digital advertising, to the extent possible under the applicable regulatory frameworks.

To remain competitive, the Company and its subsidiaries will require a continued high level of investment in marketing, sales and client support. The Company believes that its product knowledge, experience operating retail outlets, and strategic partnerships with established companies in the cannabis industry, will allow it to offset some of the risks associated with any increased competition in the retail cannabis market.

The Company believes that the experience of management in both the retail and cannabis spaces has and will continue to be a competitive advantage in navigating the highly regulated marketplace.

Vertically integrated competitors

Certain competitors in the retail cannabis industry are also Licensed Producers that are able to produce the products sold at retail stores. Such companies are generally well capitalized and have an established operating history in Canada and may have significant scale and international operations. At the time of this Annual Report, vertically integrated companies are able to compete directly with the Company and its franchise partners in the Alberta and Saskatchewan markets. However, they are subject to regulatory operating restrictions in the major markets of British Columbia and Ontario that are likely to significantly limit their ability to compete directly with the Corporation and its franchise partners in those jurisdictions.

43

Existing retailers

These competitors generally have an existing business with some kind of retail footprint (in liquor sales, cannabis accessories sales, or otherwise) and have already entered or are potentially entering the private retail cannabis market as a growth opportunity. These competitors may also be well capitalized with established retail operations in Canada.

Government retailers

The Company and its franchise partners also face competition from government wholesalers that sell directly to consumers online such as the Ontario Cannabis Store in Ontario and the Alberta Gaming, Liquor and Cannabis Commission in Alberta. In British Columbia, the Company’s franchise partners face additional direct competition from the government in the form of government-owned retail stores.

Illegal market

The Company and its franchise partners face significant competition from persons continuing to operate in the illegal cannabis market in Canada. Management believes that until there is sufficient private retail coverage, methods of engaging potential customers and types of products legally available to consumers, competition from the illicit market will remain significant.

Market Consolidation

It is anticipated that as the retail cannabis industry matures, competitors in the market will consolidate or acquire smaller operators to capitalize on cost synergies and increase their market share. To date, several of the Company’s competitors have increased their retail cannabis store counts and market share through consolidations or acquisitions, or are in the process of consolidating or making acquisitions.

Intangible Properties

The Company aims to be the most knowledgeable and trusted source of recreational cannabis by offering a premium consumer experience and quality curated cannabis products. To achieve that, the Company focuses on associating its brand with high quality product selections and a customer-first experiences. The Company recognizes the importance of its retail brand on its success and its competitiveness in the retail cannabis industry, and the need to protect and enhance its value. In an effort to protect and expand its brand, the Company has applied for, or has received, Canadian trademark protections for certain of its marks. The Company has also applied for United States trademark protections for certain of its marks.

Cycles

To date, the Spiritleaf retail cannabis store network has experienced marginal seasonality, with sales increasing in the summer months from May to August, as well as during the month of December.

Economic Dependence

The Company is not substantially dependent on any individual retail cannabis store, licence, or lease, but the maintenance of our licences and authorizations issued by provincial regulators, generally, is critical to the success of our retail business.

Our Investment and Financial Services Operations

The Company’s investment and financial services operations include the deployment of capital to investment opportunities targeting the global cannabis industry.

The Company invests in cannabis related equity instruments that are traded on public stock exchanges such as the Toronto Stock Exchange or Nasdaq. The Company may also deploy capital to cannabis-related debt and hybrid instruments targeting Canadian cannabis companies. In addition, the SunStream joint venture, in which the Company has an interest, provides financing and other financial services that target the global cannabis industry.

The Company’s investment committee is responsible for evaluating investment opportunities encompassing cannabis-related equity instruments that are traded on public stock exchanges and cannabis-related debt and hybrid instruments targeting the Canadian cannabis industry.

SunStream

On March 15, 2021, the Company and SAF Group announced they had entered into an agreement to form a 50/50 joint venture through a new corporation, SunStream. SunStream is a private company which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

On December 2, 2021, SunStream IVXX Investment Corp. (“SunStream IVXX”), an affiliate of SunStream, announced that it had submitted a draft registration statement on a confidential basis to the SEC for a proposed initial public offering of its common stock.

44

SunStream IVXX will be a specialty finance company that operates as a closed-end, non-diversified management investment company that anticipates electing to be regulated as a business development company under the Investment Company Act of 1940.

In the United States, SunStream has provided lending services to cannabis businesses in the form of secured debt and hybrid debt and derivative instruments. Sundial, through its involvement in the SunStream joint venture, is classified as having indirect ancillary involvement in the U.S. marijuana industry as referenced in CSA Staff Notice 51-352, which states that ancillary involvement arises when an issuer provides goods and/or services not limited to financing, branding, recipes, leasing, consulting or administrative services to third parties who are directly involved in the U.S. marijuana industry.

Cannabis (or, as referred to in the United States, marijuana) is illegal under U.S. federal law and the enforcement of relevant U.S. laws poses a significant risk to the results of our operations and financial results. For further information about the risks related to U.S. federal laws and regulations with respect to SunStream’s operations, see “Item 3D. Risk Factors—Risks related to our investments—Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis would likely result in SunStream’s inability to execute its business plan and may subject us to significant civil or criminal liability and other adverse consequences”. The risk of federal enforcement and other risks associated with the Company’s business are described in “Item 3D—Risk Factors”.

The Company’s involvement in SunStream could have an undetermined impact on the Company’s ability to access both public and private capital.

The Company’s balance sheet exposure is limited to its equity-investment in SunStream of $412.9 million at December 31, 2021, and its share of profit of equity-accounted investees of $32.9 million for the year ended December 31, 2021.

Legal advice has been obtained by SunStream and the Company regarding applicable U.S. federal and state law in relation to SunStream’s business.

The Company is not aware of any of the businesses of recipients of SunStream services being in non-compliance with applicable licensing requirements and the regulatory framework enacted by the U.S. states in which they operate.

SunStream’s investment committee, which includes Sundial’s Chief Executive Officer, is responsible for evaluating investment and financing opportunities encompassing secured debt, hybrid securities and distressed debt and equity targeting the global cannabis industry.

Specialized Skill and Knowledge

All aspects of the Company’s investments require specialized skills and knowledge. The Company’s investment committee and SunStream’s investment committee are comprised of individuals with extensive experience and expertise in areas including, but not limited to, deal sourcing, investment management, client management, reporting and operational requirements, and cannabis operations.

Specialized skills and knowledge are important to the Company’s success as it continues to evolve its investments, and we continue to build on the skills and knowledge required within our organization to meet our financial goals.

Competitive Conditions

Since 2019, the equity capital availability to the Canadian cannabis sector has become increasingly selective and largely unobtainable for smaller licensed producers. This provides a significant opportunity to strategically invest in and consolidate smaller licensed producers with premium offerings and/or scalable intellectual property to attractive valuations.

Historically, many of the larger licensed producers were able to obtain asset-backed bank credit facilities secured by their cultivation assets. However, the slower than expected ramp up of Canadian national sales caused the banks to significantly reduce their exposure through 2019 and 2020. Bank appetite remains tepid at best for the largest licensed producers and current outstanding credit facilities generally have burdensome covenant packages despite many borrowers having net-cash positions.

The global legal cannabis market is expected to grow substantially over the next few years as public sentiment continues to drive legalization worldwide. Market growth will require an immense amount of capital at a time when regulatory hurdles have sidelined many traditional sources of capital, such as banks and private equity. This has created opportunities to generate attractive risk adjusted returns for investors in Canada, the United States and internationally.

Foreign Operations

The investments segment is dependent upon foreign operations as the majority of the investments through the SunStream joint venture are outside of Canada.

45

Investing

Policy and Objectives

General – The overall objective of the Company’s investment policy is to protect or enhance funds flow and shareholder value consistent with the Company’s business plan. The policy applies to the investment of all cash, short-term and long-term financial assets of the Company.

Return on Investment – The Company’s investment activities shall be constructed with the objective of attaining a rate of return while meeting the above objectives.

Capital Preservation – Preservation of capital is a primary objective of the Company’s investment activities. Investments shall be undertaken in a manner that seeks to ensure the preservation of capital, while managing market risk, credit risk and interest rate risk.

Liquidity – Investments shall remain sufficiently liquid in order to meet all reasonably anticipated operating capital requirements.

Standard of Care – Investments shall be made with judgement and care, under circumstances then prevailing, which persons of prudence, discretion and intelligence would exercise.

Ethics and Conflicts of Interest – Officers and employees involved with the investment process shall refrain from personal business activity that could conflict with proper execution and management of the investment program or impair their ability to make impartial investment decisions. Any such personal business activity shall require proper disclosures to the chief executive officer and chief financial officer and to the audit committee in case of a material investment.

Permitted Investment Activities

The following types of investment activities are expressly permitted subject to board of director approved investment activities and limits under which an investment activity may be conducted:

• Investments in cash

• Equity investments

• Debt investments

• Investments in shares, warrants or other equities, convertible debt securities, derivatives, swaps, options or futures

• Other investments, subject to board approval

Regulatory Framework in Canada

Background to the Cannabis Act and Regulations

On December 13, 2016, the Task Force on Cannabis Legalization and Regulation, which was established by the Canadian federal government to seek input on the design of a new system to legalize, regulate and restrict access to cannabis, published its report outlining its recommendations. On April 13, 2017, the Canadian federal government released Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, which proposed the enactment of the Cannabis Act to regulate the production, distribution and sale of cannabis for unqualified adult use.

On October 17, 2018, the Cannabis Act, together with its accompanying regulations, including the Cannabis Regulations and the IHR and, together with the Cannabis Regulations, the Regulations, came into force. The Regulations, among other things, outline the rules for the legal cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis and hemp in Canada, including the various classes of licences that can be granted, and set standards for cannabis products that became available for legal sale on October 17, 2018.

Pursuant to the regulatory framework, each province and territory in Canada is also permitted to adopt its own laws governing the distribution, sale and consumption of cannabis and cannabis accessory products within the province or territory. See “— Provincial and Territorial Regulatory Framework for Adult-Use Cannabis” below.

Given that the Cannabis Act and the Regulations were only recently enacted and are still developing, the impact of the regulatory framework on our business is uncertain. See “Risk Factors — Risks Related to Our Business and Risks Related to Our Markets and Industry”. Cannabis for adult use only recently became legal in Canada. As a result, the industry and the regulations governing the industry are rapidly developing, and if they develop in ways that differ from our expectations, our business and results of operations may be adversely impacted”.

Adult-Use Cannabis

The Cannabis Act provides a licensing and permitting scheme for the cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis for non-medicinal use (i.e., adult use), to be implemented by regulations made under the Cannabis Act.

In particular, among other things, the Cannabis Act:

46

• Restricts the amounts of cannabis that individuals can possess and distribute, public consumption and use, and prohibits the sale of cannabis unless authorized by the Cannabis Act.

• Permits individuals who are 18 years of age or older to cultivate, propagate, and harvest up to and including four cannabis plants in their dwelling-house, propagated from a seed or plant material authorized by the Cannabis Act.

• Restricts (but does not strictly prohibit) the promotion and display of cannabis, cannabis accessories and services related to cannabinoids to consumers, including restrictions on branding and a prohibition on false or misleading promotion and on sponsorships.

• Permits the informational promotion of cannabis by entities licensed to produce, sell or distribute cannabis in specified circumstances to individuals 18 years and older.

• Introduces packaging and labelling requirements for cannabis and cannabis accessories and prohibits the sale of cannabis or cannabis accessories that could be appealing to young persons.

• Provides the designated minister with the power to recall any cannabis or class of cannabis on reasonable grounds that such a recall is necessary to protect public health or public safety.

• Permits the establishment of a national cannabis tracking system.

• Provides powers to inspectors for the purpose of administering and enforcing the Cannabis Act and a system for administrative monetary penalties.

Cannabis for Medical Purposes

Effective October 17, 2018, the Cannabis Act and the Cannabis Regulations replaced the CDSA’s Access to Cannabis for Medical Purposes Regulations (Canada) (the “ACMPR”), as the governing regulations in respect of the production, sale and distribution of medical cannabis and related oil products in Canada. Transitional provisions of the Cannabis Act provide that every licence to produce and sell cannabis issued under the ACMPR that was in force immediately before the day on which the Cannabis Act came into force was deemed to be a licence issued under the Cannabis Act, and that such licence will continue in force until it is revoked or expires.

The Cannabis Regulations set out the regime for medical cannabis following legalization, which is substantively the same as the ACMPR with adjustments to create consistency with rules for non-medical use, improve patient access, and reduce the risk of abuse within the medical access system. Patients who have the authorization of their healthcare provider continue to have access to cannabis under the Cannabis Act and Cannabis Regulations, either purchased directly from a federally licensed entity under the Cannabis Act and the Cannabis Regulations, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them in the manner prescribed.

Licences, Permits and Authorizations

The Cannabis Regulations establish six classes of licences:

• licence for cultivation;

• licence for processing;

• licence for analytical testing;

• licence for sale;

• licence for research; and

• a cannabis drug licence.

The Cannabis Regulations also create sub-classes for cultivation licences (standard cultivation, micro-cultivation and nursery) and processing licences (standard processing and micro-processing). Different licences, and each sub-class therein, carry differing rules and requirements that are intended to be proportional to the public health and safety risks posed by each licence category and each sub-class. Producers holding production and sales licences under the ACMPR were transferred to similar licences under the Cannabis Act. Licences issued under the Cannabis Regulations have associated expiry dates and are subject to renewal requirements.

As of May 8, 2019, Health Canada required that new applicants for cannabis licences under the Cannabis Act have a fully built site that meets all requirements of the Cannabis Regulations at the time of their application.

Security Clearances

Certain people associated with cannabis licensees, including individuals occupying “key positions”, such as directors, officers, individuals who exercise, or are in a position to exercise, direct control over the corporation licensee, and individuals identified by the Canadian Federal Minister of Health (the “Minister of Health”), must hold a valid security clearance issued by the Minister of Health.

47

Under the Cannabis Regulations, the Minister of Health may refuse to grant security clearances to individuals with associations to organized crime or with past convictions for, or an association with, drug trafficking, corruption or violent offences. Individuals who have histories of nonviolent, lower-risk criminal activity (for example, simple possession of cannabis, or small-scale cultivation of cannabis plants) are not precluded from participating in the legal cannabis industry. However, grant of security clearance to such individuals is at the discretion of the Minister of Health and such applications will be reviewed on a case-by-case basis.

All of our directors and executive officers have obtained security clearance from Health Canada. Failure by an individual in a key operational position to maintain or renew his or her security clearance could result in a reduction or complete suspension of our operations. See “Risk Factors — Risks Related to Our Business and Risks Related to Our Markets and Industry — Our future success is dependent on our ability to attract or retain key personnel”.

Cannabis Tracking System

Under the Cannabis Act, the Minister of Health is authorized to establish and maintain a national cannabis tracking system. The purpose of this system is to track cannabis throughout the supply chain, to help prevent cannabis from being diverted to an illicit market or activity and to help prevent illicit cannabis from being a source of supply of cannabis in the legal market. Pursuant to the Ministry of Health’s Cannabis Tracking System Order, holders of a federal licence for cultivation, a licence for processing or a licence for sale for medical purposes that authorizes the possession of cannabis, must report monthly to the Minister of Health with specific information about their authorized activities with cannabis (e.g. cannabis inventory quantities), in the form and manner specified by the Minister of Health. The order also provides for monthly reporting by provincial bodies and provincially authorized private retailers of certain information in the form and manner specified by the Minister of Health.

Cannabis Products

The Cannabis Regulations set out the requirements for the sale of cannabis products at the retail level, including the THC content and serving size of cannabis products and cannabis products containing CBD. As of October 17, 2019, the Cannabis Act and the Cannabis Regulations permit the sale, subject to certain transitional periods, of only dried cannabis, fresh cannabis, edible cannabis, cannabis extracts, cannabis topicals, cannabis plants and cannabis plant seeds, each as defined in the Cannabis Act.

Prior to the coming-into-effect of the amended forms of the Cannabis Act and Cannabis Regulations, which occurred on October 17, 2019, the Cannabis Act only permitted the sale of dried cannabis, cannabis oil, fresh cannabis, cannabis plants and cannabis plant seeds. The amended forms of the Cannabis Act and Cannabis Regulations (i) remove cannabis oil from the list of permitted classes of cannabis products and (ii) authorize and regulate the production and sale of edible cannabis, cannabis extracts and cannabis topicals.

The amended forms of the Cannabis Act and Cannabis Regulations introduced restrictions on product composition specific to each of edible cannabis, cannabis extracts and cannabis topicals, including specific THC limits. Examples of other class-specific restrictions include:

• Edible cannabis: must be shelf stable; only food and food additives will be allowed to be used as ingredients in edible cannabis and the use of food additives will need to be in accordance with the limits and purposes that are prescribed for foods; must not have caffeine added, however the use of ingredients containing naturally occurring caffeine will be permitted in edible cannabis products provided that the total amount of caffeine in each immediate container does not exceed 30 milligrams; must not contain alcohol in excess of 0.5% w/w; must not contain anything that would cause the sale of the edible cannabis, if it was a food regulated under the Food and Drugs Act (Canada), to be prohibited and must not be fortified with vitamins or mineral nutrients.

• Cannabis extracts: must not contain ingredients that are sugars, sweeteners or sweetening agents, nor any ingredient listed on Column 1 of Schedule 2 to the Tobacco and Vaping Products Act (Canada) (which is a list of ingredients that are prohibited in vaping products) except if those ingredients and their levels are naturally occurring in an ingredient used to produce the extract.

• Cannabis topicals: must not contain anything that may cause injury to the health of the consumer when the product is used as intended or in a reasonably foreseeable way.

As is the case for cannabis oil, a processing licence is required in order to legally produce edible cannabis, cannabis extracts and cannabis topicals. Though a processing licence is required in order to package and label all types of cannabis products for sale to consumers. Holders of processing licences issued prior to October 17, 2019, were required to amend their processing licences before they could begin manufacturing products constituting edible cannabis, cannabis extracts or cannabis topicals. The Cannabis Regulations require the filing of a notice with Health Canada at least 60 days before releasing a new cannabis product to the market. As a result, mid-December 2019, was the earliest date that any products constituting edible cannabis, cannabis extracts or cannabis topicals could be made available for sale to consumers.

In addition, if a holder of a processing licence chooses to process edible cannabis and food products on the same site, then the production, packaging, labelling, and storage of cannabis and the production, packaging, and labelling of food products must be

48

conducted in distinctly separate portions of the holder’s licensed facility. All cannabis production is required to occur in a sufficiently separate area from any food production.

Packaging, Labeling and Advertising

The Cannabis Regulations set out requirements pertaining to the packaging and labelling of cannabis products. These requirements are intended to promote informed consumer choice and allow for the safe handling and transportation of cannabis, while also reducing the appeal of cannabis to youth. The Cannabis Regulations require all cannabis products to be packaged in a manner that is tamper-proof and child resistant.

Limits are also imposed on the use of colors, graphics, and other special characteristics of packaging. For example, all-over packaging wraps must be clear, and the interior surface and exterior surface of any container in which a cannabis product is packaged must be one uniform color. Cannabis package labels must include specific information, such as (i) product source information, including brand name, the class of cannabis and the name, phone number and email of the licensed processor or cultivator, (ii) mandatory warnings, including rotating health warning messages on Health Canada’s list of standard health warnings; (iii) the Health Canada standardized cannabis symbol; and (iv) information specifying THC and CBD content. Amendments to the Cannabis Regulations effective as of October 17, 2019, impose additional packaging and labelling requirements for all classes of cannabis production.

A cannabis product’s brand name may only be displayed once on the principal display panel or, if there are separate principal display panels for English and French, only once on each principal display panel. It can be in any font style and any size, so long as it is equal to or smaller than the health warning message. The font must not be in metallic or fluorescent color. In addition to the brand name, only one other brand element can be displayed. Such brand element must meet the same requirements as the brand name, noted above, and if an image, it must be in a size equal to or smaller than the surface area of the standardized cannabis symbol.

Promotion of cannabis is strictly regulated in Canada. For example, promotion is largely restricted to be implemented in a limited number of prescribed manners (e.g., at the point of sale) and is subject to prescribed conditions set out in the Cannabis Act and the Cannabis Regulations. Also, among other restrictions, the Cannabis Act prohibits testimonials and endorsements, lifestyle branding, depictions of a person, character or animal, whether real or fictional, and promotion that is appealing to young persons.

Health Products Containing Cannabis

Health Canada is taking a scientific, evidenced-based approach for the oversight of health products with cannabis that are approved with health claims, including prescription drugs. Under the current regulatory framework, these health products are subject to the Food and Drugs Act (Canada) and its regulations, in addition to the Cannabis Act and the Regulations. For many of these products, such as drugs, pre-market approval is required.

Drug Approval Process

Manufacturers of prescription drugs must receive authorization from Health Canada before prescription drugs may be sold. In order to obtain such authorization, a manufacturer must file a robust regulatory submission with evidence of safety, efficacy and quality of the proposed drug. As part of the approval process, Health Canada reviews the evidence submitted to ensure that the product complies with applicable safety, efficacy and quality requirements. Health Canada’s review of the evidence and a manufacturer’s response to Health Canada’s inquiries can take several years from the date that the manufacturer files its regulatory submission. A manufacturer is prohibited from marketing its product claiming to provide a health benefit, until Health Canada issues the authorization to the manufacturer for the product for the health benefit. There is no assurance that Health Canada will issue an authorization for a product. The typical regulatory process for prescription drug approval from pre-market to post-market in Canada, involves (1) pre-clinical studies, using for example, laboratory studies involving cell or tissue samples, or tests conducted on animals, to collect preliminary safety and efficacy data, (2) clinical trials on human subjects, which require authorization by Health Canada to collect further safety and efficacy data, (3) a drug submission with Health Canada, (4) drug submission review by Health Canada, (5) market authorization decision by Health Canada, and (6) post-market authorization public access to the drug product, subject to surveillance, inspection and investigation by Health Canada. In the United States, drug approval is regulated by the FDA and follows a similar process.

Import and Export Permits for Medical or Scientific Purposes

Pursuant to the Cannabis Act, import and export licences and permits will only be issued for medical or scientific purposes, or for industrial hemp. The Cannabis Regulations set out the process by which a licence holder may apply for an import or export permit for medical or scientific purposes. A permit must be obtained for each shipment of cannabis. An application for an import or export permit must contain specific information including the name and address of the holder, licence number and specifics of the particular shipment including the intended use of the cannabis and specific shipment details. The Cannabis Regulations contain reporting requirements in respect of the import and export of cannabis in reliance on a permit issued under the Cannabis Regulations.

49

Provincial and Territorial Regulatory Framework for Adult-Use Cannabis

Pursuant to the regulatory framework, each province and territory in Canada is also permitted to adopt its own laws governing the distribution, sale and consumption of adult-use cannabis and cannabis accessory products within the province or territory. As a result, provincial and territorial governments may choose to set lower maximum permitted quantities for individuals and higher age requirements. Currently, each of the Canadian provincial and territorial jurisdictions has established a minimum age of 19 years old for the consumption of adult-use cannabis, except for Québec and Alberta, where the minimum age is 21 and 18, respectively.

Retail-distribution models vary nationwide from one province and territory to another. All Canadian provinces and territories have implemented mechanisms for the distribution and sale of cannabis for adult-use purposes within their jurisdictions. Quebec, New Brunswick, Nova Scotia and Prince Edward Island have adopted government-run models for retail and distribution. Ontario, British Columbia, Alberta, Manitoba and Newfoundland have adopted hybrid models, with some aspects, including stores, distribution and online retail being government-run, (subject to certain exceptions for private online sales), while allowing for private retail. Saskatchewan has implemented a private retail system. Yukon, Northwest Territories and Nunavut have adopted a model that resembles their government-run liquor distribution model. However, New Brunswick has introduced plans to incorporate privately owned cannabis retail stores into its permitted distribution model. As the laws continue to evolve, and the distribution models mature, there is no assurance that provincial and territorial legislation enacted for the purpose of regulating adult-use cannabis will remain the same or otherwise continue to allow, or be conducive to, our business model. Differences and changes in provincial and territorial regulatory frameworks could result in, among other things, increased compliance and supply costs.

Municipal and regional governments may also choose to impose additional requirements and regulations on the sale of adult-use cannabis, adding further uncertainty and risk to our business. Municipal by-laws may restrict the number of adult-use cannabis retail outlets that are permitted in a certain geographical area, or restrict the geographical locations wherein such retail outlets may be opened. See “Risk Factors — Risks Related to Our Business and Risks Related to Our Markets and Industry — Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.”

As of the date of this Annual Report, we believe we are in compliance in all material respects with the Cannabis Act and the Regulations, and all other applicable Canadian federal and provincial laws and regulatory requirements relating to cannabis, with the exception of obtaining security clearance from Health Canada for certain of our executive officers and directors, which we are working to obtain. In addition, our directors, officers and certain other key employees are subject to security regulations due to the nature of our industry, which may make it more difficult for us to attract, develop and retain talent. See “Risk Factors — Risks Related to Our Business and Risks Related to Our Markets and Industry — Our future success is dependent on our ability to attract or retain key personnel.”

C. Organizational structure.

Below, and attached as Exhibit 8.1 to this Annual Report, is the list of our significant subsidiaries as at December 31, 2021, each of which is directly or indirectly wholly-owned by Sundial unless otherwise indicated.

Subsidiaries	Principal activity	Jurisdiction of incorporation	Equity ownership	Non-controlling interest (“NCI”)
KamCan Products Inc.	Inactive	British Columbia, Canada	100%	0%
Sundial Deutschland GmbH	Inactive	Germany	100%	0%
2657408 Ontario Inc.	Operations	Ontario, Canada	100%	0%
NGBA-BC Holdings Ltd.	Operations	British Columbia, Canada	100%	0%
Sundial Insurance (Bermuda) Ltd.	Operations	Bermuda	100%	0%
Inner Spirit Holdings Ltd.	Operations	Alberta, Canada	100%	0%
Spirit Leaf Inc.	Operations	Alberta, Canada	100%	0%
Spirit Leaf Corporate Inc.	Operations	Alberta, Canada	100%	0%
Spirit Leaf Ontario Inc.(1)	Operations	Ontario, Canada	0%	100%

50

(1) This entity may be considered to be “controlled” by the Company solely for the purposes of IFRS, but the entity is not controlled by the Company within the meaning of applicable corporate law. For the purposes of IFRS, control of this entity is determined by the Company being exposed to variable returns and having the ability to affect those returns through its power over the entity.

D. Property, plants and equipment.

Information regarding our material tangible fixed assets is as follows:

	Olds, Alberta	Rocky View, Alberta
Format	Indoor Modular	Indoor
Primary Purpose	Cultivation and Extraction	Research and Development
Capital expenditures to December 31, 2021	$183 million	$8 million
Facility Size at December 31, 2021 (Sq. Ft.)	448,000	31,000
Production Capacity at December 31, 2021	71 million grams	—
Utilized Capacity at December 31, 2021	28 million grams	—

Asset Optimization Initiatives

The Company has suspended construction of its Merritt Facility in British Columbia and is evaluating all options to maximize the value of its asset base. In January 2020, the Company entered into an agreement to sell its Kamloops, British Columbia, property for $2.1 million. The transaction closed on March 27, 2020.

On December 28, 2020, we announced a concentrates licensing agreement based out of our Rocky View Facility. Within the agreement is a non-binding purchase condition to sell the Rocky View Facility for $5.0 million.

There are no planned facility expansions at this time.

Retail Operations

All of the corporate-owned and franchised Spiritleaf retail cannabis stores are operated from leased premises. The terms of the leases may vary from location to location, but the Company and its franchise partners typically aim for a lease term of five years, with an option for at least one subsequent renewal for a further five years.

The Company has a real estate development team and custom mapping software, along with relationships and leases with most major landlords across Canada. It uses the data from over 70 operating locations to help identify variables that make for an ideal location.

Item 4A. Unresolved Staff Comments

None.

Item 5. Operating and Financial Review and Prospects

A. Operating Results

Refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1 filed herewith for a discussion of our financial condition and results of operations as of and for the year ended December 31, 2021 as compared to the year ended December 31, 2020.

A discussion of our financial condition and results of operations as of and for the year ended December 31, 2020 as compared to the year ended December 31, 2019 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed as Exhibit 15.2 to our annual report on form 20-F for the year ended December 31, 2020, filed with the SEC on March 17, 2021.

B. Liquidity and Capital Resources

For a discussion of liquidity and capital resources as of and for the year ended December 31, 2021 as compared to December 31, 2020, refer to the sections entitled “Cash Flow Summary” and “Liquidity and Capital Resources” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1

51

A discussion of liquidity and capital resources as of and for the year ended December 31, 2020 as compared to December 31, 2019, can be found in the sections entitled “Cash Flow Summary” and “Liquidity and Capital Resources” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed as Exhibit 15.2 to our annual report on form 20-F for the year ended December 31, 2020, filed with the SEC on March 17, 2021.

C. Research and Development, Patents and Licences, etc.

See “Item 4.B –Business Overview” above.

D. Trend Information

See “Item 4.B –Business Overview—Our Industry” and the section entitled “Strategy & Outlook” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

E. Off-Balance Sheet Arrangements

None.

F. Tabular Disclosure of Contractual Obligations

See the section entitled “Contractual Commitments and Contingencies” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

52

Item 6. Directors, Senior Management and Employees

A. Directors and senior management.

The following table sets forth certain information regarding our directors and executive officers as of the date of this Annual Report. The terms of office of each of our directors expires on the date of the next annual meeting of our shareholders. The business address for our directors and executive officers is c/o Sundial Growers Inc., #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3.

Name, Province or State and Country of Residence	Age	Position/Title
Zachary George Connecticut, USA	43	Chief Executive Officer and Director
James Keough Alberta, Canada	58	Chief Financial Officer
Andrew Stordeur Alberta, Canada	42	President and Chief Operating Officer
Ryan Hellard British Columbia, Canada	33	Chief Strategy Officer
Greg Mills(1) Ontario, Canada	59	Non-Executive Chairman and Director
Gregory Turnbull(1) Alberta, Canada	67	Director
Bryan Pinney(1) Alberta, Canada	69	Director
Lori Ell(1) Alberta, Canada	55	Director

(1) Independent director for the purposes of National Instrument 58-101 – Disclosure of Corporate Governance Practices (the “NI 58-101”), of the Canadian Securities Administrators and the Nasdaq Stock Market Rules (the “Nasdaq Rules”). See “—Corporate Governance—Director Independence”.

 Biographical Information Regarding Our Directors and Executive Officers

Zachary George – Chief Executive Officer and Director

Mr. George joined Sundial as director in November 2019 and was appointed Chief Executive Officer in January 2020. Mr. George has spent more than 15 years evaluating catalyst-based investment opportunities across the capital structure of North American companies with a focus on real assets. Mr. George has worked in a management capacity, including as a chief executive officer, with numerous corporate boards to turn around operations, affect corporate action and implement governance policies to maximize shareholder value.

James Keough – Chief Financial Officer

Mr. Keough joined Sundial as Chief Financial Officer in May 2018. Mr. Keough began his career with KPMG and Ernst & Young in Canada and Europe. Prior to joining Sundial, he was a tax and finance consultant as a Chartered Professional Accountant (“CPA, CA”), for two and a half years. Prior to that role, he served for 20 years as Chief Financial Officer of a diversified private company with operations in energy, real estate and hospitality. Mr. Keough holds a Bachelor of Commerce degree from the University of Calgary. He holds chartered public accountant (“CPA”), CA, and CPA (USA) designations.

Andrew Stordeur – President and Chief Operating Officer

Mr. Stordeur joined the Company as Chief Commercial Officer in March 2018 and became President – Canada in May 2019 and President and Chief Operating Officer in January 2020. From August 2011 to March 2018, Mr. Stordeur held increasingly senior sales-related positions, including Chief Sales and Customer Officer, at Molson Coors, and has also spent time at Mars Canada. Mr. Stordeur completed a Bachelor of Arts degree (sociology) at the University of Calgary and a Master of Business Administration degree at Queen’s University.

53

Ryan Hellard – Chief Strategy Officer

Mr. Hellard joined the Company as the Chief Marketing and Product Officer in March 2018 and was appointed Chief Strategy Officer on June 1, 2021. From 2012 and until joining Sundial, he held increasingly senior roles, including as President, at AppColony, an agency that develops marketing strategies and digital solutions for Canadian companies. Mr. Hellard completed a Bachelor of Commerce degree at the University of Calgary.

Greg Mills – Non-Executive Chairman and Director

Mr. Mills joined our board of directors in June 2019. Mr. Mills has 34 years of experience in capital markets, including 20 years with RBC Dominion Securities Inc. Mr. Mills has extensive leadership experience, having served as managing director of RBC Capital Markets’ Global Equities division and on RBC Capital Markets’ Spending and Global Risk committees. Mr. Mills is currently a director of RISE Life Sciences Corp. and was previously a director of RBC USA Holdco Corporation. Mr. Mills holds a Bachelor of Science degree in geology from the University of Windsor.

Gregory Turnbull – Director

Mr. Turnbull joined our board of directors in October 2018. Mr. Turnbull is a former partner in the Calgary office of McCarthy Tétrault LLP. He has worked as a lawyer since 1980, having held a variety of roles with firms including Gowlings LLP, Donahue LLP and MacKimmie Matthews. In addition to being a director of the Company, Mr. Turnbull is a director of Sleeping Giant Capital Corporation. Throughout his career, Mr. Turnbull has served as an officer or director of many other public and private companies. He is a member of the Law Society of Alberta, the Canadian Bar Association and the Calgary Bar Association. He holds a Bachelor of Arts degree (with honors) from Queen’s University and a Bachelor of Law degree from the University of Toronto. He is chair of the board of Alberta health Services and has also previously been chair of the Calgary Zoo.

Bryan D. Pinney – Director

Mr. Pinney joined our board of directors in December 2019. Mr. Pinney was a partner with Deloitte between 2002 and 2015. He served as Calgary Managing Partner from 2002 through 2007, as National Managing Partner of Audit & Assurance from 2007 to 2010, and Vice-Chair until 2015. Prior to joining Deloitte, Mr. Pinney was a partner with Andersen LLP and served as Calgary Managing Partner from 1991 through May of 2002. Mr. Pinney is currently a Board Member with TransAlta Corporation, serving on their Audit and HR Compensation Committees. He is also the lead Board Director for North American Energy Partners Inc. Previously, Mr. Pinney served as Chair of the Board of Governors of Mount Royal University and on numerous other non-profit boards. He is also a director on one private company. He is a Fellow of the Institute of Chartered Accountants, a Chartered Business Valuator and is a graduate of the Ivey Business School at the University of Western Ontario with an honours degree in Business Administration. He is also a graduate of the Canadian Institute of Corporate Directors.

Lori Ell – Director

Ms. Ell joined our board of directors in July 2021. Ms. Ell has over 25 years of broad-based executive experience working with multi-billion dollar, start up, and midmarket companies in diverse industries including food manufacturing and technology. Her most recent position is President of Growing Ideas, a business consulting practice located in Calgary, Alberta. Ms. Ell sits on the board of directors of the Sawridge Group. She is a director on two Canadian Federal Departmental Audit Committees – Crown-Indigenous Relations and Northern Affairs Canada and Indigenous Services Canada. Previously, Ms. Ell served as chair of the board of AgJunction Inc., where she previously held interim president and chief executive officer roles. Ms. Ell has also served on a number of other retail and food processing boards. From 2004 to 2012, Ms. Ell was the President of Agristar Inc., an agri-food manufacturing company. Prior thereto, Ms. Ell was Chief Financial Officer for Quortech Solutions Ltd. a technology company. Ms. Ell is a Certified Public Accountant, holds a Bachelor or Management degree and holds an ICD.D designation from the Institute of Corporate Directors.

B. Compensation.

Overview

In order to succeed in the highly competitive and evolving market in which we operate, we need to attract, retain and motivate a highly talented executive team. Our executive compensation program is designed to achieve the following objectives:

• provide compensation opportunities in order to attract and retain talented, high-performing and experienced executive officers, whose knowledge, skills and performance are critical to our success;

• motivate our executive team to achieve our strategic business and financial objectives;

• align the interests of our executive officers with those of our shareholders by tying a meaningful portion of compensation directly to the long-term value and growth of our business; and

54

• provide incentives that encourage appropriate levels of risk-taking by our executive team.

We currently offer our executive officers, including our NEOs, cash compensation in the form of base salary and annual short-term incentives that will reward participants for the achievement of pre-established corporate, team and individual goals and objectives. From time to time, our board of directors may also grant discretionary cash bonuses to our executives to reward them for exemplary performance. Long-term annual incentives may consist of stock options, performance share units (“PSUs”) and/or restricted share units (“RSUs”).

Our compensation philosophy is to motivate our employees to participate directly in the value that their efforts create for shareholders because our employees are also shareholders. We believe that equity-based compensation awards motivate our executive officers to achieve our strategic business and financial objectives, and also align their interests with the long-term interests of our shareholders.

We continue to evaluate our compensation philosophy and compensation program on an ongoing basis to ensure that we are providing competitive compensation opportunities for our executive team as a publicly traded company in this evolving industry. As part of the annual compensation review process, we expect to be guided by the philosophy and objectives outlined above, as well as other factors that may become relevant.

Base Salary

Base salary is provided as a fixed source of compensation for our executive officers. Base salaries are determined on an individual basis, taking into account the scope of the executive officer’s role, responsibilities, expertise and prior experience. Base salaries for our executive officers, including our NEOs, are expected to be reviewed annually by the board of directors and may be adjusted based on the executive officer’s success in meeting or exceeding individual objectives, as well as to maintain market competitiveness. In addition, base salaries can be adjusted by the board of directors throughout the year to reflect promotions or other changes in the scope or breadth of an executive officer’s role or responsibilities.

Short-Term Annual Cash Incentive

Our short-term annual cash incentive plan is designed to reward the achievement of pre-determined corporate, team and personal goals and objectives over the ensuing year, with the intention of aligning compensation with corporate strategies. Annual incentive targets under the plan may be set as a percentage of the relevant executive officer’s base salary and payout of the annual cash incentive (if any) are linked to the achievement of corporate, team and personal performance. In order to further increase alignment with shareholders, executives and employees also have the ability to elect to receive short-term cash incentive payments in the form of RSUs.

Long-Term Equity Incentives

Stock Option Plan and Restricted and Performance Share Unit Plan

The Sundial Growers Inc. Stock Option Plan (the “Option Plan”) and Sundial Growers Inc. Restricted and Performance Share Unit Plan (the “RSU Plan”) each provide eligible participants with compensation opportunities that will support the achievement of the Company’s performance objectives, align the interests of eligible participants with those of the Company’s shareholders, and attract, retain and motivate eligible participants critical to the long-term success of the Company and its subsidiaries.

Benefit Plans

We provide our executive officers, including our NEOs, with life, medical, dental and vision insurance programs on the same basis as other employees, or an allowance to purchase individual benefit and insurance coverage. We offer these benefits consistent with local market practice.

Perquisites

We do not offer significant perquisites as part of our compensation program.

Executive Share Ownership Guidelines

Our executive share ownership guidelines are intended to further align the interests of our executive officers with those of our shareholders. The ownership guidelines establish minimum equity ownership levels for executive officers based on a multiple of their base salary and their level of seniority. Executive officers are expected to meet the prescribed ownership levels within five years of the later of our initial offering and the date of their appointment to an executive position.

55

The following table shows the expected ownership guideline for the executive officers:

Level	Base Salary Multiple
Chief Executive Officer	3x
Other Executive Officers	2x

 Summary Compensation Table

Our named executive officers (“NEOs”) for the fiscal year ended December 31, 2021 were our Chief Executive Officer, Zachary George, Chief Financial Officer, James Keough, President and Chief Operating Officer, Andrew Stordeur, and Chief Strategy Officer Ryan Hellard. For the fiscal year ended December 31, 2021, the aggregate compensation and benefits accrued or paid to our then serving executive officers for services in all capacities was $7,256,963, and the aggregate compensation paid to each of our NEOs is set forth below:

Name and Principal Position	Year	Salary(1)	Share- Based Awards(2)	Option- Based Awards(3)	Annual Incentive Plans	All Other Compensation(4)	Total Compensation(5)
Zachary George Chief Executive Officer and Director	2021	$500,000	$4,574,520	$—	$250,000	$45,369	$5,369,889
James Keough Chief Financial Officer	2021	$321,875	$247,787	$—	$100,000	$32,869	$702,531
Andrew Stordeur President and Chief Operating Officer	2021	$400,000	$240,162	$—	$—	$46,715	$686,877
Ryan Hellard Chief Strategy Officer	2021	$250,000	$196,704	$—	$25,000	$25,962	$497,666

Notes:

(1) Represents the base salary paid in Fiscal 2021.

(2) All share-based awards were granted pursuant to the RSU Plan in the form of RSUs. The fair-value of the share-based awards shown were calculated by multiplying the total number of units granted to each NEO on the grant date by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

(3) No option-based awards were granted in Fiscal 2021.

(4) None of our NEOs are entitled to perquisites or other personal benefits which, in aggregate, are worth over $50,000 or over 10% of their base salary.

(5) All monetary amounts in this table are in CAD$ unless otherwise specified.

The table below shows the incremental payments that would be made to our NEOs under the terms of their employment agreements upon the occurrence of certain events.

Name and Principal Position	Event	Severance(1)	Option- Based Awards(2)	Other Payments(1)	Total(1)
Zachary George	Termination without cause	$1,400,000	—	$21,000	$1,421,000
Chief Executive Officer and Director	Termination and change of control	$1,400,000	—	$21,000	$1,421,000
James Keough	Termination without cause	$650,000	—	$9,750	$659,750
Chief Financial Officer	Termination and change of control	$325,000	—	$9,750	$334,750
Andrew Stordeur	Termination without cause	$800,000	—	$12,000	$812,000
President and Chief Operating Officer	Termination and change of control	$800,000	—	$12,000	$812,000
Ryan Hellard	Termination without cause	$500,000	—	$7,500	$507,500
Chief Strategy Officer	Termination and change of control	$500,000	—	$7,500	$507,500

56

Notes:

(1) Mr. George’s severance, other payments and total are in USD.

(2) All option-based awards were out-of-the money, based on the December 31, 2021 price of US$0.5780 (CAD$0.7328) per common share.

 Outstanding Option-Based Awards and Share-Based Awards

The following table sets out information on the outstanding warrants and other option-based awards held by each of our NEOs as at December 31, 2021.

Name	Number of common shares underlying unexercised option-based awards	Exercise price (USD)	Expiration date	Value of unexercised in-the- money option- based awards(1)
Zachary George Chief Executive Officer	—	$—	—	$—
James Keough Chief Financial Officer	80,000 108,000 160,000 75,000	$2.97 2.97 6.25 0.83	August 14, 2023 August 1, 2024 June 15, 2027 May 27, 2030	$— — — —
Andrew Stordeur President and Chief Operating Officer	38,400 38,400 115,200 160,000 100,000 192,000 192,000	$0.63 0.63 0.63 6.25 0.83 0.63 3.13	March 6, 2023 March 6, 2024 August 1, 2024 January 11, 2027 May 27, 2030 5 years from vest date 5 years from vest date	$— — — — — — —
Ryan Hellard Chief Strategy Officer	38,400 38,400 115,200 160,000 100,000 192,000 192,000	$0.63 0.63 0.63 6.25 0.83 0.63 3.13	March 1, 2023 March 1, 2024 August 1, 2024 January 11, 2027 May 27, 2030 5 years from vest date 5 years from vest date	$— — — — — — —

Notes:

(1) All option-based awards were out-of-the money, based on the December 31, 2021 price of US$0.5780 (CAD$0.7328) per common share.

The following table sets out information on the outstanding share-based awards held by each of our NEOs as at December 31, 2021.

Name	Number of common shares underlying unvested share-based awards	Value of share-based awards that have not vested(2)	Value of vested share-based awards not distributed(3)
Zachary George Chief Executive Officer	RSUs:4,000,000 DSUs:—	$3,049,680 —	$— 91,153
James Keough Chief Financial Officer	RSUs:241,667	$193,871	$—
Andrew Stordeur President and Chief Operating Officer	RSUs:310,000	$274,827	$—
Ryan Hellard Chief Strategy Officer	RSUs:255,334	$226,736	$—

Notes:

(1) All monetary amounts are in CAD$ unless otherwise specified.

(2) The value of the share-based awards that have not yet vested were calculated by multiplying the total number of units that have not yet vested by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

(3) The value of the share-based awards that have not been distributed were calculated by multiplying the total number of units that have not been distributed by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

57

Incentive Plan Awards – Value Expected to be Vested or Earned During the Year

The following table sets out, for each of our NEOs, the value of the option-based awards and share-based awards that vested in accordance with their terms as of December 31, 2021.

Name and Principal Position	Option-Based Awards – Value Vested During 2021(1)	Share-Based Awards – Value Vested During 2021
Zachary George Chief Executive Officer	$—	$3,708,357
James Keough Chief Financial Officer	$—	$253,320
Andrew Stordeur President and Chief Operating Officer	$—	$194,773
Ryan Hellard Chief Strategy Officer	$—	$161,166

Notes:

(1) The option-based awards held by each of our NEOs that vested during 2021, altogether were 91,666 options, were out-of-the money, based on the December 31, 2021 price of US$0.5780 (CAD$0.7328) per common share.

Employment Agreements

The Company has entered into employment agreements with each of our NEOs. The material terms of the employment agreements are discussed below.

Zachary George, Chief Executive Officer

The Company may terminate Mr. George at any time, without cause, and the Company will be required to provide him with his accrued but unpaid annual base salary, pay for accrued and unused vacation and business expenses up to the termination date (the “Accrued Obligations”), plus (i) termination notice of two years (which may be provided as pay in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) any unvested stock options or restricted share units will immediately vest on the termination date. The receipt of the separation package is conditioned on Mr. George’s execution of a release of claims.

Pursuant to Mr. George’s employment agreement, if a change of control occurs, and his employment with the Company is subsequently or contemporaneously terminated by the Company or its successor, Mr. George will be entitled to receive, within thirty (30) days after such termination, a lump sum payment equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits.

Mr. George’s employment agreement also contains a customary confidentiality covenant and certain covenants that will continue to apply following the termination of his employment, including non-competition and non-solicitation provisions which are in effect during Mr. George’s employment and for the twelve months following the termination of his employment (collectively, the “Restrictive Covenants”).

James Keough, Chief Financial Officer

The Company may terminate Mr. Keough at any time without cause and the Company will be required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), and (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Keough will immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Keough’s execution of a release of claims.

Pursuant to Mr. Keough’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Keough will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) one year of his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits.

Mr. Keough’s employment agreement also contains the Restrictive Covenants.

58

Andrew Stordeur, President and Chief Operating Officer, former President – Canada

The Company may terminate Mr. Stordeur at any time without cause and the Company will be required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) all of his outstanding performance warrants will immediately vest on the cessation date. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Stordeur will immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Stordeur’s execution of a release of claims.

Pursuant to Mr. Stordeur’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Stordeur will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits, and all of his outstanding performance warrants will immediately vest on the cessation date.

Mr. Stordeur’s employment agreement also contains the Restrictive Covenants.

Ryan Hellard, Chief Strategy Officer

The Company may terminate Mr. Hellard at any time without cause and the Company will be required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) all of his outstanding performance warrants will immediately vest on the cessation date. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Hellard will immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Hellard’s execution of a release of claims.

Pursuant to Mr. Hellard’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Hellard will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits, and all of his outstanding performance warrants will immediately vest on the cessation date.

Mr. Hellard’s employment agreement also contains the Restrictive Covenants.

Director Compensation

Our board of directors, on the recommendation of our compensation committee, is responsible for reviewing and approving any changes to the directors’ compensation arrangements. The aggregate of compensation and benefits in kind, accrued or paid to our directors in the year ended December 31, 2021 for services in all capacities was $350,546.

In consideration for serving on our board of directors, each director, other than directors who are employees of the Company (the “Excluded Directors”), is paid an annual cash retainer of $75,000. In addition, for serving during the Company’s first year as a publicly traded company, Messrs Turnbull and Mills and Ms. Cannon each received $175,000 in deferred share units at the IPO price in equal installments on September 30, 2019, December 31, 2019, March 31, 2020 and June 30, 2020. Mr, Tamkee received $43,750 in deferred share units at the IPO price prior to his resignation from the board effective December 14, 2019. Upon joining the board on November 27, 2019, and prior to him becoming our Chief Executive Officer, Mr. George became entitled to receive $350,000 during the time he serves as Chair of the Operating and Capital Committee and 250,000 deferred share units in equal installments on December 1, 2019, March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021, December 31, 2021 and March 31, 2022. Upon joining the board on December 16, 2019, Mr. Pinney was entitled to $175,000 in deferred share units payable in equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020. The number of deferred share units issuable are determined by the installment payment divided by the fair market value of our common shares on each installment date.

If a change of control occurs, all of these equity grants (except those granted to Mr. Mills and Mr. Turnbull) will immediately vest.

In addition, to reflect the additional workload required in respect of special projects performed, Mr. George was entitled to receive 500,000 warrants (subsequently amended to an entitlement to 500,000 stock options in accordance with the Option Plan, in equal installments on, March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022. The unvested portion of Mr. George’s compensation as a director in the form of stock options was cancelled for no consideration when he became Chief Executive Officer on January 29, 2020. Since becoming our Chief Executive Officer, Mr. George has not received additional compensation for his director services.

In addition, to reflect the additional workload and responsibilities of his position as Non-Executive Chairman of our board of directors, Mr. Mills was entitled to receive $600,000 during our first year as a publicly traded company in deferred share units at the IPO price in equal on September 30, 2019, December 31, 2019, March 31, 2020, and June 30, 2020 (the “IPO DSUs”). In addition,

59

Mr. Mills was issued 720,000 warrants on July 1, 2019 to purchase our common shares, with an exercise price of $6.25 per warrant. Under the terms of Mr. Mills’ director services agreement, those warrants vest in three equal annual installments in the event Mr. Mills assumes the position of Executive Chairman and will expire five years from the vesting date; however, if Mr. Mills does not assume the position of Executive Chairman by December 31, 2021, then all of such warrants will expire. In addition, if Mr. Mills were to assume the position of Executive Chairman, he would receive an annual salary of $500,000 payable quarterly in equal installments. While Mr. Mills’ director services agreement contemplates that he may assume the position of Executive Chairman as early as July 2020, upon the resignation of our former Executive Chairman, Edward Hellard, on January 29, 2020, our board of directors did not agree to nominate Mr. Mills, and Mr. Mills has not agreed to serve as our Executive Chairman as of the date of this Annual Report.

Furthermore, on July 1, 2019, Mr. Mills was issued 80,000 warrants to purchase our common shares, with an exercise price of $7.50 per warrant, which vest if, during the term of Mr. Mills’ director services agreement, the equity market capitalization value of the Company (as calculated in accordance with the agreement) exceeds $5.5 billion. These warrants expire three years following the vesting date.

In addition, on May 28, 2020, to reflect the additional workload and responsibilities of our board of directors in recognition for their contributions in the restructuring of the Company, and the closing of the following transactions: (i) the sale of Bridge Farm, (ii) a new Credit Agreement with senior lenders, (iii) the issuance of a new second lien security to SAF, and (iv) a new capital infusion of at least $10 million, Mr. Mills received 600,000 deferred share units with an aggregate value of $710,222, Mr. Turnbull received 200,000 deferred share units with an aggregate value of $236,741, Ms. Cannon received 200,000 deferred share units with an aggregate value of $236,741, and Mr. Pinney received 85,000 deferred share units with an aggregate value of $100,615. With respect to all of these deferred share units, half of each deferred share unit granted were vested as of the time of grant, and the remaining half became vested as of December 31, 2020.

In addition, on May 28, 2020, for the balance of the 2020 calendar year and each successive year until otherwise determined by our board of directors, the independent non-management directors, other than the chair of our board of directors, will receive annual cash compensation of $75,000 payable in quarterly instalments, and will receive $225,000 in compensation to be paid in the form of deferred share units. The chair of our board will receive annual cash compensation of $125,000 payable in quarterly instalments and $575,000 in compensation to be paid in the form of deferred share units. In accordance with the May 28, 2020 board resolution, Messrs. Pinney and Turnbull and Ms. Cannon each received $225,000 in deferred share units in equal instalments on June 15, 2020, September 15, 2020, December 15, 2020, March 15, 2021, and June 15, 2021. Mr. Mills received $575,000 in deferred share units in equal instalments on June 15, 2020, September 15, 2020, December 15, 2020, March 15, 2021, and June 15, 2021.

If a change of control occurs, Mr. Mills will be entitled to receive any unpaid portion of the annual cash retainer for the calendar year in which the change of control occurs and any unpaid portion of the IPO DSUs. In addition, if a change of control occurs, all outstanding warrants held by Mr. Mills and Mr. Turnbull will immediately vest.

In accordance with the May 28, 2020 board resolution, Messrs Pinney and Turnbull each received $225,000 in deferred share units and $75,000 cash compensation for the 2021 calendar year, Ms. Cannon received $225,000 in deferred share units and $75,000 cash compensation prorated for her time served on the board from January 1, 2021 to July 7, 2021, Ms. Ell received $225,000 in deferred share units and $75,000 cash compensation prorated for her time served on the board from July 7, 2021 to December 31, 2021. Mr. Mills received $575,000 in deferred share units and $125,000 cash compensation for the 2021 calendar year.

In addition, on February 16, 2021, a discretionary DSU allocation was granted. Mr. Mills received 500,000 deferred share units with an aggregate value of $1,321,944, Mr. Turnbull, Ms. Cannon, and Mr. Pinney each received 250,000 deferred share units with an aggregate value of $660,972. With respect to all of these deferred share units, half of each deferred share unit granted vested as of June 15, 2021, and the remaining half vested as of December 15, 2021.

All directors will be reimbursed for their reasonable out-of-pocket expenses incurred while serving as directors.

 Director Share Ownership Guidelines

We have director share ownership guidelines for directors (other than Excluded Directors) to further align the interests of such directors with those of our shareholders. The ownership guidelines have established minimum equity ownership levels for each of our directors, other than Excluded Directors, based on a multiple of their annual retainer. Directors subject to the ownership guidelines are expected to meet the prescribed ownership levels within five years of the later of (i) the completion of the IPO and (ii) the date of their appointment to the board of directors. Common shares and other equity-based awards will be included in determining an individual’s equity ownership value. The expected ownership guideline for these directors is three times their annual retainer.

C. Board practices.

Composition of our Board of Directors

Under our amended articles of incorporation, our board of directors consists of a minimum of one and a maximum of 15 directors as determined from time to time by the directors. Our board of directors is currently comprised of five directors, and under the ABCA, as a reporting issuer, we must have no fewer than three directors. Under the ABCA, a director may be removed with or without cause by

60

a resolution passed by a majority of the votes cast by shareholders present in person or by proxy at a meeting and who are entitled to vote. The directors are appointed at the annual general meeting of shareholders and the term of office for each of the directors expires at the time of our next annual shareholders meeting. Our articles of incorporation provide that, between annual general meetings of our shareholders, the directors may appoint one or more additional directors, but the number of additional directors may not at any time exceed one-third of the number of directors who held office at the expiration of the last meeting of our shareholders. Under the ABCA, at least one quarter of our directors must be resident Canadians as defined in the ABCA.

Majority Voting Policy

We have a majority voting policy to the effect that a nominee for election as a director of the Company who does not receive a greater number of votes “for” than votes “withheld” with respect to the election of directors by shareholders will be expected to offer to tender his or her resignation to the chairman of our board of directors promptly following the meeting of shareholders at which the director was elected. The nominating and corporate governance committee will consider such offer and make a recommendation to our board of directors about whether to accept it or not. Our board of directors will promptly accept the resignation unless it determines, in consultation with the nominating and corporate governance committee, that there are exceptional circumstances that should delay the acceptance of the resignation or justify rejecting it. Our board of directors will make its decision and announce it in a press release within 90 days following the meeting of shareholders. A director who tenders a resignation pursuant to our majority voting policy will not participate in any meeting of our board of directors or the nominating and corporate governance committee at which the resignation is considered. Our majority voting policy will not apply for contested meetings at which the number of directors nominated for election is greater than the number of seats available on the board.

Director Term Limits and Other Mechanisms of Board Renewal

Our board of directors has not adopted director term limits or other automatic mechanisms of board renewal. Rather than adopting formal term limits, mandatory age-related retirement policies and other mechanisms of board renewal, the nominating and corporate governance committee of our board of directors is developing a skills and competencies matrix for our board of directors as a whole and for individual directors. The nominating and corporate governance committee also conducts a process for the assessment of our board of directors, each committee and each director regarding his or her effectiveness and contribution and reports evaluation results to our board of directors on a regular basis.

Director Independence

Under the Nasdaq Rules, independent directors must comprise a majority of a listed company’s board of directors. For purposes of the Nasdaq Rules, an independent director means a person other than an executive officer or employee of the company who, in the opinion of the board of directors, has no relationship with the company that would interfere with the exercise of independent judgement in carrying out the responsibilities of a director. Under National Instrument 58-101 – Disclosure of Corporate Governance Practices (“NI 58-101”), a director is considered to be independent if he or she is independent within the meaning of Section 1.4 of National Instrument 52-110—Audit Committees (“NI 52-110”). Section 1.4 of NI 52-110 generally provides that a director is independent if he or she has no direct or indirect relationship with the issuer which could, in the view of the issuer’s board of directors, be reasonably expected to interfere with the exercise of the director’s independent judgement.

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, our board of directors has determined that as of December 31, 2021, Messrs. Mills, Turnbull and Pinney, and Ms. Ell, representing four of the five members of our board of directors, are “independent” as that term is defined under the Nasdaq Rules and NI 58-101. In making this determination, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director. As of December 31, 2021, Mr. George was not independent by reason of the fact that Mr. George was our Chief Executive Officer.

Certain members of our board of directors are also members of the boards of other public companies. See “—Biographical Information Regarding Our Directors and Executive Officers”. Our board of directors has not adopted a director interlock policy but is keeping informed of other public directorships held by its members.

Mandate of the Board of Directors

Our board of directors is responsible for supervising the management of our business and affairs, including providing guidance and strategic oversight to management. Our board adopted a formal mandate that includes the following:

• appointing our Chief Executive Officer;

• developing the corporate goals and objectives that our Chief Executive Officer is responsible for meeting and reviewing the performance of our Chief Executive Officer against such corporate goals and objectives;

61

• taking steps to satisfy itself as to the integrity of our Chief Executive Officer and other executive officers and that our Chief Executive Officer and other executive officers create a culture of integrity throughout the organization;

• reviewing and approving our code of conduct and reviewing and monitoring compliance with the code of conduct and our enterprise risk management processes;

• reviewing and approving management’s strategic and business plans and our financial objectives, plans and actions, including significant capital allocations and expenditures; and

• reviewing and approving material transactions not in the ordinary course of business.

Meetings of Independent Directors

Our board of directors holds regularly scheduled quarterly meetings as well as ad hoc meetings from time to time. The independent members of our board of directors also meet, as required, without the non-independent directors and members of management before or after each regularly scheduled board meeting.

A director who has a material interest in a matter before our board of directors or any committee on which he or she serves is required to disclose such interest as soon as the director becomes aware of it. In situations where a director has a material interest in a matter to be considered by our board of directors or any committee on which he or she serves, such director may be required to absent himself or herself from the meeting while discussions and voting with respect to the matter are taking place. Directors will also be required to comply with the relevant provisions of the ABCA regarding conflicts of interest.

 Position Descriptions

Our board of directors has written terms of reference for the chairman which set out his or her key responsibilities, including duties relating to determining the frequency, dates and locations of meetings and setting board of directors meeting agendas, chairing board of directors and shareholder meetings and carrying out any other or special assignments or any functions as may be requested by our board of directors or management, as appropriate.

Our board of directors has written terms of reference for each of the committee chairs which set out each of the committee chair’s key responsibilities, including duties relating to determining the frequency, dates and locations of meetings and setting committee meeting agendas, chairing committee meetings, reporting to our board of directors and carrying out any other special assignments or any functions as may be requested by our board of directors.

In addition, our board of directors, in conjunction with our Chief Executive Officer, has developed and implemented a written position description for the role of our Chief Executive Officer.

Orientation and Continuing Education

We have implemented an orientation program for new directors under which a new director will meet separately with the chairman of our board of directors, members of the senior executive team and the secretary.

The nominating and corporate governance committee is responsible for coordinating orientation and continuing director development programs relating to the committee’s mandate. The chairman of our board of directors is responsible for overseeing director continuing education designed to maintain or enhance the skills and abilities of our directors and to ensure that their knowledge and understanding of our business remains current.

Code of Conduct

We have adopted a code of conduct applicable to all of our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer, which is a “code of ethics” as defined in section 406(c) of SOX and which is a “code” under NI 58-101. The code of conduct sets out our fundamental values and standards of behavior that are expected from our directors, officers and employees with respect to all aspects of our business. The objective of the code of conduct is to provide guidelines for maintaining our integrity, reputation and honesty with a goal of honoring others’ trust in us at all times as well as to deter wrongdoing and promote (i) honest and ethical behavior and fair dealing by our directors, officers, employees, consultants and contractors, (ii) full, fair, accurate, timely and understandable disclosure in filings with the SEC and other public communications, (iii) compliance with applicable governmental rules and regulations, and (iv) accountability for adherence to the code of conduct and prompt reporting of its violations.

The full text of the code of conduct has been posted on our website at www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this Annual Report, and the inclusion of our website address in this Annual Report is only for reference. If we make any amendment to the code of conduct or grant any waiver therefrom, whether explicit or implicit, to a director or executive officer, we will disclose the nature of such amendment or waiver on our website to the extent required by, and in accordance with, the rules and regulations of the SEC and the Canadian securities regulatory authorities.

 Monitoring Compliance with the Code of Conduct

62

Our nominating and corporate governance committee is responsible for reviewing and evaluating the code of conduct at least annually and recommends any necessary or appropriate changes to our board of directors for consideration. The nominating and corporate governance committee assists our board of directors with the monitoring of compliance with the code of conduct and is responsible for considering any waivers therefrom (other than waivers applicable to members of the nominating and corporate governance committee, which are considered by the audit committee, or waivers applicable to our directors or executive officers, which are subject to review by our board of directors as a whole).

Requirement for Directors and Officers to Disclose Interest in a Contract or Transaction

In accordance with the ABCA, each director and officer must disclose the nature and extent of any interest that he or she has in a material contract or material transaction whether made or proposed with us, if the director or officer is a party to the contract or transaction, is a director or an officer or an individual acting in a similar capacity of a party to the contract or transaction or has a material interest in a party to the contract or transaction. Subject to certain limited exceptions under the ABCA, no director may vote on a resolution to approve a material contract or material transaction which is subject to such disclosure requirement.

Benefits upon Termination of Employment

The service contracts with our directors do not provide for any benefits upon termination of employment, other than a “tail” directors and officers insurance policy.

Complaint Reporting

In order to foster a climate of openness and honesty in which any concern or complaint pertaining to a suspected violation of the law, our code of conduct or any of our policies, or any unethical or questionable act or behavior, our code of conduct requires that our employees promptly report the violation or suspected violation. In order to ensure that violations or suspected violations can be reported without fear of retaliation, harassment or an adverse employment consequence, we have adopted a whistleblowing policy which contains procedures that are aimed to facilitate confidential, anonymous submissions of complaints by our directors, officers, employees and others.

Diversity

We believe that having a diverse board of directors can offer a breadth and depth of perspectives that enhance the board’s performance. We value diversity of abilities, experience, perspective, education, gender, background, race and national origin. Recommendations concerning director nominees are based on merit and past performance, as well as expected contribution to the board’s performance and, accordingly, diversity is taken into consideration. As of December 31, 2021, we had one female director, which represents 20% of our board.

We similarly believe that having a diverse and inclusive organization overall is beneficial to our success, and we are committed to diversity and inclusion at all levels of our organization to ensure that we attract, retain and promote the brightest and most talented individuals. We have recruited and selected senior management candidates that represent a diversity of business understanding, personal attributes, abilities and experience.

We do not currently have a formal policy for the representation of women on the board of directors or senior management of the company. We already take gender and other diversity representation into consideration as part of our overall recruitment and selection process. We have not adopted targets for gender or other diversity representation, in part due to the need to consider a balance of criteria for each individual appointment. We do not believe that quotas or strict rules set out in a formal policy would result in improved identification or selection of the best candidates. Quotas based on specific criteria would limit our ability to ensure that the overall composition of the board of directors and senior management meets the needs of our organization and our shareholders.

The composition of the board of directors is shaped by the selection criteria established by the nominating and corporate governance committee. This is achieved through developing an evergreen list of potential candidates for anticipated board vacancies who fit the committee’s list of evolving selection criteria, ensuring that diversity considerations are taken into account in senior management, monitoring the level of female representation on the board and in senior management positions, continuing to broaden recruiting efforts to attract and interview qualified female candidates, and committing to retention and training to ensure that our most talented employees are promoted from within our organization, all as part of our overall recruitment and selection process to fill board or senior management positions as the need arises.

Committees of the Board of Directors

We have an audit committee, a compensation committee, a nominating and corporate governance committee, and an operations and capital committee with each committee having a written charter.

63

Audit Committee

Our audit committee is comprised of Greg Mills and Lori Ell, and chaired by Bryan Pinney. Our board of directors has determined that each of Greg Mills, Lori Ell and Bryan Pinney is financially literate and meets the independence requirements for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and NI 52-110. Our board of directors has determined that Bryan Pinney is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate” within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act. For a description of the education and experience of each member of the audit committee, see “—Biographical Information Regarding Our Directors and Executive Officers”.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of the audit committee, consistent with the rules of the Nasdaq, the SEC and NI 52-110 and our audit committee reviews the charter annually. The principal purpose of our audit committee is to oversee the accounting and financial reporting processes and audits of the Company and to assist our board of directors in discharging its oversight of:

• the quality and integrity of our financial statements and related information;

• the independence, qualifications, appointment and performance of our external auditor;

• our disclosure controls and procedures, internal control over financial reporting and management’s responsibility for assessing and reporting on the effectiveness of such controls;

• our compliance with applicable legal and regulatory requirements; and

• our enterprise risk management processes.

Our audit committee is directly responsible for the appointment, retention and compensation of external auditors and for considering their independence and any potential conflicts of interest. Our audit committee has access to all of our books, records, facilities and personnel and is able to request any information about us as it may deem appropriate. It also has the authority in its sole discretion and at our expense, to retain and set the compensation of outside legal, accounting or other advisors as necessary to assist in the performance of its duties and responsibilities.

Our audit committee also reviews our policies and procedures for reviewing and approving or ratifying related-party transactions and is responsible for reviewing and approving or ratifying all related-party transactions.

Compensation Committee

Our compensation committee is comprised of Lori Ell and Bryan Pinney and is chaired by Greg Mills. Under SEC and the Nasdaq Rules, there are heightened independence standards for members of the compensation committee. Our board of directors has determined that each of Lori Ell, Bryan Pinney and Greg Mills meet this heightened standard and are also independent for purposes of NI 58-101. For a description of the background and experience of each member of our compensation committee, see “—Biographical Information Regarding Our Directors and Executive Officers”.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of the compensation committee consistent with the rules of the Nasdaq, the SEC and the guidance of the Canadian securities regulatory authorities and our compensation committee reviews the charter annually. The compensation committee’s purpose is to assist the board in its oversight of executive compensation, management development and succession, director compensation and executive compensation disclosure. The principal responsibilities and duties of the compensation committee include:

• reviewing at least annually our executive compensation plans;

 • in the absence of the Chief Executive Officer, evaluating at least once a year our Chief Executive Officer’s performance in light of the goals and objectives established by our board of directors and based on such evaluation, providing recommendations to our board of directors regarding the Chief Executive Officer’s annual compensation;

• reviewing on an annual basis the evaluation process and compensation structure for our executive officers and, in consultation with our Chief Executive Officer, reviewing the performance of the other executive officers in order to make recommendations to our board of directors with respect to the compensation for such officers; and

• reviewing and, if appropriate, recommending to our board of directors the approval of any adoption, amendment and termination of our incentive and equity-based incentive compensation plans (and the aggregate number of shares to be reserved for issuance thereunder), and overseeing their administration and discharging any duties imposed on the compensation committee by any of those plans.

Further particulars of the process by which compensation for our executive officers is and will be determined are provided under the heading “Executive Compensation”.

64

Our compensation committee also has the authority in its sole discretion and at our expense, to appoint, compensate and oversee any compensation consultant, legal counsel or other adviser, upon taking into consideration various factors which could impact such consultant’s, counsel’s or adviser’s independence.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee is comprised of Bryan Pinney and Lori Ell, and chaired by Gregory Turnbull, each of whom is independent for purposes of NI 58-101 and the Nasdaq Rules.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of our nominating and corporate governance committee. The nominating and corporate governance committee’s purpose is to assist our board of directors in:

• identifying individuals qualified to become members of our board of directors;

• selecting, or recommending that our board of directors select, director nominees for the next annual meeting of shareholders and determining the composition of our board of directors and its committees;

• developing and overseeing a process to assess our board of directors, the chairman of the board of directors, the committees of the board of directors, the chairs of the committees, individual directors and management; and

• developing and implementing our corporate governance guidelines.

In identifying new candidates for our board of directors, the nominating and corporate governance committee considers what competencies and skills our board of directors, as a whole, should possess and assess what competencies and skills each existing director possesses, considering our board of directors as a group, and the personality and other qualities of each director, as these may ultimately determine the boardroom dynamic.

It is the responsibility of the nominating and corporate governance committee to regularly evaluate the overall efficiency of our board of directors and our chairman and all board committees and their chairs. As part of its mandate, the nominating and corporate governance committee conducts the process for the assessment of our board of directors, each committee and each director regarding his, her or its effectiveness and contribution, and report evaluation results to our board of directors on a regular basis.

D. Employees.

As of December 31, 2021, we employed 580 total employees, comprised of 184 full-time employees and 396 hourly employees.

We consider relations with our employees to be good and have never experienced a work stoppage. None of our employees are represented by a labor union or subject to a collective bargaining agreement.

E. Share ownership.

See “Item 7A Major Shareholders and Related Party Transactions—Major Shareholders".

See “Item 6B Directors, Senior Management and Employees—Compensation” for information regarding option-based awards.

Item 7. Major Shareholders and Related Party Transactions

A. Major shareholders.

The following table sets forth information relating to the beneficial ownership of our shares as of April 1, 2022, by:

• each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares;

• each of our current directors;

• each of our current executive officers; and

• all the foregoing directors and executive officers as a group.

Beneficial ownership is determined in accordance with SEC rules. The information is not necessarily indicative of beneficial ownership for any other purpose. In general, under these rules a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares voting power or investment power with respect to such security. In addition, the rules include common shares issuable pursuant to the exercise of stock options, warrants or other convertible securities that are either immediately exercisable or exercisable on or before May 31, 2022, which is 60 days after April 1, 2022. These shares are deemed to be outstanding and beneficially owned by the person holding those options, warrants or other convertible securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person, except with respect to the percentage

65

ownership of all directors and executive officers as a group. The information contained in the following table is not necessarily indicative of beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial ownership of those shares. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

The percentage of common shares beneficially owned is based on 2,385,211,502 common shares outstanding as of April 1, 2022. The address for each of our directors and executive officers listed below is c/o Sundial Growers Inc., #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3.

	Common Shares Beneficially Owned
Directors and Executive Officers	Number	Percent
Zachary George	*	*
James Keough	*	*
Andrew Stordeur	*	*
Ryan Hellard	*	*
Greg Mills	*	*
Gregory Turnbull	*	*
Bryan Pinney	*	*
Lori Ell	*	*
All current directors and executive officers as a group (eight persons)(1)	*	*

*Represents beneficial ownership of less than one percent.

As of April 1, 2022, we had 614 record holders of our common shares, with 544 record holders in Canada, representing 17.83% of our outstanding common shares, 64 record holders in the United States, representing 82.17% of our outstanding common shares and six record holders in other foreign jurisdictions, representing less than one percent of our outstanding common shares.

B. Related party transactions.

In addition to the compensation arrangements discussed under “Executive Compensation”, the following is a description of the material terms of those transactions with related parties to which we are party and which we are required to disclose pursuant to the disclosure rules of the SEC.

Agreements with Directors and Officers

Indemnity Agreements

We have entered into indemnity agreements with each of our directors and officers undertaking to indemnify each of them to the fullest extent permitted by law from and against all liabilities, costs, charges and expenses incurred as a result of actions in the exercise of their duties as a director or officer.

Please see “Item 6B Directors, Senior Management and Employees—Compensation” for information regarding details on employment agreements and agreements with directors.

Registration Rights Agreement

Upon completion of the IPO, we entered into a registration rights agreement, with Edward Hellard, pursuant to which Mr. Hellard was granted certain registration rights. The registration rights terminated when Mr. Hellard’s holdings represented less than 10% of our outstanding common shares.

Equity Awards

We describe our equity awards under “Item 6B Directors, Senior Management and Employees—Compensation—Long-Term Equity Incentives”.

Interest of Management and Others in Material Transactions

On January 15, 2018, we entered into a credit agreement with 2082033 Alberta Ltd., controlled by our Executive Chairman, and subsequently amended and restated this agreement on August 16, 2018, as the Investment and Royalty Agreement. In the fiscal year

66

ended December 31, 2018, a total of $10.9 million had been invested under the Investment and Royalty Agreement in consideration for the issuance of 7,149,035 of our common shares to our Executive Chairman. In July 2019, we issued an additional 50,963 shares to our Executive Chairman in consideration for advancing the remaining funds available to be advanced under the Investment and Royalty Agreement. In addition, in July 2019, we and our Executive Chairman agreed to terminate the Investment and Royalty Agreement for aggregate consideration of 3,680,000 common shares, 480,000 share purchase warrants (each exercisable for one common share at an exercise price of $15.94 for a period of three years from the date of issue) and a cash payment of $9.5 million. Upon completion of our IPO, the purchase was completed resulting in a loss on a financial obligation of $59.6 million based on our IPO price of US$13.00 per share. The cash payment of $9.5 million was made on September 19, 2019.

Additionally, in the fiscal year ended December 31, 2018, we entered into an agreement with 2119694 Alberta Inc., a company controlled by Stanley Swiatek, who resigned as director in connection with the execution of the agreement, to repurchase a total of 9,815,701 common shares, at a weighted average price of $1.69 per common share, for total consideration of $16.5 million, $6.9 million of which was paid by granting an unsecured, subordinated promissory note accruing interest at a rate of 1% per month until repayment. As at March 31, 2019, $14,000 in interest had been accrued on the promissory note, and a balance, including accrued interest, of $6.9 million remained outstanding. The full balance outstanding was repaid in June 2019.

We had entered into a professional services agreement, dated May 8, 2017, with AppColony Inc., a company controlled by our former Executive Chairman and in which our Chief Strategy Officer was a shareholder, for marketing, brand research, development and promotional services. The agreement provided for an initial term of two years, with specific services to be performed and amounts to be charged in respect of such services to be agreed between the parties from time to time pursuant to one or more statements of work. The initial term of this agreement had expired and on July 8, 2019, we have entered into a new professional services agreement with AppColony Inc. for certain information technology project and development services to be agreed between the parties from time to time pursuant to one or more statements of work, for a total monthly retainer of $0.3 million. The term of this agreement is two years. We paid AppColony $1.1 million during the year ended December 31, 2020 and had no amounts owing at December 31, 2020. We paid AppColony Inc. $3.1 million during the year ended December 31, 2019 and owed a balance of $0.3 million at December 31, 2019 for services related to this agreement. AppColony Inc. ceased to be a related party with the resignation of our former Executive Chairman from our board of directors in April 2020.

In the fiscal year ended December 31, 2019, we paid $0.3 million for research and development services and for access and licence of certain strains of cannabis for research purposes, with a balance of $19,031 owing as at December 31, 2019, to PlantBiosis Ltd. and Inplanta Biotechnology Inc., in both of which one of our former non-executive employees, Dr. Igor Kovalchuk, maintained influence. During the year ended December 31, 2020, we paid these companies $30,000 and owed nothing for their services.

One of our directors, Gregory Turnbull, is a former partner at McCarthy Tétrault LLP, a law firm that provides legal services to the Company. We paid McCarthy Tétrault LLP $2.5 million during the year ended December 31, 2020 and owed a balance of $0.5 million at December 31, 2020, which was fully paid during 2021. We paid $3.9 million during the year ended December 31, 2019 and owed a balance of $0.4 million at December 31, 2019. McCarthy Tétrault LLP ceased to be a related party with the retirement of Gregory Turnbull from McCarthy Tétrault in December 2020.

On April 1, 2019, we entered into an employment agreement with our former Vice President, Processing, in connection with which we have also agreed to purchase certain equipment for THC and CBD extraction from the employee in consideration for $900,000 payable, at the employee’s option, in monthly installments of $100,000 beginning with July 2019, or in our shares, at a price per share equivalent to 90% of the fair market value of one share following the closing of the IPO.

In May 2019, one of our directors, Greg Mills, subscribed to our offering of senior convertible notes, in the aggregate amount of $100,000 of the total $92.3 million raised in the offering.

Except as set out above or described elsewhere in this Annual Report, there are no material interests, direct or indirect, of any of our directors or executive officers, any shareholder that beneficially owns, or controls or directs (directly or indirectly), more than 10% of any class or series of our outstanding voting securities, or any associate or affiliate of any of the foregoing persons, in any transaction within the preceding three fiscal years that has materially affected or is reasonably expected to materially affect us or any of our subsidiaries.

Indebtedness of Directors, Executive Officers and Employees

Except as set out below or described elsewhere in this Annual Report, as of the date of this Annual Report, none of our directors, executive officers, employees, former directors, former executive officers or former employees or any of our subsidiaries, and none of their respective associates, is indebted to us or any of our subsidiaries or another entity whose indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar agreement or understanding provided by us or any of our subsidiaries, except, as the case may be, for routine indebtedness as defined under applicable securities legislation.

Aggregate Indebtedness

67

(in thousands)
Purpose	To us or our Subsidiaries	To Another Entity
Share purchases	—	—
Other	—	—

We had entered into separate shareholder loan agreements to advance funds to our non-executive employees, Frank Luke Fallwell and Gregg Wigeland. These loans bear interest ranging from 0.0% to 1.5% per annum and are secured by the employees’ holdings of shares or warrants, as applicable, in the Company. They are repayable in full upon the employees’ departure, a change of control of the Company, sale of the Company or conclusion of the applicable term of the loan (which ranges from on demand to three years). As at December 31, 2019, $200,000 had been advanced under these loan agreements. During the year ended December 31, 2020, $61,250 was repaid and the balance outstanding at December 31, 2020 was $138,750. During the year ended December 31, 2021, the balance of $138,750 was settled and at December 31, 2021 there was no balance outstanding.

We have also entered into a loan agreement to advance funds to a non-executive employee, Jamie Cox. The loan of $90,000 to Jamie Cox had been repaid in the first quarter of 2019.

Overall, as at December 31, 2021, we did not owe anything to related parties, including employees, directors and corporations related to these individuals, and such parties owed nothing to us.

Indebtedness of Directors and Executive Officers under Securities Purchase and Other Programs

We had entered into shareholder loan agreements with our Former Chief Executive Officer, Torsten Kuenzlen, on February 15, 2018 and with our President and Chief Operating Officer, Andrew Stordeur, on April 6, 2018. Mr. Stordeur was entitled to a loan facility of up to $510,000 and Mr. Kuenzlen was entitled to a loan facility of up to $200,000 per year. Each of the loans bore interest at a rate of 2.5% per annum and was secured against the borrowers’ shareholdings in the Company. The loans were repayable in full upon the officers’ departure, a change of control of the Company or sale of the Company. $245,000 had been advanced to Mr. Stordeur, and $400,000 has been advanced to Mr. Kuenzlen. Prior to June 30, 2019, these loans were settled in full and were no longer outstanding.

For a description of certain other related party transactions, see note 30 to our audited consolidated financial statements for the fiscal periods ended December 31, 2021 and 2020.

Directed Share Program

As part of our IPO completed in August 2019, the underwriters had reserved for sale, at the public offering price, up to 5% of our common shares being offered in the offering to certain individuals, including certain of our officers, directors and employees, as part of a directed share program. Certain of our officers, directors and employees participated in this program and acquired shares thereunder.

C. Interests of experts and counsel.

Not applicable.

Item 8. Financial Information

A. Consolidated Statements and Other Financial Information.

The Company’s Annual Financial Statements are included beginning on page F-1 of this Annual Report.

Legal Proceedings

Securities Class Actions

In connection with our IPO, we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re Sundial Growers Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re Sundial Growers Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions assert claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally allege that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well

68

as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also includes allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021 and remains subject to such court approval. As of December 31, 2021, we have recorded a reserve in the amount of $8.9 million in respect of this matter.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. Sundial Growers Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserts claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Exchange Act, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleges that the company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

We can provide no assurance as to the outcome of such proceedings or any other litigation matter in which we are a party. In particular, securities class action lawsuits are typically costly to defend, and divert the attention of management and other resources from operations and, accordingly, even if resolved in our favor, could have a material adverse effect on our business, financial condition, results of operations and liquidity and may force us to reduce or cease operations or seek relief under the applicable bankruptcy or insolvency laws.

LP Supply Agreements

We have several supply agreements or arrangements with other licensed cannabis producers (“LP Supply Agreements”), a certain number of which provide obligations for us to deliver bulk cannabis for resale by such other producer under its own brand.

Although we do not have a supply agreement with the province of Quebec, we do have a licence to sell cannabis to licensed producers, including those based in Quebec. We have received notice of a legal proceeding commenced against us in the province of Quebec by another licensed cannabis producer, which is based in Quebec, alleging breach of an LP Supply Agreement and have filed a statement of defence. As of December 31, 2021, we have recorded a reserve in the amount of $2.6 million in respect of this matter. All litigation steps have been completed, including discoveries and our filing of a defence, and the parties are awaiting to be called by the court to schedule the trial.

Other Proceedings

Our former Vice President, Processing, has sued us for $630,000 in respect of unpaid consideration for certain equipment we have purchased from him, unpaid wages and wrongful termination. We believe we have meritorious defenses to this claim and intend to vigorously defend it, but we can provide no assurance as to the outcome of this proceeding. We have recorded a reserve in the amount of $150,000 in respect of this matter.

Zenabis filed a petition with the Supreme Court of British Columbia for a determination of the amount required to repay and terminate the Royalty. Zenabis sought the court’s determination of the correct calculation of the amount required to exercise an option to buy out the amended Royalty, which Zenabis contended was nil and Sundial asserted was $13.7 million. The court subsequently dismissed the petition and did not decide the merits of the case. Zenabis had 30 days from December 17, 2021 to file a notice of appeal in respect of the court’s findings, but they did not do so.

We have been named as a defendant in a claim commenced in the Court of Queen’s Bench of Alberta by statement of claim filed on June 17, 2021 whereby the plaintiff alleges that he was entitled to 25% ownership of Sundial and was not paid for his interest prior to our IPO. We dispute any liability to the plaintiff. We do not plan to file a statement of defence unless requested to do so.

One of our former employees commenced a claim against us for $ 425,000, plus costs and interest, in respect of wrongful termination and severance pay. We have filed a statement of defence as of November 8, 2021. The proceeding’s next stage involves the exchange of Affidavits of Records.

Sun 8 Holdings Inc. (“Sun 8”) commenced a claim against us in the Court of Queen’s Bench of Alberta by statement of claim filed on November 30, 2021 whereby Sun 8 sought judgement in the amount of $930,070.49 plus interest and costs, specific performance of certain contractual obligations it was asserted we owe Sun 8, and $100,000 for alleged breach of a duty of good faith and honest performance and corollary relief. The basis of the claim was an allegation that we failed to pay Sun 8 royalty amounts due to Sun 8,

69

and that we had not provided information required by contract. The claim has been settled in full, and the settlement is complete subject to two post-closing items that remain outstanding.

Potential Litigation Proceedings

From time to time, in addition to the litigation proceedings described above, we may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include, among other matters, commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to our securities and litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business and results of operations.

Dividend Policy

We have never paid dividends on our common shares. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. As such, we do not intend to declare or pay cash dividends on our common shares in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our earnings, operating results, financial condition and current and anticipated cash needs. Our future ability to pay cash dividends on our common shares may be limited by the terms of any then-outstanding debt or preferred securities.

B. Significant changes.

Not applicable.

Item 9. The Offer and Listing.

A. Offer and listing details.

Not applicable.

B. Plan of distribution.

Not applicable.

C. Markets.

The Company’s common shares were listed on the Nasdaq in the United States for trading in U.S. dollars since August 1, 2019 under the symbol “SNDL”.

D. Selling shareholders

Not applicable.

E. Dilution.

Not applicable.

F. Expenses of the issue.

Not applicable.

Item 10. Additional Information.

A. Share capital.

Not applicable.

B. Memorandum and articles of association.

Reference is made to the section entitled “Description of Share Capital—Other Important Provisions of our Amended Articles of Incorporation, By-Laws and the ABCA” and “Description of Share Capital—Comparison of Alberta Corporate Law and Our Articles of Incorporation and Delaware Corporate Law” in the Company’s prospectus, filed with the SEC on July 31, 2019.

70

C. Material contracts.

We have not entered into any material contracts outside the ordinary course of business other than as described elsewhere in this Annual Report or exhibits hereto.

D. Exchange controls.

There is no limitation imposed by Canadian law or by our amended articles of incorporation on the right of a non-resident to hold or vote our common shares, other than discussed below.

Competition Act

Limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition (the “Commissioner”), to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. This legislation grants the Commissioner jurisdiction, for up to one year after the acquisition has been substantially completed, to challenge this type of acquisition by seeking a remedial order, including an order to prohibit the acquisition or require divestitures, from the Canadian Competition Tribunal, which may be granted where the Competition Tribunal finds that the acquisition substantially prevents or lessens, or is likely to substantially prevent or lessen, competition.

This legislation would also require any person or persons who intend to acquire more than 20% of our voting shares or, if such person or persons already own more than 20% of our voting shares prior to the acquisition, more than 50% of our voting shares, to file a notification with the Canadian Competition Bureau if certain financial thresholds are exceeded. These financial thresholds would be exceeded if: (i) we have assets in Canada or revenues in or from Canada generated from those assets of $96 million or more (this threshold is adjusted annually); and (ii) we and the potential acquirer together have assets in Canada or revenues from sales in, from or into Canada of $400 million or more. Where a notification is required, unless an exemption is available, the legislation prohibits completion of the acquisition until the expiration of the applicable statutory waiting period, unless the Commissioner either waives or terminates such waiting period or issues an advance ruling certificate. The Commissioner’s review of a notifiable transaction for substantive competition law considerations may take longer than the statutory waiting period.

Investment Canada Act

The Investment Canada Act requires each “non-Canadian” (as defined in the Investment Canada Act) who acquires “control” of an existing “Canadian business”, to file a notification in prescribed form with the responsible federal government department or departments not later than 30 days after closing, provided the acquisition of control is not a reviewable transaction under the Investment Canada Act. Subject to certain exemptions, a transaction that is reviewable under the Investment Canada Act may not be implemented until an application for review has been filed and the responsible minister of the federal cabinet has determined that the investment is likely to be of “net benefit to Canada” taking into account certain factors set out in the Investment Canada Act. Under the Investment Canada Act, an investment in our common shares by a non-Canadian would be reviewable only if it were an investment to acquire control of us pursuant to the Investment Canada Act and our enterprise value was equal to or greater than $1.568 billion for “trade agreement investors” (which include United States or EU investors, among certain others) and $1.045 billion for other investors from World Trade Organization (“WTO”), member countries. Lower financial thresholds apply to state-owned or influenced enterprises and non-WTO investors. These thresholds are adjusted annually.

Under the national security review regime in the Investment Canada Act, review on a discretionary basis may also be undertaken by the federal government in respect to a much broader range of investments by a non-Canadian to “acquire, in whole or part, or to establish an entity carrying on all or any part of its operations in Canada.” No financial threshold applies to a national security review. The relevant test is whether such investment by a non-Canadian could be “injurious to national security.” The responsible ministers have broad discretion to determine whether an investor is a non-Canadian and therefore subject to national security review. Review on national security grounds is at the discretion of the responsible ministers and may occur on a pre- or post-closing basis.

Other

There is no law, governmental decree or regulation in Canada that restricts the export or import of capital, or which would affect the remittance of dividends or other payments by us to non-resident holders of our common shares, other than withholding tax requirements.

E. Taxation.

Certain U.S. Federal Income Tax Considerations for U.S. Persons

The following is a general discussion of the principal U.S. federal income tax consequences of the acquisition, ownership and disposition of our common shares that are generally applicable to a U.S. Holder, as defined below. This summary assumes that the common shares are held as capital assets (generally, property held for investment), within the meaning of the U.S. Internal Revenue

71

Code of 1986, as amended (the “Code”), in the hands of a U.S. Holder at all relevant times. This discussion is based on the Code, final, temporary and proposed Treasury regulations thereunder (the “Treasury Regulations”) pertinent judicial decisions, interpretive rulings of the U.S. Internal Revenue Service (the “IRS”), and such other authorities as we have considered relevant. Future legislative, judicial, or administrative modifications, revocations, or interpretations, which may or may not be retroactive, may result in U.S. federal income tax consequences significantly different from those discussed herein. This discussion is not binding on the IRS. No ruling has been or will be sought or obtained from the IRS with respect to any of the U.S. federal tax consequences discussed herein. There can be no assurance that the IRS will not challenge any of the conclusions described herein or that a U.S. court will not sustain such a challenge.

This discussion does not address the U.S. federal income tax consequences to U.S. Holders subject to special rules, including U.S. Holders that (i) are banks, financial institutions, or insurance companies, (ii) are regulated investment companies or real estate investment trusts, (iii) are brokers, dealers, or traders in securities or currencies, (iv) are tax-exempt organizations, (v) are governments or agencies or instrumentalities thereof, (vi) elect to mark their securities to market, (vii) hold the common shares as part of hedges, straddles, constructive sales, conversion transactions, or other integrated investments, (ix) acquire the common shares as compensation for services or through the exercise or cancellation of employee stock options or warrants, (x) have a functional currency other than the U.S. dollar, (xi) own or have owned directly, indirectly, or constructively, shares of the Company representing 10% or more of the voting power or value of the Company, or (xii) are subject to the alternative minimum tax.

In addition, this discussion does not address tax considerations relevant to U.S. Holders under any non-U.S., state or local tax laws, the Medicare tax on net investment income, U.S. federal estate, gift tax, or other non-income tax, or the alternative minimum tax. Each U.S. Holder is urged to consult its tax advisors regarding the U.S. federal, state, local, and non-U.S. income and other tax considerations of an investment in the common shares.

As used herein, “U.S. Holder” means a beneficial owner of common shares that is (i) an individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation (or other entity taxable as a corporation for U.S. federal tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source, or (iv) a trust that (a) is subject to the primary supervision of a court within the United States and for which one or more U.S. persons have authority to control all substantial decisions or (b) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

If a pass-through entity, including a partnership or other entity taxable as a partnership for U.S. federal income tax purposes, holds common shares, the U.S. federal income tax treatment of an owner or partner generally will depend on the status of such owner or partner and on the activities of the pass-through entity. A U.S. person that is an owner or partner of a pass-through entity holding the common shares is urged to consult its own tax advisor.

PFIC Rules

A non-U.S. corporation, such as the Company, will be classified as a PFIC for U.S. federal income tax purposes for a taxable year, if either (a) 75% or more of the gross income of the Company consists of certain types of passive income (which we refer to as the “income test”) or (b) 50% or more of the value of the Company’s assets either produce passive income or are held for the production of passive income. The value of the Company’s assets for this purpose is expected to be based, in part, on the quarterly average of the fair market value of such assets (which we refer to as the “asset test”). “Gross income” generally includes all sales revenues less the cost of goods sold. “Passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions, but does not include active business gains arising from the sale of certain commodities.

For purposes of the PFIC income test and asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and asset test described above, and assuming certain other requirements are met, “passive income” does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain “related persons” (as defined in the Code), to the extent such items are properly allocable to the income of such related person that is not passive income.

There is a significant risk that the Company may be classified as a PFIC for the tax year ending December 31, 2021. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, the Company’s PFIC status for the current year and future years cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any PFIC determination made by the Company. Each U.S. Holder should consult its own tax advisor regarding the Company’s status as a PFIC and the PFIC status of each non-U.S. subsidiary of the Company.

72

In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.

If the Company is a PFIC in 2021 or any other year in which a U.S. Holder owns common shares, the U.S. federal income tax consequences to a U.S. Holder of the purchase of common shares and the acquisition, ownership, and disposition of common shares will depend on whether such U.S. Holder makes a “qualified electing fund” or “QEF” election under Section 1295 of the Code (a “QEF Election”) or makes a mark-to-market election under Section 1296 of the Code (a “Mark-to-Market Election”) with respect to common shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election (a “Non-Electing U.S. Holder”) will be subject to certain adverse tax treatment described below.

A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code with respect to (a) any gain recognized on the sale or other taxable disposition of common shares and (b) any excess distribution received on the common shares. A distribution generally will be an “excess distribution” to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder’s holding period for the common shares, if shorter).

Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of common shares of a PFIC, and any excess distribution received on such common shares (or a distribution by a subsidiary PFIC to its shareholder that is deemed to be received by a U.S. Holder) must be ratably allocated to each day in a Non-Electing U.S. Holder’s holding period for the common shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferential tax rates, as discussed below). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible.

If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds common shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. If the Company ceases to be a PFIC, a Non-Electing U.S. Holder may terminate this deemed PFIC status with respect to common shares by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code as discussed above) as if such common shares were sold on the last day of the last tax year for which the Company was a PFIC.

Mark-to-Market Election

A U.S. Holder may make a Mark-to-Market Election with respect to common shares only if the common shares are marketable stock. The common shares generally will be “marketable stock” if the common shares are regularly traded on a national securities exchange that is registered with the SEC (including the Nasdaq). If such stock is traded on such a qualified exchange or other market, such stock generally will be considered “regularly traded” for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the common shares are “regularly traded” as described in the preceding sentence, the common shares are expected to be marketable stock. We believe that the Company’s common shares were “regularly traded” in each quarter of 2021 and expect that the common shares should continue to be “regularly traded” in 2022. However, there can be no assurance that the common shares will be “regularly traded” in the current or any subsequent calendar quarters. U.S. Holders should consult their own tax advisors regarding the marketable stock rules.

A U.S. Holder that makes a Mark-to-Market Election with respect to its common shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such common shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder’s holding period for the common shares and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the common shares.

A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares, as of the close of such tax year over (b) such U.S. Holder’s tax basis in the common shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (i) such U.S. Holder’s adjusted tax basis in the common shares, over (ii) the fair market value of such common shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).

A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder’s tax basis in the common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of common shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary

73

income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).

A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed U.S. federal income tax return (taking into account any extensions to file such U.S. federal income tax return). A timely Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the common shares cease to be “marketable stock” or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election.

Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the common shares, no such election may be made with respect to the stock of any subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to eliminate the interest charge and other income inclusion rules described above with respect to deemed dispositions of subsidiary PFIC stock or distributions from a subsidiary PFIC to its shareholder.

QEF Election

A U.S. Holder that makes a QEF Election for the first tax year in which the Company is treated as a PFIC generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its common shares. However, a U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such U.S. Holder’s pro rata share of (a) the Company’s net capital gain, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the Company’s ordinary earnings, which will be taxed as ordinary income to such U.S. Holder. Generally, “net capital gain” is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and “ordinary earnings” are the excess of (a) “earnings and profits” over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as “personal interest,” which is not deductible.

A U.S. Holder that makes a timely QEF Election generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents “earnings and profits” that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder’s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of common shares.

The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as “timely” for purposes of avoiding the default PFIC rules discussed above if such QEF Election is made for the first year in the U.S. Holder’s holding period for the common shares in which the Company is a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year (taking into account any extensions to file such U.S. federal income tax return). If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the subsidiary PFIC for the QEF rules to apply to both PFICs.

A QEF Election will apply to the tax year for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which we were not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.

U.S. Holders should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Holders with a PFIC Annual Information Statement or other information that such U.S. Holders are required to report under the QEF rules, in the event that we are a PFIC. Thus, U.S. Holders may not be able to make a QEF Election with respect to their common shares. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.

A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed U.S. federal income tax return. However, if the Company does not provide the required information, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.

74

Distributions on the Common Shares

Subject to the PFIC rules discussed above, the gross amount of any distribution paid by the Company will generally be subject to U.S. federal income tax as foreign source dividend income to the extent paid out of the Company’s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such amount will be includable in gross income by a U.S. Holder as ordinary income on the date that such U.S. Holder actually or constructively receives the distribution in accordance with such holder’s regular method of accounting for U.S. federal income tax purposes. The amount of any distribution made by the Company in property other than cash will be the fair market value (determined in U.S. dollars) of such property on the date of the distribution. Because the Company does not intend to calculate its earnings and profits on the basis of U.S. federal income tax principles, any distribution paid will generally be treated as a dividend for U.S. federal income tax purposes. Dividends paid by the Company will not be eligible for the dividends received deduction allowed to corporations.

To the extent that a distribution exceeds the amount of the Company’s current and accumulated earnings and profits, as determined under U.S. federal income tax principles, such distribution will be treated first as a tax-free return of capital, causing a reduction in a U.S. Holder’s adjusted basis in the common shares held by such U.S. Holder (thereby increasing the amount of gain, or decreasing the amount of loss, to be recognized by such U.S. Holder upon a subsequent disposition of the common shares), with any amount that exceeds such U.S. Holder’s adjusted basis being taxed as a capital gain recognized on a sale or exchange (as discussed below).

So long as the common shares are listed on the Nasdaq or the Company is eligible for benefits under the Income Tax Convention between the U.S. and Canada, dividends that a U.S. Holder receives from the Company will be “qualified dividend income” if certain holding period and other requirements (including a requirement that the Company is not a PFIC in the year of the dividend or the immediately preceding year) are met. Qualified dividend income of an individual or other non-corporate U.S. Holder is subject to a reduced maximum U.S. federal income tax rate. However, if the Company is a PFIC in the year of the dividend or was a PFIC in the immediately preceding year, distributions on the common shares will not constitute “qualified dividend income” eligible for the preferential tax rates described above.

Subject to certain limitations, Canadian tax withheld with respect to distributions made on the common shares may be treated as foreign taxes eligible for credit against a U.S. Holder’s U.S. federal income tax liability. Alternatively, a U.S. Holder may, subject to applicable limitations, elect to deduct the otherwise creditable Canadian withholding taxes for U.S. federal income tax purposes. The rules governing the foreign tax credit are complex and involve the application of rules that depend upon a U.S. Holder’s particular circumstances. Accordingly, a U.S. Holder is urged to consult its tax advisor regarding the availability of the foreign tax credit under its particular circumstances.

Sale, Exchange or Other Taxable Disposition of the Common Shares

Subject to the PFIC rules discussed above, a U.S. Holder generally will recognize gain or loss upon the taxable sale, exchange or other disposition of the common shares in an amount equal to the difference between (i) the U.S. dollar value of the amount realized upon the sale, exchange or other taxable disposition and (ii) such U.S. Holder’s adjusted tax basis in the common shares. A U.S. Holder’s adjusted tax basis in such common shares will generally be its U.S. dollar cost. Generally, such gain or loss will be capital gain or loss and will be long-term capital gain or loss if, on the date of the sale, exchange or other taxable disposition, such U.S. Holder has held the common shares for more than one year. If such U.S. Holder is an individual or other non-corporate U.S. Holder, long-term capital gains will be subject to a reduced maximum U.S. federal income tax rate. The deductibility of capital losses is subject to limitations under the Code. Gain or loss, if any, that a U.S. Holder realizes upon a sale, exchange or other taxable disposition of the common shares generally will be treated as having a U.S. source for U.S. foreign tax credit limitation purposes.

Receipt of Foreign Currency

The U.S. dollar value of any cash distribution made in Canadian dollars to a U.S. Holder will be calculated by reference to the exchange rate prevailing on the date of actual or constructive receipt of the distribution, regardless of whether the Canadian dollars are converted into U.S. dollars at that time. For U.S. Holders following the accrual method of accounting, the amount realized on a disposition of the common shares for an amount in Canadian dollars will be the U.S. dollar value of this amount on the date of disposition. On the settlement date, such U.S. Holder will recognize U.S. source foreign currency gain or loss (taxable as ordinary income or loss) equal to the difference (if any) between the U.S. dollar value of the amount received based on the exchange rates in effect on the date of sale or other disposition and the settlement date. However, in the case of shares traded on an established securities market that are sold by a cash method U.S. Holder (or an accrual method U.S. Holder that so elects), the amount realized will be based on the spot rate in effect on the settlement date for the disposition, and no exchange gain or loss will be recognized at that time. A U.S. Holder will generally have a basis in Canadian dollars equal to their U.S. dollar value on the date of receipt of such distribution, on the date of disposition, or, in the case of cash method U.S. Holders (and accrual method U.S. Holders that so elects), on the date of settlement. Any U.S. Holder that receives payment in Canadian dollars and converts or disposes of the Canadian dollars after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss and that generally will be U.S. source income or loss for foreign tax credit purposes. U.S. Holders are urged to consult their own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of Canadian dollars.

75

Information with Respect to Foreign Financial Assets

Individuals and certain entities that own “specified foreign financial assets,” generally with an aggregate value in excess of $50,000 are generally required to file an information report on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to such assets with their tax returns for each year in which they hold shares. “Specified foreign financial assets” include any financial accounts maintained by certain foreign financial institutions, as well as securities issued by non-U.S. persons if they are not held in accounts maintained by financial institutions. U.S. Holders are urged to consult their tax advisors regarding the application of this reporting requirement to their ownership of the common shares.

Information Reporting and Backup Withholding

In general, information reporting will apply to dividends paid to a U.S. Holder in respect of the common shares and the proceeds received by such U.S. Holder from the sale, exchange or other disposition of the common shares within the United States unless such U.S. Holder is a corporation or other exempt recipient. Backup withholding may apply to such payments if a U.S. Holder fails to provide a taxpayer identification number or certification of exempt status or fails to report dividend and interest income in full. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or credit against a U.S. Holder’s U.S. federal income tax liability, provided that the required information is timely furnished to the IRS.

Disclosure Requirements for Certain U.S. Holders Recognizing Significant Losses

A U.S. Holder that claims significant losses in respect of common shares for U.S. federal income tax purposes (generally (i) $10 million or more in a taxable year or $20 million or more in any combination of taxable years for corporations or partnerships all of whose partners are corporations, (ii) $2 million or more in a taxable year or $4 million or more in any combination of taxable years for all other taxpayers, or (iii) $50,000 or more in a taxable year for individuals or trusts) with respect to a foreign currency transaction, may be required to file Form 8886 for “reportable transactions.” U.S. Holders should consult their own tax advisors concerning any possible disclosure obligation with respect to the common shares.

Certain Canadian Federal Income Tax Considerations

The following is a general summary, as of the date hereof, of the principal Canadian federal income tax considerations under the Income Tax Act (Canada) and the regulations thereunder (collectively, the “Tax Act”) generally applicable to a holder who as beneficial owner acquires, owns, or disposes of common shares of the Company and who, at all relevant times, for purposes of the Tax Act: (a) holds the common shares as capital property; (b) deals at arm’s length with the Company; and (c) is not affiliated with the Company (a “Holder”). Generally, the common shares will be capital property to a Holder unless they are acquired or held in the course of carrying on a business or as part of an adventure or concern in the nature of trade.

This summary does not apply to a Holder: (a) that is a “financial institution”, as defined in the Tax Act for purposes of the mark-to-market rules; (b) an interest in which is a “tax shelter investment”, as defined in the Tax Act; (c) that is a “specified financial institution”, as defined in the Tax Act; (d) that has made an election under the Tax Act to determine its Canadian tax results in a currency other than Canadian currency; (e) that has entered or will enter into a “derivative forward agreement” or a “synthetic disposition arrangement”, each as defined in the Tax Act, with respect to its common shares; (f) that receives dividends on the common shares under or as part of a “dividend rental arrangement”, as defined in the Tax Act; (g) that is exempt from tax under Part I of the Tax Act; or (h) that is a partnership.

Additional considerations, not discussed herein, may apply to a Holder that (a) is a corporation resident in Canada for the purposes of the Tax Act and (b) is, or becomes, or does not deal at arm’s length for purposes of the Tax Act with a corporation resident in Canada that is or becomes, as part of a transaction or series of transactions or events that includes the acquisition of common shares, controlled by a non-resident corporation or a non-resident person or group of non-resident persons not dealing at arm’s length (comprised of any combination of non-resident corporations, non-resident individuals or non-resident trusts) for purposes of the “foreign affiliate dumping” rules in section 212.3 of the Tax Act.  All such Holders should consult their own tax advisors.

This summary is based on the facts set out in this Annual Report, the current provisions of the Tax Act, all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date of hereof (“Canadian Tax Proposals”) and an understanding of the current published administrative policies of the Canada Revenue Agency. This summary assumes that all Canadian Tax Proposals will be enacted in the form proposed, however no assurance can be made that the Canadian Tax Proposals will be enacted in the form proposed or at all. This summary is not exhaustive of all possible Canadian federal income tax considerations and, other than the Canadian Tax Proposals, does not take into account or anticipate any changes in law or in administrative policy, whether by legislative, regulatory, administrative or judicial decision or action, nor does it take into account provincial, territorial or non-Canadian tax legislation or considerations, which may differ significantly from the Canadian federal income tax considerations discussed herein.

This summary is of a general nature only and is not exhaustive of all possible Canadian federal income tax considerations applicable to the acquisition, ownership or disposition of the common shares. The income and other tax consequences of acquiring, owning or disposing of common shares will vary depending on a Holder’s particular status and circumstances. This summary is not intended to

76

be, nor should it construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to acquiring, holding or disposing of the common shares having regard to their particular circumstances.

Currency Conversion

Generally, for purposes of the Tax Act, all amounts relating to the acquisition, ownership or disposition of the common shares must be converted into Canadian dollars based on the exchange rates as determined in accordance with the Tax Act. The amount of any dividends required to be included in the income of, and capital gains or capital losses realized by, a Holder may be affected by fluctuations in the Canadian exchange rate.

Canadian Holders

The following summary applies to a Holder who, for purposes of the Tax Act, and at all relevant times, is, or is deemed to be, resident in Canada (a “Canadian Holder”). A Canadian Holder whose common shares do not otherwise qualify as capital property may in certain circumstances make an irrevocable election in accordance with subsection 39(4) of the Tax Act to have their common shares, and every other “Canadian security” (as defined in the Tax Act) owned by such Canadian Holder in the taxation year of the election and in all subsequent taxation years, deemed to be capital property.  Canadian Holders whose common shares might not otherwise be considered to be capital property should consult their own tax advisors concerning this election.

Dividends on Common Shares

Dividends received or deemed to be received on the common shares by a Canadian Holder who is an individual (including certain trusts) will be included in computing the Canadian Holder’s income for the taxation year in which such dividends are received and will be subject to the gross-up and dividend tax credit rules of the Tax Act that apply to taxable dividends received from “taxable Canadian corporations” (as defined in the Tax Act), including the enhanced gross-up and dividend tax credit in respect of dividends designated by the Company as “eligible dividends” in accordance with the Tax Act. There may be limitations on the Company’s ability to designate dividends and deemed dividends as eligible dividends. Dividends received by a Canadian Holder who is an individual (including certain trusts) may result in such Canadian Holder being liable for alternative minimum tax under the Tax Act. Canadian Holders who are individuals should consult their own tax advisors in this regard.

Dividends received or deemed to be received on the common shares by a Canadian Holder that is a corporation will be included in computing the corporation’s income for the taxation year in which such dividends are received, but such dividends will generally be deductible in computing the corporation’s taxable income for that taxation year, subject to all relevant restrictions under the Tax Act. In certain circumstances, subsection 55(2) of the Tax Act will treat a taxable dividend received by a Canadian Holder that is a corporation as proceeds of disposition or a capital gain, rather than a dividend. Canadian Holders that are corporations should consult their own tax advisors having regard to their own circumstances.

A Canadian Holder that is a “private corporation” or a “subject corporation” (each as defined in the Tax Act) will generally be liable under Part IV of the Tax Act for an additional tax on dividends received or deemed to be received on common shares to the extent that such dividends are deductible in computing the Canadian Holder’s taxable income.  Such additional tax may be refundable in certain circumstances. A Canadian Holder that is, throughout the relevant taxation year, a “Canadian-controlled private corporation” as defined in the Tax Act or a “substantive CCPC” as proposed to be defined in the Tax Act as announced in the Federal Budget released by the government of Canada on April 7, 2022 (“Budget 2022”), may be liable to pay an additional tax, refundable in certain circumstances, on its “aggregate investment income” which is defined in the Tax Act to include dividends to the extent that such dividends are not deductible in computing the Canadian Holder’s taxable income for the taxation year.

Dispositions of Common Shares

Generally, on the disposition or deemed disposition of common shares by a Canadian Holder, the Canadian Holder will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition in respect of such common shares, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base of the common shares to the Canadian Holder immediately before the disposition or deemed disposition. Such capital gain (or capital loss) will be subject to the tax treatment described under “Taxation of Capital Gains and Capital Losses.”

The adjusted cost base to the Canadian Holder of a common share will be determined at any particular time by averaging the cost of such common share with the adjusted cost base of the other common shares owned by the Canadian Holder as capital property at that time and by making certain other adjustments required under the Tax Act.

Taxation of Capital Gains and Capital Losses

Generally, one-half of the amount of any capital gain (a “taxable capital gain”), realized by a Canadian Holder on a disposition of common shares in a taxation year must be included in computing such Canadian Holder’s income for that year, and one-half of any capital loss (an “allowable capital loss”), realized by a Canadian Holder on a disposition of common shares in a taxation year must be deducted from any taxable capital gains realized by the Canadian Holder in the year, subject to and in accordance with the provisions

77

of the Tax Act. Allowable capital losses in excess of taxable capital gains realized in a taxation year may be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized in such years, subject to and in accordance with the provisions of the Tax Act.

The amount of any capital loss realized by a Canadian Holder that is a corporation on the disposition or deemed disposition of a common share may be reduced by the amount of any dividends received (or deemed to be received) by the Canadian Holder on such common share to the extent and under the circumstances prescribed by the Tax Act. Similar rules may apply where a common share is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Such Canadian Holders should consult their own tax advisors.

A taxable capital gain realized by a Canadian Holder who is an individual (including certain trusts) may give rise to a liability for alternative minimum tax.

A Canadian Holder that is throughout the relevant taxation year a “Canadian-controlled private corporation” (as defined in the Tax Act) or a “substantive-CCPC” (as proposed to be defined in the Tax Act as announced in Budget 2022) may be liable to pay an additional tax on certain investment income, including taxable capital gains (but excluding dividends or deemed dividends deductible in computing taxable income). Such additional tax may be refundable in certain circumstances.

Non-Canadian Holders

The following summary applies to a Holder who, for purposes of the Tax Act and any relevant income tax treaty or convention, at all relevant times, (a) is not (and is not deemed to be) resident in Canada and (b) will not use or hold (and will not be deemed to use or hold) the common shares in, or in the course of carrying on a business or part of a business in Canada (a “Non-Canadian Holder”).  This summary does not apply to a Non-Canadian Holder that carries on an insurance business in Canada and elsewhere or an “authorized foreign bank” (as defined in the Tax Act).

Dividends on Common Shares

Dividends paid or credited on the common shares or deemed to be paid or credited on the common shares to a Non-Canadian Holder will generally be subject to Canadian withholding tax at the rate of 25% of the gross amount of the dividend, subject to any reduction in the rate of withholding to which the Non-Canadian Holder may be entitled under an applicable income tax convention between Canada and the country in which the Non-Canadian Holder is resident. For example, under the Canada United States Tax Convention (1980), as amended (the “Canada-U.S. Tax Treaty”), where dividends on the common shares are considered to be paid to or derived by a Non-Canadian Holder that is a beneficial owner of the dividends and is a U.S. resident for the purposes of, and is fully entitled to benefits of, the Canada-U.S. Tax Treaty, the applicable rate of Canadian withholding tax is generally reduced to 15%.

Dispositions of Common Shares

A Non-Canadian Holder will not be subject to tax under the Tax Act on any capital gain realized on a disposition or deemed disposition of common shares, nor will capital losses arising from the disposition, or deemed disposition, of a common shares, be recognized under the Tax Act, unless at the time of disposition the common shares are “taxable Canadian property” to the Non-Canadian Holder for purposes of the Tax Act and the Non-Canadian Holder is not entitled to relief under an applicable income tax convention between Canada and the country in which the Non-Canadian Holder is resident.

Generally, the common shares will not constitute “taxable Canadian property” to a Non-Canadian Holder at a particular time provided that the common shares are listed at that time on a “designated stock exchange” (as defined in the Tax Act), which includes the Nasdaq, unless at any particular time during the 60-month period immediately preceding such time: (i) at least 25% or more of the issued shares of any class or series of the capital stock of the Company was owned by or belonged to any combination of (A) the Non-Canadian Holder, (B) persons with whom the Non-Canadian Holder does not deal at arm’s length, and (C) partnerships in which the Non-Canadian Holder or a person described in (b) holds a membership interest directly or indirectly through one or more partnerships, and (ii) more than 50% of the fair market value of the common shares was derived, directly or indirectly, from one or any combination of: (a) real or immoveable property situated in Canada, (b) “Canadian resource properties” (as defined in the Tax Act), (c) “timber resource properties” (as defined in the Tax Act), and (d) options in respect of, or interests in, or for civil law rights in, property in any of the foregoing whether or not the property exists. Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, common shares could be deemed to be “taxable Canadian property.” Non-Canadian Holders whose common shares may constitute “taxable Canadian property” should consult their own tax advisors.

In the event that the common shares constitute taxable Canadian property of a Non-Canadian Holder and any capital gain that would be realized on the disposition therefor is not exempt from tax under the Tax Act or pursuant to an applicable income tax treaty or convention, the Canadian income tax consequences discussed above under “Canadian Holders – Dispositions of Common Shares” and “Canadian Holders – Taxation of Capital Gains and Capital Losses” will generally apply to the Non-Canadian Holder.

F. Dividends and paying agents.

Not applicable

78

G. Statement by experts.

Not applicable

H. Documents on display.

We are a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act and Rule 3b-4 under the Exchange Act, and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we do not file the same reports that a U.S. domestic issuer would file with the SEC, although we are required to file or furnish to the SEC the continuous disclosure documents that we are required to file in Canada under Canadian securities laws.

Copies of our financial statements and other continuous disclosure documents required under Canadian securities laws are available for viewing on SEDAR at www.sedar.com.

We will provide without charge to each person, including any beneficial owner, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this Annual Report (not including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: #300, 919 - 11 Avenue SW Calgary, AB, T2R 1P3 Attention: Sophie Pilon, phone number: +1 587-327-2017.

I. Subsidiary Information.

Not applicable.

Item 11. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Interest rate risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Credit Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Credit risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Liquidity Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Liquidity risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Foreign Currency Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Foreign currency risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Item 12. Description of Securities Other than Equity Securities.

Not applicable.

79

PART II

Item 13. Defaults, Dividend Arrearages and Delinquencies.

None.

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.

A. – D. Material Modifications to the Rights of Security Holders

None.

E. Use of Proceeds

Not applicable.

Item 15. Controls and Procedures.

See the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Item 16A. Audit Committee Financial Expert.

The Company’s audit committee is comprised of Greg Mills and Lori Ell, and chaired by Bryan Pinney. Our board of directors has determined that each of Greg Mills, Lori Ell and Bryan Pinney is financially literate and meets the independence requirements for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and NI 52-110. Our board of directors has determined that Bryan Pinney is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate” within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act. For information relating to qualifications and experience of each audit committee member, see “Item 6B Directors, Senior Management and Employees—Compensation”.

Item 16B. Code of Ethics.

The Company’s board of directors has adopted a code of conduct applicable to all of our directors and employees, including our Chief Executive Officer and Chief Financial Officer. This code qualifies as a “code of ethics” as defined in section 406(c) of SOX and which is a “code” under NI 58-101. The Company’s code of conduct is available at www.sndlgroup.com. Information contained on, or that can be accessed through, the Company’s website is not incorporated by reference into this Annual Report.

If we make any amendment to the code of conduct or grant any waiver therefrom, whether explicit or implicit, to a director or executive officer, we will disclose the nature of such amendment or waiver on our website to the extent required by, and in accordance with, the rules and regulations of the SEC and the Canadian securities regulatory authorities.

Item 16C. Principal Accountant Fees and Services.

The following table summarizes the fees charged by KPMG (Calgary, Alberta, Canada; Auditor Firm ID: 85), the Company’s independent auditor, in the fiscal years ended December 31, 2021 and December 31, 2021:

	Fees billed for the fiscal year ended
Service Retained	December 31, 2021	December 31, 2020
Audit fees(1)	$2,800,190	$1,423,635
Audit-related fees(2)	—	—
Tax fees(3)	—	3,317
All other fees	—	—

(1) “Audit fees” include fees necessary to perform the annual audit or reviews of the consolidated financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings and engagements.

(2) “Audit-related fees” include fees for assurance and related services by our independent auditor that are reasonably related to the performance of the audit or review of our financial statements other than those included in “Audit Fees”.

(3) “Tax Fees” include fees for all tax services other than those included in “Audit Fees” and “Audit-Related Fees”. This category includes fees for tax compliance, tax advice and tax planning.

The audit committee is responsible for the pre-approval of all non-audit services to be provided by the Company’s auditor.

80

Item 16D. Exemptions from the Listing Standards for Audit Committees.

Not applicable.

Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

Not applicable.

Item 16F. Change in Registrant’s Certifying Accountant.

On April 7, 2022, the Company received notice of the decision of KPMG LLP (“KPMG”) to not stand for reappointment as the Company’s independent auditor for fiscal year 2022 at its upcoming annual general meeting of shareholders. KPMG’s decision not to stand for reappointment as the Company’s independent auditor was considered and approved by the Company’s audit committee and board of directors. The Company’s audit committee is in the process of selecting a new independent registered public accounting firm to serve as its auditor and will engage such firm as soon as reasonably practicable.

For the years ended December 31, 2021 and December 31, 2020, no report by KPMG on the Company’s consolidated financial statements contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles.

For the years ended December 31, 2021 and December 31, 2020 and through the date hereof, (i) there were no disagreements (as that term is used in Item 16F(a)(1)(iv) of Form 20-F and the related instructions) between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference thereto in its reports upon on the Company’s audited consolidated financial statements for the years ended December 31, 2021 and December 31, 2020, and (ii) there were no “reportable events” as such term is defined in Item 16F(a)(1)(v) of Form 20-F, other than the material weaknesses in the Company’s internal control over financial reporting (i) disclosed in the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1 and (ii) previously disclosed in the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached as Exhibit 15.1 to the Company’s annual report on Form 20-F for the year ended December 31, 2020, filed with the SEC on March 18, 2021.

The Company has provided a copy of this disclosure to KPMG and requested that they furnish it with a letter addressed to the SEC stating whether KPMG agrees with the above statements, and if not, stating the respects in which it does not agree. A copy of the letter from KPMG addressed to the SEC, dated the date hereof, is being filed herewith.

Item 16G. Corporate Governance.

The Nasdaq Rules include certain accommodations in the corporate governance requirements that allow foreign private issuers, such as us, to follow “home country” corporate governance practices in lieu of the otherwise applicable corporate governance standards of the Nasdaq. The application of such exceptions requires that we disclose any significant ways in which our corporate governance practices differ from the Nasdaq Rules that we do not follow. Although our shares are listed on the Nasdaq, we continue to follow Canadian corporate governance practices in lieu of the requirement under Rule 5620(c) of the Nasdaq Rules that a company’s bylaws provide for a quorum for any meeting of the holders of the company’s common shares that is not less than 33 1/3% of the outstanding common shares of the company. Our by-laws provide that a quorum of shareholders is constituted by the holders of at least 25% of the shares entitled to vote at the meeting, present in person or represented by proxy, and at least two persons entitled to vote at the meeting, present in person or represented by proxy. In addition, we do not follow Rule 5635 of the Nasdaq Rules that requires that shareholder approval be required for the Company to issue securities in connection with certain events, such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, rights issues at or below market price, certain private placements, directed issues at or above market price and issuance of convertible notes. Neither Canadian securities laws nor Alberta corporate law require shareholder approval for such transactions, except where such transactions constitute a “related party transaction” or “business combination” under Canadian securities laws or where such transaction is structured in a way that requires shareholder approval under the ABCA, in which case, we intend to follow our home country requirements.

Item 16H. Mine Safety Disclosure

Not applicable.

81

PART III

Item 17. Financial Statements.

See Item 18. – “Financial Statements.”

Item 18. Financial Statements.

Our Annual Financial Statements are included at the end of this Annual Report.

Item 19. Exhibits.

List all exhibits filed as part of the registration statement or annual report, including exhibits incorporated by reference.

Exhibit Number	Description	Method of Filing
1.1	Articles of incorporation of Sundial Growers Inc., as currently in effect	Incorporated by reference to Exhibit 4.1 to the Registrant’s registration statement on Form S-8, filed with the SEC on August 9, 2019
1.2	Bylaws of Sundial Growers Inc. as currently in effect	Incorporated by reference to Exhibit 3.2 to the Registrant’s registration statement on Form F-1/A, filed with the SEC on July 30, 2019
2.1	Specimen Share Certificate	Incorporated by reference to Exhibit 3.2 to the Registrant’s registration statement on Form F-1/A, filed with the SEC on July 30, 2019
2.2	Description of Securities of the Registrant Registered under Section 12 of the Exchange Act	Incorporated by reference to Exhibit 2.4 to the Registrant’s annual report on Form 20-F, filed with the SEC on March 31, 2020
2.3	Securities Purchase Agreement dated as of June 5, 2020 by and among Sundial Growers Inc. and each of the investors listed on the Schedule of Buyers attached thereto, including the forms of the related convertible notes, warrants and registration rights agreement	Incorporated by reference to Exhibit 99.5 to the Registrant’s current report on Form 6-K, filed with the SEC on June 8, 2020
2.4	Form of Series A and B Warrants	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on August 18, 2020
2.5	Form of New Warrant	Incorporated by reference to Exhibit 99.2 to the Registrant’s current report on Form 6-K, filed with the SEC on February 19, 2021
4.1†	Share Purchase Agreement, dated December 29, 2020 by and among Sundial Growers Inc., 2657408 Ontario Inc. and the other parties named therein	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on January 20, 2021
4.2†	Share Purchase Agreement, dated December 29, 2020 by and among Sundial Growers Inc. and the parties named therein	Incorporated by reference to Exhibit 99.2 to the Registrant’s current report on Form 6-K, filed with the SEC on January 20, 2021
4.3†	Amended and Restated Debenture (Fifth Amendment), dated June 18, 2020, by among 2657408 Ontario Inc., as agent and nominee for the lenders named therein from time to time, Zenabis Investments Ltd. as the Corporation, and the guarantors named therein	Incorporated by reference to Exhibit 99.3 to the Registrant’s current report on Form 6-K, filed with the SEC on January 20, 2021

82

4.5†	Amended and Restated Monitoring Services Agreement, dated April 22, 2020, by and among NGBA-BC Holdings Ltd., as consultant, Zenabis Investments Ltd., as the Company, and 2657408 Ontario Inc., as the lender.	Incorporated by reference to Exhibit 99.4 to the Registrant’s current report on Form 6-K, filed with the SEC on January 20, 2021
4.6	Amended and Restated Equity Distribution Agreement, by and between Sundial Growers Inc. and A.G.P./Alliance Global Partners	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on January 21, 2021
8.1	List of Subsidiaries	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
12.1	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
12.2	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
13.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
13.2	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
15.1	Management’s Discussion and Analysis of Financial Condition and Results of Operations	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
16.1	Letter from KPMG LLP regarding Changes in Registrant’s Certifying Accountant	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
23.1	Consent of KPMG LLP	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2021
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
†	Portions of this exhibit have been omitted pursuant to Item 601(a)(6), Item 601(b)(2)(ii) or Item 601(b)(10)(iv), as applicable, of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed or include information the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

83

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

	Sundial Growers Inc.
Date: April 27, 2022	By:	/s/ Zachary George
		Name: Zachary George
		Title: Chief Executive Officer

84

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Sundial Growers Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated statements of financial position of Sundial Growers Inc. and subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and its financial performance and its cash flows for each of the years in the three-year period ended December 31, 2021 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated April 27, 2022 expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of Equity-Accounted Investee

As described in note 17 to the consolidated financial statements, the Company’s underlying investments in its equity-accounted investee as of December 31, 2021, are recorded at fair value through profit and loss. On March 15, 2021 the Company entered into a joint venture through a new corporation called SunStream Bancorp Inc. (the “Joint Venture”) with a capital contribution of $396.6 million. The Joint Venture’s principal business is making indirect investments in the global cannabis sector.  The Company records its interest in the Joint Venture using the equity method. The Joint Venture records its investments at fair value through profit and loss each reporting period.  The valuation of the investments held by the Joint Venture requires estimates including market prices, volatility and discount rates. The Joint Venture engaged valuation professionals to assess the fair value of the investments.

We identified the Joint Venture’s measurement of the fair value of its investments as a critical audit matter. A high degree of subjectivity and auditor judgment was required to evaluate the Joint Venture’s estimates of market prices, volatility and discount rates used to calculate the fair value of its investments. Minor changes to these estimates could have a significant effect on the Joint Venture’s calculation of the fair value of its investments, and as a result, the carrying value of the Joint Venture. Additionally, the audit effort associated with these estimates required valuation professionals with specialized skills and knowledge.

F-1

The following are the primary procedures we performed to address this critical audit matter. We evaluated the competence, capabilities and objectivity of the valuation professionals engaged by the Joint Venture to assess the fair value of the investments.  In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:

• evaluating the Joint Venture’s methodologies used in estimating the fair value of the investments,

• evaluating the Joint Venture’s estimates of market prices, volatility and discount rates by comparing to publicly available market data for comparable entities, and

• developing a range of independent estimates and comparing them to the fair value of the investments determined by the Joint Venture.

Valuation of Investment at Fair Value Through Profit and Loss

As described in note 16 to the consolidated financial statements, the Company has a special purpose vehicle that owns an investment in Zenabis Investments Ltd., which is recorded at fair value through profit and loss.  The carrying value of the investment is $48.6 million as of December 31, 2021. The valuation of the investment requires estimates including the discount rate.  The Company engaged valuation professionals to assess the fair value of the investment.

We identified the measurement of the fair value of the investment as a critical audit matter. A high degree of subjectivity and auditor judgment was required to evaluate the estimate of the discount rate used to determine the fair value of the investment. Minor changes to this estimate could have a significant effect on the fair value of the investment. Additionally, the audit effort associated with this estimate required valuation professionals with specialized skills and knowledge.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the competence, capabilities and objectivity of the valuation professionals engaged by the Company to assess the fair value of the investment.  In addition, we involved valuation professionals with specialized skills and knowledge who assisted in:

• evaluating the methodology used in estimating the fair value of the investment,

• evaluating the estimate of the discount rate by comparing to publicly available market data for comparable entities, and

• developing a range of independent estimates and comparing them to the fair value of the investment determined by the Company.

Impairment of the Olds Cash Generating Unit

As discussed in notes 3 and 13 to the consolidated financial statements, the Company’s long-lived assets, including interests in equity-accounted investees, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment.  The Company identified an indicator of impairment at June 30, 2021 for the Olds cash generating unit (“CGU”) arising from the curtailment in the utilization of the capacity of the Olds facility, and as a result performed an impairment test to estimate the recoverable amount of its long-lived assets using discounted expected future cash flows.  The Company recorded an asset impairment charge of $60 million.  The estimated recoverable amount involves estimates, including the forecasted cash flows, terminal multiple and the discount rate.

We identified the evaluation of the calculation of the recoverable amount of the Olds CGU at June 30, 2021 to be a critical audit matter. A high degree of subjectivity and auditor judgment was required to evaluate the forecasted cash flows, including total addressable market, (“TAM”), market share escalation factor, gross margin escalation factor, terminal multiple and discount rate used to calculate the recoverable amount of the Olds CGU.  Minor changes in these estimates could have a significant effect on the Company’s calculation of the recoverable amount of the Olds CGU.  Additionally, the nature and extent of audit effort associated with these estimates required the involvement of valuation specialists with specialized skills and knowledge.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the forecasted cash flows, TAM and market share escalation factor by comparing to historical results and publicly available capital market analyst reports. We evaluated the gross margin escalation factor by comparing to the Company’s historical gross margin growth of the Olds CGU and to the Company’s budgets and forecasts. We evaluated the Company’s budgets and forecasts by assessing the Company’s intent and ability to carry out particular course of actions, which included consideration of whether the Company has the financial resources and other means to carry out the actions.  In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:

• evaluating the methodology used in calculating the recoverable amount,

• evaluating the Company’s terminal multiple by comparing to the long-term nominal gross domestic product forecasts in Canada, and

• evaluating the Company’s determination of the discount rate by comparing to publicly available market data for comparable entities.

F-2

We have served as the Company’s auditor since 2018.

/s/ KPMG LLP

Chartered Professional Accountants

Calgary, Alberta

April 27, 2022

F-3

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Sundial Growers Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Sundial Growers Inc. and subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weaknesses, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of the Company as of December 31, 2021 and 2020, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated April 27, 2022 expressed an unqualified opinion on those consolidated financial statements.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management’s assessment:

• An ineffective control environment resulting from an insufficient number of financial reporting and accounting, and information technology (IT) personnel with the appropriate knowledge, experience or training commensurate with the Company’s financial reporting requirements.

• The insufficient number of personnel described above contributed to an ineffective risk assessment process necessary to identify changes to its operations and to identify all relevant risks of material misstatement and to evaluate the implications of relevant risks on its internal control over financial reporting.

• An ineffective information and communication process resulting from a combination of deficiencies within its information technology general and application controls (“ITGCs”) across the systems supporting the Company’s financial reporting process, including access controls and administrator-level access resulting in a lack of segregation of duties, resulting in insufficient controls to ensure the relevance, timeliness and quality of information used in control activities.

• As a consequence of the above and as a result of inadequate segregation of duties and secondary review, the Company had ineffective control activities related to the design, implementation and operating effectiveness of process level and financial reporting controls which had a pervasive impact on the Company's internal control over financial reporting.

These material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2021 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.

The Company acquired Inner Spirit Holdings Ltd. during 2021, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as at December 31, 2021, Inner Spirit Holdings Ltd.’s internal control over financial reporting associated with 1% of current assets, 21% of long-term assets, 15% of current liabilities, 51% of long-term liabilities, 24% of total gross revenues and 0% of loss included in the consolidated financial statements of the Company as of and for the year ended December 31, 2021. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Inner Spirit Holdings Ltd.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Internal Control over Financial Reporting found in Management’s Discussion and Analysis. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

F-4

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Chartered Professional Accountants

Calgary, Canada

April 27, 2022

F-5

Sundial Growers Inc.

Consolidated Financial Statements

For the years ended December 31, 2021 and 2020, and 2019

(Expressed in thousands of Canadian dollars)

F-1

Sundial Growers Inc.

Consolidated Statements of Financial Position

(Expressed in thousands of Canadian dollars)

As at	Note	December 31, 2021			December 31, 2020 (1)
Assets
Current Assets
Cash and cash equivalents			558,251			60,376
Restricted cash	8		27,013			5,333
Marketable securities	9		83,724			—
Accounts receivable	10		10,865			15,898
Biological assets	11		4,410			3,531
Inventory	12		29,503			25,613
Prepaid expenses and deposits			4,355			4,622
Investments	16		3,065			—
Assets held for sale	13		2,998			2,998
Net investment in subleases	14		3,991			—
			728,175			118,371
Non-current assets
Long-term deposits			7,725			2,633
Property, plant and equipment	13		63,189			116,928
Net investment in subleases	14		22,571			—
Intangible assets	15		4,709			5,063
Investments	16		70,498			51,876
Equity-accounted investees	17		412,858			—
Goodwill	5		114,537			—
Total assets			1,424,262			294,871
Liabilities
Current liabilities
Accounts payable and accrued liabilities	18		38,452			23,308
Current portion of lease obligations	20		5,701			409
Derivative warrants	19		21,700			428
			65,853			24,145
Non-current liabilities
Lease obligations	20		27,769			1,031
Other liabilities	21		4,505			—
Total liabilities			98,127			25,176
Shareholders’ equity
Share capital	23(b)		2,035,704			762,046
Warrants	23(c)		8,092			6,138
Contributed surplus			60,734			59,344
Contingent consideration	17(b)		2,279			2,279
Accumulated deficit (1)			(788,510	)		(558,128	)
Accumulated other comprehensive income			7,607			—
Total shareholders’ equity			1,325,906			271,679
Non-controlling interest (1)			229			(1,984	)
Total liabilities and shareholders’ equity			1,424,262			294,871

(1) Recast – refer to note 17(b).

Commitments (note 35)

Subsequent events (notes 17(a), 24(c) and 36)

See accompanying notes to the consolidated financial statements.

Approved by the Board:
“Signed” Bryan Pinney	“Signed” Zachary George
Director	Director

F-2

Sundial Growers Inc.

Consolidated Statements of Loss and Comprehensive Loss

(Expressed in thousands of Canadian dollars, except per share amounts)

		Year ended December 31
	Note	2021			2020 (1)			2019
Gross revenue	25		67,279			73,321			66,927
Excise taxes			11,151			12,403			3,365
Net revenue			56,128			60,918			63,562
Cost of sales	12		48,601			51,740			46,721
Inventory obsolescence	12		16,978			45,913			—
Gross margin before fair value adjustments			(9,451	)		(36,735	)		16,841
Change in fair value of biological assets	11		4,708			5,432			30,340
Change in fair value realized through inventory			(2,247	)		(18,566	)		(10,685	)
Gross margin			(6,990	)		(49,869	)		36,496
Interest and fee revenue	26		13,149			—			—
Investment loss	26		(44,501	)		—			—
Share of profit of equity-accounted investees	17(a)		32,913			—			—
General and administrative	27		38,370			32,029			38,934
Sales and marketing	27		5,043			5,737			8,068
Research and development			2,446			488			2,410
Depreciation and amortization	13,15		4,726			4,711			595
Share-based compensation	24		12,307			8,566			38,698
Restructuring costs			874			6,470			—
Asset impairment	13		60,000			79,191			162
Government subsidies	28		(2,180	)		(4,128	)		—
Loss on cancellation of contracts			5,116			2,471			—
Loss from operations			(132,131	)		(185,404	)		(52,371	)
Transaction costs			(17,566	)		(3,587	)		(8,481	)
Finance costs, net	29		(3,756	)		(3,819	)		(24,216	)
Change in estimate of fair value of derivative warrants	19		(77,834	)		(12,995	)		—
Foreign exchange gain (loss)			531			(1,000	)		(939	)
Loss on financial obligation			—			—			(60,308	)
Gain (loss) on disposition of PP&E			235			488			8
Other expenses	17(b)		(1,932	)		—			—
Loss before income tax			(232,453	)		(206,317	)		(146,307	)
Income tax recovery	22		2,271			—			3,609
Net loss from continuing operations			(230,182	)		(206,317	)		(142,698	)
Net loss from discontinued operations	6		—			(33,627	)		(128,931	)
Net loss			(230,182	)		(239,944	)		(271,629	)
Equity-accounted investees - share of OCI, net of tax	17(a)		7,607			—			—
Gain on translation of foreign operations			—			600			6,866
Comprehensive loss			(222,575	)		(239,344	)		(264,763	)
Net loss from continuing operations attributable to:
Sundial Growers Inc. (1)			(230,382	)		(199,619	)		(142,533	)
Non-controlling interest (1)			200			(6,698	)		(165	)
			(230,182	)		(206,317	)		(142,698	)
Net loss attributable to:
Sundial Growers Inc. (1)			(230,382	)		(233,246	)		(271,464	)
Non-controlling interest (1)	17(b)		200			(6,698	)		(165	)
			(230,182	)		(239,944	)		(271,629	)
Comprehensive loss attributable to:
Sundial Growers Inc. (1)			(222,775	)		(232,646	)		(264,598	)
Non-controlling interest (1)			200			(6,698	)		(165	)
			(222,575	)		(239,344	)		(264,763	)
Net loss per common share attributable to Sundial Growers Inc.
Basic and diluted	31	$	(0.12	)	$	(1.07	)	$	(3.17	)

(1) Recast – refer to note 17(b).

See accompanying notes to the consolidated financial statements.

F-3

Sundial Growers Inc.

Consolidated Statements of Changes in Shareholders’ Equity

(Expressed in thousands of Canadian dollars)

	Note	Share capital			Warrants			Contributed surplus			Convertible notes – equity component			Contingent consideration		Accumulated deficit (1)			Accumulated other comprehensive income			Non- controlling interest (1)			Total equity
Balance at December 31, 2018			65,133			3,108			9,493			3,232			—		(88,874	)		—			—			(7,908	)
Net loss			—			—			—			—			—		(271,464	)		—			(165	)		(271,629	)
Other comprehensive income			—			—			—			—			—		—			6,866			—			6,866
Share issuances			198,378			—			—			—			—		—			—			—			198,378
Shares issued to related parties			63,460			5,833			—			—			—		—			—			—			69,293
Share issuance costs			(12,770	)		—			—			—			—		—			—			—			(12,770	)
Business acquisitions			39,849			—			—			—			2,279		—			—			4,879			47,007
Convertible debt - conversions			113,526			6,731			—			(3,232	)		—		—			—			—			117,025
Warrants reclassified from liability			—			16,091			—			—			—		—			—			—			16,091
Warrants exercised			21,882			(3,932	)		—			—			—		—			—			—			17,950
Share-based compensation			2,515			—			37,009			—			—		—			—			—			39,524
Employee warrants exercised			17,681			—			(16,310	)		—			—		—			—			—			1,371
Balance at December 31, 2019			509,654			27,831			30,192			—			2,279		(360,338	)		6,866			4,714			221,198
Net loss (1)			—			—			—			—			—		(233,246	)		—			(6,698	)		(239,944	)
Other comprehensive income			—			—			—			—			—		—			600			—			600
Share issuances	23(b)		176,931			—			—			—			—		—			—			—			176,931
Share issuance costs	23(b)		(5,593	)		—			—			—			—		—			—			—			(5,593	)
Convertible debt - conversions			63,002			—			—			—			—		—			—			—			63,002
Derivative warrants exercised	19		55,912			—			—			—			—		—			—			—			55,912
Warrants issued	23(c)		—			306			—			—			—		—			—			—			306
Warrants expired	23(c)		—			(21,999	)		21,999			—			—		—			—			—			—
Dispositions	6		(38,447	)		—			—			—			—		35,456			(7,466	)		—			(10,457	)
Share-based compensation			52			—			7,688			—			—		—			—			—			7,740
Employee awards exercised			535			—			(535	)		—			—		—			—			—			—
Balance at December 31, 2020			762,046			6,138			59,344			—			2,279		(558,128	)		—			(1,984	)		269,695
Net (loss) earnings			—			—			—			—			—		(230,382	)		—			200			(230,182	)
Other comprehensive income			—			—			—			—			—		—			7,607			—			7,607
Loss of control of subsidiary	17(b)		—			—			—			—			—		—			—			2,013			2,013
Share issuances	23(b)		977,425			—			—			—			—		—			—			—			977,425
Share issuance costs	23(b)		(16,371	)		—			—			—			—		—			—			—			(16,371	)
Derivative warrants exercised	19		277,136			—			—			—			—		—			—			—			277,136
Acquisition	5		26,216			1,771			—			—			—		—			—			—			27,987
Convertible debenture settlement	5		2,671			—			—			—			—		—			—			—			2,671
Warrants issued	23(c)		—			361			—			—			—		—			—			—			361
Warrants exercised	23(c)		178			(178	)		—			—			—		—			—			—			—
Share-based compensation	24		8			—			12,715			—			—		—			—			—			12,723
Employee awards exercised			6,395			—			(6,194	)		—			—		—			—			—			201
Modification of equity-settled plan	24(d)		—			—			(5,131	)		—			—		—			—			—			(5,131	)
Balance at December 31, 2021			2,035,704			8,092			60,734			—			2,279		(788,510	)		7,607			229			1,326,135

(1) Recast – refer to note 17(b).

See accompanying notes to the consolidated financial statements.

F-4

Sundial Growers Inc.

Consolidated Statements of Cash Flows

(Expressed in thousands of Canadian dollars)

		Year ended December 31
	Note	2021			2020			2019
Cash provided by (used in):
Operating activities
Net loss from continuing operations for the period			(230,182	)		(206,317	)		(142,698	)
Items not involving cash:
Income tax recovery	22		(2,271	)		—			(3,609	)
Change in fair value of biological assets	11		(4,708	)		(5,432	)		(30,340	)
Share-based compensation	24		12,307			8,566			38,698
Depreciation and amortization	13,15		9,603			11,582			6,296
(Gain) loss on disposition of PP&E			(235	)		(488	)		(8	)
Inventory obsolescence	12		16,978			45,913			—
Transaction costs			—			—			1,279
Finance costs	29		3,716			(3,734	)		11,070
Change in estimate of fair value of derivative warrants	19		77,834			12,995			—
Loss on cancellation of contracts			2,870			671			—
Loss on financial obligation			—			—			60,308
Unrealized foreign exchange (gain) loss			(63	)		(757	)		671
Restructuring costs			—			448			—
Warrants issued for services	23(c)		—			306			—
Asset impairment	13		60,000			79,191			162
Share of profit of equity-accounted investees	17(a)		(32,913	)		—			—
Other expenses	17(b)		1,864			—			—
Gain on disposition of marketable securities	9,26		(20,213	)		—			—
Unrealized loss on marketable securities	9,26		64,714			—			—
Additions to marketable securities	9		(158,101	)		—			—
Proceeds from disposal of marketable securities	9		29,876			—			—
Income distributions from equity-accounted investees	17(a)		15,021			—			—
Change in non-cash working capital	30		(1,534	)		(5,259	)		(41,626	)
Net cash used in operating activities from continuing operations			(155,437	)		(62,315	)		(99,797	)
Net cash provided by operating activities from discontinued operations	6		—			4,820			(12,939	)
Net cash used in operating activities			(155,437	)		(57,495	)		(112,736	)
Investing activities
Additions to property, plant and equipment	13		(3,793	)		(3,024	)		(110,271	)
Additions to intangible assets	15		—			(150	)		—
Additions to investments			(24,206	)		(51,876	)		—
Additions to equity-accounted investees	17(a)		(395,569	)		—			—
Capital distributions from equity-accounted investees	17(a)		10,481			—			—
Proceeds from disposal of PP&E	13		194			2,109			51
Acquisition	5		(82,775	)		—			(77,023	)
Change in non-cash working capital	30		(612	)		(11,319	)		1,659
Net cash used in investing activities from continuing operations			(496,280	)		(64,260	)		(185,584	)
Net cash used in investing activities from discontinued operations	6		—			(6,617	)		(27,560	)
Net cash used in investing activities			(496,280	)		(70,877	)		(213,144	)
Financing activities
Proceeds from convertible notes, net of costs			—			18,070			90,373
Change in restricted cash	8		(21,680	)		10,494			(15,477	)
(Repayment) proceeds of long-term debt			—			(84,493	)		99,182
Payments on lease obligations, net			(1,008	)		(420	)		(292	)
Proceeds from issuance of shares and registered offerings, net of costs	23(b)		1,062,310			181,841			177,202
Proceeds from exercise of derivative warrants	19		119,318			20,391			—
Proceeds from exercise of equity classified warrants			—			—			17,950
Proceeds from exercise of employee warrants	24		201			—			1,371
Exercise of cash-settled DSUs	24		(315	)		—			—
Convertible debenture settlement	5		(9,354	)		—			—
Payment on exercise of contingent consideration warrants	5,23(c)		(219	)		—			—
Settlement of convertible notes			—			—			(4,190	)
Settlement of financial obligation			—			—			(9,500	)
Change in non-cash working capital	30		348			(2,498	)		2,147
Net cash provided by financing activities from continuing operations			1,149,601			143,385			358,766
Net cash used in financing activities from discontinued operations	6		—			(639	)		(499	)
Net cash provided by financing activities			1,149,601			142,746			358,267
Effect of exchange rate changes on cash held in foreign currency			(9	)		665			(1,171	)
Change in cash and cash equivalents			497,875			15,039			31,216
Cash and cash equivalents, beginning of period			60,376			45,337			14,121
Cash and cash equivalents, end of period			558,251			60,376			45,337

See accompanying notes to the consolidated financial statements.

F-5

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

1. Description of business

Sundial Growers Inc. (“Sundial” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006.

The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.

The principal activities of the Company are the production, distribution and sale of cannabis in Canada pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada.

Sundial and its subsidiaries currently operate solely in Canada. Through its joint venture SunStream Bancorp Inc. (note 17(a)), the Company also provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”.

COVID-19

The global impact of COVID-19 has contributed to uncertainty as to the health of the global economy. The Company has implemented several pandemic-related procedures and protocols at its facilities, including enhanced screening measures, enhanced cleaning and sanitation processes with increased frequency, encouraging social distancing measures and directing employees to work from home if possible. At the retail store level, the Company has implemented enhanced in-store procedures including increased frequency of cleaning, installing safety shields and reducing paper materials. The Company has also adapted its business model by moving toward online sales platforms that enable customers to order products online for fast pickup and payment in store. The Company believes that it can maintain safe operations with these pandemic-related procedures and protocols in place.

2. Basis of presentation

a) Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2021.

These consolidated financial statements were approved and authorized for issue by the board of directors of Sundial (the “Board”) on April 27, 2022.

b) Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, deferred share units (“DSUs”) and certain financial instruments (note 32(a)) which are measured at fair value with changes in fair value recorded in earnings.

c) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the functional and presentation currency of the Company and its Canadian-based subsidiaries. Sundial Deutschland GmbH uses the European Euro as its functional currency. The Company’s equity-accounted joint venture uses the United States dollar as its functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions.

F-6

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign subsidiaries that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries into Canadian dollars are recognized in other comprehensive income (“OCI”).

In preparing the Company’s consolidated financial statements, the financial statements of the foreign equity-accounted joint venture are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of the foreign equity-accounted joint venture are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of the foreign equity-accounted joint venture are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of the foreign equity-accounted joint venture into Canadian dollars are recognized in OCI. The Company’s consolidated financial statements include its share of the Canadian dollar profit or loss and OCI of the equity-accounted joint venture.

d) Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases.

Subsidiaries	Principal activity	Jurisdiction of incorporation	Equity ownership			Non-controlling interest ("NCI")
KamCan Products Inc.	Inactive	British Columbia, Canada		100	%		0	%
Sundial Deutschland GmbH	Inactive	Germany		100	%		0	%
2657408 Ontario Inc.	Operations	Ontario, Canada		100	%		0	%
NGBA-BC Holdings Ltd.	Operations	British Columbia, Canada		100	%		0	%
Sundial Insurance (Bermuda) Ltd.	Operations	Bermuda		100	%		0	%
Inner Spirit Holdings Ltd.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Corporate Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Ontario Inc. (1)	Operations	Ontario, Canada		0	%		100	%

(1) This entity may be considered to be “controlled” by the Company solely for the purposes of IFRS, but the entity is not controlled by the Company within the meaning of applicable corporate law. For the purposes of IFRS, control of this entity is determined by the Company being exposed to variable returns and having the ability to affect those returns through its power over the entity.

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

RESTRICTED CASH AND CASH EQUIVALENTS

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading position, and (ii) minimum funding requirements for two separate captive insurance structures.

F-7

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labor related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory is valued at Company-owned stores at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined by the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as

F-8

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the consolidated statements of loss and comprehensive loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

Production facilities20 years

Equipment1 to 10 years

Right-of-use assetsShorter of estimated useful life or lease term

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with IAS 38.

The Company’s intangible assets at December 31, 2021, are comprised of the following:

• Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

• Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

F-9

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

(i)Financial assets

The Company applies an expected credit loss, or “ECL”, model to all financial assets not held at fair value through profit and loss, or “FVTPL”, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECL’s are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECL’s are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E and intangible assets, including goodwill, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of assets’ estimated fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit, or “CGU”).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset (or CGU) is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) previously. A reversal of an impairment loss is recognized immediately in the statements of loss and comprehensive loss.

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

F-10

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or Fair Value Through Other Comprehensive Income depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognize in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at Fair Value Through Other Comprehensive Income.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

F-11

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2021 and 2020.

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in the consolidated statements of loss and comprehensive loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

REVENUE

Under IFRS 15, to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation

F-12

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and certain promotional activities and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift certificate.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and being stewards of the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they are utilizing the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38 “Intangible Assets”. Research and development costs comprise consulting fees and licence acquisition fees. No development costs have been capitalized as at December 31, 2021, or December 31, 2020.

F-13

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

INCOME TAXES

Income taxes are recognized in the consolidated statements of loss and comprehensive loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and includes any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities, and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each consolidated statements of financial position date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

F-14

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transactions costs associated with business combinations are expensed as incurred.

FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in net earnings. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right-of-use asset and a lease obligation at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease obligation. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease obligation is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease obligation is subsequently increased by the interest cost on the lease obligation and decreased by lease payments made. Lease payments are allocated between the liability and interest expense. Interest expense is recognized on the lease obligation using the effective interest rate method and payments are applied against the lease obligation.

F-15

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The carrying amounts of the right-of-use assets, lease obligations, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset.

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2021 and did not have a material impact on the Company’s consolidated financial statements:

•COVID-19 Related Rent Concessions (Amendments to IFRS 16)

•Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2022, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2021. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

F-16

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

•Onerous contracts – Cost of Fulfilling a Contract (Amendments to IAS 37)

•IFRS 17 Insurance Contracts (Amendments to IFRS 17)

4. Significant accounting estimates, assumptions and judgements

The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated.

Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following:

IMPAIRMENTS

CGU’s are defined as the lowest grouping of integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructures and the way in which management monitors the Company’s operations.

The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licences from Health Canada, total addressable market, market share escalation factor, gross margin escalation factor, terminal multiple and discount rates. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s.

BIOLOGICAL ASSETS AND INVENTORY

Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest.

Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged.

Revenue

Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in

F-17

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

some cases, have a right of product return or warranty period. The estimate of potential future returns includes the use of estimates and assumptions and are subject to change as new information becomes available.

CONVERTIBLE INSTRUMENTS

Convertible notes are compound financial instruments which are accounted for separately by their components: a financial liability and an equity instrument. The financial liability, which represents the obligation to pay coupon interest on the convertible notes in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance.

The identification of the components of convertible notes is based on interpretations of the substance of the contractual arrangement and therefore requires judgement from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of the fair value of the liability is also based on various assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors.

ACQUISITIONS

The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under IFRS 3. This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes.

Investments

The Company’s investment at FVTPL is a financial asset measured at fair value each reporting period. The determination of the fair value of the investment requires judgement from management and the main assumption is the discount rate.

equity-accounted investees

The Company’s interest in a joint venture is accounted for using the equity-method. The current investment portfolio of the joint venture is comprised of secured debt and hybrid instruments which include options and warrants. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss.

The determination of the fair value of the underlying investments is based on a discounted cash methodology and requires judgement from management. The discounted cash flows are based on various assumptions, including an estimation of market prices, volatility and discount rates.

5. Business acquisition

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

The Inner Spirit Transaction consideration was comprised of (i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share), (ii) an aggregate 24.4 million Sundial common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.0835 of a Sundial common share for each Inner Spirit common share) and (iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

F-18

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed. The purchase price allocation and the amount of deferred income taxes arising on their recognition is not final as the Company is continuing to verify information required to determine the fair value of property, plant and equipment, net investment in subleases, goodwill and lease liabilities. The Company expects a portion of goodwill to be allocated to intangible assets upon finalization of the purchase price allocation.

The fair value of consideration paid was as follows:

	July 20, 2021
Cash		92,583
Issuance of common shares		26,216
Contingent consideration		1,150
		119,949

The fair value of the assets and liabilities acquired was as follows:

	July 20, 2021
Cash		9,808
Accounts receivable		750
Prepaid expenses and deposits		853
Inventory		2,733
Property, plant and equipment		12,108
Net investment in subleases		23,751
Goodwill		114,537
Accounts payable and accrued liabilities		(2,678	)
Convertible debentures		(12,025	)
Lease liabilities		(29,481	)
Financial guarantee liability		(407	)
		119,949

The Company recorded adjustments to the fair value in the fourth quarter of 2021 to reflect facts and circumstances in existence at the date of acquisition. These adjustments related to the inclusion of Spirit Lead Ontario Inc. and changes in preliminary valuation assumptions, including amounts allocated to property, plant and equipment, net investments in subleases, intangible assets, lease liabilities and deferred tax liability. All measurement period adjustments were offset to goodwill. It is expected that further allocations will be made between these account categories upon finalization of the preliminary purchase price allocation prior to the end of the second quarter of 2022.

As new information obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, then the accounting for the acquisition will be revised.

On August 4, 2021, the Company settled the convertible debenture liability through the issuance of 2.5 million common shares valued at $2.7 million and a cash payment of $9.3 million. Due to the change of control from the Inner Spirit Transaction, debenture holders were entitled to receive Sundial common shares and a cash payment based on a prescribed formula.

The fair value of the Inner Spirit warrants has been estimated as $1.2 million and is made up of the following components: (i) equity component of $1.8 million (note 23(c)), (ii) liability component of $0.3 million and (iii) asset component of $0.9 million.

The consolidated financial statements incorporate the operations of Inner Spirit commencing July 20, 2021. During the period July 20, 2021, to December 31, 2021, the Company recorded revenues of $16.1 million and net earnings of $1.1 million. Had the acquisition closed on January 1, 2021, management estimates that for the period January 1, 2021, to July 19, 2021, revenue would have increased by $20.4 million and net earnings would have increased by $7.4 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2021.

F-19

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The Company incurred acquisition-related costs of $1.9 million which have been included in transaction costs.

6. Discontinued operations

On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Project Seed Topco (“Bridge Farm”) which closed on June 5, 2020.

The comparative statement of loss and comprehensive loss and statement of cash flows has been presented to show the discontinued operation separately from continuing operations.

Results of discontinued operations

	Year ended December 31
	2021		2020 (1)			2019 (2)
Gross revenue		—		22,139			12,298
Net revenue		—		22,139			12,298
Cost of sales		—		15,633			9,426
Gross margin before fair value adjustments		—		6,506			2,872
Change in fair value of biological assets		—		1,064			386
Change in fair value realized through inventory		—		(1,122	)		—
Gross margin		—		6,448			3,258
General and administrative		—		8,585			5,515
Sales and marketing		—		1,418			820
Depreciation and amortization		—		2,752			3,482
Foreign exchange		—		1,057			(1,779	)
Share-based compensation		—		(826	)		826
Goodwill impairment		—		—			100,305
Loss from operations		—		(6,538	)		(105,911	)
Transaction costs		—		—			(1,588	)
Finance costs		—		(10,083	)		(3,982	)
Loss on contingent consideration		—		(2,252	)		(18,645	)
Gain on investment		—		—			165
Gain on disposition of PP&E		—		—			13
Loss on disposition of Bridge Farm		—		(14,979	)		—
Loss before income tax		—		(33,852	)		(129,948	)
Income tax recovery		—		225			1,017
Net loss (3)		—		(33,627	)		(128,931	)

(1) Period January 1, 2020, to June 5, 2020

(2) Period July 2, 2019, to December 31, 2019

(3) Net loss from the discontinued operations is attributable entirely to the owners of the Company.

F-20

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Effect of disposal on the financial position of the company

Cash and cash equivalents	2,963
Accounts receivable	15,641
Biological assets	2,831
Inventory	787
Property, plant and equipment	88,698
Goodwill	11,345
Intangible assets	23,884
Accounts payable and accrued liabilities	(22,792	)
Lease obligation	(14,894	)
Deferred tax liability	(3,115	)
Accumulated other comprehensive income	(7,466	)
Net assets and liabilities	97,882
Consideration received
Term Debt Facility	45,000
Contingent consideration liability	34,912
Cancellation of common shares	2,991
Total consideration	82,903
Loss on disposition	(14,979	)

7. Segment information

Late in the fourth quarter of 2020 the Company began the deployment of capital toward strategic investments. The Company developed an internal capital program to evaluate these and potential future investments, which is a new and separate business line from its cannabis operations.

Based on the allocation of the Company’s resources by the chief operating decision maker and the information used to analyze the performance of the business, the Company concluded that beginning in Q1 2021, it had two reportable segments: cannabis operations and investments. The acquisition of Inner Spirit (note 5) has led to a third reportable segment: retail operations. For the year ended December 31, 2020, there was only one reportable segment and therefore no comparative segment information.

The Company’s reportable segments are organized by business line and are comprised of three reportable segments: cannabis operations, retail operations and investments. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada. Retail operations include the private sale of recreational cannabis through wholly owned and franchise retail cannabis stores. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any reportable segment are reported as “Corporate”.

	Cannabis			Retail (1)		Investments			Corporate			Total
As at December 31, 2021
Total assets		147,887			153,624		1,093,596			29,155			1,424,262
Year ended December 31, 2021
Net revenue		40,037			16,091		—			—			56,128
Gross margin		(15,499	)		8,509		—			—			(6,990	)
Interest and fee revenue		—			—		13,149			—			13,149
Loss on marketable securities		—			—		(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—			—		32,913			—			32,913
Depreciation and amortization		3,108			721		—			897			4,726
Earnings (loss) before tax		(117,990	)		1,835		(5,837	)		(110,461	)		(232,453	)

F-21

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

(1) Period July 20, 2021, to December 31, 2021

Geographical disclosure

As at December 31, 2021, the Company had non-current assets related to operations in the United States of $412.9 million. For the year ended December 31, 2021, share of profit of equity-accounted investees related to operations in the United States was $32.9 million.

8. Restricted cash

As at	December 31, 2021		December 31, 2020
Letters of credit		—		5,333
Securities collateral		7,773		—
Captive insurance		19,240		—
		27,013		5,333

Securities collateral is comprised of a cash balance to satisfy margin requirements on the Company’s option trading position.

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures. The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate Cell Captive. The Cell Captive was funded with $12.1 million and is required to be fully funded at all times. The second structure is a wholly incorporated subsidiary, Sundial Insurance (Bermuda) Ltd., which was incorporated to provide separate and additional coverage and funded with $7.1 million.

9. Marketable securities

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Additions		158,101			—
Dispositions		(9,663	)		—
Change in fair value recognized in profit or loss		(64,714	)		—
Balance, end of period		83,724			—

During the year ended December 31, 2021, proceeds of $29.9 million were received for dispositions of marketable securities and a gain on disposition of $20.2 million was recognized (note 26).

Marketable securities have been designated as FVTPL (note 32).

The components of marketable securities are as follows:

As at	December 31, 2021			December 31, 2020
Equity securities		83,802			—
Put and call options		(78	)		—
		83,724			—

10. Accounts receivable

As at	December 31, 2021		December 31, 2020
Trade receivables		10,865		15,786
Other receivables		—		112
		10,865		15,898

F-22

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The Company has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Refer to note 32 for credit risk disclosures.

11. Biological assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		3,531			14,309
Increase in biological assets due to capitalized costs		25,880			39,957
Net change in fair value of biological assets		4,708			6,496
Transferred to inventory upon harvest		(29,709	)		(54,388	)
Disposition of Bridge Farm (note 6)		—			(2,831	)
Foreign currency translation		—			(12	)
Balance, end of year		4,410			3,531

Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2021		December 31 2020		December 31 2021		December 31 2020
Yield per square foot of growing space (1)	Grams		49		45		435		347
Average net selling price (2)	$/gram		4.49		5.13		1,014		1,022
After harvest cost to complete and sell	$/gram		1.06		1.32		249		291

(1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

These assumptions are estimates that are subject to volatility in market prices and several uncontrollable factors. The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2021, it is estimated that the Company’s biological assets will yield approximately 5,672 kilograms (December 31, 2020 – 5,507 kilograms) of dry cannabis when harvested. During the year ended December 31, 2021, the Company harvested 22,784 kilograms of dry cannabis (year ended December 31, 2020 – 27,972 kilograms).

F-23

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

12. Inventory

As at	December 31, 2021		December 31, 2020
Harvested cannabis		22,710		20,358
Cannabis supplies and consumables		4,361		5,255
Retail		2,397		—
Millwork		35		—
		29,503		25,613

During the year ended December 31, 2021, inventories of $48.6 million were recognized in cost of sales as an expense (year ended December 31, 2020 - $51.7 million). During the year ended December 31, 2021, the Company recognized inventory write downs of $17.5 million (year ended December 31, 2020 - $56.9 million), of which $17.0 million (year ended December 31, 2020 - $45.9 million) was recognized as an impaired and obsolete inventory provision, and $0.5 million (year ended December 31, 2020 - $11.0 million) was included in the change in fair value realized through inventory as the fair value component of the impaired and obsolete inventory provision.

13. Property, plant and equipment

	Land			Production facilities			Equipment			Right of use assets			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2019		26,606			166,442			24,021			16,509			58,031			291,609
Additions		8			213			2,886			763			4,319			8,189
Transfers from CIP		509			8,212			2,287			—			(11,008	)		—
Reclass to assets held for sale		(1,547	)		—			—			—			(1,451	)		(2,998	)
Dispositions		(499	)		(162	)		(50	)		(825	)		(991	)		(2,527	)
Disposition of Bridge Farm (note 6)		(16,300	)		(21,587	)		(249	)		(14,431	)		(39,734	)		(92,301	)
Foreign currency translation		(137	)		(181	)		(1	)		(122	)		(347	)		(788	)
Balance at December 31, 2020		8,640			152,937			28,894			1,894			8,819			201,184
Acquisition (note 5)		—			4,169			2,209			5,730			—			12,108
Additions		—			593			1,975			579			1,209			4,356
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(468	)		(301	)		(165	)		(177	)		(1,111	)
Balance at December 31, 2021		12,388			157,231			32,777			8,038			6,103			216,537
Accumulated amortization and impairment
Balance at December 31, 2019		3			5,400			3,697			363			162			9,625
Depreciation		475			6,249			4,847			638			—			12,209
Impairment		—			60,658			—			—			5,659			66,317
Dispositions		—			(37	)		(44	)		(176	)		—			(257	)
Disposition of Bridge Farm (note 6)		(473	)		(2,879	)		—			(251	)		—			(3,603	)
Foreign currency translation		(5	)		(27	)		—			(3	)		—			(35	)
Balance at December 31, 2020		—			69,364			8,500			571			5,821			84,256
Depreciation		—			2,914			5,438			897			—			9,249
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			(10	)		(147	)		—			(157	)
Balance at December 31, 2021		—			132,278			13,928			1,321			5,821			153,348
Net book value
Balance at December 31, 2020		8,640			83,573			20,394			1,323			2,998			116,928
Balance at December 31, 2021		12,388			24,953			18,849			6,717			282			63,189

F-24

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

During the year ended December 31, 2021, depreciation expense of $4.9 million was capitalized to biological assets and inventory (year ended December 31, 2020 – $6.9 million).

Due to curtailment in the utilization of a portion of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates, the Company determined that indicators of impairment existed at June 30, 2021. The impairment test for the Company’s Olds CGU used a value in use approach based on internal cash flow estimates at June 30, 2021, and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s Olds CGU of $60.0 million as at June 30, 2021, as the estimated recoverable amount for this CGU of $70.0 million was lower than the respective carrying amount. The estimated value in use for the Company’s Olds CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $7.3 million.

At December 31, 2021, the Company determined that no further indicators of impairment existed or indicators that a previous impairment should be reversed, and no impairment test was required.

During the year ended December 31, 2020, the Company determined that indicators of impairment existed with respect to the Company’s British Columbia CGU as a result of the Company’s disposition of its Kamloops property and decision to suspend further construction and development activities on its Merritt facility due to market conditions and available financing. Approximately $10.0 million had been invested into the Merritt facility which consisted of land and CIP. A test for impairment was performed at March 31, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their fair value less costs of disposal and an impairment of $5.7 million was recorded to write down the assets to their recoverable amount. The fair value measurement is categorized within Level 3 of the fair value hierarchy. The recoverable amount of these assets was further reduced to $2.9 million due to the Company receiving utility deposits back on deferral of construction of the facility. Management is committed to a plan to sell the Merritt facility and the asset is available for immediate sale, resulting in the reclassification to assets held for sale on the consolidated statements of financial position.

During the year ended December 31, 2020, the Company determined that indicators of impairment existed with respect to the Company’s Alberta CGU as a result of decreasing estimates for the size of the potential Canadian cannabis market, the Company curtailing the number of flowering rooms being used for cultivation at its Olds facility and the carrying value of the Company’s total net assets significantly exceeding the Company’s market capitalization. A test for impairment was performed at September 30, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets, using a value in use approach based on internal cash flow estimates and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account forecasted Canadian cannabis industry activity market size and Sundial’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, the Company determined there was an impairment of the Company’s Alberta CGU of $60.0 million as at September 30, 2020, as the estimated recoverable amount for this CGU of $154.0 million was lower than the respective carrying amount.

On December 28, 2020, the Company announced a concentrates licensing agreement based out of its Rocky View facility. Within the agreement is a non-binding purchase agreement to sell the Rocky View facility for $5.0 million. The estimated recoverable amount of the Rocky View facility was determined to be its fair value less costs of disposal and an impairment of $0.7 million was recorded to write down the assets to their recoverable amount of $5.0 million. The fair value measurement is categorized within Level 3 of the fair value hierarchy.

All of the above impairments were recognized in the Company’s cannabis reporting segment.

F-25

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

14. Net investment in subleases

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Acquisition (note 5)		23,751			—
Additions		3,951			—
Finance income		573			—
Rents recovered (payments made directly to landlords)		(1,713	)		—
Dispositions		—			—
Balance, end of year		26,562			—
Current portion		3,991			—
Long-term		22,571			—

Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

15. Intangible assets

	Brands and trademarks			Patents		Customer relationships			Other			Total
Cost
Balance at December 31, 2019		8,386			13,551		19,578			3,778			45,293
Additions		150			—		—			—			150
Disposition of Bridge Farm (note 6)		(3,066	)		—		(19,415	)		(3,747	)		(26,228	)
Foreign currency translation		(25	)		—		(163	)		(31	)		(219	)
Balance at December 31, 2020		5,445			13,551		—			—			18,996
Balance at December 31, 2021		5,445			13,551		—			—			18,996
Accumulated amortization and impairment
Balance at December 31, 2019		131			—		976			191			1,298
Depreciation		441			677		842			165			2,125
Impairment		—			12,874		—			—			12,874
Disposition of Bridge Farm (note 6)		(190	)		—		(1,801	)		(353	)		(2,344	)
Foreign currency translation		—			—		(17	)		(3	)		(20	)
Balance at December 31, 2020		382			13,551		—			—			13,933
Depreciation		354			—		—			—			354
Balance at December 31, 2021		736			13,551		—			—			14,287
Net book value
Balance at December 31, 2020		5,063			—		—			—			5,063
Balance at December 31, 2021		4,709			—		—			—			4,709

Brands and trademarks related to intellectual property purchased from Sun 8 Holdings Inc. with a useful life of 15 years and other intellectual property with a useful life of 12 years.

Patents consisted of intellectual property acquired through the acquisition of Pathway RX Inc. (“Pathway”) comprised of proprietary rights to certain technology, copyrights and trademarks with a useful life of 20 years. During the year ended December 31, 2020, the Company determined that indicators of impairment existed regarding the Pathway intellectual property due to the Company’s decision to reduce its focus on medical cannabis research. The estimated recoverable amount of the intangible assets was determined to be their fair value less costs of disposal and an impairment of $12.9 million was recorded to write down the assets to their recoverable amount of nil.

F-26

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Brands and trademarks related to intellectual property acquired as part of the Bridge Farm acquisition, customer relationships and other intangible assets consisting of non-compete clauses and energy credits were disposed of as part of the sale of Bridge Farm (note 6).

16. Investments

As at	December 31, 2021		December 31, 2020
Investments at amortized cost (A)		24,987		—
Investment at FVTPL (B)		48,576		51,876
		73,563		51,876
Current portion		3,065		—
Long-term		70,498		51,876

A) INvestments at amortized cost

On February 16, 2021, the Company announced a $22 million strategic investment (the “Indiva Investment”) in Indiva Limited (“Indiva”). The Indiva Investment closed on February 23, 2021. The Indiva Investment was completed in the form of a brokered private placement of 25 million common shares of Indiva at a price of $0.44 per common share, for gross proceeds of $11 million, and a non-revolving secured term loan to Indiva in the principal amount of $11 million (the “Term Loan”). The Term Loan bore interest at a rate of 9% per annum and has a maturity date of February 23, 2024.

On October 4, 2021, the Company provided an additional $8.5 million principal loan to Indiva and has amended the Term Loan. The amended Term Loan has an interest rate of 15% per annum and the maturity date of February 23, 2024 has not changed. Accrued and unpaid interest of $0.3 million was added to the outstanding principal balance, bringing the total principal outstanding to $19.8 million.

The Term Loan has been designated as measured at amortized cost (note 32). The common shares are measured at Fair Value Through Profit or Loss (“FVTPL”) and are included in marketable securities (note 9).

On April 26, 2021, the Company closed a $3.0 million convertible debenture with a private company with a maturity date of October 26, 2021, and an interest rate of 9% per annum. The maturity date was extended to April 26, 2022, and the interest rate increased to 12% per annum. The Company has the right, but not the obligation, to convert all or any portion of the outstanding principal into common shares at a price equal to a conversion formula until the maturity date. The convertible debenture has been designated as measured at amortized cost (note 32).

The Company has entered into several promissory notes with Spiritleaf franchise partners, with interest rates ranging from prime plus a margin of 5.5% per annum to 8% per annum, with maturity dates of 5 years. The promissory notes have been designated as measured at amortized cost (note 32).

The following table summarizes the carrying amount of investments at amortized cost as at December 31, 2021:

As at	December 31, 2021
Secured term loan		19,417
Convertible debenture		3,065
Spiritleaf franchise partners		2,505
		24,987

B) Investment at fvtpl

The Company owns a special purpose vehicle (the “Zenabis Investment”) that owns $51.9 million of aggregate principal amount of senior secured debt of Zenabis Investments Ltd. (the “Zenabis Senior Loan”) of Zenabis Investments Ltd. (“Zenabis”). The Zenabis Senior Loan is secured by the assets of Zenabis and its subsidiaries and is guaranteed by Zenabis Global Inc. On June 1, 2021, Zenabis was acquired by HEXO Corp. The Zenabis Senior Loan

F-27

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

bears interest at a rate of 14% per annum and has a maturity date of March 31, 2025. Pursuant to the terms of the Zenabis Senior Loan, Zenabis will also pay the Company a royalty based on quarterly sales revenue from its medical, recreational and wholesale cannabis lines net of value added or sales taxes. The royalty is payable for 32 fiscal quarters and is payable for quarters in which Zenabis accomplishes certain sales revenue targets.

The Company is in negotiations with Zenabis for the repayment and termination of the Zenabis Senior Loan as Zenabis is in breach of certain covenants. Zenabis filed a petition with the Supreme Court of British Columbia to determine the value of the royalty. The court dismissed the petition and did not decide the merits of the case. Zenabis had 30 days from December 17, 2021 to file a notice of appeal in respect of the court’s findings, but they did not do so.

The Zenabis Investment has been designated as FVTPL (note 32). As of April 27, 2022, all required payments have been made in respect of the Zenabis Senior Loan, including $100,000 per month in monitoring fees payable to the Company.

Due to the credit risk associated with Zenabis and its parent, and uncertainty of the completion of their proposed restructuring, the Company has adjusted the fair value of the Zenabis Senior Loan downward by $3.3 million in accordance with the requirements of IFRS. In the event that facts and circumstances change the fair value will be adjusted accordingly. The fair value determination does not attribute value to the associated royalty due to its inherent uncertainty, or monitoring fee.

17. Equity-accounted investees

As at	December 31, 2021		December 31, 2020
Interest in joint venture (A)		412,858		—
Interest in associate (B)		—		—
		412,858		—

A) Interest in joint venture

On March 15, 2021, the Company and SAF Group announced they had entered into an agreement to form a 50/50 joint venture through a new corporation, SunStream Bancorp Inc. (“SunStream”). SunStream is a private company, incorporated under the Business Corporations Act (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

SunStream is structured as a separate vehicle and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method.

The current investment portfolio of SunStream is comprised of secured debt and hybrid debt and derivative instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risks and other risks specific to each investment.

As at December 31, 2021, the Company had contributed $395.6 million out of the total $538.0 million that has been committed. Subsequent to December 31, 2021, the Company contributed $70.3 million to SunStream.

F-28

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858

SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

The following table summarizes the financial information of SunStream:

As at	December 31, 2021
Current assets (including cash and cash equivalents: $0.2 million)		789
Non-current assets		407,860
Current liabilities		(1,596	)
Non-current liabilities		—
Net assets (liabilities) (100%)		407,053
Year ended December 31, 2021
Revenue		36,203
Profit from operations		32,841
Other comprehensive income		9,878
Total comprehensive income		42,747

B) Interest in associate

On March 23, 2021, the Company’s equity interest in its subsidiary, Pathway, decreased from 50% to 25%, resulting in a loss of control. The Company decreased its equity interest in connection with amending the licence agreement that provides for use of Pathway’s intellectual property. Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a wide range of medical conditions.

As a result of the loss of control, the Company has de-recognized the assets and liabilities of Pathway, and the non-controlling interest arising upon the acquisition of Pathway. A loss on loss of control of $1.9 million was recognized during the three months ended March 31, 2021. The fair value of the Company’s remaining investment in Pathway was determined to be nil as the Company had fully impaired the intangible asset, which consisted of intellectual property, during the year ended December 31, 2020 as described below, and there are no other assets that would give rise to a measured fair value amount attributable to the remaining 25% interest.

Adjustment to comparative information

During Q4 2020, and as disclosed in the annual consolidated financial statements of the Company as at and for the year ended December 31, 2020, the Company recognized an impairment of $12.9 million on the intangible assets held within Pathway. During the preparation of the Q1 2021 interim consolidated financial statements, the Company determined that the allocable amount of this impairment was not attributed to the non-controlling interest. The comparative December 31, 2020, consolidated statement of financial position has been recast to attribute 50% of the impairment of intangible assets recorded to the non-controlling interest as the related intangible assets related entirely to Pathway, the Company’s 50% owned subsidiary.

The recast of the consolidated statement of financial position as at December 2020 resulted in a reduction in non-controlling interest of $6.4 million from the previously reported amount of $4.4 million to the recast amount of negative $2.0 million, and a decrease in accumulated deficit of $6.4 million from the previously reported amount of

F-29

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

$564.5 million to the recast amount of $558.1 million and a decrease in loss per share attributable to the Company of $0.03 from the previously reported amount of $1.10 to the recast amount of $1.07.

This recast has no effect on the consolidated 2020 annual net loss or comprehensive loss or on any previously issued interim consolidated financial statements of the Company. The effect of this recast on the Company’s annual results for 2020 is a decrease to the presentation of the net loss attributable to the Company of $6.4 million from the previously reported amount of $206.0 million to the recast amount of $199.6 million, and an increase in the presentation of the net loss attributable to non-controlling interest of $6.4 million from the previously reported amount of $0.3 million to the recast amount of $6.7 million.

Contingent consideration

Contingent consideration was from the acquisition of Pathway in 2019. Contingent consideration valued at $2.3 million represents the granting of up to 280,000 warrants to purchase common shares of the Company at an exercise price of $1.81 per share, subject to the achievement of certain gross revenue milestones derived from Pathway royalty activities.

18. Accounts payable and accrued liabilities

	December 31, 2021		December 31, 2020
Trade payables		4,172		4,849
Accrued and other liabilities		34,280		18,459
		38,452		23,308

19. Derivative warrants

	December 31, 2021			December 31, 2020
Balance, beginning of year		428			—
2021 Series A and B Warrants - fair value on issuance (A)		62,680			—
2021 Additional Series A and B Warrants - fair value on issuance (B)		38,576			—
New Warrants - fair value on issuance recognized in profit or loss (C)		106,531			—
Agent Warrants - fair value on issuance (D)		—			504
Secured Convertible Note Warrants - fair value on issuance (E)		—			6,683
Unsecured Convertible Notes Warrants - fair value on issuance (F)		—			3,961
2020 Series A and B Warrants - fair value on issuance (G)		—			11,784
Change in fair value recognized in profit or loss		(28,697	)		12,995
Converted to common shares		(157,818	)		(35,521	)
Unrealized foreign exchange loss		—			22
Balance, end of year		21,700			428

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

(a) 2021 Series A and B Warrants

On February 2, 2021, the Company issued 100.0 million series A units (the “Series A Units”), each consisting of one common share and one-half series A warrant (collectively, the “2021 Series A Warrants”) to purchase one common share and 33.3 million series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “2021 Series B Warrants”) to purchase one common share and one-half 2021 Series A Warrant to purchase one common share (collectively, the “January 2021 Units Offering”). Each Series A Unit was sold at a price of US$0.75 per unit and each Series B Unit was sold at a price of US$0.75 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$100.0 million. The 2021 Series A Warrants and 2021 Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the 2021 Series A Warrants was US$0.80 per common share and the exercise price of the 2021 Series B Warrants was US$0.0001 per common share.

F-30

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

On February 2, 2021, the entire 33.3 million 2021 Series B Warrants were exercised resulting in the issuance of 33.3 million common shares.

On February 10, 2021, 3.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 3.3 million common shares and gross proceeds to the Company of US$2.7 million.

On February 22, 2021, the remaining 63.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million. In connection with this exercise, the New Warrants were granted (refer to C below).

(b) 2021 Additional series A and B warrants

On February 4, 2021, the Company issued 60.5 million additional series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “2021 Additional Series A Warrants”) to purchase one common share and 14.0 million additional series B units (the “Additional Series B Units”), each consisting of one pre-funded additional series B warrant (the “2021 Additional Series B Warrants”) to purchase one common share and one-half 2021 Additional Series A Warrant to purchase one common share, (collectively, the “February 2021 Units Offering”). Each Additional Series A Unit was sold at a price of US$1.00 per unit and each Additional Series B Unit was sold at a price of US$1.00 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$74.5 million. The 2021 Additional Series A Warrants and 2021 Additional Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the 2021 Additional Series A Warrants was US$1.10 per common share and the exercise price of the 2021 Additional Series B Warrants was US$0.0001 per common share.

On February 4, 2021, the entire 14.0 million 2021 Additional Series B Warrants were exercised resulting in the issuance of 14.0 million common shares.

On February 10, 2021, 2.3 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 2.3 million common shares and gross proceeds to the Company of US$2.5 million.

On February 22, 2021, the remaining 35.0 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the New Warrants were granted (refer to C below).

(c) new warrants

On February 22, 2021, (i) the remaining 63.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million and (ii) the remaining 35.0 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the Company issued 98.3 million new warrants to the holders of the 2021 Series A Warrants and 2021 Additional Series A Warrants (the “New Warrants”), each entitling the holder to purchase one common share at an exercise price of US$1.50, subject to customary anti-dilution adjustments. The Company has granted the holders the right to have the common shares issuable upon exercise of the New Warrants registered pursuant to a registration statement filed with the SEC. Such

F-31

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

registration statement was filed with the SEC on March 3, 2021. The New Warrants are immediately exercisable and have a term of 42 months from March 18, 2021, which is the effective date of the registration statement. As at December 31, 2021, 98.3 million New Warrants remained outstanding.

(d) Agent warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to the placement agents to acquire up to 1.08 million common shares at an initial exercise price of US$1.00 per common share (the “Agent Warrants”).

During the year ended December 31, 2021, the entire 1.08 million Agent Warrants were exercised. 540,000 Agent Warrants were exercised at a weighted average exercise price of US$1.00 per warrant resulting in the issuance of 356,949 common shares. There were no gross proceeds to the Company as the exercise was conducted on a cashless basis. The other 540,000 Agent Warrants were exercised at a weighted average exercise price of US$1.00 per warrant resulting in the issuance of 540,000 common shares and gross proceeds to the Company of US$0.5 million.

(e) Secured convertible note warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.00 per warrant and common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.20 per warrant (the “Secured Convertible Note Warrants”). The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance.

During the period October 22, 2020, to December 31, 2020, the entire 35.0 million Secured Convertible Note Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of $8.0 million.

(f) Unsecured convertible notes warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to acquire up to 14.5 million common shares at an initial exercise price of US$0.9338 per common share (the “Unsecured Convertible Notes Warrants”). The Unsecured Convertible Notes Warrants were issued on June 5, 2020, were immediately exercisable, and expire 42 months from the date that the underlying common shares become freely tradeable, which was July 16, 2020. In certain circumstances, the Unsecured Convertible Notes Warrants are subject to forced exercise provisions whereby the Company can force exercise should the volume weighted average price of the Company’s common shares exceed US$2.8014.

As a result of sales under the ATM Program, the exercise price of the Unsecured Convertible Notes Warrants was adjusted to US$0.1766 per common share. The foregoing exercise price may be further adjusted as the result of future sales under the ATM Program or other offerings, if any.

During the period July 16, 2020, to December 31, 2020, 14.0 million Unsecured Convertible Notes Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 14.0 million common shares and gross proceeds to the Company of $3.2 million. As at December 31, 2021, 0.5 million Unsecured Convertible Notes Warrants remained outstanding.

(g) 2020 Series A and B warrants

On August 18, 2020, in connection with the August 2020 registered offering, the Company issued 40.1 million series A warrants (“2020 Series A Warrants”) and 14.3 million series B warrants (“2020 Series B Warrants”). The 2020 Series A Warrants and 2020 Series B Warrants are exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the 2020 Series A Warrants are US$0.75 per common share and the exercise price of the 2020 Series B Warrants are US$0.0001 per common share.

On August 19, 2020, 9.2 million 2020 Series B Warrants were converted into common shares and on August 20, 2020, the remaining 5.1 million 2020 Series B Warrants were converted into common shares.

F-32

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

As a result of sales under the At-the-Market (“ATM”) Program, the exercise price of the 2020 Series A Warrants was adjusted to US$0.1766 per common share. The exercise price of the 2020 Series A Warrants may be further adjusted as the result of future sales under the ATM Program or other offerings, if any.

During the period August 18, 2020, to December 31, 2020, 39.6 million 2020 Series A Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 39.6 million common shares and gross proceeds to the Company of $9.1 million. As at December 31, 2021, 0.5 million 2020 Series A Warrants remained outstanding.

The following table summarizes outstanding derivative warrants as at December 31, 2021:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		0.1766		500,000		3.6
Unsecured Convertible Notes Warrants (1)		0.1766		500,000		2.0
New Warrants		1.50		98,333,334		2.6
				99,333,334		2.6

(1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

20. Lease obligations

	December 31, 2021			December 31, 2020
Balance, beginning of year		1,440			16,949
Acquisition (note 5)		29,481			—
Liabilities incurred		4,514			763
Lease payments		(2,721	)		(937	)
Dispositions		(20	)		(735	)
Interest expense		776			416
Disposition of Bridge Farm (note 6)		—			(14,894	)
Foreign currency translation		—			(122	)
Balance, end of year		33,470			1,440
Current portion		5,701			409
Long-term		27,769			1,031

The Company’s minimum lease payments are as follows:

	December 31, 2021
Less than one year		5,938
One to three years		10,514
Three to five years		8,424
Thereafter		13,629
Minimum lease payments		38,505
Amounts representing finance charges		(5,035	)
Net minimum lease payments		33,470

The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2021.

F-33

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

21. Other liabilities

	December 31, 2021		December 31, 2020
Financial guarantee liability (A)		466		—
DSU liability (B)		4,039		—
		4,505		—

(A) Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of expected credit losses in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs in the consolidated statement of loss and comprehensive loss.

(B) DSU liability

DSUs are granted to directors and generally vest in equal instalments over one year. The Company intended to settle the DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle the DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end.

22. Income taxes

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in the consolidated statement of loss and comprehensive loss for the years ended December 31, 2021, December 31, 2020 and December 31, 2019:

	December 31, 2021			December 31, 2020			December 31, 2019
Loss before taxes		(232,453	)		(206,317	)		(146,307	)
Statutory income tax rates		23.0	%		24.0	%		26.5	%
Expected income tax recovery		(53,464	)		(49,516	)		(38,771	)
Non-deductible share-based compensation		2,308			1,970			10,474
Non-deductible finance expense		2			2,130			15,981
Revaluation of the fair value of warrant liabilities		17,902			—			—
Non-deductible portion of capital losses		5,118			—			—
Other non-deductible expenses		610			348			2,621
Change in tax rates		—			1,528			3,305
Deferred tax benefits not recognized		25,253			43,540			2,781
Income tax (recovery) expense		(2,271	)		—			(3,609	)

F-34

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2021			December 31, 2020
Deferred tax assets (liabilities):
Inventory		20,472			8,388
Biological assets		(9,509	)		(8,388	)
Net investment in subleases		(6,109	)		—
Lease obligations		(8,371	)		—
Marketable securities		7,442			—
Equity-accounted investee		(3,925	)		—
Net deferred tax asset (liability)		—			—

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2021		December 31, 2020
Unrecognized deductible temporary differences:
Property, plant and equipment		84,322		36,782
Intangible assets		183		536
Share issue costs		23,835		11,112
Investments		3,300		—
Lease obligations		69,865		—
Financial obligations and other		4,100		1,054
Inventory and biological assets		—		34,781
Non-capital losses & SR&ED		219,165		171,205
Unrecognized deductible temporary differences		404,770		255,470

The movement in deferred income tax liability is as follows:

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			3,365
Acquisition of Inner Spirit		—			—
Recognized in profit and loss		(2,271	)		—
Recognized in other comprehensive income		2,271			(25	)
Recognized in discontinued operations (note 6)		—			(225	)
Disposition of Bridge Farm (note 6)		—			(3,115	)
Balance, end of year		—			—

The Company has $218.5 million (December 31, 2020 - $171.2 million) of non-capital losses available for future periods that will expire prior to 2037-2041. There are $60.0 million of uncertain losses that have not been recognized.

23. Share capital and warrants

(a) Authorized

The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

F-35

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

(b) Issued and outstanding

		December 31, 2021					December 31, 2020
	Note	Number of Shares		Carrying Amount			Number of Shares			Carrying Amount
Balance, beginning of year			918,844,133		762,046			107,180,423			509,654
Share issuances			956,806,648		977,425			337,696,867			176,931
Share issuance costs			—		(16,371	)		—			(5,593	)
Acquisition	5		24,431,278		26,216			—			—
Convertible debenture settlement	5		2,488,754		2,671			373,371,318			63,002
Disposition of Bridge Farm	6		—		—			(2,716,271	)		(38,447	)
Derivative warrants exercised	19		152,146,950		277,136			102,836,429			55,912
Warrants exercised	23(c)		195,711		178			—			—
Employee awards exercised (1)	24(c)		5,494,883		6,403			475,367			587
Balance, end of year			2,060,408,357		2,035,704			918,844,133			762,046

(1) Included in employee awards exercised are 875,000 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Excluded from employee awards exercised are 500,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

ATM Offering Program

During the year ended December 31, 2021, the Company issued 796.3 million common shares at a weighted average exercise price of US$0.8597 for gross proceeds of $855.2 million (US$684.6 million) through its ATM programs.

2021 Registered Offerings

In connection with the January 2021 Units Offering, the Company issued 100.0 million common shares (note 19a) and in connection with the February 2021 Units Offering, the Company issued 60.5 million common shares (note 19b). Total proceeds from the two offerings allocated to share capital were $122.2 million.

(c) Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2019		6,165,324			27,831
Warrants issued		544,000			306
Warrants expired		(3,232,434	)		(5,908	)
Warrants cancelled		(2,452,890	)		(16,091	)
Balance at December 31, 2020		1,024,000			6,138
Acquisition (note 5)		2,097,828			1,771
Warrants issued		640,000			361
Warrants exercised		(195,711	)		(178	)
Balance at December 31, 2021		3,566,117			8,092

During the year ended December 31, 2021, the Company issued 640,000 warrants to Sun 8 Holdings Inc. (“Sun 8”) with an exercise price of $0.94 per unit, in conjunction with achieving minimum thresholds of revenue derived from the brands or cultivars that the Company acquired from Sun 8 during the year ended December 31, 2019.

During the year ended December 31, 2021, 195,711 warrants that formed part of the contingent consideration from the Inner Spirit Transaction, were exercised resulting in a net payment of $0.2 million representing the difference between the exercise prices and the cash consideration (note 5). The carrying value of the exercised warrants was adjusted from warrants to share capital.

F-36

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes outstanding warrants as at December 31, 2021:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Acquisition of financial obligation		15.94		480,000		0.5
Financial services		4.60		544,000		7.6
Acquired from Inner Spirit (1)		0.34		1,902,117		2.2
Sun 8		0.94		640,000		4.0
		3.20		3,566,117		3.1

(1) Inner Spirit warrants are exchangeable for 0.0835 Sundial common shares in accordance with the Inner Spirit Transaction consideration (note 5) and have been presented based on the number of Sundial common shares that are issuable.

24. Share-based compensation

The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, RSUs and DSUs. Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants.

The components of share-based compensation expense are as follows:

	Year ended December 31
	2021			2020			2019
Equity-settled expense
Simple warrants (A)		2,899			1,539			23,918
Performance warrants (A)		361			(42	)		11,023
Stock options (B)		(14	)		651			98
Restricted share units (C)		6,789			4,069			220
Shares issued for services		—			—			2,320
Cash-settled expense
Deferred share units (i) (D)		2,272			2,349			1,119
		12,307			8,566			38,698

(i) Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each period end. Fluctuations in the fair value are recognized during the period in which they occur.

In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to estimate the fair value of units granted during the years ended December 31, 2021, December 31, 2020 and December 31, 2019 through the application of the following assumptions:

	December 31, 2021	December 31, 2020	December 31, 2019
Risk-free interest rate	0.45%	0.28% - 0.29%	1.41% - 1.88%
Expected life of units (years)	5	10	2 - 10
Expected annualized volatility	168%	143%	97% - 116%
Expected dividend yield	Nil	Nil	Nil
Weighted average Black-Scholes value of each unit	$0.56	$1.13 - $1.17	$0.67 - $23.55

Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that the units granted are expected to be outstanding. The risk-free rate was based on Government of Canada bond rates of comparable duration.

F-37

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Equity-settled plans

a) Simple and performance warrants

The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants do not expire.

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19
Forfeited		(668,800	)		3.36		(204,800	)		5.48
Exercised		(120,000	)		0.94		(80,000	)		1.09
Expired		(41,600	)		3.45		—			0.00
Balance at December 31, 2021		2,594,200		$	4.86		1,387,200		$	4.18

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2020:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2019		9,815,000		$	4.01		5,798,822		$	2.66
Forfeited		(6,390,400	)		3.79		(4,126,822	)		2.04
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19

The following table summarizes outstanding simple and performance warrants as at December 31, 2021:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$0.63 - $0.94		889,400		0.72		2.21		889,400		0.72		2.21
$1.25 - $1.88		—		—		—		—		—		—
$2.97 - $4.53		351,200		3.09		3.09		303,200		3.06		3.02
$6.25 - $9.38		1,219,200		6.29		4.72		499,200		6.35		4.70
$12.50 - $37.50		134,400		23.91		5.52		40,000		19.61		4.05
		2,594,200	$	4.86		3.68		1,731,800	$	3.19		3.11
Performance warrants
$0.63 - $0.94		458,667		0.68	n/a			458,667		0.68	n/a
$1.25 - $1.88		189,333		1.51	n/a			181,333		1.50	n/a
$2.97 - $4.53		504,000		3.16	n/a			504,000		3.16	n/a
$6.25 - $9.38		144,533		7.23	n/a			38,400		6.25	n/a
$12.50 - $37.50		90,667		28.24	n/a			—		—	n/a
		1,387,200	$	4.18	n/a			1,182,400	$	2.04	n/a

F-38

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

b) Stock options

The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and expire ten years after the grant date.

The following table summarizes changes in stock options during the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		720,600		$	1.82
Forfeited		(275,000	)		2.60
Expired		(1,000	)		3.15
Balance at December 31, 2021		444,600		$	1.33

No stock options were granted in 2021. The following table summarizes changes in stock options during the year ended December 31, 2020:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2019		623,850		$	4.33
Granted		481,600			1.16
Forfeited		(384,850	)		4.96
Balance at December 31, 2020		720,600		$	1.82

The following table summarizes outstanding stock options as at December 31, 2021:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$1.15		325,000		8.41		108,332		8.41
$1.19		81,600		8.49		81,600		8.49
$3.15		38,000		6.35		20,500		6.06
		444,600		8.25		210,432		8.21

c) Restricted share units

RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares.

The following table summarizes changes in RSUs during the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		1,656,916
Granted		12,381,525
Forfeited		(1,582,628	)
Exercised		(4,919,883	)
Balance at December 31, 2021		7,535,930

F-39

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes changes in RSUs during the year ended December 31, 2020:

	RSUs outstanding
Balance at December 31, 2019		48,883
Granted		3,002,213
Forfeited		(43,813	)
Exercised		(1,350,367	)
Balance at December 31, 2020		1,656,916

Subsequent to December 31, 2021, the Company granted 15.6 million RSUs to employees as part of its long-term incentive program.

Cash-settled plans

d) Deferred share units

DSUs are granted to directors and generally vest in equal instalments over one year. The Company intended to settle the DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle the DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities.

As at December 31, 2021, included in other liabilities is $4.0 million relating to the fair value of cash-settled DSUs (note 21).

The following table summarizes changes in DSUs during the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		3,323,263
Granted		2,489,173
Exercised		(300,000	)
Balance at December 31, 2021		5,512,436

As at December 31, 2021, 0.6 million DSUs were exercisable.

The following table summarizes changes in DSUs during the year ended December 31, 2020:

	DSUs outstanding
Balance at December 31, 2019		367,924
Granted		3,265,503
Forfeited		(310,164	)
Balance at December 31, 2020		3,323,263

25. Gross revenue

Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers. Retail revenue is derived from retail cannabis sales to customers, franchise revenue consisting of royalty, advertising and franchise fee revenue, and other revenue consisting of millwork, supply and accessories revenue.

F-40

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

	Year ended December 31
	2021		2020		2019
Cannabis revenue
Provincial boards		41,338		55,315		13,386
Medical		8		32		24
Licensed producers		9,842		17,974		53,517
Cannabis revenue (1)		51,188		73,321		66,927
Retail revenue (2)
Retail		10,207		—		—
Franchise		4,251		—		—
Other (millwork, supply, accessories)		1,633		—		—
Retail revenue		16,091		—		—
Gross revenue		67,279		73,321		66,927

(1) The Company had three major customers (which are provincial boards) each with revenue in excess of 10% of total cannabis revenue. Sales to these major customers totaled $28.2 million for the year ended December 31, 2021 (year ended December 31, 2020 – four major customers with total sales of $43.9 million, year ended December 31, 2019 – four major customers with total sales of $40.7 million).

(2) For the period July 20, 2021 to December 31, 2021.

The following table disaggregates cannabis revenue by form for the periods noted:

	Year ended December 31
	2021		2020		2019
Revenue from dried flower		39,572		51,424		58,246
Revenue from vapes		4,743		18,447		504
Revenue from oil		1,665		3,145		8,177
Revenue from edibles and concentrates		2,555		305		—
Revenue from services		2,653		—		—
Gross revenue		51,188		73,321		66,927

The Company has recognized the following receivables from contracts with customers:

	December 31, 2021		December 31, 2020		December 31, 2019
Receivables, included in 'trade receivables' (note 10)		10,865		15,786		20,281

Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2021, an impairment of $0.2 million (December 31, 2020 - $0.5 million reversal) has been recognized on receivables from contracts with customers (note 32).

26. Investment revenue

	Year ended December 31
	2021		2020		2019
Interest and fee revenue
Interest revenue from investments at amortized cost		1,654		—		—
Interest and fee revenue from investments at FVTPL		8,514		—		—
Interest revenue from cash		2,981		—		—
		13,149		—		—

F-41

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

	Year ended December 31
	2021			2020		2019
Investment revenue
Realized gains		20,213			—		—
Unrealized losses (note 9)		(64,714	)		—		—
		(44,501	)		—		—

27. Other operating expenses

A) General and administrative

	Year ended December 31
	2021		2020		2019
Salaries and wages		18,675		11,634		15,262
Consulting fees		1,112		2,193		6,896
Office and general		7,560		9,843		9,533
Professional fees		6,530		4,658		3,559
Director fees		351		365		188
Other		4,142		3,336		3,496
		38,370		32,029		38,934

B) Sales and marketing

	Year ended December 31
	2021		2020		2019
Marketing		3,671		4,839		3,093
Events		191		393		2,961
Research		43		57		199
Media		1,138		448		1,815
		5,043		5,737		8,068

28. Government subsidies

In March 2020, the federal government launched the Canadian Emergency Wage Subsidy (“CEWS”) to help businesses impacted by the COVID-19 pandemic keep and rehire employees.

The Company became eligible for the CEWS based on decreases in revenue and for the year ended December 31, 2021, the subsidy of $2.1 million (2020 - $4.0 million) was recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CEWS.

In October 2020, the federal government launched the Canadian Emergency Rent Subsidy (“CERS”) to help businesses impacted by the COVID-19 pandemic cover part of their commercial rent or property taxes. The CERS program provides a base rent subsidy that is available to organizations that continue to see decreasing revenues and an additional top up for organizations that must either close or significantly restrict their activities due to a public health order. CERS was available from September 27, 2020, until June 2021.

F-42

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The Company became eligible for CERS based on decreases in revenue and for the year ended December 31, 2020, the subsidy of $0.1 million was recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CERS.

29. Finance costs

	Year ended December 31
	2021			2020			2019
Cash finance expense
Interest on Syndicated Credit Agreement		—			4,546			1,746
Interest on Term Debt Facility		—			2,936			3,478
Other finance costs		40			286			9,202
		40			7,768			14,426
Non-cash finance expense (income)
Change in fair value of investment at FVTPL		3,300			—			—
Interest on lease liabilities		776			—			—
Financial guarantee liability recovery		59			—			—
Accretion		—			1,622			5,511
Amortization of debt issue costs		—			1,782			1,586
Change in fair value of convertible notes		—			(7,141	)		—
Other		154			3			3,973
		4,289			(3,734	)		11,070
Interest income		(573	)		(215	)		—
Interest capitalized relating to CIP		—			—			(1,280	)
		3,756			3,819			24,216

F-43

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

30. Supplemental cash flow disclosures

	Year ended December 31
	2021			2020			2019
Cash provided by (used in):
Accounts receivable		7,328			(2,037	)		(19,625	)
Biological assets		3,829			13,789			19,328
Inventory		(18,318	)		(12,315	)		(57,977	)
Prepaid expenses and deposits		(3,922	)		2,280			(7,213	)
Investments		(402	)		—			—
Property, plant and equipment		22			—			—
Accounts payable and accrued liabilities		9,665			(20,793	)		27,819
Convertible notes		—			—			(152	)
		(1,798	)		(19,076	)		(37,820	)
Changes in non-cash working capital relating to:
Operating		(1,534	)		(5,259	)		(41,626	)
Investing		(612	)		(11,319	)		1,659
Financing		348			(2,498	)		2,147
		(1,798	)		(19,076	)		(37,820	)
Cash interest paid		—			6,094			13,753

31. Loss per share

	Year ended December 31
	2021			2020			2019
Weighted average shares outstanding (000s)
Basic and diluted (1)		1,860,380			218,645			85,750
Continuing operations
Net loss attributable to Sundial Growers Inc.		(230,382	)		(199,619	)		(142,533	)
Per share - basic and diluted	$	(0.12	)	$	(0.92	)	$	(1.67	)
Discontinued operations
Net loss attributable to Sundial Growers Inc.		—			(33,627	)		(128,931	)
Per share - basic and diluted	$	—		$	(0.15	)	$	(1.50	)
Net loss attributable to Sundial Growers Inc.		(230,382	)		(233,246	)		(271,464	)
Per share - basic and diluted	$	(0.12	)	$	(1.07	)	$	(3.17	)

(1) For the year ended December 31, 2021, there were 3.6 million equity classified warrants, 99.3 million derivative warrants, 2.6 million simple warrants, 1.4 million performance warrants, 0.4 million stock options and 7.5 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2020 – 1.0 million equity classified warrants, 1.0 million derivative warrants, 3.4 million simple warrants, 1.7 million performance warrants, 0.7 million stock options and 1.7 million RSUs, year ended December 31, 2019 – 6.2 million equity classified warrants, 9.8 million simple warrants, 5.8 million performance warrants, 0.6 million stock options and 0.1 million RSUs).

F-44

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

32. Financial instruments

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVTPL, accounts payable and accrued liabilities and derivative warrants.

a) Fair value

The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions.

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700
			Fair value measurements using
December 31, 2020	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Investments at FVTPL		51,876		—		—		51,876
Financial liabilities
Derivative warrants (1)		428		—		—		428

(1) The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Marketable securities are designated as FVTPL. The fair value of marketable securities is re-measured each reporting period with changes in fair value recognized in the consolidated statement of loss and comprehensive loss. The fair value of marketable securities is estimated by using current quoted prices in active markets for identical assets.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

As at December 31, 2021, the Company did not have any financial instruments measured at Level 2 fair value.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The investment designated as FVTPL is re-measured each reporting period with changes in the fair value recognized in the consolidated statement of loss and comprehensive loss within finance costs. The fair value of

F-45

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

the investment was estimated by using a discounted cash flow analysis. The main assumption used in the calculation was the determination of a credit-adjusted discount rate.

Derivative warrants are designated as FVTPL. The fair value of derivative warrants is re-measured each reporting period with changes in fair value recognized in the consolidated statement of loss and comprehensive loss within finance costs. The fair value of derivative warrants is estimated by using a valuation model. Assumptions used in these calculations include volatility, discount rate and various probability factors.

At December 31, 2021, a 10% change in the material assumptions would change the estimated fair value of derivative warrant liabilities by approximately $4.0 million.

There were no transfers between Levels 1, 2 and 3 inputs during the period.

b) Credit risk management

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 to accounts receivable and has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2021		December 31, 2020
Impairment loss (reversal) on trade receivables		214		(506	)
Impairment loss (reversal) on other receivables		798		(126	)
		1,012		(632	)

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2021 was as follows:

	December 31, 2021		December 31, 2020
Balance, beginning of year		120		752
Net remeasurement of impairment loss allowance		1,012		(632	)
Balance, end of year		1,132		120

The Company applies the general approach under IFRS 9 to investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition. The general approach compares the risk of a default occurring at the reporting date with the risk of a default occurring at the date of initial recognition. The Company has evaluated the credit risk of its investments, taking into consideration the risk of default, historical credit loss experience, financial factors specific to the debtors and general economic conditions and determined the expected credit loss to be nil.

The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments.

F-46

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

c) Market risk management

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities and put and call options.

At December 31, 2021, a 10% change in the market prices would change the fair value of marketable securities by approximately $8.4 million.

The Company had the following risk management contracts relating to marketable securities outstanding as at December 31, 2021:

As at December 31, 2021	Quantity		Expiry	Proceeds		Fair value
Sold put options		2,174	Feb 18, 2022		34		27
Sold put options		1,329	Mar 18, 2022		65		51
		3,503			99		78

d) Liquidity risk management

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

The timing of expected cash outflows relating to financial liabilities at December 31, 2021 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		38,452		—		—		—		38,452
Lease obligations		5,938		10,514		8,424		13,629		38,505
Financial guarantee liability		—		466		—		—		466
Balance, end of period		44,390		10,980		8,424		13,629		77,423

33. Related party transactions

a) Loan receivable agreements

At December 31, 2020, the Company had advanced $139 thousand under employee loan agreements. The terms were non-interest bearing and secured by shareholdings in the Company. During the year ended December 31, 2021, the full $139 thousand loan balance was settled. At December 31, 2021, the outstanding loan balance was nil.

b) Related party transactions and balances

	Transactions				Balance outstanding
	Year ended December 31		Year ended December 31		December 31		December 31
	2021		2020		2021		2020
Marketing, brand research and development (a)		—		1,144		—		—
Legal services (b)		—		2,462		—		(510	)
		—		3,606		—		(510	)

(a) A former member of the Board controlled a company that provides marketing, brand research and development services.

(b) A member of the Board was a partner at a law firm prior to his departure which provides legal services to the Company.

F-47

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

All transactions were conducted at the exchange amount agreed to with the related parties.

c) Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2021		2020		2019
Salaries and short-term benefits		2,348		1,944		3,295
Share-based compensation		8,275		7,629		23,715
		10,623		9,573		27,010

34. Capital management

The Company defines capital as shareholders’ equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to:

• Maintain financial flexibility in order to preserve the ability to meet financial obligations;

• Deploy capital to provide an appropriate investment return to shareholders; and,

• Maintain a capital structure that allows various financing alternatives.

35. Commitments and contingencies

(a) Commitments

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2021 of $2.5 million (December 31, 2020 - $1.5 million).

(b) Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re Sundial Growers Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re Sundial Growers Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions assert claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally allege that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic

F-48

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also includes allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021 and remains subject to such court approval.

In connection with the settlement agreement, the Company has an unrecognized contingent asset of $2 million, representing the difference between the settlement amount and the deductible under the Company’s directors and officers insurance policy. A contingent asset is disclosed when an inflow of economic resources is probable. A receivable for the $2 million will not be recognized until written confirmation of payment is received from the insurers.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. Sundial Growers Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserts claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) the Securities Exchange Act of 1934, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleges that the company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

The Company can provide no assurance as to the outcome of these proceedings or any other litigation matter in which we are a party. In particular, securities class action lawsuits are typically costly to defend, and divert the attention of management and other resources from operations and, accordingly, even if resolved in our favor, could have a material adverse effect on our business, financial condition, results of operations and liquidity and may force us to reduce or cease operations or seek relief under the applicable bankruptcy or insolvency laws.

36. Subsequent events

Alcanna Inc. Acquisition

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company will acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximately 63% equity interest in Nova Cannabis Inc. (“Nova”), a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 320.6 million Sundial common shares valued at $280.4 million based on the fair value of each common share of the Company on the closing date (8.85 of a Sundial common share for each Alcanna common share).

Due to the proximity of the closing of the Alcanna Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

F-49

Sundial Growers Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2021

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Nasdaq minimum bid requirement

As previously reported, the Company was notified by Nasdaq on August 9, 2021, that the bid price for its common shares did not meet the minimum bid price of US$1.00 per share requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). At that time, the Company was required to regain compliance by February 7, 2022. On February 8, 2022, the Company received a 180-day extension to regain compliance with the Minimum Bid Requirement. As a result, the Company has until August 8, 2022, to regain compliance with the Minimum Bid Requirement.

If at any time prior to August 8, 2022, the closing bid price of the Company’s common stock is at least US$1.00 per share for a minimum of ten consecutive business days, the Company will be considered by Nasdaq to have regained compliance with the Minimum Bid Requirement.

The Company will actively monitor its closing bid price during the compliance period and intends to take appropriate measures to remedy the deficiency and regain compliance with the Minimum Bid Requirement.

Sun 8 Holdings Inc.

In 2019, the Company purchased intellectual property from Sun 8 Holdings Inc. (“Sun 8”) consisting of cannabis brands and products. The agreement included future consideration in the form of warrants to acquire up to 1.8 million common shares at an exercise price of $0.94, contingent upon achieving minimum thresholds of revenue derived from the acquired brands and cultivars over five years. The agreement also included royalty payments based on defined harvest metrics and merchandise sold under the acquired brands.

Subsequent to December 31, 2021, the Company and Sun 8 mutually terminated the service and sale agreement entered into in 2019. The Company issued 3.7 million common shares with a value of $2.9 million and made a cash payment of $3.1 million to cancel the royalty agreement and the non-competition agreement, as well as acknowledge vesting of 0.6 million performance warrants. The remaining 1.2 million warrants will not vest, and the Company is relieved of any future obligation pertaining to the warrants.

Investments

Subsequent to December 31, 2021, the Company entered into a promissory note with a private company with a principal amount of $5.0 million, an interest rate of 15% per annum and a maturity date of February 9, 2025.

Subsequent to December 31, 2021, the Company and Delta 9 Cannabis Inc. (“Delta 9”) entered into a note purchase agreement with an aggregate principal amount of $10.0 million, an interest rate of 10% per annum and a maturity date of March 30, 2025.

F-50

EX-8.1

Exhibit 8.1

Sundial Growers Inc.

Significant Subsidiaries of the Registrant

Name	Jurisdiction of Incorporation
KamCan Products Inc.	British Columbia, Canada
Sundial Deutschland GmbH	Germany
2657408 Ontario Inc.	Ontario, Canada
NGBA-BC Holdings Ltd.	British Columbia, Canada
Sundial Insurance (Bermuda) Ltd.	Bermuda
Inner Spirit Holdings Ltd.	Alberta, Canada
Spirit Leaf Inc.	Alberta, Canada
Spirit Leaf Corporate Inc.	Alberta, Canada
Spirit Leaf Ontario Inc.	Ontario, Canada

EX-12.1

EXHIBIT 12.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

I, Zachary George, certify that:

1. I have reviewed this annual report on Form 20-F of Sundial Growers Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Sundial Growers Inc. as of, and for, the periods presented in this report;

4. The other certifying officer of Sundial Growers Inc. and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Sundial Growers Inc. and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Sundial Growers Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of disclosure controls and procedures of Sundial Growers Inc. and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in internal control over financial reporting of Sundial Growers Inc. that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect internal control over financial reporting of Sundial Growers Inc.; and

5. The other certifying officer of Sundial Growers Inc. and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the auditors of Sundial Growers Inc. and the audit committee of the board of directors of Sundial Growers Inc. (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the ability of Sundial Growers Inc. to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the internal control over financial reporting of Sundial Growers Inc.

Date: April 27, 2022

/s/ Zachary George

Chief Executive Officer

EX-12.2

EXHIBIT 12.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

I, James Keough, certify that:

1. I have reviewed this annual report on Form 20-F of Sundial Growers Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Sundial Growers Inc. as of, and for, the periods presented in this report;

4. The other certifying officer of Sundial Growers Inc. and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Sundial Growers Inc. and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Sundial Growers Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of disclosure controls and procedures of Sundial Growers Inc. and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in internal control over financial reporting of Sundial Growers Inc. that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect internal control over financial reporting of Sundial Growers Inc.; and

5. The other certifying officer of Sundial Growers Inc. and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the auditors of Sundial Growers Inc. and the audit committee of the board of directors of Sundial Growers Inc. (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the ability of Sundial Growers Inc. to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the internal control over financial reporting of Sundial Growers Inc.

Date: April 27, 2022

/s/ James Keough

Chief Financial Officer

EX-13.1

EXHIBIT 13.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Zachary George, Chief Executive Officer of Sundial Growers Inc., certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Annual Report on Form 20-F of Sundial Growers Inc. for the period ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sundial Growers Inc.

Date: April 27, 2022

/s/ Zachary George

Chief Executive Officer

EX-13.2

EXHIBIT 13.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James Keough, Chief Financial Officer of Sundial Growers Inc., hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Annual Report on Form 20-F of Sundial Growers Inc. for the period ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sundial Growers Inc.

Date: April 27, 2022

/s/ James Keough

Chief Financial Officer

EX-15.1

EXHIBIT 15.1

Sundial Growers Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the year ended December 31, 2021

Management’s Discussion and Analysis

This Management’s Discussion and Analysis (“MD&A”) of the financial condition and performance of Sundial Growers Inc. (“Sundial” or the “Company”) for the year ended December 31, 2021 is dated April 27, 2022. This MD&A should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 and the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 (collectively, the “Audited Financial Statements”) and the risks identified under “Risk Factors” below and in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 (the “Annual Report”). This MD&A has been prepared in accordance with National Instrument 51-102 - Continuous Disclosure Obligations and is presented in thousands of Canadian dollars, except where otherwise indicated.

MD&A – Table of Contents

COMPANY OVERVIEW	3
RECENT DEVELOPMENTS	4
OTHER DEVELOPMENTS	5
OPERATIONAL AND FINANCIAL HIGHLIGHTS	8
CONSOLIDATED RESULTS	9
OPERATING SEGMENTS	12
CANNABIS OPERATIONS SEGMENT RESULTS	12
RETAIL OPERATIONS SEGMENT RESULTS	17
INVESTMENT OPERATIONS SEGMENT RESULTS	17
DISCONTINUED OPERATIONS – ORNAMENTAL FLOWERS	19
FOURTH QUARTER 2021	20
SELECTED QUARTERLY INFORMATION	23
SELECTED ANNUAL INFORMATION	24
LIQUIDITY AND CAPITAL RESOURCES	25
CONTRACTUAL COMMITMENTS AND CONTINGENCIES	28
SPECIFIED FINANCIAL MEASURES	29
RELATED PARTIES	31
OFF BALANCE SHEET ARRANGEMENTS	31
CRITICAL ACCOUNTING POLICIES AND ESTIMATES	32
NEW ACCOUNTING PRONOUNCEMENTS	32
RISK FACTORS	32
DISCLOSURE CONTROLS AND PROCEDURES	32
INTERNAL CONTROL OVER FINANCIAL REPORTING	33
REMEDIATION	34
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING	35
ABBREVIATIONS	35
FORWARD-LOOKING INFORMATION	35
ADDITIONAL INFORMATION	36

1

COMPANY OVERVIEW

Sundial (“SNDL”, “Sundial” or the “Company”) is a licensed producer that grows cannabis using state-of-the-art indoor facilities with corporate-owned and franchised retail operations focused on the retail sale of cannabis products and accessories, and investment operations targeting the global cannabis industry. Sundial was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. The Company’s common shares are listed under the symbol “SNDL” on the NASDAQ Capital Market (“Nasdaq”).

Sundial is headquartered in Calgary, Alberta, with operations in Olds, Alberta, and Rocky View County, Alberta, and corporate-owned and franchised retail stores in five provinces across Canada.

The principal activities of the Company are the production, distribution and sale of cannabis in Canada pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada.

Sundial currently produces and markets cannabis products for the Canadian adult-use market. Sundial’s purpose-built indoor modular grow rooms create consistent, highly controlled cultivation environments and are the foundation of the Company’s production of high-quality, strain-specific cannabis products. Sundial’s operations cultivate cannabis using an individualized “room” approach, in approximately 448,000 square feet of total space. The Company has established supply agreements with nine Canadian provinces and has a distribution network that covers 98% of the national adult-use cannabis industry.

The Company’s primary focus has been on producing and distributing premium inhalable products and brands. Upon receiving a licence from Health Canada to sell cannabis oil products, the Company began the sale and distribution of cannabis vape products in December 2019. The Company is currently marketing its adult-use products under its Top Leaf (Premium), Sundial Cannabis (Premium Core), Palmetto (Core)and Grasslands (Value) brands and intends to introduce new products under these brands as it expands its brand portfolio. The Company also operates the Spiritleaf retail banner. Spiritleaf aims to be the most knowledgeable and trusted source of recreational cannabis by offering a premium consumer experience and quality curated cannabis products.

Sundial and its subsidiaries currently operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. (“SunStream”), the Company also provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

Sundial’s overall strategy is to build sustainable, long-term shareholder value by improving liquidity and cost of capital while optimizing the capacity and capabilities of its production facilities in the creation of a consumer-centric brand and product portfolio. Sundial’s retail operations will continue to build a Canadian retail brand and a network of retail cannabis stores across Canadian jurisdictions where the private distribution of cannabis is legal. Sundial’s investment operations seek to deploy capital through direct and indirect investments and partnerships throughout the global cannabis industry.

To achieve this, Sundial will continue to focus on:

• Meeting evolving consumer preferences by being a consumer-centric organization;

• Delivering industry-leading, best-in-class brands and products with a focus on inhalables;

• Driving quality in all aspects of our operation and being positioned to deliver products that consumers want when they want them;

• Improving cost discipline and maintaining a variable cost structure to adapt to industry dynamics; and

• Strategically deploying capital with a focus on maximizing cash flows and long-term shareholder value.

2

RECENT DEVELOPMENTS

ALCANNA INC. ACQUISITION

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company will acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximately 63% equity interest in Nova Cannabis Inc. (“Nova”), a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 320.6 million Sundial common shares valued at $280.4 million based on the fair value of each common share of the Company on the closing date (8.85 of a Sundial common share for each Alcanna common share).

Due to the proximity of the closing of the Alcanna Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Initiation of share repurchase program

On November 11, 2021, the Company announced that the board of directors of Sundial (the “Board”) approved a new share repurchase program (the "Share Repurchase Program") which authorizes the Company to repurchase, from time to time, up to an aggregate of $100 million (the "Share Repurchase Amount") of its outstanding common shares through open market purchases at prevailing market prices. Notwithstanding the Share Repurchase Amount, Sundial may only purchase a maximum of 102.8 million common shares under the Share Repurchase Program, representing approximately 5% of the issued and outstanding common shares as at the date of announcement.

Subject to the foregoing limitations, the Share Repurchase Program commenced on November 19, 2021 and will expire on November 19, 2022. The Share Repurchase Program does not require the Company to purchase any minimum number of common shares, and repurchases maybe suspended or terminated at any time at the Company's discretion. The actual number of common shares which may be purchased pursuant to the Share Repurchase Program and the timing of any purchases will be determined by Sundial’s management and the Board. All common shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation.

No common shares were repurchased during the year ended December 31, 2021.

STRATEGIC CAPITAL PARTNERSHIP

On March 15, 2021, the Company and SAF Group (“SAF”) announced they had entered into an agreement to form a 50/50 joint venture through a new corporation, SunStream. SunStream is a private company which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. See “Investment Results – Share of profit of equity-accounted investees” for more information.

On July 7, 2021, the Company announced that it had increased its commitment to SunStream to $538.0 million from the previously announced commitment of $188 million. As of April 27, 2022, the Company had contributed $465.9 million to SunStream. The Company’s balance sheet exposure is limited to its equity-investment in SunStream of $412.9 million at December 31, 2021, and its share of profit of equity-accounted investees of $32.9 million for the year ended December 31, 2021.

In the United States, SunStream has provided lending services to cannabis businesses in the form of secured debt and hybrid debt and derivative instruments. Sundial, through its involvement in the SunStream joint venture, is classified as having indirect ancillary involvement in the U.S. marijuana industry as referenced in CSA Staff Notice 51-352, which states that ancillary involvement arises when an issuer provides goods and/or services not limited to financing, branding, recipes, leasing, consulting or administrative services to third parties who are directly involved in the U.S. marijuana industry.

Cannabis (or, as referred to in the United States, marijuana) is illegal under U.S. federal law and the enforcement of relevant U.S. laws poses a significant risk to the results of our operations and financial results. For further information about the risks related to U.S. federal laws and regulations with respect to SunStream’s operations as well as the risk of federal enforcement and other risks associated with the Company’s business, see the risks identified under “Risk Factors” below and in the Annual Report.

3

The Company’s involvement in SunStream could have anundetermined impact on the Company’s ability to access both public and private capital.

Legal advice has been obtained by SunStream and the Company regarding applicable U.S. federal and state law in relation to SunStream’s business.

The Company is not aware of any of the businesses of recipients of SunStream services being in non-compliance with applicable licensing requirements and the regulatory framework enacted by the U.S. states in which they operate.

SunStream’s investment committee is responsible for evaluating investment and financing opportunities encompassing secured debt, hybrid securities and distressed debt and equity targeting the global cannabis industry.

capital Activities

During the year ended December 31, 2021, the Company issued an aggregate of 796.3 million common shares at a weighted average price of US$0.8597 per share for gross proceeds of $855.2 million (US$684.6 million) through its at-the-market (“ATM”) programs. The Company also completed two registered direct offerings for gross proceeds of $223.4 million and received gross proceeds of $118.6 million from the exercise of warrants issued in connection with those registered direct offerings (see “Other Developments – Registered Direct Offerings” for more information). At December 31, 2021, the Company had an unrestricted cash balance of $557.4 million.

The capital raised was used to fund the deployment of capital toward strategic investments. The Company developed an internal capital program to evaluate these and potential future investments, which the Company viewed as a new and separate business line from its cannabis and retail operations.

Based on the allocation of the Company’s resources by the chief operating decision maker and the information used to analyze the performance of the business, the Company concluded that beginning in Q1 2021, it had a new operating segment: investments.

See “Financial Results – Consolidated” for more information on operating segments.

OTHER DEVELOPMENTS

Registered direct offerings

On February 2, 2021, the Company issued 100.0 million series A units (the “Series A Units”), each consisting of one common share and one-half series A warrant (collectively, the “Series A Warrants”) to purchase one common share and 33.3 million series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “Series B Warrants”) to purchase one common share and one-half Series A Warrant to purchase one common share (collectively, the “January 2021 Units Offering”). Each Series A Unit was sold at a price of US$0.75 per unit and each Series B Unit was sold at a price of US$0.75 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$100.0 million. The Series A Warrants and Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the Series A Warrants was US$0.80 per common share and the exercise price of the Series B Warrants was US$0.0001 per common share.

On February 2, 2021, the entire 33.3 million Series B Warrants were exercised resulting in the issuance of 33.3 million common shares.

On February 10, 2021, 3.3 million Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 3.3 million common shares and gross proceeds to the Company of US$2.7 million.

On February 4, 2021, the Company issued 60.5 million additional Series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “Additional Series A Warrants”) to purchase one common share and 14.0 million additional series B units (the “Additional Series B Units”), each consisting of one pre-funded additional series B warrant (the “Additional Series B Warrants”) to purchase one common share and one-half Additional Series A Warrant to purchase one common share, (collectively, the “February 2021 Units Offering”). Each Additional Series A Unit was sold at a price of US$1.00 per unit and each Additional Series B Unit was sold at a price of US$1.00 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$74.5 million. The Additional Series A Warrants and Additional Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the Additional Series A Warrants was US$1.10 per common share and the exercise price of the Additional Series B Warrants was US$0.0001 per common share.

4

On February 4, 2021, the entire 14.0 million Additional Series B Warrants were exercised resulting in the issuance of 14.0 million common shares.

On February 10, 2021, 2.3 million Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 2.3 million common shares and gross proceeds to the Company of US$2.5 million.

On February 22, 2021, (i) the remaining 63.3 million Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million and (ii) the remaining 35.0 million Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the Company issued 98.3 million new warrants (the “New Warrants”), each entitling the holder to purchase one common share at an exercise price of US$1.50, subject to customary anti-dilution adjustments. The Company has granted the holders rights to have the common shares issuable upon exercise of the New Warrants registered pursuant to a registration statement filed with the SEC. Such registration statement was filed with the SEC on March 3, 2021. The New Warrants are immediately exercisable and have a term of 42 months from March 18, 2021, which is the effective date of the registration statement.

Reduction in pathway ownership

On March 23, 2021, the Company’s equity interest in its subsidiary, Pathway RX Inc. (“Pathway”), decreased from 50% to 25%, resulting in a loss of control. The Company decreased its equity interest in connection with amending the licence agreement that provides for use of Pathway’s intellectual property.

Acquisition of Inner SPirit Holdings and Spiritleaf Retail Cannabis Network

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

The Inner Spirit Transaction consideration was comprised of (i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share), (ii) an aggregate 24.4 million Sundial common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.0835 of a Sundial common share for each Inner Spirit common share) and (iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

COVID-19

The Company is monitoring daily developments in the COVID-19 pandemic and actions taken by the government authorities in response thereto. As the safety of employees, communities and family is a priority for the Company, it will continue to commit to all current safety protocols in place, which include physical distancing, enhanced cleaning and sanitation processes and frequency, installation of safety shields in retail outlets and enhanced screening measures prior to allowing employees and visitors into the facilities. The Company believes that it can maintain safe operations with these pandemic-related procedures and protocols in place.

NASDAQ MINIMUM BID REQUIREMENT

On August 9, 2021, the Company was notified by the Nasdaq Listing Qualifications Department that the closing bid price of the Company’s common shares for the 30 consecutive business day period from June 25, 2021, to August 6, 2021 did not meet the minimum bid price of US$1.00 per share requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The notice has no immediate effect on the trading of the Company’s common shares on the Nasdaq.

Pursuant to the Nasdaq Listing Rules, the Company had been provided with a compliance period of 180 calendar days from the date of notification in which to regain compliance with the Minimum Bid Requirement. As a result, the Company had until February 7, 2022, to regain compliance with the Minimum Bid Requirement. On February 8, 2022, the Company received a 180-day extension to regain compliance with the Minimum Bid Requirement. As a result, the Company has until August 8, 2022, to regain compliance with the Minimum Bid Requirement. If at any time prior to August 8, 2022, the closing bid price of the Company’s common stock is at least US$1.00 per share for a minimum of ten consecutive business days, the Company will be considered by Nasdaq to have regained compliance with the Minimum Bid Requirement.

5

If the Company does not regain compliance with the Minimum Bid Requirement by August 8, 2022, it intends to implement a reverse share split in the third quarter of 2022, subject to prior shareholder approval, which is expected to be obtained at the Company’s 2022 Annual General Meeting.

OPERATIONAL AND FINANCIAL HIGHLIGHTS

The following table summarizes selected operational and financial information of the Company for the periods noted.

($000s, except as indicated)	YTD 2021			YTD 2020			Change			% Change
Financial
Gross revenue		67,279			73,321			(6,042	)		-8	%
Net revenue		56,128			60,918			(4,790	)		-8	%
Cost of sales		48,601			51,740			(3,139	)		-6	%
Gross margin		(6,990	)		(49,869	)		42,879			86	%
Gross margin %		-12	%		-82	%					69	%
Gross margin before fair value adjustments (1)(2)		(9,451	)		(36,735	)		27,284			74	%
Gross margin before fair value adjustments % (2)		-17	%		-60	%					72	%
Interest and fee revenue		13,149			—			13,149			100	%
Investment loss		(44,501	)		—			(44,501	)		-100	%
Loss from operations		(132,131	)		(185,404	)		53,273			29	%
Net loss from continuing operations (3)		(230,382	)		(199,619	)		(30,763	)		-15	%
Per share, basic and diluted (3)		(0.12	)		(0.91	)		0.79			87	%
Net loss from discontinued operations (3)		—			(33,627	)		33,627			100	%
Per share, basic and diluted (3)		—			(0.15	)		0.15			100	%
Net loss (3)		(230,382	)		(233,246	)		2,864			1	%
Per share, basic and diluted (3)		(0.12	)		(1.07	)		0.95			89	%
Adjusted EBITDA from continuing operations (2)		32,086			(25,583	)		57,669			225	%
Statement of Financial Position
Cash and cash equivalents		558,251			60,376			497,875			825	%
Biological assets		4,410			3,531			879			25	%
Inventory		29,503			25,613			3,890			15	%
Property, plant and equipment		63,189			116,928			(53,739	)		-46	%
Total assets		1,424,262			294,871			1,129,391			383	%
Operational
Kilogram equivalents sold		18,019			23,500			(5,481	)		-23	%
Average gross selling price per gram (4)		2.84			3.12			(0.28	)		-9	%
Average net selling price per gram (5)		2.22			2.59			(0.37	)		-14	%

(1) Includes inventory obsolescence and impairment of $17.0 million for the year ended December 31, 2021, and $45.9 million for year ended December 31, 2020.

(2) Adjusted EBITDA from continuing operations, gross margin before fair value adjustments and gross margin before fair value adjustments percentage are specified financial measures that do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

(3) Net loss and related per share amounts are attributable to owners of the Company.

(4) Net of payment discounts with respect to sales under Sundial’s supply agreements with Canadian provincial boards.

(5) Net of excise tax.

6

CONSOLIDATED RESULTS

General and administrative

	Year ended December 31
($000s)	2021		2020
Salaries and wages		18,675		11,634
Consulting fees		1,112		2,193
Office and general		7,560		9,843
Professional fees		6,530		4,658
Director compensation		351		365
Other		4,142		3,336
		38,370		32,029

General and administrative expenses for the year ended December 31, 2021 were $38.4 million compared to $32.0 million for the year ended December 31, 2020. The increase of $6.4 million was mainly due to increases in salaries and wages and professional fees, partially offset by decreases in consulting fees and office and general expenses. The increase in salaries and wages was due to the Inner Spirit Transaction and increased compensation related to the roll out of a new incentive plan given the improvement in liquidity during the year. The increase in professional fees was largely due to an increase in legal fees and accounting service fees associated with investment operations and the Company’s efforts to enhance internal control over financial reporting. The decrease in consulting fees is mainly due to consulting costs incurred in the comparative period relating to business process improvements. The decrease in office and general expenses is mostly due to a decrease in insurance expenses.

Sales and marketing

	Year ended December 31
($000s)	2021		2020
Sales and marketing		5,043		5,737

Sales and marketing expenses consist of brand development and promotion expenses, marketing services and related costs.

Sales and marketing expenses for the year ended December 31, 2021 were $5.0 million compared to $5.7 million for the year ended December 31, 2020. The decrease of $0.7 million was mainly due to a decrease in general marketing and media expenses.

Share-based compensation

	Year ended December 31
($000s)	2021			2020
Equity-settled expense
Simple warrants		2,899			1,539
Performance warrants		361			(42	)
Stock options		(14	)		651
Restricted share units		6,789			4,069
Cash-settled expense
Deferred share units		2,272			2,349
		12,307			8,566

Share-based compensation expense includes the expense related to the Company’s issuance of simple and performance warrants, stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees, directors, and others at the discretion of the Company’s Board.

The fair value of the Company’s common shares is based on public trading data. The estimated fair value of the Company’s common shares at the time of grant is used to determine the associated share-based compensation expense. The Company

7

determines the amount of share-based compensation expense for equity settled awards by utilizing the Black-Scholes pricing model with inputs based on the terms of the award, including the strike price, and other estimates and assumptions, including the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of the awards granted.

The Company intended to settle DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities. As at December 31, 2021, included in other liabilities is $4.0 million relating to the fair value of cash-settled DSUs. The DSUs will be accounted for as a liability and marked to market at each period end.

Share-based compensation expense for the year ended December 31, 2021 was $12.3 million compared to $8.6 million for the year ended December 31, 2020. The increase of $3.7 million was primarily due to increases in simple warrant expense and RSU expense. Simple warrant expense in the comparative period was reduced by a significant number of unvested simple warrant forfeitures. No simple warrants were granted in the current or comparative period. RSU expense increased due to an increase in the number and value of units granted.

Transaction costs

	Year ended December 31
($000s)	2021		2020
Transaction costs		17,566		3,587

Transaction costs for the year ended December 31, 2021 were $17.6 million compared to $3.6 million for the year ended December 31, 2020. Transaction costs include costs associated with the registered offerings, the Inner Spirit Transaction, the Alcanna Transaction, legal costs and various financing initiatives.

Finance costs

	Year ended December 31
($000s)	2021			2020
Cash finance expense
Interest on Term Debt Facility		—			2,936
Interest on Syndicated Credit Agreement		—			4,546
Other finance costs		40			286
		40			7,768
Non-cash finance expense
Change in fair value of investment at FVTPL		3,300			—
Interest on lease liabilities		776			—
Financial guarantee liability expense		59			—
Accretion		—			1,622
Amortization of debt issue costs		—			1,782
Change in fair value of convertible notes		—			(7,141	)
Other		154			3
		4,289			(3,734	)
Interest income		(573	)		(215	)
		3,756			3,819

Finance costs include interest expense related to lease obligations, change in fair value of investment at FVTPL and certain other expenses. Finance costs in the prior year included interest on the Company’s indebtedness, accretion expense and amortization of debt issue costs associated with the Company’s indebtedness, change in fair value of convertible notes and certain other expenses.

8

Finance costs for the year ended December 31, 2021 were $3.8 million compared to $3.8 million for the year ended December 31, 2020. Decreases in interest expense, accretion and amortization of debt issue costs due to the extinguishment and settlement of the Company’s long-term debt, were offset by the change in fair value of convertible notes from the comparative period and change in fair value of the investment at FVTPL.

Change in estimate of fair value of derivative warrants

	Year ended December 31
($000s)	2021		2020
Change in estimate of fair value of derivative warrants		77,834		12,995

Change in estimate of fair value of derivative warrants for the year ended December 31, 2021 was an expense of $77.8 million compared to an expense of $13.0 million for the year ended December 31, 2020. The increased expense of $64.8 million was due to an increase in the number of derivative warrants issued and exercised. In the current period, 103.9 million series A warrants were issued and exercised, and 98.3 million New Warrants were issued. The expense in the comparative period related to changes in fair value of the secured convertible note warrants (35.0 million issued and exercised), the unsecured convertible note warrants (14.5 million issued and 0.5 million outstanding) and the 2020 series A warrants (40.1 million issued and 0.5 million outstanding).

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability, pursuant to IFRS requirements due to the warrant exercise prices being denominated in United States dollars. Refer to note 32 in the condensed consolidated interim financial statements for valuation methodology. The Company has no cash obligation with respect to the derivative warrants, and its only obligation is to deliver common shares if, and when, warrants are exercised.

Income tax recovery

	Year ended December 31
($000s)	2021		2020
Income tax recovery		2,271		—

Income tax recovery for the year ended December 31, 2021 was $2.3 million and was due to the recognition of previously unrecognized tax assets to offset income taxes arising from the recognition of other comprehensive income.

Net loss from continuing operations

	Year ended December 31
($000s)	2021			2020
Net loss from continuing operations		(230,182	)		(206,317	)

Net loss for the year ended December 31, 2021 was $230.2 million compared to a net loss of $206.3 million for year ended December 31, 2020. The increased loss of $23.9 million was mostly due to lower net revenue ($4.7 million), investment losses ($44.5 million), higher general and administrative expenses ($6.3 million), higher transaction costs ($14.0 million) and change in fair value of derivative warrant liabilities ($64.8 million), partially offset by lower cost of sales ($3.1 million), lower inventory obsolescence provision ($28.9 million), change in fair value realized through inventory ($16.3 million), interest and fee revenue ($13.1 million), share of profit of equity-accounted investees ($32.9 million), lower asset impairment ($19.2 million) and income tax recovery ($2.3 million).

Adjusted EBITDA from continuing operations

	Year ended December 31
($000s)	2021		2020
Adjusted EBITDA from continuing operations (1)		32,086		(25,583	)

(1) Adjusted EBITDA from continuing operations is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

9

Adjusted EBITDA from continuing operations was $32.1 million for the year ended December 31, 2021 compared to a loss of $25.6 million for the year ended December 31, 2020. The increase was due to the following:

• Introduction of investment revenue;

• Introduction of interest and fee revenue; and

• Introduction of share of profit of equity-accounted investees; and

• Decrease in cost of sales.

The increase was partially offset by:

• a decrease in net revenue, primarily as a result of decreases in selling prices and kilogram equivalents sold; and

• an increase in general and administrative expenses, primarily as a result of increases in salaries and wages.

OPERATING SEGMENTS

Late in the fourth quarter of 2020 the Company began the deployment of capital toward strategic investments. The Company developed an internal capital program to evaluate these and potential future investments, which is a new and separate business line from its cannabis and retail operations.

Based on the allocation of the Company’s resources by the chief operating decision maker and the information used to analyze the performance of the business, the Company concluded that beginning in Q1 2021, it had two reportable segments: cannabis operations and investments. The acquisition of Inner Spirit has on July 20, 2021, led to a third reportable segment: retail operations. For the year ended December 31, 2020, there was only one reportable segment and therefore no comparative segment information.

The Company’s reportable segments are organized by business line and are comprised of three reportable segments: cannabis operations, retail operations and investments. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada. Retail operations include the private sale of recreational cannabis through corporate-owned and franchise retail cannabis stores. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any reportable segments are reported as “Corporate”.

($000s)	Cannabis			Retail (1)		Investments			Corporate			Total
As at December 31, 2021
Total assets		147,887			153,624		1,093,596			29,155			1,424,262
Year ended December 31, 2021
Net revenue		40,037			16,091		—			—			56,128
Gross margin		(15,499	)		8,509		—			—			(6,990	)
Interest and fee revenue		—			—		13,149			—			13,149
Loss on marketable securities		—			—		(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—			—		32,913			—			32,913
Depreciation and amortization		3,108			721		—			897			4,726
Earnings (loss) before tax		(117,990	)		1,835		(5,837	)		(110,461	)		(232,453	)

(1) Period July 20, 2021 to December 31, 2021

CANNABIS OPERATIONS SEGMENT RESULTS

Kilogram equivalents sold

	Year ended December 31
	2021		2020
Provincial boards		12,583		10,952
Medical		4		4
Licensed producers		5,432		12,544
Total kilogram equivalents sold		18,019		23,500

10

For the year ended December 31, 2021, the Company sold 18,019 kilogram equivalents of cannabis compared to 23,500 kilogram equivalents for the year ended December 31, 2020. The decrease of 5,481 kilogram equivalents sold was due to a decrease in kilogram equivalents sold to other licensed producers (“LPs”), partially offset by an increase in kilogram equivalents sold to provincial boards. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

The Company’s calculation of kilogram equivalents (or other measurement equivalents stated in this MD&A, such as gram equivalents) is based upon internal estimates and may not be comparable to similar measures used by other companies.

Selling price

	Year ended December 31
($/gram equivalent)	2021			2020
Provincial boards	$	3.29		$	5.05
Medical	$	9.80		$	8.00
Licensed producers	$	1.81		$	1.43
Average gross selling price	$	2.84		$	3.12
Excise taxes	$	(0.62	)	$	(0.53	)
Average net selling price	$	2.22		$	2.59

For the year ended December 31, 2021, the average net selling price was $2.22 per gram equivalent compared to $2.59 for the year ended December 31, 2020. The decrease of $0.37 per gram equivalent was mainly due to lower prices for provincial board sales, partially offset by slightly higher prices for sales to other LPs. Provincial board sales prices have decreased due to continued growth of the discount segment and undersupply of available quality product.

The principal drivers of the Company’s realized prices are the formats of the products sold (currently both bulk and packaged flower, inhalables and accessories, trim, bulk extracted oil, edibles and concentrates) and the channels in which products are sold (principally Canadian provincial boards and LPs).

Excise taxes are the federal excise duties and additional provincial or territorial duties payable on adult-use cannabis products. Excise taxes for the year ended December 31, 2021 and 2020 are only calculated based on adult-use end-consumer packaged cannabis sales.

Revenue

Revenue by form

	Year ended December 31
($000s)	2021		2020
Revenue from dried flower		39,572		51,424
Revenue from vapes		4,743		18,447
Revenue from oil		1,665		3,145
Revenue from edibles and concentrates		2,555		305
Revenue from services		2,653		—
Gross revenue		51,188		73,321

11

Revenue by channel

	Year ended December 31
($000s, except as indicated)	2021			2020
Provincial boards		41,338			55,315
Medical		8			32
Licensed producers		9,842			17,974
Gross revenue		51,188			73,321
Excise taxes		(11,151	)		(12,403	)
Net revenue		40,037			60,918
Gross revenue per gram sold	$	2.84		$	3.12
Net revenue per gram sold	$	2.22		$	2.59

The Company’s revenue comprises bulk and packaged sales under the Cannabis Act pursuant to its supply agreements with Canadian provincial boards and to other LPs. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

The Company has entered into a concentrates licensing agreement with a third party based out of its Rocky View facility. Administrative fees and facility fees charged under the licensing agreement are recorded as revenue from services.

Gross revenue for the year ended December 31, 2021 was $51.2 million compared to $73.3 million for the year ended December 31, 2020. The decrease of $22.1 million was due to a decrease in kilogram equivalents sold to other LPs and a decrease in selling prices. Provincial board revenue decreased by $14.0 million due to a decrease in selling prices, partially offset by an increase in kilogram equivalents sold. LP revenue decreased by $8.2 million due to a decrease in kilogram equivalents sold, partially offset by an increase in selling prices.

Excise taxes are the federal excise duties and additional provincial or territorial duties payable on adult-use cannabis products at the time such product is shipped from the production facility in its final consumer-facing packaging. Federal duties on adult-use cannabis products are calculated as the greater of (i) $0.25 per gram of flowering material, (ii) $0.75 per gram of non-flowering material or $0.25 per viable seed or seedling and (iii) 2.5% of the dutiable amount as calculated in accordance with the Excise Act, 2001. The rates of provincial or territorial duties vary.

Excise taxes for the year ended December 31, 2021 were $11.2 million compared to $12.4 million for the year ended December 31, 2020. The decrease of $1.2 million was due to a shift in product mix from non-flowering material to flowering material which has a lower excise tax rate, even though total kilogram equivalents sold to provincial boards increased compared to the prior period.

Cost of sales

	Year ended December 31
($000s, except as indicated)	2021		2020
Cost of sales		41,019		51,740
Cost of sales per gram sold	$	2.28	$	2.20

Cost of sales includes three main categories: pre-harvest, post-harvest and shipment and fulfillment costs. These costs are incurred in respect of cultivating, harvesting, processing and packaging cannabis products. Pre-harvest costs include all direct and indirect costs incurred between initial recognition and the point of harvest, including labour-related costs, grow consumables, materials, utilities, facilities costs and depreciation related to production facilities. Post-harvest costs include all direct and indirect costs incurred subsequent to the point of harvest, including labour-related costs, consumables, materials, utilities and facilities costs. Shipment and fulfillment costs include packaging, transportation, quality control and testing costs.

Cost of sales for the year ended December 31, 2021 were $41.0 million compared to $51.7 million for the year ended December 31, 2020. The decrease of $10.7 million was due to a decrease in kilogram equivalents sold compared to the prior period, partially offset by an increase in the cost of sales per gram sold compared to the prior period. Cost of sales per gram sold for the year ended December 31, 2021 were $2.28 compared to $2.20 for the year ended December 31, 2020. The increase of $0.08 per gram sold was due to the Company moving away from bulk sales to other LPs, which have materially lower per gram costs, to branded sales to provincial boards, partially offset by decreases in per gram costs across all branded product formats,

12

reflecting the Company’s focus on cost optimization and offering the most competitive and profitable strains and brands to customers.

Gross margin

	Year ended December 31
($000s)	2021			2020
Net revenue		40,037			60,918
Cost of sales		41,019			51,740
Inventory obsolescence and impairment		16,978			45,913
Gross margin before fair value adjustments (1)		(17,960	)		(36,735	)
Change in fair value of biological assets		4,708			5,432
Change in fair value realized through inventory		(2,247	)		(18,566	)
Gross margin		(15,499	)		(49,869	)

(1) Gross margin before fair value adjustments is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

Gross margin before fair value adjustments

Gross margin before fair value adjustments is defined as net revenue less cost of sales and inventory obsolescence and impairment before adjusting for the non-cash changes in the fair value adjustments on the sale of inventory and the growth of biological assets.

Gross margin before fair value adjustments for the year ended December 31, 2021 was negative $18.0 million compared to negative $36.7 million for the year ended December 31, 2020. The increase of $18.7 million was due to lower cost of sales relating to lower sales volumes and a lower inventory obsolescence provision compared to the prior period, partially offset by lower net revenue. The inventory obsolescence provision was applied to vapes, oil, concentrates, bulk flower and shake due to price compression in the market, as well as certain packaging inventory. The inventory obsolescence provision in the comparative period was applied across all cannabis inventory formats, bulk and packaged, due to a lack of market demand and aging inventory.

The total inventory obsolescence and impairment recognized during the year ended December 31, 2021 was $17.5 million, with $17.0 million relating to cost of sales and $0.5 million relating to the change in fair value realized through inventory. The total inventory obsolescence and impairment recognized during the year ended December 31, 2020 was $56.9 million, with $45.9 million relating to cost of sales and $11.0 million relating to the change in fair value realized through inventory.

Change in fair value of biological assets

Biological assets consist of cannabis plants in various stages of vegetation, including clones, which have not been harvested. Net unrealized changes in fair value of biological assets less cost to sell during the period are included in the results of operations for the related period. Biological assets are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusted for the amount for the expected selling price less costs to sell per gram.

Change in fair value of biological assets for the year ended December 31, 2021 was an increase of $4.7 million compared to an increase of $5.4 million for the year ended December 31, 2020. The decrease of $0.7 million was primarily due to a decrease in the expected number of plants, partially offset by an increase in the expected selling price less costs to sell per gram.

Change in fair value realized through inventory

	Year ended December 31
($000s)	2021			2020
Change in fair value realized through inventory sold		(1,730	)		(7,581	)
Change in fair value recognized through inventory obsolescence provision		(517	)		(10,985	)
Change in fair value realized through inventory		(2,247	)		(18,566	)

13

Change in fair value realized through inventory comprises fair value adjustments associated with the cost of inventory when such inventory is sold. Inventories are carried at the lower of cost and net realizable value. When sold, the cost of inventory is recorded as cost of sales, while fair value adjustments are recorded as change in fair value realized through inventory.

The change in fair value realized through inventory for the year ended December 31, 2021 was a decrease of $2.2 million compared to a decrease of $18.6 million for the year ended December 31, 2020. The increase of $16.4 million was due to the fair value component of the excess and obsolete inventory provision in the comparative period and the reversal of larger prior period changes in fair value of biological assets as they are transferred to inventory and sold.

Restructuring costs

	Year ended December 31
($000s)	2021		2020
Restructuring costs		—		6,470

Restructuring costs of $6.5 million for the year ended December 31, 2020 represent severance costs relating to workforce reductions, legal, professional and consulting fees that relate directly to the restructuring and finance costs associated with the amendment and extinguishment of long-term debt.

Asset impairment

	Year ended December 31
($000s)	2021		2020
Asset impairment		60,000		79,191

The Company determined that indicators of impairment existed during the second quarter in the year ended December 31, 2021, with respect to the Company’s Olds cash generating unit (“CGU”) as a result of curtailment in the utilization of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates. A test for impairment was performed at June 30, 2021, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their value in use and an impairment of $60.0 million was recorded to write down the assets to their estimated recoverable amount.

At December 31, 2021, the Company determined that no indicators of impairment existed or indicators that a previous impairment should be reversed, and no impairment test was required.

The Company determined that indicators of impairment existed during the year ended December 31, 2020, with respect to the Company’s British Columbia CGU as a result of the Company’s disposition of its Kamloops property and decision to suspend further construction and development activities on its Merritt facility due to market conditions and available financing. Approximately $10.0 million had been invested into the Merritt facility which consisted of land and construction in progress. A test for impairment was performed at March 31, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their fair value less costs of disposal and an impairment of $5.7 million was recorded to write down the assets to their recoverable amount.

The Company determined that indicators of impairment existed during the year ended December 31, 2020, with respect to the Company’s Alberta CGU as a result of decreasing estimates for the size of the potential Canadian cannabis market, the Company curtailing the number of flowering rooms being used for cultivation at its Olds facility and the carrying value of the Company’s total net assets significantly exceeding the Company’s market capitalization. A test for impairment was performed at September 30, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their value in use and an impairment of $60.0 million was recorded to write down the assets to their estimated recoverable amount.

During the year ended December 31, 2020, the Company determined that indicators of impairment existed regarding the Pathway intellectual property due to the Company’s decision to reduce its focus on medical cannabis research. The estimated recoverable amount of the intangible assets was determined to be their fair value less costs of disposal and an impairment of $12.9 million was recorded to write down the assets to their recoverable amount.

On December 28, 2020, the Company licensed all of its Rocky View facility to a third party concentrates manufacturer. Within the agreement is a non-binding purchase agreement to sell the Rocky View facility for $5.0 million. The estimated recoverable

14

amount of the Rocky View facility was determined to be its fair value less costs of disposal and an impairment of $0.7 million was recorded to write down the assets to their recoverable amount.

RETAIL OPERATIONS SEGMENT RESULTS

GROSS revenue

	Year ended December 31
($000s)	2021		2020
Retail		10,207		—
Franchise		4,251		—
Other (millwork, supply, accessories)		1,633		—
Gross revenue		16,091		—

Gross revenue for the period July 20, 2021, to December 31, 2021, was $16.1 million. Retail revenue is comprised of retail cannabis sales to private customers from corporate-owned stores. Franchise revenue is comprised of royalty revenue, advertising revenue and franchise fees. Prior to opening, Spiritleaf franchised retail cannabis stores purchase millwork (store fixtures) from the Company. Once a franchise Spiritleaf retail cannabis store is open and operating, it purchases supplies and Spiritleaf accessories from the Company to sell to customers.

GROSS MARGIN

	Year ended December 31
($000s)	2021		2020
Gross revenue		16,091		—
Cost of sales		7,582		—
Gross margin		8,509		—

Gross margin for the period July 20, 2021, to December 31, 2021, was $8.5 million. Cost of sales for retail operations is comprised of the cost of pre-packaged cannabis.

System-wide retail sales

System-wide retail sales represent the aggregate revenue earned by both franchised and corporate-owned Spiritleaf retail cannabis stores, and do not solely represent the retail segment’s revenue. The Company only receives royalties, advertising and franchise fees in respect of the franchised Spiritleaf retail cannabis store revenue. The system-wide retail sales measure is useful to management in evaluating brand scale and market penetration and is used by management to assess the financial and operating performance of the Company and the strength of the Company’s market position relative to its competitors.

System-wide retail sales for the period July 20, 2021 to December 31, 2021 were as follows:

	Year ended December 31
($000s)	2021			2020
Gross revenue		16,091			—
Less:
Franchise revenue		(4,251	)		—
Other revenue		(1,633	)		—
Add:
Franchise store sales (1)		64,739			—
System-wide retail sales (1)		74,946			—

(1) System-wide retail sales and franchise store sales are specified financial measures that do not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

15

INVESTMENTOPERATIONS SEGMENT RESULTS

Interest and fee revenue

	Year ended December 31
($000s)	2021		2020
Interest and fee revenue
Interest revenue from investments at amortized cost		1,654		—
Interest and fee revenue from investments at Fair Value Through Profit or Loss		8,514		—
Interest revenue from cash		2,981		—
		13,149		—

Interest and fee revenue for the year ended December 31, 2021, was $13.1 million and was generated from cannabis-related investments. The Company continues to build its investment portfolio with a focus on maximizing risk-adjusted cash flows and shareholder value.

Investment revenue

	Year ended December 31
($000s)	2021			2020
Investment revenue
Realized gains		20,213			—
Unrealized losses		(64,714	)		—
		(44,501	)		—

Investment revenue is comprised of realized and unrealized gains on marketable securities. Investment revenue for the year ended December 31, 2021, was negative $44.5 million and was mostly due to unrealized losses driven by decreasing share prices of the Company’s investments in Village Farms International, Inc. and The Valens Company, partially offset by realized gains on the disposition of marketable securities. The Company continues to strategically deploy capital with a focus on maximizing risk-adjusted cash flows and shareholder value.

Share of profit of equity-accounted investees

	Year ended December 31
($000s)	2021		2020
Net profit		32,913		—

Share of profit of equity-accounted investees is comprised of the Company’s share of the net profit generated from its investments in SunStream. The current investment portfolio of SunStream is comprised of secured debt and hybrid debt and derivative instruments with United States based cannabis businesses. Refer to note 3 in the Audited Financial Statements for a description of the accounting policy and to note 17(a) in the Audited Financial Statements for a description of the nature of the investments.

During the year ended December 31, 2021, the Company recognized $32.9 million as its share of profit of equity-accounted investees.

Restructuring costs

	Year ended December 31
($000s)	2021		2020
Restructuring costs		874		—

Restructuring costs of $0.9 million for the year ended December 31, 2021, represent legal fees associated with the proposed public offering of a SunStream subsidiary.

16

DISCONTINUED OPERATIONS – ORNAMENTAL FLOWERS

On February 22, 2019, the Company, through its wholly owned subsidiary, Sundial UK Limited, signed a sale and purchase agreement to acquire all the issued and outstanding shares of Project Seed Topco Limited (“Bridge Farm”). The acquisition closed on July 2, 2019.

On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Bridge Farm to a company affiliated with the former management sellers that were parties to the original acquisition (the “Bridge Farm Purchaser”) in exchange for (i) the assumption by the Bridge Farm Purchaser of $45 million of the total $115 million principal amount outstanding under the Term Debt Facility (thereby reducing the Company’s then outstanding obligations thereunder to $70 million), (ii) the assumption by the Bridge Farm Purchaser of contingent consideration liabilities related to the additional share obligation and remaining earn out obligation under the original Bridge Farm acquisition agreement dated July 2, 2019, and (iii) the cancellation of approximately 2.7 million Sundial common shares, representing all of the shares currently held by the management sellers of Bridge Farm issued in connection with the original acquisition of Bridge Farm by the Company in 2019 (collectively, the “Bridge Farm Disposition”).

The sale of Bridge Farm closed on June 5, 2020. The Bridge Farm operations comprised the entire Ornamental Flower segment that was located in the United Kingdom. The comparative consolidated statement of loss and comprehensive loss and statement of cash flows in the financial statements for the year ended December 31, 2020 have been presented to show the discontinued operation separately from continuing operations. The Company no longer has an Ornamental Flower segment.

During the period January 1, 2020, to June 5, 2020, the Company recorded revenues of $22.1 million from Bridge Farm and a net loss of $33.6 million from Bridge Farm, which includes a loss on the disposition of Bridge Farm of $15.0 million.

Capital expenditures with respect to discontinued operations during the period January 1, 2020, to June 5, 2020, consisted of $4.4 million mainly related to the Bridge Farm Clay Lake facility.

FOURTH QUARTER 2021

($000s, except as indicated)	Q4 2021			Q4 2020			Change			% Change
Financial
Gross revenue		25,630			16,865			8,765			52	%
Net revenue		22,719			13,853			8,866			64	%
Cost of sales		15,918			10,638			5,280			50	%
Gross margin		(2,499	)		(4,695	)		2,196			47	%
Gross margin %		-11	%		-34	%					23	%
Gross margin before fair value adjustments (1)(2)		(2,901	)		(5,060	)		2,159			43	%
Gross margin before fair value adjustments % (2)		-13	%		-37	%					24	%
Interest and fee revenue		3,647			—			3,647			100	%
Investment loss		(41,755	)		—			(41,755	)		100	%
Loss from operations		(44,000	)		(32,677	)		(11,323	)		-35	%
Net loss from continuing operations (3)		(54,990	)		(57,622	)		2,632			5	%
Per share, basic and diluted (3)		(0.03	)		(0.11	)		0.08			73	%
Net loss (3)		(54,990	)		(57,622	)		2,632			5	%
Per share, basic and diluted (3)		(0.03	)		(0.11	)		0.08			73	%
Adjusted EBITDA from continuing operations (2)		18,425			(5,633	)		24,058			427	%
Operational
Kilogram equivalents sold		5,202			7,247			(2,045	)		-28	%
Average gross selling price per gram (4)		3.01			2.33			0.69			30	%
Average net selling price per gram (5)		2.45			1.91			0.54			28	%

17

(1) Includes inventory obsolescence and impairment of $9.7 million for the three months ended December 31, 2021, and $8.3 million for three months ended December 31, 2020.

(2) Adjusted EBITDA from continuing operations, gross margin before fair value adjustments and gross margin before fair value adjustments percentage are specified financial measures that do not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

(3) Net loss and related per share amounts are attributable to owners of the Company.

(4) Net of payment discounts with respect to sales under Sundial’s supply agreements with Canadian provincial boards.

(5) Net of excise tax.

CONSOLIDATED

General and administrative expenses for the three months ended December 31, 2021 were $11.6 million compared to $6.5 million for the three months ended December 31, 2020. The increase of $5.1 million was mainly due to increases in salaries and wages. The increase in salary and wages was due to the Inner Spirit Transaction and increased compensation related to the roll out of a new incentive plan given the improvement in liquidity during the year.

Sales and marketing expenses for the three months ended December 31, 2021 were $1.5 million compared to $2.3 million for the three months ended December 31, 2020. The decrease of $0.8 million was due to a decrease in general marketing expenses.

Share-based compensation expense for the three months ended December 31, 2021 was $2.4 million compared to $1.5 million for the three months ended December 31, 2020. The increase of $0.9 million was due to increases in simple warrant expense, partially offset by a decrease in RSU expense and DSU expense. Simple warrant expense in the comparative period was a recovery caused by a significant number of unvested simple warrant forfeitures. RSU expense decreased due to a decrease in value of units granted in the comparative period. DSU expense decreased due to a decrease in the fair value of the DSU liability from when it was initially recognized during the three months ended September 30, 2021.

Transaction costs for the three months ended December 31, 2021, were $7.8 million compared to $0.8 million for the three months ended December 31, 2020. Transaction costs in the current period relate to the Inner Spirit Transaction, the Alcanna Transaction and legal costs, as compared to legal costs and various financing initiatives in the comparative period.

Finance costs for the three months ended December 31, 2021 were $3.5 million compared to $5.0 million for the three months ended December 31, 2020. The decrease of $1.5 million was due to the change in fair value of convertible notes from the comparative period, decreases in interest expense, accretion and amortization of debt issue costs due to the extinguishment and settlement of the Company’s long-term debt.

Change in estimate of fair value of derivative warrants for the three months ended December 31, 2021 was a recovery of $8.2 million compared to an expense of $23.5 million for the three months ended December 31, 2020. The increase of $31.7 million was due to a recovery in the current period relating to the decrease in the estimated fair value of the 98.3 million New Warrants and an expense in the prior period relating to an increase in estimated fair value of secured convertible note warrants, unsecured convertible note warrants and series A warrants.

Net loss for the three months ended December 31, 2021 was $54.8 million compared to a net loss of $64.1 million for three months ended December 31, 2020. The decrease of $9.3 million was largely due to interest and fee revenue ($3.6 million), share of profit of equity-accounted investees ($19.3 million), lower asset impairments ($13.5 million) and change in fair value of derivative warrant liabilities ($31.7 million), partially offset by investment losses ($41.8 million) and transaction costs ($7.0 million).

Adjusted EBITDA from continuing operations was $18.4 million for the three months ended December 31, 2021 compared to a loss of $5.6 million for the three months ended December 31, 2020. The increase was due to the following:

• Increase in net revenue including Spiritleaf;

• Introduction of investment revenue;

• Introduction of interest and fee revenue; and

• Introduction of share of profit of equity-accounted investees.

The increase was partially offset by:

• Increase in cost of sales including Spiritleaf; and

• Increase in general and administrative expenses.

CANNABIS

For the three months ended December 31, 2021, the Company sold 5,202 kilogram equivalents of cannabis compared to 7,247 kilogram equivalents for the three months ended December 31, 2020. The decrease of 2,045 kilogram equivalents sold was due

18

to a decrease in kilogram equivalents sold to other licensed producers (“LPs”) and a slight decrease in kilogram equivalents sold to provincial boards. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

For the three months ended December 31, 2021, the average net selling price was $2.45 per gram equivalent compared to $1.91 for the three months ended December 31, 2020. The increase of $0.54 per gram equivalent was largely due to an increase in prices for sales to other LPs, partially offset by lower prices for provincial board sales. The comparative period included large bulk sales to other LPs resulting in a low price per gram average. Provincial board sales prices have decreased due to continued growth of the discount segment and undersupply of available quality product.

Gross revenue for the three months ended December 31, 2021 was $15.7 million compared to $16.9 million for the three months ended December 31, 2020. The decrease of $1.2 million was due to a decrease in kilogram equivalents sold, partially offset by an increase in selling prices. Provincial board revenue decreased by $3.1 million due to a decrease in selling prices and a slight decrease in kilogram equivalents sold. LP revenue increased by $2.0 million due to a decrease in kilogram equivalents sold, partially offset by an increase in selling prices.

Excise taxes for the three months ended December 31, 2021 were $2.9 million compared to $3.0 million for the three months ended December 31, 2020. The decrease of $0.1 million was due to a decrease in sales to provincial boards from the comparative period.

Cost of sales for the three months ended December 31, 2021 were $10.8 million compared to $10.6 million for the three months ended December 31, 2020. The increase of $0.2 million was due to an increase in the cost of sales per gram sold compared to the prior period, partially offset by a decrease in kilogram equivalents sold compared to the prior period. Cost of sales per gram sold for the three months ended December 31, 2021 were $2.08 compared to $1.47 for the three months ended December 31, 2020. The increase of $0.61 was mostly due to the comparative period including several large quantity bulk sales to other LPs, resulting in a low cost of sales per gram sold average.

Gross margin before fair value adjustments for the three months ended December 31, 2021 was negative $7.8 million compared to negative $5.1 million for the three months ended December 31, 2020. The decrease of $2.7 million was due to lower net revenue and a higher inventory obsolescence provision compared to the prior period. The inventory obsolescence provision was applied primarily to vapes, oil, bulk flower and shake due to price compression in the market. The inventory obsolescence provision in the comparative period was applied across all cannabis inventory formats, bulk and packaged, due to a lack of market demand and aging inventory.

Change in fair value of biological assets for the three months ended December 31, 2021 was an increase of $2.2 million compared to an increase of $0.6 million for the three months ended December 31, 2020. The increase of $1.6 million was mainly due to an increase in the expected selling price less costs to sell per gram.

The change in fair value realized through inventory for the three months ended December 31, 2021 was a decrease of $1.8 million compared to a decrease of $0.2 million for the three months ended December 31, 2020. The decrease of $1.6 million was due to the fair value component of the excess and obsolete inventory provision and the reversal of smaller prior period changes in fair value of biological assets as they are transferred to inventory and sold.

RETAIL

Gross revenue for the three months ended December 31, 2021, was $10.0 million, comprised of retail, franchise and other revenue. Gross margin for the three months ended December 31, 2021, was $4.9 million.

INVESTMENT

Interest and fee revenue for the three months ended December 31, 2021, was $3.6 million, generated from cannabis-related investments.

Investment loss for the three months ended December 31, 2021, was $41.8 million, and was due to unrealized losses driven by decreasing market prices of the related investments.

Share of profit of equity-accounted investees for the three months ended December 31, 2021, was $19.3 million, representing the Company’s share of the net profit generated from its investments in SunStream.

19

SELECTED QUARTERLY INFORMATION

The following table summarizes selected consolidated operating and financial information of the Company for the preceding eight quarters.

	2021												2020
($000s, except as indicated)	Q4			Q3			Q2			Q1			Q4 (2)			Q3			Q2			Q1
Gross revenue (1)		25,630			17,162			12,739			11,748			16,865			15,525			24,341			16,590
Gross investment revenue (loss)		(38,108	)		(14,699	)		5,706			15,749			—			—			—			—
Gross margin		(2,499	)		1,782			(2,821	)		(3,452	)		(4,695	)		(19,544	)		(15,137	)		(10,493	)
Net income (loss) from continuing operations attributable to owners of the Company		(54,990	)		11,311			(52,287	)		(134,416	)		(57,622	)		(71,386	)		(32,750	)		(37,861	)
Per share, basic		(0.03	)		0.006			(0.03	)		(0.09	)		(0.11	)		(0.53	)		(0.31	)		(0.35	)
Per share, diluted		(0.03	)		0.005			(0.03	)		(0.09	)		(0.11	)		(0.53	)		(0.31	)		(0.35	)
Net loss from discontinued operations attributable to owners of the Company		—			—			—			—			—			—			(27,593	)		(6,034	)
Per share, basic and diluted		—			—			—			—			—			—			(0.26	)		(0.06	)
Net loss attributable to owners of the Company		(54,990	)		11,311			(52,287	)		(134,416	)		(57,622	)		(71,386	)		(60,343	)		(43,895	)
Per share, basic		(0.03	)		0.006			(0.03	)		(0.09	)		(0.11	)		(0.53	)		(0.57	)		(0.41	)
Per share, diluted		(0.03	)		0.005			(0.03	)		(0.09	)		(0.11	)		(0.53	)		(0.57	)		(0.41	)
Adjusted EBITDA from continuing operations (3)		18,425			10,539			(205	)		3,327			(5,633	)		(4,409	)		(3,898	)		(11,643	)

(1) Gross revenue from continuing operations.

(2) Q4 2020 net loss from continuing operations, net loss attributable to owners of the Company and the per share amounts have been recast to attribute 50% of the impairment of intangible assets recorded to non-controlling interest. Refer to note 17(b) in the consolidated financial statements for the year ended December 31, 2021.

(3) Adjusted EBITDA from continuing operations is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

During the eight most recent quarters the following items have had a significant impact on the Company’s financial results and results of operations:

• disposition of Bridge Farm;

• issuance and conversion of convertible notes and warrants;

• extinguishment and repayment of the Company’s long-term debt;

• implementing several streamlining and efficiency initiatives which included workforce optimizations;

• issuance of equity securities in various registered offerings;

• issuance of common shares under various at-the-market programs;

• entering into and acquiring several cannabis-related investments;

• investing and disposing of marketable securities;

• decreasing ownership in Pathway;

• shift to include investment strategy as part of operations;

• price discounts and provisions for product returns;

• impairment of property, plant and equipment;

• provisions for inventory obsolescence;

• investing in SunStream; and

• acquisition of Inner Spirit.

20

SELECTED ANNUAL INFORMATION

The following table summarizes selected financial information of the Company for the three most recently completed financial years.

	Year ended December 31			Year ended December 31			Year ended December 31
($000s, except as indicated)	2021			2020			2019
Gross revenue (1)		67,279			73,321			66,927
Net loss (1)(2)		(230,382	)		(199,619	)		(142,533	)
Per share, basic and diluted (1)	$	(0.12	)	$	(0.91	)	$	(1.67	)
Total assets		1,424,262			294,871			510,036
Total non-current liabilities		32,274			1,031			19,592

(1) Gross revenue, net loss and net loss per share are from continuing operations and net loss and net loss per share areattributable to owners of the Company.

(2) Year ended December 31, 2020, net loss from continuing operations has been recast to attribute 50% of the impairment of intangible assets recorded to non-controlling interest. Refer to note 17(b) in the Audited Financial Statements.

GROSS REVENUE

During the year ended December 31, 2021, gross revenue decreased by $6.0 million due to a decrease in kilogram equivalents sold and a decrease in selling prices, partially offset by the post acquisition retail revenue.

During the year ended December 31, 2020, gross revenue increased by $6.4 million due to an increase in provincial board sales, partially offset by a decrease in sales to other LP’s.

During the year ended December 31, 2019, gross revenue increased by $66.9 million due to the Company commencing production in the third quarter of 2018 with sales beginning in January 2019, as well as the ramp up in production with the expansion completed of the Olds facility.

Net loss

During the year ended December 31, 2021, net loss increased by $30.8 million due to lower net revenue, investment losses, higher general and administrative expenses, transaction costs and change in fair value of derivative warrant liabilities, partially offset by lower cost of sales, lower inventory obsolescence provision, change in fair value through inventory, lower asset impairment and income tax recovery. The lower net revenue and cost of sales was due to a decrease in kilogram equivalents sold. Investment losses were due to unrealized losses caused by decreasing market prices of the related investments. The increase in general and administrative expenses was due to higher salaries and wages and professional fees, partially offset by lower office and general expenses. Transaction costs related to acquisitions and legal costs. The change in fair value of derivative warrant liabilities was due to an increase in warrants granted and exercised during the period.

During the year ended December 31, 2020, net loss increased by $57.1 million due to a lower gross margin and higher asset impairment, partially offset by lower share-based compensation, finance costs and loss on financial obligation. The lower gross margin was due to an inventory obsolescence provision and changes in fair value of biological assets and fair value realized through inventory. Asset impairments were recorded for property, plant and equipment and intangible assets. Share-based compensation decreased due to the accelerated vesting in the prior year and a decrease in the value of awards granted. The financial obligation was terminated in the prior year and had no current year impact.

During the year ended December 31, 2019, net loss increased by $86.0 million due to higher general and administrative expense, share-based compensation expense, transaction costs, finance costs and loss on financial obligation, partially offset by a higher gross margin. The increase in general and administrative expenses was to support growth and expansion initiatives, as a result of becoming a public company and costs related to the introduction of new product lines and the ramp up of cannabis production and sales. The increase in share-based compensation expense was due to increased awards granted to employees and the accelerated vesting of share-based compensation awards upon completion of the Company’s initial public offering (“IPO”). Transaction costs were related to the acquisition of Bridge Farm and the IPO. The increase in finance costs was due to increased debt levels. The loss on financial obligation was due to the termination of the investment and royalty agreement.

21

Total assets

During the year ended December 31, 2021, total assets increased by $1,129.4 million due to increases in cash and cash equivalents, marketable securities, net investments in subleases, equity accounted investees and goodwill. Cash and cash equivalents increased mainly due to proceeds from the issuance of shares and registered offerings and proceeds from the exercise of derivative warrants. Marketable securities increased due to the Company investing in cannabis related equity instruments. Net investments in subleases and goodwill increased due to the acquisition of Inner Spirit. Equity-accounted investees increased due to investment in SunStream.

During the year ended December 31, 2020, total assets decreased by $215.2 million. The decrease was due to decreases in accounts receivable, biological assets, inventory, property, plant and equipment, intangible assets and goodwill, partially offset by an increase in investments. Accounts receivable, biological assets and inventory decreased due to the disposition of Bridge Farm and recording an inventory obsolescence provision. Property, plant and equipment and intangible assets decreased due to the disposition of Bridge Farm and asset impairments. Goodwill decreased due to the disposition of Bridge Farm. Investments increased due to acquiring an investment in a cannabis company.

During the year ended December 31, 2019, total assets increased by $399.8 million. The increase was due to increases in cash and cash equivalents, accounts receivable, biological assets, inventory, property, plant and equipment, intangible assets and goodwill. Cash and cash equivalents increased due to proceeds from debt instruments, convertible notes and the issuance of shares. Accounts receivable, biological assets and inventory increased due to the ramp up of cannabis production and sales commencing at the beginning of 2019. Property, plant and equipment, intangible assets and goodwill increased due to the acquisitions of Bridge Farm and Pathway and capital expenditures relating to the construction of the Olds facility.

Total non-current liabilities

During the year ended December 31, 2021, total non-current liabilities increased by $31.2 million. The increase was due to an increase in lease obligations from the Inner Spirit Transaction and the recognition of a DSU liability.

During the year ended December 31, 2020, total non-current liabilities decreased by $18.6 million. The decrease was due to decreases in lease obligations and deferred tax liability due to the Bridge Farm disposition.

During the year ended December 31, 2019, total non-current liabilities decreased by $28.9 million. The decrease was due to the classification of long-term debt as current at December 31, 2019, and the termination of the financial obligation.

LIQUIDITY AND CAPITAL RESOURCES

($000s)	December 31, 2021		December 31, 2020
Cash and cash equivalents		558,251		60,376

Capital resources are financing resources available to the Company and are defined as the Company’s debt and equity. The Company manages its capital resources with the objective of maximizing shareholder value and sustaining future development of the business. The Company manages its capital structure and adjusts it, based on the funds available to the Company, in order to support the Company’s activities. The Company may adjust capital spending, issue new equity or issue new debt, subject to the availability of commercial terms.

The Company’s primary need for liquidity is to fund investment opportunities, capital expenditures, working capital requirements and for general corporate purposes. The Company’s lease obligations have increased significantly due to the Inner Spirit Transaction as both corporate stores and franchise stores have leased retail space. Refer to “Contractual Commitments and Contingencies – Commitments” for an estimate of the contractual maturities of the Company’s lease obligations. The Company’s primary source of liquidity historically has been from funds received from the proceeds of common share issuances and debt financing. The Company’s ability to fund operations and investments and make planned capital expenditures depends on future operating performance and cash flows, as well as the availability of future financing – all of which is subject to prevailing economic conditions and financial, business and other factors.

Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

22

See “Recent Developments –Capital Activities” for more information.

Debt

As at December 31, 2021, the Company was debt free.

Equity

As at December 31, 2021, the Company had the following share capital instruments outstanding:

(000s)	December 31, 2021		December 31, 2020
Common shares		2,060,408		918,844
Common share purchase warrants (1)		3,566		1,024
Simple warrants (2)		2,594		3,425
Performance warrants (3)		1,387		1,672
Stock options (4)		445		721
Restricted share units		7,536		1,657

(1) 3.6 million warrants were exercisable as at December 31, 2021.

(2) 1.7 million simple warrants were exercisable as at December 31, 2021.

(3) 1.2 million performance warrants were exercisable as at December 31, 2021.

(4) 0.2 million stock options were exercisable as at December 31, 2021.

As atDecember 31, 2021, the Company had 2.06 billion shares outstanding (December 31, 2020 - 918.8 million shares).

Common shares were issued during the year ended December 31, 2021 in connection with the following transactions:

• The Company sold 796.3 million common shares under ATM Programs for gross proceeds of $855.2 million;

• Issuance of 100.0 million common shares in the January 2021 Units Offering for gross proceeds of $128.0 million;

• Exercise of all the Series B Warrants from the January 2021 Units Offering for 33.3 million common shares;

• Exercise of all the Series A Warrants from the January 2021 Offering for 66.7 million common shares and gross proceeds of $67.1 million;

• Issuance of 60.5 million common shares in the February 2021 Units Offering for gross proceeds of $95.4 million;

• Exercise of all the Additional Series B Warrants from the February 2021 Units Offering for 14.0 million common shares;

• Exercise of all the Additional Series A Warrants from the February 2021 Units Offering for 37.3 million common shares and gross proceeds of $51.5 million;

• The Company issued 24.4 million common shares relating to the acquisition of Inner Spirit;

• The Company issued 2.5 million common shares relating to the settlement of Inner Spirit convertible debentures; and

• The Company issued 5.5 million common shares related to the exercise of employee awards.

From January 1, 2022, to April 27, 2022:

• The Company issued 3.7 million common shares related to the termination of the service and sale agreement with Sun 8 Holdings Inc.

• The Company issued 320.6 million common shares related to the Alcanna Transaction

As at April 27, 2022, a total of 2.39 billion common shares were outstanding.

Capital Expenditures

	Year ended December 31
($000s)	2021		2020
Olds facility		1,420		2,345
Rocky View facility		—		—
Merritt facility (1)		—		(1,241	)
Other		2,373		1,920
Total		3,793		3,024

(1) The credit to the Merritt facility relates to the refund of provincial hydro and utility deposits.

23

Cash Flow Summary

	Year ended December 31
($000s)	2021			2020
Cash provided by (used in) continuing operations:
Operating activities		(155,437	)		(62,315	)
Investing activities		(496,280	)		(64,260	)
Financing activities		1,149,601			143,385
Effect of exchange rate changes		(9	)		665
Change in cash and cash equivalents		497,875			17,475

Cash Flow – Operating Activities

Net cash used in operating activities from continuing operations was $155.4 million for the year ended December 31, 2021 compared to $62.3 million used in operating activities for the year ended December 31, 2020. The increase of $93.1 million was due to investing in marketable securities and the change in non-cash working capital, partially offset by a decrease in net loss adjusted for non-cash items, proceeds from the disposition of marketable securities and income distributions from equity-accounted investees. The change in non-cash working capital is comprised of changes in inventory, accounts receivable, prepaid expenses and deposits and accounts payable.

Cash Flow – Investing Activities

Net cash used in investing activities from continuing operations was $496.3 million for the year ended December 31, 2021 compared to $64.3 million used in investing activities for the year ended December 31, 2020. The increase of $432.0 million was primarily due to additions to equity-accounted investees, additions to investments and the acquisition of Inner Spirit, partially offset by capital distributions received from equity-accounted investees and the change in non-cash working capital.

Cash Flow – Financing Activities

Net cash provided by financing activities from continuing operations was $1.1 billion for the year ended December 31, 2021 compared to $143.4 million provided by financing activities for the year ended December 31, 2020. The increase of $1.0 billion was largely due to proceeds from the issuance of shares, proceeds from registered offerings and proceeds from the exercise of derivative warrants, partially offset by the change in restricted cash, settlement of convertible debentures and proceeds from convertible notes in the comparative period.

Liquidity risks associated with financial instruments

Credit risk

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 and has calculated expected credit losses based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

The Company has evaluated the credit risk of its investments, taking into consideration historical credit loss experience, financial factors specific to the debtors and general economic conditions, and determined the expected credit loss to be nil.

The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable, and investments. The Company attempts to mitigate such exposure to its cash and cash equivalents by investing only in financial institutions with investment grade credit ratings or secured investments. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties.

24

Liquidity risk

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. The Company prepares forecasts to ensure sufficient liquidity to fulfil obligations and operating plans. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months.

Market risk

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities.

CONTRACTUAL COMMITMENTS AND CONTINGENCIES

a) Commitments

The information presented in the table below reflects managements estimate of the contractual maturities of the Company’s obligations at December 31, 2021.

($000s)	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		38,452		—		—		—		38,452
Lease obligations		5,938		10,514		8,424		13,629		38,505
Financial guarantee liability		—		466		—		—		466
Total		44,390		10,980		8,424		13,629		77,423

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2021 of $2.5 million (December 31, 2020 - $1.5 million).

b) Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgments or settlement terms could have a material adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re Sundial Growers Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re Sundial Growers Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions assert claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally allege that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also includes allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the

25

dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021 and remains subject to such court approval.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. Sundial Growers Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserts claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) the Securities Exchange Act of 1934, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleges that the company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

The Company can provide no assurance as to the outcome of these proceedings or any other litigation matter in which we are a party. In particular, securities class action lawsuits are typically costly to defend, and divert the attention of management and other resources from operations and, accordingly, even if resolved in our favor, could have a material adverse effect on our business, financial condition, results of operations and liquidity and may force us to reduce or cease operations or seek relief under the applicable bankruptcy or insolvency laws.

SPECIFIED FINANCIAL MEASURES

Certain specified financial measures in this MD&A including adjusted EBITDA from continuing operations, gross margin before fair value adjustments, gross margin before fair value adjustments percentage, system-wide retail sales and franchise store sales are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for measures of performance prepared in accordance with IFRS.

Non-IFRS Financial Measures

Adjusted EBITDA from continuing operations

Adjusted EBITDA from continuing operations is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA from continuing operations provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results in a similar manner to its management team. Adjusted EBITDA from continuing operations is defined as net income (loss) from continuing operations before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding change in fair value of biological assets, change in fair value realized through inventory, unrealized foreign exchange gains or losses, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment and certain one-time non-operating expenses, as determined by management.

26

The following table reconciles adjusted EBITDA from continuing operations to net income (loss)from continuing operations for the periods noted.

	Three months ended December 31						Year ended December 31
($000s)	2021			2020			2021			2020
Net income (loss) from continuing operations		(54,761	)		(64,144	)		(230,182	)		(206,317	)
Adjustments
Finance costs		3,530			4,974			3,756			3,819
Change in estimate of fair value of derivative warrants		(8,200	)		23,464			77,834			12,995
Loss on cancellation of contracts		5,116			2,471			5,116			2,471
Depreciation and amortization		352			1,297			4,726			4,711
Income tax recovery		7,787			—			(2,271	)		—
Change in fair value of biological assets		(2,158	)		(579	)		(4,708	)		(5,432	)
Change in fair value realized through inventory		1,756			214			2,247			18,566
Unrealized foreign exchange (gain) loss		(1	)		672			(63	)		(757	)
Unrealized loss on marketable securities		43,750			—			64,714			—
Share-based compensation		2,443			1,501			12,307			8,566
Asset impairment		—			13,532			60,000			79,191
Loss (gain) on disposition of PP&E		(374	)		—			(235	)		(488	)
Cost of sales non-cash component (1)		772			1,632			3,675			5,250
Inventory obsolescence		9,702			8,275			16,978			45,913
Restructuring costs		874			280			874			6,470
Transaction costs (2)		7,837			825			17,566			3,587
Government subsidies		—			(47	)		(2,180	)		(4,128	)
Other expenses		—			—			1,932			—
Adjusted EBITDA from continuing operations		18,425			(5,633	)		32,086			(25,583	)

(1) Cost of sales non-cash component is comprised of depreciation expense.

(2) Transaction costs relate to financing activities.

Gross margin before fair value adjustments

Gross margin before fair value adjustments is a non-IFRS financial measure which the Company uses to evaluate its operating performance in the Company’s cannabis operations segment. Gross margin before fair value adjustments provides useful information to investors, analysts and others in understanding and evaluating the Company’s operating results as it removes non-cash fair value metrics. Gross margin before fair value adjustments is defined as gross margin less the non-cash changes in the fair value adjustments on the sale of inventory and the growth of biological assets. Gross margin before fair value adjustments is comprised of net revenue less cost of sales and inventory obsolescence and impairment.

See “Cannabis Operations Segment Results – Gross Margin” for a table reconciling gross margin before fair value adjustments to gross margin for the periods noted.

System-wide retail sales

System-wide retail sales is a non-IFRS financial measure which the Company uses to evaluate its operating performance in the Company’s retail operations segment. System-wide retail sales provides useful information to investors, analysts and others in understanding and evaluating the Company’s brand scale and market penetration and is used by management to assess the Company’s market position relative to its competitors. System-wide retail sales is defined as the sum of the revenue reported to the Company by franchised Spiritleaf retail cannabis stores and by the Company-owned Spiritleaf retail cannabis stores.

See “Retail Operations Segment Results – System-wide retail sales” for a table reconciling system-wide retail sales to gross revenue for the periods noted.

Franchise store sales

Franchise store sales is a non-IFRS financial measure which the Company uses in the calculation of system-wide retail sales. Franchise store sales is defined as the sum of the revenue reported to the Company by franchised Spiritleaf retail cannabis stores.

27

Non-IFRS Financial Ratios

Gross margin before fair value adjustments percentage

Gross margin before fair value adjustments percentage is a non-IFRS financial ratio which the Company uses to evaluate its operating performance in the Company’s cannabis operations segment. Gross margin before fair value adjustments percentage is defined as gross margin before fair value adjustments divided by net revenue.

RELATED PARTIES

Loan receivable agreements

At December 31, 2020, the Company had advanced $139 thousand under employee loan agreements. The terms were non-interest bearing and secured by shareholdings in the Company. The loans were repayable in full upon the departure of an employee from employment, a change in control of the Company or sale of the Company. During the year ended December 31, 2021, the full $139 thousand loan balance was settled. At December 31, 2021, the outstanding loan balance was nil.

Related party transactions

	Transactions				Balance outstanding
	Year ended December 31		Year ended December 31		December 31		December 31
($000s)	2021		2020		2021		2020
Marketing, brand research and development (a)		—		1,144		—		—
Legal services (b)		—		2,462		—		(510	)
		—		3,606		—		(510	)

(a) A former member of the Board of Directors controlled a company that provides marketing, brand research and development services.

(b) A member of the Board of Directors was a partner at a law firm prior to his departure which provides legal services to the Company.

All transactions were conducted at the exchange amount agreed to with the related parties.

Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2021		2020
Salaries and short-term benefits		2,348		1,944
Share-based compensation		8,275		7,629
		10,623		9,573

OFF BALANCE SHEET ARRANGEMENTS

As at December 31, 2021, the Company did not have any off-balance sheet arrangements. The Company has certain operating or rental lease agreements, as disclosed in the Contractual Commitments and Obligations section of this MD&A, which are entered into in the normal course of operations.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company makes assumptions in applying critical accounting estimates that are uncertain at the time the accounting estimate is made and may have a significant effect on the consolidated financial statements. Critical accounting estimates include the classification and recoverable amounts of CGUs, value of biological assets and inventory, estimating potential future returns on

28

revenue, share-based compensation, convertible instruments, acquisitions and fair value of assets acquired and liabilities assumed in a business combination. Critical accounting estimates are based on variable inputs including but not limited to:

• Demand for cannabis for recreational and medical purposes;

• Price of cannabis;

• Expected sales volumes;

• Changes in market discount rates;

• Future development and operating costs;

• Costs to convert harvested cannabis to finished goods;

• Expected yields from cannabis plants;

• Potential returns and pricing adjustments;

• Facts and circumstances supporting the likelihood and amount of contingent liabilities; and

• Assumptions and methodologies for the valuation of derivative financial instruments.

Changes in critical accounting estimates can have a significant effect on net income as a result of their impact on revenue, costs of sales, provisions and impairments. Changes in critical accounting estimates can have a significant effect on the valuation of biological assets, inventory, property, plant and equipment, provisions and derivative financial instruments.

For a detailed discussion regarding the Company’s critical accounting policies and estimates, refer to the notes to the Audited Financial Statements.

NEW ACCOUNTING PRONOUNCEMENTS

The International Accounting Standards Board (IASB) and the IFRS Interpretations Committee regularly issue new and revised accounting pronouncements which have future effective dates and therefore are not reflected in the Company’s consolidated financial statements. Once adopted, these new and amended pronouncements may have an impact on the Company’s consolidated financial statements. The Company’s analysis of recent accounting pronouncements is included in the notes to the Audited Financial Statements.

RISK FACTORS

In addition to the other risks described elsewhere in this document, or a detailed discussion regarding the Company’s risk factors, refer to the “Risk Factors” section of the Annual Report.

DISCLOSURE CONTROLS AND PROCEDURES

The Company has designed disclosure controls and procedures to provide reasonable assurance that: (i) material information relating to the Company is made known to the Company’s Chief Executive Officer and Chief Financial Officer by others, particularly during the period in which the annual and interim filings are being prepared; and (ii) information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in securities legislation. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“the Exchange Act”)), as of December 31, 2021. Based on such evaluation, our Chief Executive Officer and Chief Financial officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2021, due to the material weaknesses in the Company’s internal control over financial reporting further described below

During 2021, the Company's operations expanded rapidly and significantly in scale and scope with the significant influx of capital from financing activities leading to the addition of two operating segments, retail operations and investments. As a consequence of this rapid growth, the Company became a large accelerated filer under the regulations of the Exchange Act, and did not have a sufficient number of financial reporting and accounting, and information technology personnel with the appropriate knowledge, experience or training commensurate with the Company’s financial reporting requirements at December 31, 2021.

29

However, giving full consideration to the material weaknesses, the Company has concluded that the consolidated financial statements included in the Annual Report on Form 20-F present fairly, in all material respects, the Company’s financial position, the results of its operations and its cash flows for each of the periods presented in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).

INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in NI 52-109 and Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS and includes those policies and procedures that:

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and the dispositions of our assets;

(2) provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with applicable accounting principles and that our receipts and expenditures are being made only in accordance with appropriate authorizations of our management and directors; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness for future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control— Integrated Framework (2013). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

As at December 31, 2021, the Company’s management determined that it did not maintain effective internal control over financial reporting due to the existence of the following material weaknesses:

• An ineffective control environment resulting from an insufficient number of financial reporting and accounting, and information technology (IT) personnel with the appropriate knowledge, experience or training commensurate with the Company’s financial reporting requirements.

• The insufficient number of personnel described above contributed to an ineffective risk assessment process necessary to identify changes to its operations and to identify all relevant risks of material misstatement and to evaluate the implications of relevant risks on its internal control over financial reporting.

• An ineffective information and communication process resulting from a combination of deficiencies within its information technology general and application controls (“ITGCs”) across the systems supporting the Company’s financial reporting process, including access controls and administrator-level access resulting in a lack of segregation of duties, resulting in insufficient controls to ensure the relevance, timeliness and quality of information used in control activities.

• As a consequence of the above and as a result of inadequate segregation of duties and secondary review, the Company had ineffective control activities related to the design, implementation and operating effectiveness of process level and financial reporting controls which had a pervasive impact on the Company's internal control over financial reporting.

These material weaknesses resulted in material misstatements, which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021, and also in immaterial misstatements, some of which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021. These material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.

30

In accordance with guidance issued by the Canadian Securities Administrators and the SEC, companies are permitted to exclude acquisitions from their final assessment of internal control over financial reporting for the first fiscal year in which the acquisition occurred. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has limited the evaluation of our internal control over financial reporting to exclude controls, policies and procedures and internal control over financial reporting of the recently acquired operations of Inner Spirit Holdings Ltd. (acquired on July 20, 2021). The operations of Inner Spirit Holdings Ltd. represent approximately 1% of our current assets, 21% of our long-term assets, 15% of our current liabilities, 51% of our long-term liabilities, 24% of our total gross revenues and 0% of our loss as at and for the year ended December 31, 2021.

The Company’s independent auditors, KPMG LLP, have issued an unqualified opinion on our financial statements and an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2021. These audit reports are included in the annual report on Form 20-F.

REMEDIATION

Management has implemented and continues to implement measures designed to ensure that control deficiencies are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

• developing and maintaining documentation underlying ITGCs to promote knowledge transfer upon personnel and function changes;

• developing enhanced procedures and controls related to administrator and privileged-level access to IT systems;

• implementing an IT management review, documentation and testing plan to enhance implementation and monitoring of software updates and changes with a specific focus on systems supporting our financial reporting processes;

• adding personnel with an appropriate level of knowledge, experience and training commensurate with the Company’s financial reporting requirements; and

• working with our advisors to develop a plan to improve our risk assessment process and to assist with process improvements and control remediation efforts.

At April 27, 2022 the above remediation measures are in progress and controls related to documentation of ITGCs, restricting privileged-level access and monitoring of software upgrades have been designed and implemented. The deficiencies will not be considered remediated, however, until the applicable controls operate for a sufficient period of time, and management has concluded through testing, that these controls are operating effectively.

Additionally, the Company has implemented, and tested workflows designed to remediate the lack of segregation of duties in its information technology systems and processes. The Company believes that this remediation is complete; however it will not be considered fully remediated until the other deficiencies related to the ITGCs material weakness described above are fully remediated and tested.

The Company is pursuing remediation of all of the above material weaknesses during the 2022 fiscal year.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

Except for the material weaknesses described above, as of December 31, 2021, there have been no other changes in our internal control over financial reporting (as defined in NI 52-109 and Rules 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the fourth quarter and the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

31

ABBREVIATIONS

The following provides a summary of common abbreviations used in this document:

Financial and Business Environment		Measurement
$ or C$	Canadian dollars	G or GM	Gram
IFRS	International Financial Reporting Standards	sq ft	Square feet
MD&A	Management’s Discussion and Analysis
U.S.	United States
US$	United States dollars
CBD	Cannabidiol
THC	Tetrahydrocannabinol

FORWARD-LOOKING INFORMATION

This document may contain forward-looking information concerning the Company’s business, operations and financial performance and condition, as well as its plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable technology.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. As a result, any or all of the forward-looking information in this document may turn out to be inaccurate. Factors that may case actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” herein. Although management believes that its underlying assessments and assumptions are reasonable based on currently available information, given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. All forward-looking statements in this MD&A are qualified by these cautionary statements. These statements are made as of the date of this MD&A and, except as required by applicable law, the Company assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Additionally, the Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, its financial or operating results or its securities.

This document contains estimates, projections and other information concerning the Company’s industry, business and the markets for its products. Information that is based on estimates, forecasts, projections, market research of similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from its own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

In addition, assumptions and estimates of the Company’s and industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section “Risk Factors” herein. These and other factors could cause the Company’s future performance to differ materially from the Company’s assumptions and estimates.

Further information regarding the assumptions and risks inherent in the making of forward-looking statements can be found in the Annual Report, along with the Company’s other public disclosure documents. Copies of the Annual Report and other public disclosure documents are available under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov.

32

Certain information in this MD&A is “financial outlook” within the meaning of applicable Canadian securities laws. The purpose of the financial outlook is to provide readers with disclosure of the Company’s reasonable expectations of its anticipated results. The financial outlook is provided as of the date of this MD&A. Readers are cautioned that the financial outlook may not be appropriate for other purposes.

ADDITIONAL INFORMATION

Additional information relating to the Company can be viewed under the Company’s profile on SEDAR at www.sedar.com, on the EDGAR section of the SEC’s website at www.sec.gov, or on the Company’s website at www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this MD&A, and the inclusion of our website address in this MD&A is only for reference.

33

EX-16.1

KPMG LLP

205 5th Avenue SW

Suite 3100

Calgary AB  T2P 4B9

Tel (403) 691-8000

Fax (403) 691-8008

www.kpmg.ca

Exhibit 16.1

April 27, 2022

Securities and Exchange Commission
Washington, D.C. 20549

Ladies and Gentlemen:

We are principal accountants for Sundial Growers Inc. (the “Company”) and, under the date of April 27, 2022, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2021 and 2020 and the effectiveness of internal control over financial reporting as of December 31, 2021. On April 7, 2022, we declined to stand for reappointment as the Company’s independent auditor, however, we have agreed to complete the interim review of the unaudited condensed consolidated interim financial statements as of March 31, 2022 and for the three-month period then ended. We have read the Company’s statements included under Item 16F of its Form 20-F dated April 27, 2022, and we agree with such statements.

Very truly yours,

/s/ KPMG LLP

KPMG LLP, an Ontario limited liability partnership and member firm of the KPMG global organization of independent
member firms affiliated with KPMG International Limited, a private English company limited by guarantee. KPMG
Canada provides services to KPMG LLP.

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Sundial Growers Inc.

We consent to the use of our report, dated April 27, 2022, on the consolidated financial statements of Sundial Growers Inc.(the “Entity”)  which comprise the consolidated statements of financial position as at December 31, 2021 and December 31, 2020, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively the “consolidated financial statements”), and our report dated April 27, 2022 on the effectiveness of the Entity’s internal control over financial reporting as of December 31, 2021 each of which is included in the Annual Report on Form 20-F of the Entity for the fiscal year ended December 31, 2021.

We also consent to the incorporation by reference of such reports in the Registration Statement on Form S-8 (No. 333-262233) of the Entity.

We also consent to the incorporation by reference of such reports and to the reference to our firm under the heading “Experts” in the Registration Statements on Form F-3 (No. 333-253169) and (No. 333-253813) of the Entity.

/s/ KPMG LLP

April 27, 2022

Calgary, Canada

XML

Document and Entity Information	12 Months Ended
	Dec. 31, 2021 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	Sundial Growers Inc.
Entity Central Index Key	0001766600
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Incorporation, State or Country Code	A0
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	2,060,408,357
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Trading Symbol	SNDL
Security Exchange Name	NASDAQ
Entity File Number	001-39005
Entity Address, State or Province	AB
Entity Address, Address Line One	#300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
Entity Address, Country	CA
Document Annual Report	true
Document Transition Report	false
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	KPMG
Auditor Location	Calgary, Alberta, Canada
Auditor Firm ID	85
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
City Area Code	403
Local Phone Number	948-5227
Entity Address, Country	CA
Contact Personnel Name	James Keough
Contact Personnel Email Address	investors@sundialgrowers.com

XML

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 558,251	$ 60,376
Restricted cash	27,013	5,333
Marketable securities	83,724	0
Accounts receivable	10,865	15,898
Biological assets	4,410	3,531
Inventory	29,503	25,613
Prepaid expenses and deposits	4,355	4,622
Investments	3,065	0
Assets held for sale	2,998	2,998
Net investment in subleases	3,991
Current assets	728,175	118,371
Non-current assets
Long-term deposits	7,725	2,633
Property, plant and equipment	63,189	116,928
Net investment in subleases	22,571
Intangible assets	4,709	5,063
Investments	70,498	51,876
Equity-accounted investees	412,858
Goodwill	114,537
Total assets	1,424,262	294,871
Current liabilities
Accounts payable and accrued liabilities	38,452	23,308
Current portion of lease obligations	5,701	409
Derivative warrants	21,700	428
Current liabilities	65,853	24,145
Non-current liabilities
Lease obligations	27,769	1,031
Other liabilities	4,505
Total liabilities	98,127	25,176
Shareholders’ equity
Share capital	2,035,704	762,046
Warrants	8,092	6,138
Contributed surplus	60,734	59,344
Contingent consideration	2,279	2,279
Accumulated deficit	(788,510)	(558,128)
Accumulated other comprehensive income	7,607
Total shareholders’ equity	1,325,906	271,679
Non-controlling interest	229	(1,984)
Total liabilities and shareholders’ equity	$ 1,424,262	$ 294,871

XML

Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Comprehensive Income [Abstract]
Gross revenue	$ 67,279	$ 73,321	$ 66,927
Excise taxes	11,151	12,403	3,365
Net revenue	56,128	60,918	63,562
Cost of sales	48,601	51,740	46,721
Inventory obsolescence	16,978	45,913
Gross margin before fair value adjustments	(9,451)	(36,735)	16,841
Change in fair value of biological assets	4,708	5,432	30,340
Change in fair value realized through inventory	(2,247)	(18,566)	(10,685)
Gross margin	(6,990)	(49,869)	36,496
Interest and fee revenue	13,149
Investment loss	(44,501)	0	0
Share of profit of equity-accounted investees	32,913	0	0
General and administrative	38,370	32,029	38,934
Sales and marketing	5,043	5,737	8,068
Research and development	2,446	488	2,410
Depreciation and amortization	4,726	4,711	595
Share-based compensation	12,307	8,566	38,698
Restructuring costs	874	6,470
Asset impairment	60,000	79,191	162
Government subsidies	(2,180)	(4,128)
Loss on cancellation of contracts	5,116	2,471
Loss from operations	(132,131)	(185,404)	(52,371)
Transaction costs	(17,566)	(3,587)	(8,481)
Finance costs, net	(3,756)	(3,819)	(24,216)
Change in estimate of fair value of derivative warrants	(77,834)	(12,995)	0
Foreign exchange gain (loss)	531	(1,000)	(939)
Loss on financial obligation			(60,308)
Gain (loss) on disposition of PP&E	235	488	8
Other expenses	(1,932)
Loss before income tax	(232,453)	(206,317)	(146,307)
Income tax recovery	2,271		3,609
Net loss from continuing operations	(230,182)	(206,317)	(142,698)
Net loss from discontinued operations		(33,627)	(128,931)
Net loss	(230,182)	(239,944)	(271,629)
Equity-accounted investees - share of OCI, net of tax	7,607
Gain on translation of foreign operations		600	6,866
Comprehensive loss	(222,575)	(239,344)	(264,763)
Net loss from continuing operations attributable to:
Sundial Growers Inc.	(230,382)	(199,619)	(142,533)
Non-controlling interest	200	(6,698)	(165)
Net loss from continuing operations	(230,182)	(206,317)	(142,698)
Net loss attributable to:
Sundial Growers Inc.	(230,382)	(233,246)	(271,464)
Non-controlling interest	200	(6,698)	(165)
Net loss	(230,182)	(239,944)	(271,629)
Comprehensive loss attributable to:
Sundial Growers Inc.	(222,775)	(232,646)	(264,598)
Non-controlling interest	200	(6,698)	(165)
Comprehensive loss	$ (222,575)	$ (239,344)	$ (264,763)
Net loss per common share attributable to Sundial Growers Inc.
Basic and diluted	$ (0.12)	$ (1.07)	$ (3.17)

XML

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total	Share Capital	Warrants	Contributed Surplus	Convertible Notes-Equity Components	Contingent Consideration	Accumulated Deficit	Accumulated Other Comprehensive income	Non-controlling interests [member]
Beginning balance at Dec. 31, 2018	$ (7,908)	$ 65,133	$ 3,108	$ 9,493	$ 3,232		$ (88,874)
Net (loss) earnings	(271,629)						(271,464)		$ (165)
Other comprehensive income	6,866							$ 6,866
Share issuances	198,378	198,378
Shares issued to related parties	69,293	63,460	5,833
Share issuance costs	(12,770)	(12,770)
Business acquisitions	47,007	39,849				$ 2,279			4,879
Convertible debt - conversions	117,025	113,526	6,731		(3,232)
Warrants reclassified from liability	16,091		16,091
Warrants exercised	17,950	21,882	(3,932)
Share-based compensation	39,524	2,515		37,009
Employee warrants exercised	1,371	17,681		(16,310)
Ending balance at Dec. 31, 2019	221,198	509,654	27,831	30,192		2,279	(360,338)	6,866	4,714
Net (loss) earnings	(239,944)						(233,246)		(6,698)
Other comprehensive income	600							600
Share issuances	176,931	176,931
Share issuance costs	(5,593)	(5,593)
Business acquisitions		0
Convertible debt - conversions	63,002	63,002
Warrants exercised		0
Derivative warrants exercised	55,912	55,912
Warrants issued	306		306
Warrants expired			(21,999)	21,999
Dispositions	(10,457)	(38,447)					35,456	(7,466)
Share-based compensation	7,740	52		7,688
Employee warrants exercised		535		(535)
Ending balance at Dec. 31, 2020	269,695	762,046	6,138	59,344		2,279	(558,128)		(1,984)
Net (loss) earnings	(230,182)	0	0	0	0	0	(230,382)	0	200
Other comprehensive income	7,607	0	0	0	0	0	0	7,607	0
Loss of control of subsidiary	2,013	0	0	0	0	0	0	0	2,013
Share issuances	977,425	977,425	0	0	0	0	0	0	0
Share issuance costs	(16,371)	(16,371)	0	0	0	0	0	0	0
Business acquisitions	27,987	26,216	1,771	0	0	0	0	0	0
Convertible debenture settlement	2,671	2,671	0	0	0	0	0	0	0
Convertible debt - conversions		2,671
Warrants exercised	0	178	(178)	0	0	0	0	0	0
Derivative warrants exercised	277,136	277,136	0	0	0	0	0	0	0
Warrants issued	361	0	361	0	0	0	0	0	0
Dispositions		0
Share-based compensation	12,723	8	0	12,715	0	0	0	0	0
Employee warrants exercised	201	6,395	0	(6,194)	0	0	0	0	0
Modification of equity-settled plan	(5,131)	0	0	(5,131)	0	0	0	0	0
Ending balance at Dec. 31, 2021	$ 1,326,135	$ 2,035,704	$ 8,092	$ 60,734	$ 0	$ 2,279	$ (788,510)	$ 7,607	$ 229

XML

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss from continuing operations for the period	$ (230,182)	$ (206,317)	$ (142,698)
Items not involving cash:
Income tax recovery	(2,271)	0	(3,609)
Change in fair value of biological assets	(4,708)	(5,432)	(30,340)
Share-based compensation	12,307	8,566	38,698
Depreciation and amortization	9,603	11,582	6,296
(Gain) loss on disposition of PP&E	(235)	(488)	(8)
Inventory obsolescence	16,978	45,913	0
Transaction costs	0	0	1,279
Finance costs	3,716	(3,734)	11,070
Change in estimate of fair value of derivative warrants	77,834	12,995	0
Loss on cancellation of contracts	2,870	671	0
Loss on financial obligation	0	0	60,308
Unrealized foreign exchange (gain) loss	(63)	(757)	671
Restructuring costs	0	448	0
Warrants issued for services	0	306	0
Asset impairment	60,000	79,191	162
Share of profit of equity-accounted investees	(32,913)	0	0
Other expenses	1,864	0	0
Gain on disposition of marketable securities	(20,213)	0	0
Unrealized loss on marketable securities	64,714	0	0
Additions to marketable securities	(158,101)	0	0
Proceeds from disposal of marketable securities	29,876	0	0
Income distributions from equity-accounted investees	15,021	0	0
Change in non-cash working capital	(1,534)	(5,259)	(41,626)
Net cash used in operating activities from continuing operations	(155,437)	(62,315)	(99,797)
Net cash provided by operating activities from discontinued operations	0	4,820	(12,939)
Net cash used in operating activities	(155,437)	(57,495)	(112,736)
Investing activities
Additions to property, plant and equipment	(3,793)	(3,024)	(110,271)
Additions to intangible assets	0	(150)	0
Additions to investments	(24,206)	(51,876)	0
Additions to equity-accounted investees	(395,569)	0	0
Capital distributions from equity-accounted investees	10,481	0	0
Proceeds from disposal of PP&E	194	2,109	51
Acquisition	(82,775)	0	(77,023)
Change in non-cash working capital	(612)	(11,319)	1,659
Net cash used in investing activities from continuing operations	(496,280)	(64,260)	(185,584)
Net cash used in investing activities from discontinued operations	0	(6,617)	(27,560)
Net cash used in investing activities	(496,280)	(70,877)	(213,144)
Financing activities
Proceeds from convertible notes, net of costs	0	18,070	90,373
Change in restricted cash	(21,680)	10,494	(15,477)
(Repayment) proceeds of long-term debt	0	(84,493)	99,182
Payments on lease obligations, net	(1,008)	(420)	(292)
Proceeds from issuance of shares and registered offerings, net of costs	1,062,310	181,841	177,202
Proceeds from exercise of derivative warrants	119,318	20,391	0
Proceeds from exercise of equity classified warrants	0	0	17,950
Proceeds from exercise of employee warrants	201	0	1,371
Exercise of cash-settled DSUs	(315)	0	0
Convertible debenture settlement	(9,354)	0	0
Payment on exercise of contingent consideration warrants	(219)	0	0
Settlement of convertible notes	0	0	(4,190)
Settlement of financial obligation	0	0	(9,500)
Change in non-cash working capital	348	(2,498)	2,147
Net cash provided by financing activities from continuing operations	1,149,601	143,385	358,766
Net cash used in financing activities from discontinued operations	0	(639)	(499)
Net cash provided by financing activities	1,149,601	142,746	358,267
Effect of exchange rate changes on cash held in foreign currency	(9)	665	(1,171)
Change in cash and cash equivalents	497,875	15,039	31,216
Cash and cash equivalents, beginning of period	60,376	45,337	14,121
Cash and cash equivalents, end of period	$ 558,251	$ 60,376	$ 45,337

XML

Description of Business

12 Months Ended

Dec. 31, 2021

Description Of Business [Abstract]

Description of Business

1. Description of business

Sundial Growers Inc. (“Sundial” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006.

The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.

The principal activities of the Company are the production, distribution and sale of cannabis in Canada pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada.

Sundial and its subsidiaries currently operate solely in Canada. Through its joint venture SunStream Bancorp Inc. (note 17(a)), the Company also provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”.

COVID-19

The global impact of COVID-19 has contributed to uncertainty as to the health of the global economy. The Company has implemented several pandemic-related procedures and protocols at its facilities, including enhanced screening measures, enhanced cleaning and sanitation processes with increased frequency, encouraging social distancing measures and directing employees to work from home if possible. At the retail store level, the Company has implemented enhanced in-store procedures including increased frequency of cleaning, installing safety shields and reducing paper materials. The Company has also adapted its business model by moving toward online sales platforms that enable customers to order products online for fast pickup and payment in store. The Company believes that it can maintain safe operations with these pandemic-related procedures and protocols in place.

XML

Basis of Presentation

12 Months Ended

Dec. 31, 2021

Disclosure Of Basis Of Presentation [Abstract]

Basis of Presentation

2. Basis of presentation

a) Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2021.

These consolidated financial statements were approved and authorized for issue by the board of directors of Sundial (the “Board”) on April 27, 2022.

b) Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, deferred share units (“DSUs”) and certain financial instruments (note 32(a)) which are measured at fair value with changes in fair value recorded in earnings.

c) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the functional and presentation currency of the Company and its Canadian-based subsidiaries. Sundial Deutschland GmbH uses the European Euro as its functional currency. The Company’s equity-accounted joint venture uses the United States dollar as its functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions.

In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign subsidiaries that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries into Canadian dollars are recognized in other comprehensive income (“OCI”).

In preparing the Company’s consolidated financial statements, the financial statements of the foreign equity-accounted joint venture are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of the foreign equity-accounted joint venture are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of the foreign equity-accounted joint venture are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of the foreign equity-accounted joint venture into Canadian dollars are recognized in OCI. The Company’s consolidated financial statements include its share of the Canadian dollar profit or loss and OCI of the equity-accounted joint venture.

d) Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases.

Subsidiaries	Principal activity	Jurisdiction of incorporation	Equity ownership			Non-controlling interest ("NCI")
KamCan Products Inc.	Inactive	British Columbia, Canada		100	%		0	%
Sundial Deutschland GmbH	Inactive	Germany		100	%		0	%
2657408 Ontario Inc.	Operations	Ontario, Canada		100	%		0	%
NGBA-BC Holdings Ltd.	Operations	British Columbia, Canada		100	%		0	%
Sundial Insurance (Bermuda) Ltd.	Operations	Bermuda		100	%		0	%
Inner Spirit Holdings Ltd.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Corporate Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Ontario Inc. (1)	Operations	Ontario, Canada		0	%		100	%

(1) This entity may be considered to be “controlled” by the Company solely for the purposes of IFRS, but the entity is not controlled by the Company within the meaning of applicable corporate law. For the purposes of IFRS, control of this entity is determined by the Company being exposed to variable returns and having the ability to affect those returns through its power over the entity.

XML

Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

RESTRICTED CASH AND CASH EQUIVALENTS

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading position, and (ii) minimum funding requirements for two separate captive insurance structures.

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labor related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory is valued at Company-owned stores at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined by the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as

appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the consolidated statements of loss and comprehensive loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

Production facilities20 years

Equipment1 to 10 years

Right-of-use assetsShorter of estimated useful life or lease term

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with IAS 38.

The Company’s intangible assets at December 31, 2021, are comprised of the following:

• Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

• Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

(i)Financial assets

The Company applies an expected credit loss, or “ECL”, model to all financial assets not held at fair value through profit and loss, or “FVTPL”, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECL’s are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECL’s are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E and intangible assets, including goodwill, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of assets’ estimated fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit, or “CGU”).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset (or CGU) is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) previously. A reversal of an impairment loss is recognized immediately in the statements of loss and comprehensive loss.

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or Fair Value Through Other Comprehensive Income depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognize in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at Fair Value Through Other Comprehensive Income.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2021 and 2020.

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in the consolidated statements of loss and comprehensive loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

REVENUE

Under IFRS 15, to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation

of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and certain promotional activities and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift certificate.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and being stewards of the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they are utilizing the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38 “Intangible Assets”. Research and development costs comprise consulting fees and licence acquisition fees. No development costs have been capitalized as at December 31, 2021, or December 31, 2020.

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

INCOME TAXES

Income taxes are recognized in the consolidated statements of loss and comprehensive loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and includes any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities, and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each consolidated statements of financial position date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transactions costs associated with business combinations are expensed as incurred.

FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in net earnings. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right-of-use asset and a lease obligation at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease obligation. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease obligation is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease obligation is subsequently increased by the interest cost on the lease obligation and decreased by lease payments made. Lease payments are allocated between the liability and interest expense. Interest expense is recognized on the lease obligation using the effective interest rate method and payments are applied against the lease obligation.

The carrying amounts of the right-of-use assets, lease obligations, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset.

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2021 and did not have a material impact on the Company’s consolidated financial statements:

•COVID-19 Related Rent Concessions (Amendments to IFRS 16)

•Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2022, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2021. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

•Onerous contracts – Cost of Fulfilling a Contract (Amendments to IAS 37)

•IFRS 17 Insurance Contracts (Amendments to IFRS 17)

XML

Significant Accounting Estimates, Assumptions and Judgements

12 Months Ended

Dec. 31, 2021

Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]

Significant accounting estimates, assumptions and judgements

4. Significant accounting estimates, assumptions and judgements

The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated.

Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following:

IMPAIRMENTS

CGU’s are defined as the lowest grouping of integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructures and the way in which management monitors the Company’s operations.

The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licences from Health Canada, total addressable market, market share escalation factor, gross margin escalation factor, terminal multiple and discount rates. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s.

BIOLOGICAL ASSETS AND INVENTORY

Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest.

Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged.

Revenue

Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in

some cases, have a right of product return or warranty period. The estimate of potential future returns includes the use of estimates and assumptions and are subject to change as new information becomes available.

CONVERTIBLE INSTRUMENTS

Convertible notes are compound financial instruments which are accounted for separately by their components: a financial liability and an equity instrument. The financial liability, which represents the obligation to pay coupon interest on the convertible notes in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance.

The identification of the components of convertible notes is based on interpretations of the substance of the contractual arrangement and therefore requires judgement from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of the fair value of the liability is also based on various assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors.

ACQUISITIONS

The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under IFRS 3. This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes.

Investments

The Company’s investment at FVTPL is a financial asset measured at fair value each reporting period. The determination of the fair value of the investment requires judgement from management and the main assumption is the discount rate.

equity-accounted investees

The Company’s interest in a joint venture is accounted for using the equity-method. The current investment portfolio of the joint venture is comprised of secured debt and hybrid instruments which include options and warrants. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss.

The determination of the fair value of the underlying investments is based on a discounted cash methodology and requires judgement from management. The discounted cash flows are based on various assumptions, including an estimation of market prices, volatility and discount rates.

XML

Business Acquisitions

12 Months Ended

Dec. 31, 2021

Disclosure Of Business Combinations [Abstract]

Business Acquisitions

5. Business acquisition

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

The Inner Spirit Transaction consideration was comprised of (i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share), (ii) an aggregate 24.4 million Sundial common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.0835 of a Sundial common share for each Inner Spirit common share) and (iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed. The purchase price allocation and the amount of deferred income taxes arising on their recognition is not final as the Company is continuing to verify information required to determine the fair value of property, plant and equipment, net investment in subleases, goodwill and lease liabilities. The Company expects a portion of goodwill to be allocated to intangible assets upon finalization of the purchase price allocation.

The fair value of consideration paid was as follows:

	July 20, 2021
Cash		92,583
Issuance of common shares		26,216
Contingent consideration		1,150
		119,949

The fair value of the assets and liabilities acquired was as follows:

	July 20, 2021
Cash		9,808
Accounts receivable		750
Prepaid expenses and deposits		853
Inventory		2,733
Property, plant and equipment		12,108
Net investment in subleases		23,751
Goodwill		114,537
Accounts payable and accrued liabilities		(2,678	)
Convertible debentures		(12,025	)
Lease liabilities		(29,481	)
Financial guarantee liability		(407	)
		119,949

The Company recorded adjustments to the fair value in the fourth quarter of 2021 to reflect facts and circumstances in existence at the date of acquisition. These adjustments related to the inclusion of Spirit Lead Ontario Inc. and changes in preliminary valuation assumptions, including amounts allocated to property, plant and equipment, net investments in subleases, intangible assets, lease liabilities and deferred tax liability. All measurement period adjustments were offset to goodwill. It is expected that further allocations will be made between these account categories upon finalization of the preliminary purchase price allocation prior to the end of the second quarter of 2022.

As new information obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, then the accounting for the acquisition will be revised.

On August 4, 2021, the Company settled the convertible debenture liability through the issuance of 2.5 million common shares valued at $2.7 million and a cash payment of $9.3 million. Due to the change of control from the Inner Spirit Transaction, debenture holders were entitled to receive Sundial common shares and a cash payment based on a prescribed formula.

The fair value of the Inner Spirit warrants has been estimated as $1.2 million and is made up of the following components: (i) equity component of $1.8 million (note 23(c)), (ii) liability component of $0.3 million and (iii) asset component of $0.9 million.

The consolidated financial statements incorporate the operations of Inner Spirit commencing July 20, 2021. During the period July 20, 2021, to December 31, 2021, the Company recorded revenues of $16.1 million and net earnings of $1.1 million. Had the acquisition closed on January 1, 2021, management estimates that for the period January 1, 2021, to July 19, 2021, revenue would have increased by $20.4 million and net earnings would have increased by $7.4 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2021.

The Company incurred acquisition-related costs of $1.9 million which have been included in transaction costs.

XML

Discontinued Operations

12 Months Ended

Dec. 31, 2021

Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Abstract]

Discontinued Operations

6. Discontinued operations

On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Project Seed Topco (“Bridge Farm”) which closed on June 5, 2020.

The comparative statement of loss and comprehensive loss and statement of cash flows has been presented to show the discontinued operation separately from continuing operations.

Results of discontinued operations

	Year ended December 31
	2021		2020 (1)			2019 (2)
Gross revenue		—		22,139			12,298
Net revenue		—		22,139			12,298
Cost of sales		—		15,633			9,426
Gross margin before fair value adjustments		—		6,506			2,872
Change in fair value of biological assets		—		1,064			386
Change in fair value realized through inventory		—		(1,122	)		—
Gross margin		—		6,448			3,258
General and administrative		—		8,585			5,515
Sales and marketing		—		1,418			820
Depreciation and amortization		—		2,752			3,482
Foreign exchange		—		1,057			(1,779	)
Share-based compensation		—		(826	)		826
Goodwill impairment		—		—			100,305
Loss from operations		—		(6,538	)		(105,911	)
Transaction costs		—		—			(1,588	)
Finance costs		—		(10,083	)		(3,982	)
Loss on contingent consideration		—		(2,252	)		(18,645	)
Gain on investment		—		—			165
Gain on disposition of PP&E		—		—			13
Loss on disposition of Bridge Farm		—		(14,979	)		—
Loss before income tax		—		(33,852	)		(129,948	)
Income tax recovery		—		225			1,017
Net loss (3)		—		(33,627	)		(128,931	)

(1) Period January 1, 2020, to June 5, 2020

(2) Period July 2, 2019, to December 31, 2019

(3) Net loss from the discontinued operations is attributable entirely to the owners of the Company.

Effect of disposal on the financial position of the company

Cash and cash equivalents	2,963
Accounts receivable	15,641
Biological assets	2,831
Inventory	787
Property, plant and equipment	88,698
Goodwill	11,345
Intangible assets	23,884
Accounts payable and accrued liabilities	(22,792	)
Lease obligation	(14,894	)
Deferred tax liability	(3,115	)
Accumulated other comprehensive income	(7,466	)
Net assets and liabilities	97,882
Consideration received
Term Debt Facility	45,000
Contingent consideration liability	34,912
Cancellation of common shares	2,991
Total consideration	82,903
Loss on disposition	(14,979	)

XML

Segment Information

12 Months Ended

Dec. 31, 2021

Disclosure Of Operating Segments [Abstract]

Segment Information

7. Segment information

Late in the fourth quarter of 2020 the Company began the deployment of capital toward strategic investments. The Company developed an internal capital program to evaluate these and potential future investments, which is a new and separate business line from its cannabis operations.

Based on the allocation of the Company’s resources by the chief operating decision maker and the information used to analyze the performance of the business, the Company concluded that beginning in Q1 2021, it had two reportable segments: cannabis operations and investments. The acquisition of Inner Spirit (note 5) has led to a third reportable segment: retail operations. For the year ended December 31, 2020, there was only one reportable segment and therefore no comparative segment information.

The Company’s reportable segments are organized by business line and are comprised of three reportable segments: cannabis operations, retail operations and investments. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada. Retail operations include the private sale of recreational cannabis through wholly owned and franchise retail cannabis stores. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any reportable segment are reported as “Corporate”.

	Cannabis			Retail (1)		Investments			Corporate			Total
As at December 31, 2021
Total assets		147,887			153,624		1,093,596			29,155			1,424,262
Year ended December 31, 2021
Net revenue		40,037			16,091		—			—			56,128
Gross margin		(15,499	)		8,509		—			—			(6,990	)
Interest and fee revenue		—			—		13,149			—			13,149
Loss on marketable securities		—			—		(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—			—		32,913			—			32,913
Depreciation and amortization		3,108			721		—			897			4,726
Earnings (loss) before tax		(117,990	)		1,835		(5,837	)		(110,461	)		(232,453	)

(1) Period July 20, 2021, to December 31, 2021

Geographical disclosure

As at December 31, 2021, the Company had non-current assets related to operations in the United States of $412.9 million. For the year ended December 31, 2021, share of profit of equity-accounted investees related to operations in the United States was $32.9 million.

XML

Restricted Cash

12 Months Ended

Dec. 31, 2021

Restricted Cash [Abstract]

Restricted Cash

8. Restricted cash

As at	December 31, 2021		December 31, 2020
Letters of credit		—		5,333
Securities collateral		7,773		—
Captive insurance		19,240		—
		27,013		5,333

Securities collateral is comprised of a cash balance to satisfy margin requirements on the Company’s option trading position.

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures. The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate Cell Captive. The Cell Captive was funded with $12.1 million and is required to be fully funded at all times. The second structure is a wholly incorporated subsidiary, Sundial Insurance (Bermuda) Ltd., which was incorporated to provide separate and additional coverage and funded with $7.1 million.

XML

Marketable Securities

12 Months Ended

Dec. 31, 2021

Marketable Securities Disclosure [Abstract]

Marketable Securities

9. Marketable securities

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Additions		158,101			—
Dispositions		(9,663	)		—
Change in fair value recognized in profit or loss		(64,714	)		—
Balance, end of period		83,724			—

During the year ended December 31, 2021, proceeds of $29.9 million were received for dispositions of marketable securities and a gain on disposition of $20.2 million was recognized (note 26).

Marketable securities have been designated as FVTPL (note 32).

The components of marketable securities are as follows:

As at	December 31, 2021			December 31, 2020
Equity securities		83,802			—
Put and call options		(78	)		—
		83,724			—

XML

Accounts Receivable

12 Months Ended

Dec. 31, 2021

Subclassifications Of Assets Liabilities And Equities [Abstract]

Accounts Receivable

10. Accounts receivable

As at	December 31, 2021		December 31, 2020
Trade receivables		10,865		15,786
Other receivables		—		112
		10,865		15,898

The Company has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Refer to note 32 for credit risk disclosures.

XML

Biological Assets

12 Months Ended

Dec. 31, 2021

Disclosure Of Reconciliation Of Changes In Biological Assets [Abstract]

Biological Assets

11. Biological assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		3,531			14,309
Increase in biological assets due to capitalized costs		25,880			39,957
Net change in fair value of biological assets		4,708			6,496
Transferred to inventory upon harvest		(29,709	)		(54,388	)
Disposition of Bridge Farm (note 6)		—			(2,831	)
Foreign currency translation		—			(12	)
Balance, end of year		4,410			3,531

Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2021		December 31 2020		December 31 2021		December 31 2020
Yield per square foot of growing space (1)	Grams		49		45		435		347
Average net selling price (2)	$/gram		4.49		5.13		1,014		1,022
After harvest cost to complete and sell	$/gram		1.06		1.32		249		291

(1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

These assumptions are estimates that are subject to volatility in market prices and several uncontrollable factors. The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2021, it is estimated that the Company’s biological assets will yield approximately 5,672 kilograms (December 31, 2020 – 5,507 kilograms) of dry cannabis when harvested. During the year ended December 31, 2021, the Company harvested 22,784 kilograms of dry cannabis (year ended December 31, 2020 – 27,972 kilograms).

XML

Inventory

12 Months Ended

Dec. 31, 2021

Classes Of Inventories [Abstract]

Inventory

12. Inventory

As at	December 31, 2021		December 31, 2020
Harvested cannabis		22,710		20,358
Cannabis supplies and consumables		4,361		5,255
Retail		2,397		—
Millwork		35		—
		29,503		25,613

During the year ended December 31, 2021, inventories of $48.6 million were recognized in cost of sales as an expense (year ended December 31, 2020 - $51.7 million). During the year ended December 31, 2021, the Company recognized inventory write downs of $17.5 million (year ended December 31, 2020 - $56.9 million), of which $17.0 million (year ended December 31, 2020 - $45.9 million) was recognized as an impaired and obsolete inventory provision, and $0.5 million (year ended December 31, 2020 - $11.0 million) was included in the change in fair value realized through inventory as the fair value component of the impaired and obsolete inventory provision.

XML

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Property, Plant and Equipment

13. Property, plant and equipment

	Land			Production facilities			Equipment			Right of use assets			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2019		26,606			166,442			24,021			16,509			58,031			291,609
Additions		8			213			2,886			763			4,319			8,189
Transfers from CIP		509			8,212			2,287			—			(11,008	)		—
Reclass to assets held for sale		(1,547	)		—			—			—			(1,451	)		(2,998	)
Dispositions		(499	)		(162	)		(50	)		(825	)		(991	)		(2,527	)
Disposition of Bridge Farm (note 6)		(16,300	)		(21,587	)		(249	)		(14,431	)		(39,734	)		(92,301	)
Foreign currency translation		(137	)		(181	)		(1	)		(122	)		(347	)		(788	)
Balance at December 31, 2020		8,640			152,937			28,894			1,894			8,819			201,184
Acquisition (note 5)		—			4,169			2,209			5,730			—			12,108
Additions		—			593			1,975			579			1,209			4,356
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(468	)		(301	)		(165	)		(177	)		(1,111	)
Balance at December 31, 2021		12,388			157,231			32,777			8,038			6,103			216,537
Accumulated amortization and impairment
Balance at December 31, 2019		3			5,400			3,697			363			162			9,625
Depreciation		475			6,249			4,847			638			—			12,209
Impairment		—			60,658			—			—			5,659			66,317
Dispositions		—			(37	)		(44	)		(176	)		—			(257	)
Disposition of Bridge Farm (note 6)		(473	)		(2,879	)		—			(251	)		—			(3,603	)
Foreign currency translation		(5	)		(27	)		—			(3	)		—			(35	)
Balance at December 31, 2020		—			69,364			8,500			571			5,821			84,256
Depreciation		—			2,914			5,438			897			—			9,249
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			(10	)		(147	)		—			(157	)
Balance at December 31, 2021		—			132,278			13,928			1,321			5,821			153,348
Net book value
Balance at December 31, 2020		8,640			83,573			20,394			1,323			2,998			116,928
Balance at December 31, 2021		12,388			24,953			18,849			6,717			282			63,189

During the year ended December 31, 2021, depreciation expense of $4.9 million was capitalized to biological assets and inventory (year ended December 31, 2020 – $6.9 million).

Due to curtailment in the utilization of a portion of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates, the Company determined that indicators of impairment existed at June 30, 2021. The impairment test for the Company’s Olds CGU used a value in use approach based on internal cash flow estimates at June 30, 2021, and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s Olds CGU of $60.0 million as at June 30, 2021, as the estimated recoverable amount for this CGU of $70.0 million was lower than the respective carrying amount. The estimated value in use for the Company’s Olds CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $7.3 million.

At December 31, 2021, the Company determined that no further indicators of impairment existed or indicators that a previous impairment should be reversed, and no impairment test was required.

During the year ended December 31, 2020, the Company determined that indicators of impairment existed with respect to the Company’s British Columbia CGU as a result of the Company’s disposition of its Kamloops property and decision to suspend further construction and development activities on its Merritt facility due to market conditions and available financing. Approximately $10.0 million had been invested into the Merritt facility which consisted of land and CIP. A test for impairment was performed at March 31, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their fair value less costs of disposal and an impairment of $5.7 million was recorded to write down the assets to their recoverable amount. The fair value measurement is categorized within Level 3 of the fair value hierarchy. The recoverable amount of these assets was further reduced to $2.9 million due to the Company receiving utility deposits back on deferral of construction of the facility. Management is committed to a plan to sell the Merritt facility and the asset is available for immediate sale, resulting in the reclassification to assets held for sale on the consolidated statements of financial position.

During the year ended December 31, 2020, the Company determined that indicators of impairment existed with respect to the Company’s Alberta CGU as a result of decreasing estimates for the size of the potential Canadian cannabis market, the Company curtailing the number of flowering rooms being used for cultivation at its Olds facility and the carrying value of the Company’s total net assets significantly exceeding the Company’s market capitalization. A test for impairment was performed at September 30, 2020, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets, using a value in use approach based on internal cash flow estimates and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account forecasted Canadian cannabis industry activity market size and Sundial’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, the Company determined there was an impairment of the Company’s Alberta CGU of $60.0 million as at September 30, 2020, as the estimated recoverable amount for this CGU of $154.0 million was lower than the respective carrying amount.

On December 28, 2020, the Company announced a concentrates licensing agreement based out of its Rocky View facility. Within the agreement is a non-binding purchase agreement to sell the Rocky View facility for $5.0 million. The estimated recoverable amount of the Rocky View facility was determined to be its fair value less costs of disposal and an impairment of $0.7 million was recorded to write down the assets to their recoverable amount of $5.0 million. The fair value measurement is categorized within Level 3 of the fair value hierarchy.

All of the above impairments were recognized in the Company’s cannabis reporting segment.

XML

Net Investment In Subleases

12 Months Ended

Dec. 31, 2021

Disclosure Of Net Investment In Subleases [Abstract]

Disclosure of Net Investment in Subleases Explanatory

14. Net investment in subleases

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Acquisition (note 5)		23,751			—
Additions		3,951			—
Finance income		573			—
Rents recovered (payments made directly to landlords)		(1,713	)		—
Dispositions		—			—
Balance, end of year		26,562			—
Current portion		3,991			—
Long-term		22,571			—

Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

XML

Intangible assets

12 Months Ended

Dec. 31, 2021

Disclosure Of Intangible Assets [Abstract]

Intangible Assets

15. Intangible assets

	Brands and trademarks			Patents		Customer relationships			Other			Total
Cost
Balance at December 31, 2019		8,386			13,551		19,578			3,778			45,293
Additions		150			—		—			—			150
Disposition of Bridge Farm (note 6)		(3,066	)		—		(19,415	)		(3,747	)		(26,228	)
Foreign currency translation		(25	)		—		(163	)		(31	)		(219	)
Balance at December 31, 2020		5,445			13,551		—			—			18,996
Balance at December 31, 2021		5,445			13,551		—			—			18,996
Accumulated amortization and impairment
Balance at December 31, 2019		131			—		976			191			1,298
Depreciation		441			677		842			165			2,125
Impairment		—			12,874		—			—			12,874
Disposition of Bridge Farm (note 6)		(190	)		—		(1,801	)		(353	)		(2,344	)
Foreign currency translation		—			—		(17	)		(3	)		(20	)
Balance at December 31, 2020		382			13,551		—			—			13,933
Depreciation		354			—		—			—			354
Balance at December 31, 2021		736			13,551		—			—			14,287
Net book value
Balance at December 31, 2020		5,063			—		—			—			5,063
Balance at December 31, 2021		4,709			—		—			—			4,709

Brands and trademarks related to intellectual property purchased from Sun 8 Holdings Inc. with a useful life of 15 years and other intellectual property with a useful life of 12 years.

Patents consisted of intellectual property acquired through the acquisition of Pathway RX Inc. (“Pathway”) comprised of proprietary rights to certain technology, copyrights and trademarks with a useful life of 20 years. During the year ended December 31, 2020, the Company determined that indicators of impairment existed regarding the Pathway intellectual property due to the Company’s decision to reduce its focus on medical cannabis research. The estimated recoverable amount of the intangible assets was determined to be their fair value less costs of disposal and an impairment of $12.9 million was recorded to write down the assets to their recoverable amount of nil.

Brands and trademarks related to intellectual property acquired as part of the Bridge Farm acquisition, customer relationships and other intangible assets consisting of non-compete clauses and energy credits were disposed of as part of the sale of Bridge Farm (note 6).

XML

Investments

12 Months Ended

Dec. 31, 2021

Disclosure Of Investments [Abstract]

Investments

16. Investments

As at	December 31, 2021		December 31, 2020
Investments at amortized cost (A)		24,987		—
Investment at FVTPL (B)		48,576		51,876
		73,563		51,876
Current portion		3,065		—
Long-term		70,498		51,876

A) INvestments at amortized cost

On February 16, 2021, the Company announced a $22 million strategic investment (the “Indiva Investment”) in Indiva Limited (“Indiva”). The Indiva Investment closed on February 23, 2021. The Indiva Investment was completed in the form of a brokered private placement of 25 million common shares of Indiva at a price of $0.44 per common share, for gross proceeds of $11 million, and a non-revolving secured term loan to Indiva in the principal amount of $11 million (the “Term Loan”). The Term Loan bore interest at a rate of 9% per annum and has a maturity date of February 23, 2024.

On October 4, 2021, the Company provided an additional $8.5 million principal loan to Indiva and has amended the Term Loan. The amended Term Loan has an interest rate of 15% per annum and the maturity date of February 23, 2024 has not changed. Accrued and unpaid interest of $0.3 million was added to the outstanding principal balance, bringing the total principal outstanding to $19.8 million.

The Term Loan has been designated as measured at amortized cost (note 32). The common shares are measured at Fair Value Through Profit or Loss (“FVTPL”) and are included in marketable securities (note 9).

On April 26, 2021, the Company closed a $3.0 million convertible debenture with a private company with a maturity date of October 26, 2021, and an interest rate of 9% per annum. The maturity date was extended to April 26, 2022, and the interest rate increased to 12% per annum. The Company has the right, but not the obligation, to convert all or any portion of the outstanding principal into common shares at a price equal to a conversion formula until the maturity date. The convertible debenture has been designated as measured at amortized cost (note 32).

The Company has entered into several promissory notes with Spiritleaf franchise partners, with interest rates ranging from prime plus a margin of 5.5% per annum to 8% per annum, with maturity dates of 5 years. The promissory notes have been designated as measured at amortized cost (note 32).

The following table summarizes the carrying amount of investments at amortized cost as at December 31, 2021:

As at	December 31, 2021
Secured term loan		19,417
Convertible debenture		3,065
Spiritleaf franchise partners		2,505
		24,987

B) Investment at fvtpl

The Company owns a special purpose vehicle (the “Zenabis Investment”) that owns $51.9 million of aggregate principal amount of senior secured debt of Zenabis Investments Ltd. (the “Zenabis Senior Loan”) of Zenabis Investments Ltd. (“Zenabis”). The Zenabis Senior Loan is secured by the assets of Zenabis and its subsidiaries and is guaranteed by Zenabis Global Inc. On June 1, 2021, Zenabis was acquired by HEXO Corp. The Zenabis Senior Loan

bears interest at a rate of 14% per annum and has a maturity date of March 31, 2025. Pursuant to the terms of the Zenabis Senior Loan, Zenabis will also pay the Company a royalty based on quarterly sales revenue from its medical, recreational and wholesale cannabis lines net of value added or sales taxes. The royalty is payable for 32 fiscal quarters and is payable for quarters in which Zenabis accomplishes certain sales revenue targets.

The Company is in negotiations with Zenabis for the repayment and termination of the Zenabis Senior Loan as Zenabis is in breach of certain covenants. Zenabis filed a petition with the Supreme Court of British Columbia to determine the value of the royalty. The court dismissed the petition and did not decide the merits of the case. Zenabis had 30 days from December 17, 2021 to file a notice of appeal in respect of the court’s findings, but they did not do so.

The Zenabis Investment has been designated as FVTPL (note 32). As of April 27, 2022, all required payments have been made in respect of the Zenabis Senior Loan, including $100,000 per month in monitoring fees payable to the Company.

Due to the credit risk associated with Zenabis and its parent, and uncertainty of the completion of their proposed restructuring, the Company has adjusted the fair value of the Zenabis Senior Loan downward by $3.3 million in accordance with the requirements of IFRS. In the event that facts and circumstances change the fair value will be adjusted accordingly. The fair value determination does not attribute value to the associated royalty due to its inherent uncertainty, or monitoring fee.

XML

Equity-Accounted Investees

12 Months Ended

Dec. 31, 2021

Disclosure Of Interests In Other Entities [Abstract]

Equity-Accounted Investees

17. Equity-accounted investees

As at	December 31, 2021		December 31, 2020
Interest in joint venture (A)		412,858		—
Interest in associate (B)		—		—
		412,858		—

A) Interest in joint venture

On March 15, 2021, the Company and SAF Group announced they had entered into an agreement to form a 50/50 joint venture through a new corporation, SunStream Bancorp Inc. (“SunStream”). SunStream is a private company, incorporated under the Business Corporations Act (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

SunStream is structured as a separate vehicle and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method.

The current investment portfolio of SunStream is comprised of secured debt and hybrid debt and derivative instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risks and other risks specific to each investment.

As at December 31, 2021, the Company had contributed $395.6 million out of the total $538.0 million that has been committed. Subsequent to December 31, 2021, the Company contributed $70.3 million to SunStream.

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858

SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

The following table summarizes the financial information of SunStream:

As at	December 31, 2021
Current assets (including cash and cash equivalents: $0.2 million)		789
Non-current assets		407,860
Current liabilities		(1,596	)
Non-current liabilities		—
Net assets (liabilities) (100%)		407,053
Year ended December 31, 2021
Revenue		36,203
Profit from operations		32,841
Other comprehensive income		9,878
Total comprehensive income		42,747

B) Interest in associate

On March 23, 2021, the Company’s equity interest in its subsidiary, Pathway, decreased from 50% to 25%, resulting in a loss of control. The Company decreased its equity interest in connection with amending the licence agreement that provides for use of Pathway’s intellectual property. Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a wide range of medical conditions.

As a result of the loss of control, the Company has de-recognized the assets and liabilities of Pathway, and the non-controlling interest arising upon the acquisition of Pathway. A loss on loss of control of $1.9 million was recognized during the three months ended March 31, 2021. The fair value of the Company’s remaining investment in Pathway was determined to be nil as the Company had fully impaired the intangible asset, which consisted of intellectual property, during the year ended December 31, 2020 as described below, and there are no other assets that would give rise to a measured fair value amount attributable to the remaining 25% interest.

Adjustment to comparative information

During Q4 2020, and as disclosed in the annual consolidated financial statements of the Company as at and for the year ended December 31, 2020, the Company recognized an impairment of $12.9 million on the intangible assets held within Pathway. During the preparation of the Q1 2021 interim consolidated financial statements, the Company determined that the allocable amount of this impairment was not attributed to the non-controlling interest. The comparative December 31, 2020, consolidated statement of financial position has been recast to attribute 50% of the impairment of intangible assets recorded to the non-controlling interest as the related intangible assets related entirely to Pathway, the Company’s 50% owned subsidiary.

The recast of the consolidated statement of financial position as at December 2020 resulted in a reduction in non-controlling interest of $6.4 million from the previously reported amount of $4.4 million to the recast amount of negative $2.0 million, and a decrease in accumulated deficit of $6.4 million from the previously reported amount of

$564.5 million to the recast amount of $558.1 million and a decrease in loss per share attributable to the Company of $0.03 from the previously reported amount of $1.10 to the recast amount of $1.07.

This recast has no effect on the consolidated 2020 annual net loss or comprehensive loss or on any previously issued interim consolidated financial statements of the Company. The effect of this recast on the Company’s annual results for 2020 is a decrease to the presentation of the net loss attributable to the Company of $6.4 million from the previously reported amount of $206.0 million to the recast amount of $199.6 million, and an increase in the presentation of the net loss attributable to non-controlling interest of $6.4 million from the previously reported amount of $0.3 million to the recast amount of $6.7 million.

Contingent consideration

Contingent consideration was from the acquisition of Pathway in 2019. Contingent consideration valued at $2.3 million represents the granting of up to 280,000 warrants to purchase common shares of the Company at an exercise price of $1.81 per share, subject to the achievement of certain gross revenue milestones derived from Pathway royalty activities.

XML

Accounts Payable and Accrued Liabilities

12 Months Ended

Dec. 31, 2021

Subclassifications Of Assets Liabilities And Equities [Abstract]

Accounts Payable and Accrued Liabilities

18. Accounts payable and accrued liabilities

	December 31, 2021		December 31, 2020
Trade payables		4,172		4,849
Accrued and other liabilities		34,280		18,459
		38,452		23,308

XML

Derivative Warrants

12 Months Ended

Dec. 31, 2021

Derivative Warrant Liabilities [Abstract]

Derivative Warrants

19. Derivative warrants

	December 31, 2021			December 31, 2020
Balance, beginning of year		428			—
2021 Series A and B Warrants - fair value on issuance (A)		62,680			—
2021 Additional Series A and B Warrants - fair value on issuance (B)		38,576			—
New Warrants - fair value on issuance recognized in profit or loss (C)		106,531			—
Agent Warrants - fair value on issuance (D)		—			504
Secured Convertible Note Warrants - fair value on issuance (E)		—			6,683
Unsecured Convertible Notes Warrants - fair value on issuance (F)		—			3,961
2020 Series A and B Warrants - fair value on issuance (G)		—			11,784
Change in fair value recognized in profit or loss		(28,697	)		12,995
Converted to common shares		(157,818	)		(35,521	)
Unrealized foreign exchange loss		—			22
Balance, end of year		21,700			428

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

(a) 2021 Series A and B Warrants

On February 2, 2021, the Company issued 100.0 million series A units (the “Series A Units”), each consisting of one common share and one-half series A warrant (collectively, the “2021 Series A Warrants”) to purchase one common share and 33.3 million series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “2021 Series B Warrants”) to purchase one common share and one-half 2021 Series A Warrant to purchase one common share (collectively, the “January 2021 Units Offering”). Each Series A Unit was sold at a price of US$0.75 per unit and each Series B Unit was sold at a price of US$0.75 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$100.0 million. The 2021 Series A Warrants and 2021 Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the 2021 Series A Warrants was US$0.80 per common share and the exercise price of the 2021 Series B Warrants was US$0.0001 per common share.

On February 2, 2021, the entire 33.3 million 2021 Series B Warrants were exercised resulting in the issuance of 33.3 million common shares.

On February 10, 2021, 3.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 3.3 million common shares and gross proceeds to the Company of US$2.7 million.

On February 22, 2021, the remaining 63.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million. In connection with this exercise, the New Warrants were granted (refer to C below).

(b) 2021 Additional series A and B warrants

On February 4, 2021, the Company issued 60.5 million additional series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “2021 Additional Series A Warrants”) to purchase one common share and 14.0 million additional series B units (the “Additional Series B Units”), each consisting of one pre-funded additional series B warrant (the “2021 Additional Series B Warrants”) to purchase one common share and one-half 2021 Additional Series A Warrant to purchase one common share, (collectively, the “February 2021 Units Offering”). Each Additional Series A Unit was sold at a price of US$1.00 per unit and each Additional Series B Unit was sold at a price of US$1.00 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$74.5 million. The 2021 Additional Series A Warrants and 2021 Additional Series B Warrants were exercisable immediately and had a term of five years commencing on the date of issuance. The exercise price of the 2021 Additional Series A Warrants was US$1.10 per common share and the exercise price of the 2021 Additional Series B Warrants was US$0.0001 per common share.

On February 4, 2021, the entire 14.0 million 2021 Additional Series B Warrants were exercised resulting in the issuance of 14.0 million common shares.

On February 10, 2021, 2.3 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 2.3 million common shares and gross proceeds to the Company of US$2.5 million.

On February 22, 2021, the remaining 35.0 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the New Warrants were granted (refer to C below).

(c) new warrants

On February 22, 2021, (i) the remaining 63.3 million 2021 Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million and (ii) the remaining 35.0 million 2021 Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the Company issued 98.3 million new warrants to the holders of the 2021 Series A Warrants and 2021 Additional Series A Warrants (the “New Warrants”), each entitling the holder to purchase one common share at an exercise price of US$1.50, subject to customary anti-dilution adjustments. The Company has granted the holders the right to have the common shares issuable upon exercise of the New Warrants registered pursuant to a registration statement filed with the SEC. Such

registration statement was filed with the SEC on March 3, 2021. The New Warrants are immediately exercisable and have a term of 42 months from March 18, 2021, which is the effective date of the registration statement. As at December 31, 2021, 98.3 million New Warrants remained outstanding.

(d) Agent warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to the placement agents to acquire up to 1.08 million common shares at an initial exercise price of US$1.00 per common share (the “Agent Warrants”).

During the year ended December 31, 2021, the entire 1.08 million Agent Warrants were exercised. 540,000 Agent Warrants were exercised at a weighted average exercise price of US$1.00 per warrant resulting in the issuance of 356,949 common shares. There were no gross proceeds to the Company as the exercise was conducted on a cashless basis. The other 540,000 Agent Warrants were exercised at a weighted average exercise price of US$1.00 per warrant resulting in the issuance of 540,000 common shares and gross proceeds to the Company of US$0.5 million.

(e) Secured convertible note warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.00 per warrant and common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.20 per warrant (the “Secured Convertible Note Warrants”). The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance.

During the period October 22, 2020, to December 31, 2020, the entire 35.0 million Secured Convertible Note Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of $8.0 million.

(f) Unsecured convertible notes warrants

In connection with the debt restructuring transactions during the prior year, the Company issued common share purchase warrants to acquire up to 14.5 million common shares at an initial exercise price of US$0.9338 per common share (the “Unsecured Convertible Notes Warrants”). The Unsecured Convertible Notes Warrants were issued on June 5, 2020, were immediately exercisable, and expire 42 months from the date that the underlying common shares become freely tradeable, which was July 16, 2020. In certain circumstances, the Unsecured Convertible Notes Warrants are subject to forced exercise provisions whereby the Company can force exercise should the volume weighted average price of the Company’s common shares exceed US$2.8014.

As a result of sales under the ATM Program, the exercise price of the Unsecured Convertible Notes Warrants was adjusted to US$0.1766 per common share. The foregoing exercise price may be further adjusted as the result of future sales under the ATM Program or other offerings, if any.

During the period July 16, 2020, to December 31, 2020, 14.0 million Unsecured Convertible Notes Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 14.0 million common shares and gross proceeds to the Company of $3.2 million. As at December 31, 2021, 0.5 million Unsecured Convertible Notes Warrants remained outstanding.

(g) 2020 Series A and B warrants

On August 18, 2020, in connection with the August 2020 registered offering, the Company issued 40.1 million series A warrants (“2020 Series A Warrants”) and 14.3 million series B warrants (“2020 Series B Warrants”). The 2020 Series A Warrants and 2020 Series B Warrants are exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the 2020 Series A Warrants are US$0.75 per common share and the exercise price of the 2020 Series B Warrants are US$0.0001 per common share.

On August 19, 2020, 9.2 million 2020 Series B Warrants were converted into common shares and on August 20, 2020, the remaining 5.1 million 2020 Series B Warrants were converted into common shares.

As a result of sales under the At-the-Market (“ATM”) Program, the exercise price of the 2020 Series A Warrants was adjusted to US$0.1766 per common share. The exercise price of the 2020 Series A Warrants may be further adjusted as the result of future sales under the ATM Program or other offerings, if any.

During the period August 18, 2020, to December 31, 2020, 39.6 million 2020 Series A Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 39.6 million common shares and gross proceeds to the Company of $9.1 million. As at December 31, 2021, 0.5 million 2020 Series A Warrants remained outstanding.

The following table summarizes outstanding derivative warrants as at December 31, 2021:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		0.1766		500,000		3.6
Unsecured Convertible Notes Warrants (1)		0.1766		500,000		2.0
New Warrants		1.50		98,333,334		2.6
				99,333,334		2.6

(1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

XML

Lease Obligations

12 Months Ended

Dec. 31, 2021

Lease Liabilities [Abstract]

Lease Obligations

20. Lease obligations

	December 31, 2021			December 31, 2020
Balance, beginning of year		1,440			16,949
Acquisition (note 5)		29,481			—
Liabilities incurred		4,514			763
Lease payments		(2,721	)		(937	)
Dispositions		(20	)		(735	)
Interest expense		776			416
Disposition of Bridge Farm (note 6)		—			(14,894	)
Foreign currency translation		—			(122	)
Balance, end of year		33,470			1,440
Current portion		5,701			409
Long-term		27,769			1,031

The Company’s minimum lease payments are as follows:

	December 31, 2021
Less than one year		5,938
One to three years		10,514
Three to five years		8,424
Thereafter		13,629
Minimum lease payments		38,505
Amounts representing finance charges		(5,035	)
Net minimum lease payments		33,470

The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2021.

XML

Other Liabilities

12 Months Ended

Dec. 31, 2021

Disclosure Of Other Liabilities [Abstract]

Other Liabilities

21. Other liabilities

	December 31, 2021		December 31, 2020
Financial guarantee liability (A)		466		—
DSU liability (B)		4,039		—
		4,505		—

(A) Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of expected credit losses in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs in the consolidated statement of loss and comprehensive loss.

(B) DSU liability

DSUs are granted to directors and generally vest in equal instalments over one year. The Company intended to settle the DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle the DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end.

XML

Income Taxes

12 Months Ended

Dec. 31, 2021

Major Components Of Tax Expense Income [Abstract]

Income Taxes

22. Income taxes

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in the consolidated statement of loss and comprehensive loss for the years ended December 31, 2021, December 31, 2020 and December 31, 2019:

	December 31, 2021			December 31, 2020			December 31, 2019
Loss before taxes		(232,453	)		(206,317	)		(146,307	)
Statutory income tax rates		23.0	%		24.0	%		26.5	%
Expected income tax recovery		(53,464	)		(49,516	)		(38,771	)
Non-deductible share-based compensation		2,308			1,970			10,474
Non-deductible finance expense		2			2,130			15,981
Revaluation of the fair value of warrant liabilities		17,902			—			—
Non-deductible portion of capital losses		5,118			—			—
Other non-deductible expenses		610			348			2,621
Change in tax rates		—			1,528			3,305
Deferred tax benefits not recognized		25,253			43,540			2,781
Income tax (recovery) expense		(2,271	)		—			(3,609	)

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2021			December 31, 2020
Deferred tax assets (liabilities):
Inventory		20,472			8,388
Biological assets		(9,509	)		(8,388	)
Net investment in subleases		(6,109	)		—
Lease obligations		(8,371	)		—
Marketable securities		7,442			—
Equity-accounted investee		(3,925	)		—
Net deferred tax asset (liability)		—			—

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2021		December 31, 2020
Unrecognized deductible temporary differences:
Property, plant and equipment		84,322		36,782
Intangible assets		183		536
Share issue costs		23,835		11,112
Investments		3,300		—
Lease obligations		69,865		—
Financial obligations and other		4,100		1,054
Inventory and biological assets		—		34,781
Non-capital losses & SR&ED		219,165		171,205
Unrecognized deductible temporary differences		404,770		255,470

The movement in deferred income tax liability is as follows:

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			3,365
Acquisition of Inner Spirit		—			—
Recognized in profit and loss		(2,271	)		—
Recognized in other comprehensive income		2,271			(25	)
Recognized in discontinued operations (note 6)		—			(225	)
Disposition of Bridge Farm (note 6)		—			(3,115	)
Balance, end of year		—			—

The Company has $218.5 million (December 31, 2020 - $171.2 million) of non-capital losses available for future periods that will expire prior to 2037-2041. There are $60.0 million of uncertain losses that have not been recognized.

XML

Share Capital and Warrants

12 Months Ended

Dec. 31, 2021

Share Capital And Warrants [Abstract]

Share Capital and Warrants

23. Share capital and warrants

(a) Authorized

The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

(b) Issued and outstanding

		December 31, 2021					December 31, 2020
	Note	Number of Shares		Carrying Amount			Number of Shares			Carrying Amount
Balance, beginning of year			918,844,133		762,046			107,180,423			509,654
Share issuances			956,806,648		977,425			337,696,867			176,931
Share issuance costs			—		(16,371	)		—			(5,593	)
Acquisition	5		24,431,278		26,216			—			—
Convertible debenture settlement	5		2,488,754		2,671			373,371,318			63,002
Disposition of Bridge Farm	6		—		—			(2,716,271	)		(38,447	)
Derivative warrants exercised	19		152,146,950		277,136			102,836,429			55,912
Warrants exercised	23(c)		195,711		178			—			—
Employee awards exercised (1)	24(c)		5,494,883		6,403			475,367			587
Balance, end of year			2,060,408,357		2,035,704			918,844,133			762,046

(1) Included in employee awards exercised are 875,000 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Excluded from employee awards exercised are 500,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

ATM Offering Program

During the year ended December 31, 2021, the Company issued 796.3 million common shares at a weighted average exercise price of US$0.8597 for gross proceeds of $855.2 million (US$684.6 million) through its ATM programs.

2021 Registered Offerings

In connection with the January 2021 Units Offering, the Company issued 100.0 million common shares (note 19a) and in connection with the February 2021 Units Offering, the Company issued 60.5 million common shares (note 19b). Total proceeds from the two offerings allocated to share capital were $122.2 million.

(c) Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2019		6,165,324			27,831
Warrants issued		544,000			306
Warrants expired		(3,232,434	)		(5,908	)
Warrants cancelled		(2,452,890	)		(16,091	)
Balance at December 31, 2020		1,024,000			6,138
Acquisition (note 5)		2,097,828			1,771
Warrants issued		640,000			361
Warrants exercised		(195,711	)		(178	)
Balance at December 31, 2021		3,566,117			8,092

During the year ended December 31, 2021, the Company issued 640,000 warrants to Sun 8 Holdings Inc. (“Sun 8”) with an exercise price of $0.94 per unit, in conjunction with achieving minimum thresholds of revenue derived from the brands or cultivars that the Company acquired from Sun 8 during the year ended December 31, 2019.

During the year ended December 31, 2021, 195,711 warrants that formed part of the contingent consideration from the Inner Spirit Transaction, were exercised resulting in a net payment of $0.2 million representing the difference between the exercise prices and the cash consideration (note 5). The carrying value of the exercised warrants was adjusted from warrants to share capital.

The following table summarizes outstanding warrants as at December 31, 2021:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Acquisition of financial obligation		15.94		480,000		0.5
Financial services		4.60		544,000		7.6
Acquired from Inner Spirit (1)		0.34		1,902,117		2.2
Sun 8		0.94		640,000		4.0
		3.20		3,566,117		3.1

(1) Inner Spirit warrants are exchangeable for 0.0835 Sundial common shares in accordance with the Inner Spirit Transaction consideration (note 5) and have been presented based on the number of Sundial common shares that are issuable.

XML

Share-based Compensation

12 Months Ended

Dec. 31, 2021

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Share-based Compensation

24. Share-based compensation

The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, RSUs and DSUs. Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants.

The components of share-based compensation expense are as follows:

	Year ended December 31
	2021			2020			2019
Equity-settled expense
Simple warrants (A)		2,899			1,539			23,918
Performance warrants (A)		361			(42	)		11,023
Stock options (B)		(14	)		651			98
Restricted share units (C)		6,789			4,069			220
Shares issued for services		—			—			2,320
Cash-settled expense
Deferred share units (i) (D)		2,272			2,349			1,119
		12,307			8,566			38,698

(i) Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each period end. Fluctuations in the fair value are recognized during the period in which they occur.

In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to estimate the fair value of units granted during the years ended December 31, 2021, December 31, 2020 and December 31, 2019 through the application of the following assumptions:

	December 31, 2021	December 31, 2020	December 31, 2019
Risk-free interest rate	0.45%	0.28% - 0.29%	1.41% - 1.88%
Expected life of units (years)	5	10	2 - 10
Expected annualized volatility	168%	143%	97% - 116%
Expected dividend yield	Nil	Nil	Nil
Weighted average Black-Scholes value of each unit	$0.56	$1.13 - $1.17	$0.67 - $23.55

Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that the units granted are expected to be outstanding. The risk-free rate was based on Government of Canada bond rates of comparable duration.

Equity-settled plans

a) Simple and performance warrants

The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants do not expire.

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19
Forfeited		(668,800	)		3.36		(204,800	)		5.48
Exercised		(120,000	)		0.94		(80,000	)		1.09
Expired		(41,600	)		3.45		—			0.00
Balance at December 31, 2021		2,594,200		$	4.86		1,387,200		$	4.18

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2020:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2019		9,815,000		$	4.01		5,798,822		$	2.66
Forfeited		(6,390,400	)		3.79		(4,126,822	)		2.04
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19

The following table summarizes outstanding simple and performance warrants as at December 31, 2021:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$0.63 - $0.94		889,400		0.72		2.21		889,400		0.72		2.21
$1.25 - $1.88		—		—		—		—		—		—
$2.97 - $4.53		351,200		3.09		3.09		303,200		3.06		3.02
$6.25 - $9.38		1,219,200		6.29		4.72		499,200		6.35		4.70
$12.50 - $37.50		134,400		23.91		5.52		40,000		19.61		4.05
		2,594,200	$	4.86		3.68		1,731,800	$	3.19		3.11
Performance warrants
$0.63 - $0.94		458,667		0.68	n/a			458,667		0.68	n/a
$1.25 - $1.88		189,333		1.51	n/a			181,333		1.50	n/a
$2.97 - $4.53		504,000		3.16	n/a			504,000		3.16	n/a
$6.25 - $9.38		144,533		7.23	n/a			38,400		6.25	n/a
$12.50 - $37.50		90,667		28.24	n/a			—		—	n/a
		1,387,200	$	4.18	n/a			1,182,400	$	2.04	n/a

b) Stock options

The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and expire ten years after the grant date.

The following table summarizes changes in stock options during the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		720,600		$	1.82
Forfeited		(275,000	)		2.60
Expired		(1,000	)		3.15
Balance at December 31, 2021		444,600		$	1.33

No stock options were granted in 2021. The following table summarizes changes in stock options during the year ended December 31, 2020:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2019		623,850		$	4.33
Granted		481,600			1.16
Forfeited		(384,850	)		4.96
Balance at December 31, 2020		720,600		$	1.82

The following table summarizes outstanding stock options as at December 31, 2021:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$1.15		325,000		8.41		108,332		8.41
$1.19		81,600		8.49		81,600		8.49
$3.15		38,000		6.35		20,500		6.06
		444,600		8.25		210,432		8.21

c) Restricted share units

RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares.

The following table summarizes changes in RSUs during the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		1,656,916
Granted		12,381,525
Forfeited		(1,582,628	)
Exercised		(4,919,883	)
Balance at December 31, 2021		7,535,930

The following table summarizes changes in RSUs during the year ended December 31, 2020:

	RSUs outstanding
Balance at December 31, 2019		48,883
Granted		3,002,213
Forfeited		(43,813	)
Exercised		(1,350,367	)
Balance at December 31, 2020		1,656,916

Subsequent to December 31, 2021, the Company granted 15.6 million RSUs to employees as part of its long-term incentive program.

Cash-settled plans

d) Deferred share units

DSUs are granted to directors and generally vest in equal instalments over one year. The Company intended to settle the DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle the DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities.

As at December 31, 2021, included in other liabilities is $4.0 million relating to the fair value of cash-settled DSUs (note 21).

The following table summarizes changes in DSUs during the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		3,323,263
Granted		2,489,173
Exercised		(300,000	)
Balance at December 31, 2021		5,512,436

As at December 31, 2021, 0.6 million DSUs were exercisable.

The following table summarizes changes in DSUs during the year ended December 31, 2020:

	DSUs outstanding
Balance at December 31, 2019		367,924
Granted		3,265,503
Forfeited		(310,164	)
Balance at December 31, 2020		3,323,263

XML

Gross Revenue

12 Months Ended

Dec. 31, 2021

Revenue [Abstract]

Gross Revenue

25. Gross revenue

Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers. Retail revenue is derived from retail cannabis sales to customers, franchise revenue consisting of royalty, advertising and franchise fee revenue, and other revenue consisting of millwork, supply and accessories revenue.

	Year ended December 31
	2021		2020		2019
Cannabis revenue
Provincial boards		41,338		55,315		13,386
Medical		8		32		24
Licensed producers		9,842		17,974		53,517
Cannabis revenue (1)		51,188		73,321		66,927
Retail revenue (2)
Retail		10,207		—		—
Franchise		4,251		—		—
Other (millwork, supply, accessories)		1,633		—		—
Retail revenue		16,091		—		—
Gross revenue		67,279		73,321		66,927

(1) The Company had three major customers (which are provincial boards) each with revenue in excess of 10% of total cannabis revenue. Sales to these major customers totaled $28.2 million for the year ended December 31, 2021 (year ended December 31, 2020 – four major customers with total sales of $43.9 million, year ended December 31, 2019 – four major customers with total sales of $40.7 million).

(2) For the period July 20, 2021 to December 31, 2021.

The following table disaggregates cannabis revenue by form for the periods noted:

	Year ended December 31
	2021		2020		2019
Revenue from dried flower		39,572		51,424		58,246
Revenue from vapes		4,743		18,447		504
Revenue from oil		1,665		3,145		8,177
Revenue from edibles and concentrates		2,555		305		—
Revenue from services		2,653		—		—
Gross revenue		51,188		73,321		66,927

The Company has recognized the following receivables from contracts with customers:

	December 31, 2021		December 31, 2020		December 31, 2019
Receivables, included in 'trade receivables' (note 10)		10,865		15,786		20,281

Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2021, an impairment of $0.2 million (December 31, 2020 - $0.5 million reversal) has been recognized on receivables from contracts with customers (note 32).

XML

Investment Revenue

12 Months Ended

Dec. 31, 2021

Investment Revenue [Abstract]

Investment Revenue

26. Investment revenue

	Year ended December 31
	2021		2020		2019
Interest and fee revenue
Interest revenue from investments at amortized cost		1,654		—		—
Interest and fee revenue from investments at FVTPL		8,514		—		—
Interest revenue from cash		2,981		—		—
		13,149		—		—

	Year ended December 31
	2021			2020		2019
Investment revenue
Realized gains		20,213			—		—
Unrealized losses (note 9)		(64,714	)		—		—
		(44,501	)		—		—

XML

Other Operating Expenses

12 Months Ended

Dec. 31, 2021

Expense By Nature [Abstract]

Other Operating Expenses

27. Other operating expenses

A) General and administrative

	Year ended December 31
	2021		2020		2019
Salaries and wages		18,675		11,634		15,262
Consulting fees		1,112		2,193		6,896
Office and general		7,560		9,843		9,533
Professional fees		6,530		4,658		3,559
Director fees		351		365		188
Other		4,142		3,336		3,496
		38,370		32,029		38,934

B) Sales and marketing

	Year ended December 31
	2021		2020		2019
Marketing		3,671		4,839		3,093
Events		191		393		2,961
Research		43		57		199
Media		1,138		448		1,815
		5,043		5,737		8,068

XML

Government Subsidies

12 Months Ended

Dec. 31, 2021

Government Subsidies [Abstract]

Government Subsidies

28. Government subsidies

In March 2020, the federal government launched the Canadian Emergency Wage Subsidy (“CEWS”) to help businesses impacted by the COVID-19 pandemic keep and rehire employees.

The Company became eligible for the CEWS based on decreases in revenue and for the year ended December 31, 2021, the subsidy of $2.1 million (2020 - $4.0 million) was recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CEWS.

In October 2020, the federal government launched the Canadian Emergency Rent Subsidy (“CERS”) to help businesses impacted by the COVID-19 pandemic cover part of their commercial rent or property taxes. The CERS program provides a base rent subsidy that is available to organizations that continue to see decreasing revenues and an additional top up for organizations that must either close or significantly restrict their activities due to a public health order. CERS was available from September 27, 2020, until June 2021.

The Company became eligible for CERS based on decreases in revenue and for the year ended December 31, 2020, the subsidy of $0.1 million was recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CERS.

XML

Finance Costs

12 Months Ended

Dec. 31, 2021

Disclosure Of Finance Cost [Abstract]

Finance Costs

29. Finance costs

	Year ended December 31
	2021			2020			2019
Cash finance expense
Interest on Syndicated Credit Agreement		—			4,546			1,746
Interest on Term Debt Facility		—			2,936			3,478
Other finance costs		40			286			9,202
		40			7,768			14,426
Non-cash finance expense (income)
Change in fair value of investment at FVTPL		3,300			—			—
Interest on lease liabilities		776			—			—
Financial guarantee liability recovery		59			—			—
Accretion		—			1,622			5,511
Amortization of debt issue costs		—			1,782			1,586
Change in fair value of convertible notes		—			(7,141	)		—
Other		154			3			3,973
		4,289			(3,734	)		11,070
Interest income		(573	)		(215	)		—
Interest capitalized relating to CIP		—			—			(1,280	)
		3,756			3,819			24,216

XML

Supplemental Cash Flow Disclosures

12 Months Ended

Dec. 31, 2021

Supplemental Cash Flow Disclosure [Abstract]

Supplemental Cash Flow Disclosures

30. Supplemental cash flow disclosures

	Year ended December 31
	2021			2020			2019
Cash provided by (used in):
Accounts receivable		7,328			(2,037	)		(19,625	)
Biological assets		3,829			13,789			19,328
Inventory		(18,318	)		(12,315	)		(57,977	)
Prepaid expenses and deposits		(3,922	)		2,280			(7,213	)
Investments		(402	)		—			—
Property, plant and equipment		22			—			—
Accounts payable and accrued liabilities		9,665			(20,793	)		27,819
Convertible notes		—			—			(152	)
		(1,798	)		(19,076	)		(37,820	)
Changes in non-cash working capital relating to:
Operating		(1,534	)		(5,259	)		(41,626	)
Investing		(612	)		(11,319	)		1,659
Financing		348			(2,498	)		2,147
		(1,798	)		(19,076	)		(37,820	)
Cash interest paid		—			6,094			13,753

XML

Loss Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Loss Per Share

31. Loss per share

	Year ended December 31
	2021			2020			2019
Weighted average shares outstanding (000s)
Basic and diluted (1)		1,860,380			218,645			85,750
Continuing operations
Net loss attributable to Sundial Growers Inc.		(230,382	)		(199,619	)		(142,533	)
Per share - basic and diluted	$	(0.12	)	$	(0.92	)	$	(1.67	)
Discontinued operations
Net loss attributable to Sundial Growers Inc.		—			(33,627	)		(128,931	)
Per share - basic and diluted	$	—		$	(0.15	)	$	(1.50	)
Net loss attributable to Sundial Growers Inc.		(230,382	)		(233,246	)		(271,464	)
Per share - basic and diluted	$	(0.12	)	$	(1.07	)	$	(3.17	)

(1) For the year ended December 31, 2021, there were 3.6 million equity classified warrants, 99.3 million derivative warrants, 2.6 million simple warrants, 1.4 million performance warrants, 0.4 million stock options and 7.5 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2020 – 1.0 million equity classified warrants, 1.0 million derivative warrants, 3.4 million simple warrants, 1.7 million performance warrants, 0.7 million stock options and 1.7 million RSUs, year ended December 31, 2019 – 6.2 million equity classified warrants, 9.8 million simple warrants, 5.8 million performance warrants, 0.6 million stock options and 0.1 million RSUs).

XML

Financial Instruments

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Financial Instruments

32. Financial instruments

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVTPL, accounts payable and accrued liabilities and derivative warrants.

a) Fair value

The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions.

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700
			Fair value measurements using
December 31, 2020	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Investments at FVTPL		51,876		—		—		51,876
Financial liabilities
Derivative warrants (1)		428		—		—		428

(1) The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Marketable securities are designated as FVTPL. The fair value of marketable securities is re-measured each reporting period with changes in fair value recognized in the consolidated statement of loss and comprehensive loss. The fair value of marketable securities is estimated by using current quoted prices in active markets for identical assets.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

As at December 31, 2021, the Company did not have any financial instruments measured at Level 2 fair value.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The investment designated as FVTPL is re-measured each reporting period with changes in the fair value recognized in the consolidated statement of loss and comprehensive loss within finance costs. The fair value of

the investment was estimated by using a discounted cash flow analysis. The main assumption used in the calculation was the determination of a credit-adjusted discount rate.

Derivative warrants are designated as FVTPL. The fair value of derivative warrants is re-measured each reporting period with changes in fair value recognized in the consolidated statement of loss and comprehensive loss within finance costs. The fair value of derivative warrants is estimated by using a valuation model. Assumptions used in these calculations include volatility, discount rate and various probability factors.

At December 31, 2021, a 10% change in the material assumptions would change the estimated fair value of derivative warrant liabilities by approximately $4.0 million.

There were no transfers between Levels 1, 2 and 3 inputs during the period.

b) Credit risk management

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 to accounts receivable and has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2021		December 31, 2020
Impairment loss (reversal) on trade receivables		214		(506	)
Impairment loss (reversal) on other receivables		798		(126	)
		1,012		(632	)

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2021 was as follows:

	December 31, 2021		December 31, 2020
Balance, beginning of year		120		752
Net remeasurement of impairment loss allowance		1,012		(632	)
Balance, end of year		1,132		120

The Company applies the general approach under IFRS 9 to investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition. The general approach compares the risk of a default occurring at the reporting date with the risk of a default occurring at the date of initial recognition. The Company has evaluated the credit risk of its investments, taking into consideration the risk of default, historical credit loss experience, financial factors specific to the debtors and general economic conditions and determined the expected credit loss to be nil.

The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments.

c) Market risk management

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities and put and call options.

At December 31, 2021, a 10% change in the market prices would change the fair value of marketable securities by approximately $8.4 million.

The Company had the following risk management contracts relating to marketable securities outstanding as at December 31, 2021:

As at December 31, 2021	Quantity		Expiry	Proceeds		Fair value
Sold put options		2,174	Feb 18, 2022		34		27
Sold put options		1,329	Mar 18, 2022		65		51
		3,503			99		78

d) Liquidity risk management

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

The timing of expected cash outflows relating to financial liabilities at December 31, 2021 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		38,452		—		—		—		38,452
Lease obligations		5,938		10,514		8,424		13,629		38,505
Financial guarantee liability		—		466		—		—		466
Balance, end of period		44,390		10,980		8,424		13,629		77,423

XML

Related Party Transactions

12 Months Ended

Dec. 31, 2021

Related Party Transactions [Abstract]

Related Party Transactions

33. Related party transactions

a) Loan receivable agreements

At December 31, 2020, the Company had advanced $139 thousand under employee loan agreements. The terms were non-interest bearing and secured by shareholdings in the Company. During the year ended December 31, 2021, the full $139 thousand loan balance was settled. At December 31, 2021, the outstanding loan balance was nil.

b) Related party transactions and balances

	Transactions				Balance outstanding
	Year ended December 31		Year ended December 31		December 31		December 31
	2021		2020		2021		2020
Marketing, brand research and development (a)		—		1,144		—		—
Legal services (b)		—		2,462		—		(510	)
		—		3,606		—		(510	)

(a) A former member of the Board controlled a company that provides marketing, brand research and development services.

(b) A member of the Board was a partner at a law firm prior to his departure which provides legal services to the Company.

All transactions were conducted at the exchange amount agreed to with the related parties.

c) Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2021		2020		2019
Salaries and short-term benefits		2,348		1,944		3,295
Share-based compensation		8,275		7,629		23,715
		10,623		9,573		27,010

XML

Capital Management

12 Months Ended

Dec. 31, 2021

Disclosure Of Objectives Policies And Processes For Managing Capital [Abstract]

Capital Management

34. Capital management

The Company defines capital as shareholders’ equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to:

• Maintain financial flexibility in order to preserve the ability to meet financial obligations;

• Deploy capital to provide an appropriate investment return to shareholders; and,

• Maintain a capital structure that allows various financing alternatives.

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Disclosure Of Commitments And Contingencies [Abstract]

Commitments and contingencies

35. Commitments and contingencies

(a) Commitments

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2021 of $2.5 million (December 31, 2020 - $1.5 million).

(b) Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re Sundial Growers Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re Sundial Growers Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions assert claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally allege that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic

quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also includes allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021 and remains subject to such court approval.

In connection with the settlement agreement, the Company has an unrecognized contingent asset of $2 million, representing the difference between the settlement amount and the deductible under the Company’s directors and officers insurance policy. A contingent asset is disclosed when an inflow of economic resources is probable. A receivable for the $2 million will not be recognized until written confirmation of payment is received from the insurers.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. Sundial Growers Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserts claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) the Securities Exchange Act of 1934, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleges that the company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

The Company can provide no assurance as to the outcome of these proceedings or any other litigation matter in which we are a party. In particular, securities class action lawsuits are typically costly to defend, and divert the attention of management and other resources from operations and, accordingly, even if resolved in our favor, could have a material adverse effect on our business, financial condition, results of operations and liquidity and may force us to reduce or cease operations or seek relief under the applicable bankruptcy or insolvency laws.

XML

Subsequent Events

12 Months Ended

Dec. 31, 2021

Disclosure Of Nonadjusting Events After Reporting Period [Abstract]

Subsequent events

36. Subsequent events

Alcanna Inc. Acquisition

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company will acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximately 63% equity interest in Nova Cannabis Inc. (“Nova”), a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 320.6 million Sundial common shares valued at $280.4 million based on the fair value of each common share of the Company on the closing date (8.85 of a Sundial common share for each Alcanna common share).

Due to the proximity of the closing of the Alcanna Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Nasdaq minimum bid requirement

As previously reported, the Company was notified by Nasdaq on August 9, 2021, that the bid price for its common shares did not meet the minimum bid price of US$1.00 per share requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). At that time, the Company was required to regain compliance by February 7, 2022. On February 8, 2022, the Company received a 180-day extension to regain compliance with the Minimum Bid Requirement. As a result, the Company has until August 8, 2022, to regain compliance with the Minimum Bid Requirement.

If at any time prior to August 8, 2022, the closing bid price of the Company’s common stock is at least US$1.00 per share for a minimum of ten consecutive business days, the Company will be considered by Nasdaq to have regained compliance with the Minimum Bid Requirement.

The Company will actively monitor its closing bid price during the compliance period and intends to take appropriate measures to remedy the deficiency and regain compliance with the Minimum Bid Requirement.

Sun 8 Holdings Inc.

In 2019, the Company purchased intellectual property from Sun 8 Holdings Inc. (“Sun 8”) consisting of cannabis brands and products. The agreement included future consideration in the form of warrants to acquire up to 1.8 million common shares at an exercise price of $0.94, contingent upon achieving minimum thresholds of revenue derived from the acquired brands and cultivars over five years. The agreement also included royalty payments based on defined harvest metrics and merchandise sold under the acquired brands.

Subsequent to December 31, 2021, the Company and Sun 8 mutually terminated the service and sale agreement entered into in 2019. The Company issued 3.7 million common shares with a value of $2.9 million and made a cash payment of $3.1 million to cancel the royalty agreement and the non-competition agreement, as well as acknowledge vesting of 0.6 million performance warrants. The remaining 1.2 million warrants will not vest, and the Company is relieved of any future obligation pertaining to the warrants.

Investments

Subsequent to December 31, 2021, the Company entered into a promissory note with a private company with a principal amount of $5.0 million, an interest rate of 15% per annum and a maturity date of February 9, 2025.

Subsequent to December 31, 2021, the Company and Delta 9 Cannabis Inc. (“Delta 9”) entered into a note purchase agreement with an aggregate principal amount of $10.0 million, an interest rate of 10% per annum and a maturity date of March 30, 2025.

XML

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Accounting Policies [Abstract]

Cash and cash equivalents

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

Restricted cash and cash equivalents

RESTRICTED CASH AND CASH EQUIVALENTS

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading position, and (ii) minimum funding requirements for two separate captive insurance structures.

Biological assets

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

Inventory

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labor related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory is valued at Company-owned stores at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined by the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

Property, plant, and equipment

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as

appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the consolidated statements of loss and comprehensive loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

Production facilities20 years

Equipment1 to 10 years

Right-of-use assetsShorter of estimated useful life or lease term

Intangible assets

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with IAS 38.

The Company’s intangible assets at December 31, 2021, are comprised of the following:

• Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

• Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

Joint arrangements

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

Impairment of assets

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

(i)Financial assets

The Company applies an expected credit loss, or “ECL”, model to all financial assets not held at fair value through profit and loss, or “FVTPL”, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECL’s are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECL’s are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E and intangible assets, including goodwill, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of assets’ estimated fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit, or “CGU”).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset (or CGU) is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) previously. A reversal of an impairment loss is recognized immediately in the statements of loss and comprehensive loss.

Financial instruments

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or Fair Value Through Other Comprehensive Income depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognize in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at Fair Value Through Other Comprehensive Income.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

Provisions

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2021 and 2020.

Non-monetary transactions

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

Compound financial instruments

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in the consolidated statements of loss and comprehensive loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

Revenue

REVENUE

Under IFRS 15, to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation

of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and certain promotional activities and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift certificate.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and being stewards of the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they are utilizing the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

Research and development

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38 “Intangible Assets”. Research and development costs comprise consulting fees and licence acquisition fees. No development costs have been capitalized as at December 31, 2021, or December 31, 2020.

Share-based compensation

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

Income taxes

INCOME TAXES

Income taxes are recognized in the consolidated statements of loss and comprehensive loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and includes any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities, and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each consolidated statements of financial position date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

Business combinations

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transactions costs associated with business combinations are expensed as incurred.

Goodwill

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in net earnings. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

Non-controlling Interests

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

Loss of control

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

Leases

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right-of-use asset and a lease obligation at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease obligation. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease obligation is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease obligation is subsequently increased by the interest cost on the lease obligation and decreased by lease payments made. Lease payments are allocated between the liability and interest expense. Interest expense is recognized on the lease obligation using the effective interest rate method and payments are applied against the lease obligation.

The carrying amounts of the right-of-use assets, lease obligations, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset.

Government grants

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive insurance

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 “Consolidated Financial Statements” in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

New accounting standards

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2021 and did not have a material impact on the Company’s consolidated financial statements:

•COVID-19 Related Rent Concessions (Amendments to IFRS 16)

•Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2022, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2021. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

•Onerous contracts – Cost of Fulfilling a Contract (Amendments to IAS 37)

•IFRS 17 Insurance Contracts (Amendments to IFRS 17)

XML

Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Basis Of Presentation [Abstract]

Summary of Subsidiaries

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases.

Subsidiaries	Principal activity	Jurisdiction of incorporation	Equity ownership			Non-controlling interest ("NCI")
KamCan Products Inc.	Inactive	British Columbia, Canada		100	%		0	%
Sundial Deutschland GmbH	Inactive	Germany		100	%		0	%
2657408 Ontario Inc.	Operations	Ontario, Canada		100	%		0	%
NGBA-BC Holdings Ltd.	Operations	British Columbia, Canada		100	%		0	%
Sundial Insurance (Bermuda) Ltd.	Operations	Bermuda		100	%		0	%
Inner Spirit Holdings Ltd.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Corporate Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Ontario Inc. (1)	Operations	Ontario, Canada		0	%		100	%

(1) This entity may be considered to be “controlled” by the Company solely for the purposes of IFRS, but the entity is not controlled by the Company within the meaning of applicable corporate law. For the purposes of IFRS, control of this entity is determined by the Company being exposed to variable returns and having the ability to affect those returns through its power over the entity.

XML

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Accounting Policies [Abstract]

Estimated Use Full Life Of Asset Explanatory

For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

Production facilities20 years

Equipment1 to 10 years

Right-of-use assetsShorter of estimated useful life or lease term

XML

Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Business Combinations [Abstract]

Summary of Purchase Price Allocated

The fair value of consideration paid was as follows:

	July 20, 2021
Cash		92,583
Issuance of common shares		26,216
Contingent consideration		1,150
		119,949

Summary of Fair Value of Assets and Liabilities Acquired

The fair value of the assets and liabilities acquired was as follows:

	July 20, 2021
Cash		9,808
Accounts receivable		750
Prepaid expenses and deposits		853
Inventory		2,733
Property, plant and equipment		12,108
Net investment in subleases		23,751
Goodwill		114,537
Accounts payable and accrued liabilities		(2,678	)
Convertible debentures		(12,025	)
Lease liabilities		(29,481	)
Financial guarantee liability		(407	)
		119,949

XML

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Abstract]

Summary Results of Discontinued Operations

Results of discontinued operations

	Year ended December 31
	2021		2020 (1)			2019 (2)
Gross revenue		—		22,139			12,298
Net revenue		—		22,139			12,298
Cost of sales		—		15,633			9,426
Gross margin before fair value adjustments		—		6,506			2,872
Change in fair value of biological assets		—		1,064			386
Change in fair value realized through inventory		—		(1,122	)		—
Gross margin		—		6,448			3,258
General and administrative		—		8,585			5,515
Sales and marketing		—		1,418			820
Depreciation and amortization		—		2,752			3,482
Foreign exchange		—		1,057			(1,779	)
Share-based compensation		—		(826	)		826
Goodwill impairment		—		—			100,305
Loss from operations		—		(6,538	)		(105,911	)
Transaction costs		—		—			(1,588	)
Finance costs		—		(10,083	)		(3,982	)
Loss on contingent consideration		—		(2,252	)		(18,645	)
Gain on investment		—		—			165
Gain on disposition of PP&E		—		—			13
Loss on disposition of Bridge Farm		—		(14,979	)		—
Loss before income tax		—		(33,852	)		(129,948	)
Income tax recovery		—		225			1,017
Net loss (3)		—		(33,627	)		(128,931	)

(1) Period January 1, 2020, to June 5, 2020

(2) Period July 2, 2019, to December 31, 2019

(3) Net loss from the discontinued operations is attributable entirely to the owners of the Company.

Summary of Effect of Disposal On Financial Position Explanatory

Effect of disposal on the financial position of the company

Cash and cash equivalents	2,963
Accounts receivable	15,641
Biological assets	2,831
Inventory	787
Property, plant and equipment	88,698
Goodwill	11,345
Intangible assets	23,884
Accounts payable and accrued liabilities	(22,792	)
Lease obligation	(14,894	)
Deferred tax liability	(3,115	)
Accumulated other comprehensive income	(7,466	)
Net assets and liabilities	97,882
Consideration received
Term Debt Facility	45,000
Contingent consideration liability	34,912
Cancellation of common shares	2,991
Total consideration	82,903
Loss on disposition	(14,979	)

XML

Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Operating Segments [Abstract]

Disclosure of Reportable Segments Explanatory

	Cannabis			Retail (1)		Investments			Corporate			Total
As at December 31, 2021
Total assets		147,887			153,624		1,093,596			29,155			1,424,262
Year ended December 31, 2021
Net revenue		40,037			16,091		—			—			56,128
Gross margin		(15,499	)		8,509		—			—			(6,990	)
Interest and fee revenue		—			—		13,149			—			13,149
Loss on marketable securities		—			—		(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—			—		32,913			—			32,913
Depreciation and amortization		3,108			721		—			897			4,726
Earnings (loss) before tax		(117,990	)		1,835		(5,837	)		(110,461	)		(232,453	)

(1) Period July 20, 2021, to December 31, 2021

XML

Restricted Cash (Tables)

12 Months Ended

Dec. 31, 2021

Restricted Cash [Abstract]

Disclosure of Restricted Cash

As at	December 31, 2021		December 31, 2020
Letters of credit		—		5,333
Securities collateral		7,773		—
Captive insurance		19,240		—
		27,013		5,333

XML

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2021

Marketable Securities Disclosure [Abstract]

Disclosure of Marketable Securities

9. Marketable securities

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Additions		158,101			—
Dispositions		(9,663	)		—
Change in fair value recognized in profit or loss		(64,714	)		—
Balance, end of period		83,724			—

Schedule of Components of Marketable Securities

The components of marketable securities are as follows:

As at	December 31, 2021			December 31, 2020
Equity securities		83,802			—
Put and call options		(78	)		—
		83,724			—

XML

Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2021

Subclassifications Of Assets Liabilities And Equities [Abstract]

Summary of Accounts Receivable

As at	December 31, 2021		December 31, 2020
Trade receivables		10,865		15,786
Other receivables		—		112
		10,865		15,898

XML

Biological Assets (Tables)

12 Months Ended

Dec. 31, 2021

Changes In Biological Assets [Abstract]

Summary of Change in Carrying Value of Biological Assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2021			December 31, 2020
Balance, beginning of year		3,531			14,309
Increase in biological assets due to capitalized costs		25,880			39,957
Net change in fair value of biological assets		4,708			6,496
Transferred to inventory upon harvest		(29,709	)		(54,388	)
Disposition of Bridge Farm (note 6)		—			(2,831	)
Foreign currency translation		—			(12	)
Balance, end of year		4,410			3,531

Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2021		December 31 2020		December 31 2021		December 31 2020
Yield per square foot of growing space (1)	Grams		49		45		435		347
Average net selling price (2)	$/gram		4.49		5.13		1,014		1,022
After harvest cost to complete and sell	$/gram		1.06		1.32		249		291

(1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

XML

Inventory (Tables)

12 Months Ended

Dec. 31, 2021

Classes Of Inventories [Abstract]

Summary of Inventories

As at	December 31, 2021		December 31, 2020
Harvested cannabis		22,710		20,358
Cannabis supplies and consumables		4,361		5,255
Retail		2,397		—
Millwork		35		—
		29,503		25,613

XML

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Schedule of Property Plant and Equipment

	Land			Production facilities			Equipment			Right of use assets			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2019		26,606			166,442			24,021			16,509			58,031			291,609
Additions		8			213			2,886			763			4,319			8,189
Transfers from CIP		509			8,212			2,287			—			(11,008	)		—
Reclass to assets held for sale		(1,547	)		—			—			—			(1,451	)		(2,998	)
Dispositions		(499	)		(162	)		(50	)		(825	)		(991	)		(2,527	)
Disposition of Bridge Farm (note 6)		(16,300	)		(21,587	)		(249	)		(14,431	)		(39,734	)		(92,301	)
Foreign currency translation		(137	)		(181	)		(1	)		(122	)		(347	)		(788	)
Balance at December 31, 2020		8,640			152,937			28,894			1,894			8,819			201,184
Acquisition (note 5)		—			4,169			2,209			5,730			—			12,108
Additions		—			593			1,975			579			1,209			4,356
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(468	)		(301	)		(165	)		(177	)		(1,111	)
Balance at December 31, 2021		12,388			157,231			32,777			8,038			6,103			216,537
Accumulated amortization and impairment
Balance at December 31, 2019		3			5,400			3,697			363			162			9,625
Depreciation		475			6,249			4,847			638			—			12,209
Impairment		—			60,658			—			—			5,659			66,317
Dispositions		—			(37	)		(44	)		(176	)		—			(257	)
Disposition of Bridge Farm (note 6)		(473	)		(2,879	)		—			(251	)		—			(3,603	)
Foreign currency translation		(5	)		(27	)		—			(3	)		—			(35	)
Balance at December 31, 2020		—			69,364			8,500			571			5,821			84,256
Depreciation		—			2,914			5,438			897			—			9,249
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			(10	)		(147	)		—			(157	)
Balance at December 31, 2021		—			132,278			13,928			1,321			5,821			153,348
Net book value
Balance at December 31, 2020		8,640			83,573			20,394			1,323			2,998			116,928
Balance at December 31, 2021		12,388			24,953			18,849			6,717			282			63,189

XML

Net Investment In Subleases (Table)

12 Months Ended

Dec. 31, 2021

Disclosure Of Net Investment In Subleases [Abstract]

Disclosure of Detailed Information Net Investment in Subleases Explanatory

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			—
Acquisition (note 5)		23,751			—
Additions		3,951			—
Finance income		573			—
Rents recovered (payments made directly to landlords)		(1,713	)		—
Dispositions		—			—
Balance, end of year		26,562			—
Current portion		3,991			—
Long-term		22,571			—

XML

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Intangible Assets [Abstract]

Summary of Reconciliation of Changes in Intangible Assets and Goodwill

	Brands and trademarks			Patents		Customer relationships			Other			Total
Cost
Balance at December 31, 2019		8,386			13,551		19,578			3,778			45,293
Additions		150			—		—			—			150
Disposition of Bridge Farm (note 6)		(3,066	)		—		(19,415	)		(3,747	)		(26,228	)
Foreign currency translation		(25	)		—		(163	)		(31	)		(219	)
Balance at December 31, 2020		5,445			13,551		—			—			18,996
Balance at December 31, 2021		5,445			13,551		—			—			18,996
Accumulated amortization and impairment
Balance at December 31, 2019		131			—		976			191			1,298
Depreciation		441			677		842			165			2,125
Impairment		—			12,874		—			—			12,874
Disposition of Bridge Farm (note 6)		(190	)		—		(1,801	)		(353	)		(2,344	)
Foreign currency translation		—			—		(17	)		(3	)		(20	)
Balance at December 31, 2020		382			13,551		—			—			13,933
Depreciation		354			—		—			—			354
Balance at December 31, 2021		736			13,551		—			—			14,287
Net book value
Balance at December 31, 2020		5,063			—		—			—			5,063
Balance at December 31, 2021		4,709			—		—			—			4,709

XML

Investments (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Investments [Abstract]

Investments Other Than Investments Accounted for Using Equity Method

As at	December 31, 2021		December 31, 2020
Investments at amortized cost (A)		24,987		—
Investment at FVTPL (B)		48,576		51,876
		73,563		51,876
Current portion		3,065		—
Long-term		70,498		51,876

Disclosure of Carrying Amount of Investments at Amortized Cost

The following table summarizes the carrying amount of investments at amortized cost as at December 31, 2021:

As at	December 31, 2021
Secured term loan		19,417
Convertible debenture		3,065
Spiritleaf franchise partners		2,505
		24,987

XML

Equity-Accounted Investees (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Interests In Other Entities [Abstract]

Schedule of Equity Method Investments Table

As at	December 31, 2021		December 31, 2020
Interest in joint venture (A)		412,858		—
Interest in associate (B)		—		—
		412,858		—

Disclosure of joint ventures

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858

Summary of Financial Information of SunStream

The following table summarizes the financial information of SunStream:

As at	December 31, 2021
Current assets (including cash and cash equivalents: $0.2 million)		789
Non-current assets		407,860
Current liabilities		(1,596	)
Non-current liabilities		—
Net assets (liabilities) (100%)		407,053
Year ended December 31, 2021
Revenue		36,203
Profit from operations		32,841
Other comprehensive income		9,878
Total comprehensive income		42,747

XML

Accounts Payable and Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Subclassifications Of Assets Liabilities And Equities [Abstract]

Summary of Accounts Payable and Accrued Liabilities

	December 31, 2021		December 31, 2020
Trade payables		4,172		4,849
Accrued and other liabilities		34,280		18,459
		38,452		23,308

XML

Derivative Warrant Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Derivative Warrant Liabilities [Abstract]

Summary of Derivative Warrants

	December 31, 2021			December 31, 2020
Balance, beginning of year		428			—
2021 Series A and B Warrants - fair value on issuance (A)		62,680			—
2021 Additional Series A and B Warrants - fair value on issuance (B)		38,576			—
New Warrants - fair value on issuance recognized in profit or loss (C)		106,531			—
Agent Warrants - fair value on issuance (D)		—			504
Secured Convertible Note Warrants - fair value on issuance (E)		—			6,683
Unsecured Convertible Notes Warrants - fair value on issuance (F)		—			3,961
2020 Series A and B Warrants - fair value on issuance (G)		—			11,784
Change in fair value recognized in profit or loss		(28,697	)		12,995
Converted to common shares		(157,818	)		(35,521	)
Unrealized foreign exchange loss		—			22
Balance, end of year		21,700			428

Summary of Outstanding Derivative Warrants

The following table summarizes outstanding derivative warrants as at December 31, 2021:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		0.1766		500,000		3.6
Unsecured Convertible Notes Warrants (1)		0.1766		500,000		2.0
New Warrants		1.50		98,333,334		2.6
				99,333,334		2.6

(1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

XML

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2021

Lease Liabilities [Abstract]

Summary of Lease Obligations

20. Lease obligations

	December 31, 2021			December 31, 2020
Balance, beginning of year		1,440			16,949
Acquisition (note 5)		29,481			—
Liabilities incurred		4,514			763
Lease payments		(2,721	)		(937	)
Dispositions		(20	)		(735	)
Interest expense		776			416
Disposition of Bridge Farm (note 6)		—			(14,894	)
Foreign currency translation		—			(122	)
Balance, end of year		33,470			1,440
Current portion		5,701			409
Long-term		27,769			1,031

Summary of Minimum Lease Payments

The Company’s minimum lease payments are as follows:

	December 31, 2021
Less than one year		5,938
One to three years		10,514
Three to five years		8,424
Thereafter		13,629
Minimum lease payments		38,505
Amounts representing finance charges		(5,035	)
Net minimum lease payments		33,470

XML

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Other Liabilities [Abstract]

Schedule Of Other Liabilities

	December 31, 2021		December 31, 2020
Financial guarantee liability (A)		466		—
DSU liability (B)		4,039		—
		4,505		—

(A) Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of expected credit losses in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs in the consolidated statement of loss and comprehensive loss.

(B) DSU liability

DSUs are granted to directors and generally vest in equal instalments over one year. The Company intended to settle the DSUs by issuing common shares, however, during the year ended December 31, 2021, the Company changed its intention to settle the DSUs to making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. Accordingly, $5.1 million representing the previously recognized fair value of the DSUs, was reclassified from contributed surplus to other liabilities.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end.

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Major Components Of Tax Expense Income [Abstract]

Summary of Income Tax Expense (Recovery)

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in the consolidated statement of loss and comprehensive loss for the years ended December 31, 2021, December 31, 2020 and December 31, 2019:

	December 31, 2021			December 31, 2020			December 31, 2019
Loss before taxes		(232,453	)		(206,317	)		(146,307	)
Statutory income tax rates		23.0	%		24.0	%		26.5	%
Expected income tax recovery		(53,464	)		(49,516	)		(38,771	)
Non-deductible share-based compensation		2,308			1,970			10,474
Non-deductible finance expense		2			2,130			15,981
Revaluation of the fair value of warrant liabilities		17,902			—			—
Non-deductible portion of capital losses		5,118			—			—
Other non-deductible expenses		610			348			2,621
Change in tax rates		—			1,528			3,305
Deferred tax benefits not recognized		25,253			43,540			2,781
Income tax (recovery) expense		(2,271	)		—			(3,609	)

Summary of Deferred Tax Assets (Liabilities)

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2021			December 31, 2020
Deferred tax assets (liabilities):
Inventory		20,472			8,388
Biological assets		(9,509	)		(8,388	)
Net investment in subleases		(6,109	)		—
Lease obligations		(8,371	)		—
Marketable securities		7,442			—
Equity-accounted investee		(3,925	)		—
Net deferred tax asset (liability)		—			—

Summary of Unrecognized Deductible Temporary Differences

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2021		December 31, 2020
Unrecognized deductible temporary differences:
Property, plant and equipment		84,322		36,782
Intangible assets		183		536
Share issue costs		23,835		11,112
Investments		3,300		—
Lease obligations		69,865		—
Financial obligations and other		4,100		1,054
Inventory and biological assets		—		34,781
Non-capital losses & SR&ED		219,165		171,205
Unrecognized deductible temporary differences		404,770		255,470

Summary of Movement in Deferred Income Tax Liability

The movement in deferred income tax liability is as follows:

	December 31, 2021			December 31, 2020
Balance, beginning of year		—			3,365
Acquisition of Inner Spirit		—			—
Recognized in profit and loss		(2,271	)		—
Recognized in other comprehensive income		2,271			(25	)
Recognized in discontinued operations (note 6)		—			(225	)
Disposition of Bridge Farm (note 6)		—			(3,115	)
Balance, end of year		—			—

XML

Share Capital and Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Share Capital And Warrants [Abstract]

Summary of Issued and Outstanding

(b) Issued and outstanding

		December 31, 2021					December 31, 2020
	Note	Number of Shares		Carrying Amount			Number of Shares			Carrying Amount
Balance, beginning of year			918,844,133		762,046			107,180,423			509,654
Share issuances			956,806,648		977,425			337,696,867			176,931
Share issuance costs			—		(16,371	)		—			(5,593	)
Acquisition	5		24,431,278		26,216			—			—
Convertible debenture settlement	5		2,488,754		2,671			373,371,318			63,002
Disposition of Bridge Farm	6		—		—			(2,716,271	)		(38,447	)
Derivative warrants exercised	19		152,146,950		277,136			102,836,429			55,912
Warrants exercised	23(c)		195,711		178			—			—
Employee awards exercised (1)	24(c)		5,494,883		6,403			475,367			587
Balance, end of year			2,060,408,357		2,035,704			918,844,133			762,046

(1) Included in employee awards exercised are 875,000 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Excluded from employee awards exercised are 500,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

Summary of Common Share Purchase Warrants

(c) Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2019		6,165,324			27,831
Warrants issued		544,000			306
Warrants expired		(3,232,434	)		(5,908	)
Warrants cancelled		(2,452,890	)		(16,091	)
Balance at December 31, 2020		1,024,000			6,138
Acquisition (note 5)		2,097,828			1,771
Warrants issued		640,000			361
Warrants exercised		(195,711	)		(178	)
Balance at December 31, 2021		3,566,117			8,092

Summary of Outstanding Warrants

The following table summarizes outstanding warrants as at December 31, 2021:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Acquisition of financial obligation		15.94		480,000		0.5
Financial services		4.60		544,000		7.6
Acquired from Inner Spirit (1)		0.34		1,902,117		2.2
Sun 8		0.94		640,000		4.0
		3.20		3,566,117		3.1

(1) Inner Spirit warrants are exchangeable for 0.0835 Sundial common shares in accordance with the Inner Spirit Transaction consideration (note 5) and have been presented based on the number of Sundial common shares that are issuable.

XML

Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Components of Share-based Compensation Expense

The components of share-based compensation expense are as follows:

	Year ended December 31
	2021			2020			2019
Equity-settled expense
Simple warrants (A)		2,899			1,539			23,918
Performance warrants (A)		361			(42	)		11,023
Stock options (B)		(14	)		651			98
Restricted share units (C)		6,789			4,069			220
Shares issued for services		—			—			2,320
Cash-settled expense
Deferred share units (i) (D)		2,272			2,349			1,119
		12,307			8,566			38,698

(i) Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each period end. Fluctuations in the fair value are recognized during the period in which they occur.

Black-Scholes Option Pricing Model to Estimate the Fair Value of Units Granted

In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to estimate the fair value of units granted during the years ended December 31, 2021, December 31, 2020 and December 31, 2019 through the application of the following assumptions:

	December 31, 2021	December 31, 2020	December 31, 2019
Risk-free interest rate	0.45%	0.28% - 0.29%	1.41% - 1.88%
Expected life of units (years)	5	10	2 - 10
Expected annualized volatility	168%	143%	97% - 116%
Expected dividend yield	Nil	Nil	Nil
Weighted average Black-Scholes value of each unit	$0.56	$1.13 - $1.17	$0.67 - $23.55

Summary of Changes in Simple and Performance Warrants

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19
Forfeited		(668,800	)		3.36		(204,800	)		5.48
Exercised		(120,000	)		0.94		(80,000	)		1.09
Expired		(41,600	)		3.45		—			0.00
Balance at December 31, 2021		2,594,200		$	4.86		1,387,200		$	4.18

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2020:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2019		9,815,000		$	4.01		5,798,822		$	2.66
Forfeited		(6,390,400	)		3.79		(4,126,822	)		2.04
Balance at December 31, 2020		3,424,600		$	4.41		1,672,000		$	4.19

Summarizes Outstanding Simple and Performance Warrants

The following table summarizes outstanding simple and performance warrants as at December 31, 2021:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$0.63 - $0.94		889,400		0.72		2.21		889,400		0.72		2.21
$1.25 - $1.88		—		—		—		—		—		—
$2.97 - $4.53		351,200		3.09		3.09		303,200		3.06		3.02
$6.25 - $9.38		1,219,200		6.29		4.72		499,200		6.35		4.70
$12.50 - $37.50		134,400		23.91		5.52		40,000		19.61		4.05
		2,594,200	$	4.86		3.68		1,731,800	$	3.19		3.11
Performance warrants
$0.63 - $0.94		458,667		0.68	n/a			458,667		0.68	n/a
$1.25 - $1.88		189,333		1.51	n/a			181,333		1.50	n/a
$2.97 - $4.53		504,000		3.16	n/a			504,000		3.16	n/a
$6.25 - $9.38		144,533		7.23	n/a			38,400		6.25	n/a
$12.50 - $37.50		90,667		28.24	n/a			—		—	n/a
		1,387,200	$	4.18	n/a			1,182,400	$	2.04	n/a

Summary of Changes in Stock Options

The following table summarizes changes in stock options during the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		720,600		$	1.82
Forfeited		(275,000	)		2.60
Expired		(1,000	)		3.15
Balance at December 31, 2021		444,600		$	1.33

No stock options were granted in 2021. The following table summarizes changes in stock options during the year ended December 31, 2020:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2019		623,850		$	4.33
Granted		481,600			1.16
Forfeited		(384,850	)		4.96
Balance at December 31, 2020		720,600		$	1.82

Summary of Outstanding Stock Options

The following table summarizes outstanding stock options as at December 31, 2021:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$1.15		325,000		8.41		108,332		8.41
$1.19		81,600		8.49		81,600		8.49
$3.15		38,000		6.35		20,500		6.06
		444,600		8.25		210,432		8.21

Summary of Changes in Restricted Share Units

The following table summarizes changes in RSUs during the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		1,656,916
Granted		12,381,525
Forfeited		(1,582,628	)
Exercised		(4,919,883	)
Balance at December 31, 2021		7,535,930

The following table summarizes changes in RSUs during the year ended December 31, 2020:

	RSUs outstanding
Balance at December 31, 2019		48,883
Granted		3,002,213
Forfeited		(43,813	)
Exercised		(1,350,367	)
Balance at December 31, 2020		1,656,916

Summary of Changes in Deferred Share Units

The following table summarizes changes in DSUs during the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		3,323,263
Granted		2,489,173
Exercised		(300,000	)
Balance at December 31, 2021		5,512,436

The following table summarizes changes in DSUs during the year ended December 31, 2020:

	DSUs outstanding
Balance at December 31, 2019		367,924
Granted		3,265,503
Forfeited		(310,164	)
Balance at December 31, 2020		3,323,263

XML

Gross Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Revenue [Abstract]

Disaggregation of Revenue from Contracts with Customers

	Year ended December 31
	2021		2020		2019
Cannabis revenue
Provincial boards		41,338		55,315		13,386
Medical		8		32		24
Licensed producers		9,842		17,974		53,517
Cannabis revenue (1)		51,188		73,321		66,927
Retail revenue (2)
Retail		10,207		—		—
Franchise		4,251		—		—
Other (millwork, supply, accessories)		1,633		—		—
Retail revenue		16,091		—		—
Gross revenue		67,279		73,321		66,927

(1) The Company had three major customers (which are provincial boards) each with revenue in excess of 10% of total cannabis revenue. Sales to these major customers totaled $28.2 million for the year ended December 31, 2021 (year ended December 31, 2020 – four major customers with total sales of $43.9 million, year ended December 31, 2019 – four major customers with total sales of $40.7 million).

(2) For the period July 20, 2021 to December 31, 2021.

The following table disaggregates cannabis revenue by form for the periods noted:

	Year ended December 31
	2021		2020		2019
Revenue from dried flower		39,572		51,424		58,246
Revenue from vapes		4,743		18,447		504
Revenue from oil		1,665		3,145		8,177
Revenue from edibles and concentrates		2,555		305		—
Revenue from services		2,653		—		—
Gross revenue		51,188		73,321		66,927

Summary of Receivables from Contracts with Customers

The Company has recognized the following receivables from contracts with customers:

	December 31, 2021		December 31, 2020		December 31, 2019
Receivables, included in 'trade receivables' (note 10)		10,865		15,786		20,281

XML

Investment Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Investment Revenue [Abstract]

Summary of Interest and Fee Revenue

	Year ended December 31
	2021		2020		2019
Interest and fee revenue
Interest revenue from investments at amortized cost		1,654		—		—
Interest and fee revenue from investments at FVTPL		8,514		—		—
Interest revenue from cash		2,981		—		—
		13,149		—		—

Summary of Investment Revenue

	Year ended December 31
	2021			2020		2019
Investment revenue
Realized gains		20,213			—		—
Unrealized losses (note 9)		(64,714	)		—		—
		(44,501	)		—		—

XML

Other Operating Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Expense By Nature [Abstract]

Summary of General and Administrative Expense

	Year ended December 31
	2021		2020		2019
Salaries and wages		18,675		11,634		15,262
Consulting fees		1,112		2,193		6,896
Office and general		7,560		9,843		9,533
Professional fees		6,530		4,658		3,559
Director fees		351		365		188
Other		4,142		3,336		3,496
		38,370		32,029		38,934

Summary of Sales and Marketing Expense

	Year ended December 31
	2021		2020		2019
Marketing		3,671		4,839		3,093
Events		191		393		2,961
Research		43		57		199
Media		1,138		448		1,815
		5,043		5,737		8,068

XML

Finance Costs (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Finance Cost [Abstract]

Summary of Finance Costs

	Year ended December 31
	2021			2020			2019
Cash finance expense
Interest on Syndicated Credit Agreement		—			4,546			1,746
Interest on Term Debt Facility		—			2,936			3,478
Other finance costs		40			286			9,202
		40			7,768			14,426
Non-cash finance expense (income)
Change in fair value of investment at FVTPL		3,300			—			—
Interest on lease liabilities		776			—			—
Financial guarantee liability recovery		59			—			—
Accretion		—			1,622			5,511
Amortization of debt issue costs		—			1,782			1,586
Change in fair value of convertible notes		—			(7,141	)		—
Other		154			3			3,973
		4,289			(3,734	)		11,070
Interest income		(573	)		(215	)		—
Interest capitalized relating to CIP		—			—			(1,280	)
		3,756			3,819			24,216

XML

Supplemental Cash Flow Disclosures (Tables)

12 Months Ended

Dec. 31, 2021

Supplemental Cash Flow Disclosure [Abstract]

Summary of Changes in Non-cash Working Capital

	Year ended December 31
	2021			2020			2019
Cash provided by (used in):
Accounts receivable		7,328			(2,037	)		(19,625	)
Biological assets		3,829			13,789			19,328
Inventory		(18,318	)		(12,315	)		(57,977	)
Prepaid expenses and deposits		(3,922	)		2,280			(7,213	)
Investments		(402	)		—			—
Property, plant and equipment		22			—			—
Accounts payable and accrued liabilities		9,665			(20,793	)		27,819
Convertible notes		—			—			(152	)
		(1,798	)		(19,076	)		(37,820	)
Changes in non-cash working capital relating to:
Operating		(1,534	)		(5,259	)		(41,626	)
Investing		(612	)		(11,319	)		1,659
Financing		348			(2,498	)		2,147
		(1,798	)		(19,076	)		(37,820	)
Cash interest paid		—			6,094			13,753

XML

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Summary of Loss Per Share

	Year ended December 31
	2021			2020			2019
Weighted average shares outstanding (000s)
Basic and diluted (1)		1,860,380			218,645			85,750
Continuing operations
Net loss attributable to Sundial Growers Inc.		(230,382	)		(199,619	)		(142,533	)
Per share - basic and diluted	$	(0.12	)	$	(0.92	)	$	(1.67	)
Discontinued operations
Net loss attributable to Sundial Growers Inc.		—			(33,627	)		(128,931	)
Per share - basic and diluted	$	—		$	(0.15	)	$	(1.50	)
Net loss attributable to Sundial Growers Inc.		(230,382	)		(233,246	)		(271,464	)
Per share - basic and diluted	$	(0.12	)	$	(1.07	)	$	(3.17	)

(1) For the year ended December 31, 2021, there were 3.6 million equity classified warrants, 99.3 million derivative warrants, 2.6 million simple warrants, 1.4 million performance warrants, 0.4 million stock options and 7.5 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2020 – 1.0 million equity classified warrants, 1.0 million derivative warrants, 3.4 million simple warrants, 1.7 million performance warrants, 0.7 million stock options and 1.7 million RSUs, year ended December 31, 2019 – 6.2 million equity classified warrants, 9.8 million simple warrants, 5.8 million performance warrants, 0.6 million stock options and 0.1 million RSUs).

XML

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700
			Fair value measurements using
December 31, 2020	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Investments at FVTPL		51,876		—		—		51,876
Financial liabilities
Derivative warrants (1)		428		—		—		428

(1) The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2021		December 31, 2020
Impairment loss (reversal) on trade receivables		214		(506	)
Impairment loss (reversal) on other receivables		798		(126	)
		1,012		(632	)

Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2021 was as follows:

	December 31, 2021		December 31, 2020
Balance, beginning of year		120		752
Net remeasurement of impairment loss allowance		1,012		(632	)
Balance, end of year		1,132		120

Risk Management Contracts Relating to Marketable Securities

The Company had the following risk management contracts relating to marketable securities outstanding as at December 31, 2021:

As at December 31, 2021	Quantity		Expiry	Proceeds		Fair value
Sold put options		2,174	Feb 18, 2022		34		27
Sold put options		1,329	Mar 18, 2022		65		51
		3,503			99		78

Timing of Expected Cash Outflows Relating to Financial Liabilities

The timing of expected cash outflows relating to financial liabilities at December 31, 2021 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		38,452		—		—		—		38,452
Lease obligations		5,938		10,514		8,424		13,629		38,505
Financial guarantee liability		—		466		—		—		466
Balance, end of period		44,390		10,980		8,424		13,629		77,423

XML

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2021

Related Party Transactions [Abstract]

Summary of Related Party Transactions and Balances

b) Related party transactions and balances

	Transactions				Balance outstanding
	Year ended December 31		Year ended December 31		December 31		December 31
	2021		2020		2021		2020
Marketing, brand research and development (a)		—		1,144		—		—
Legal services (b)		—		2,462		—		(510	)
		—		3,606		—		(510	)

(a) A former member of the Board controlled a company that provides marketing, brand research and development services.

(b) A member of the Board was a partner at a law firm prior to his departure which provides legal services to the Company.

Compensation of Key Management Personnel

c) Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2021		2020		2019
Salaries and short-term benefits		2,348		1,944		3,295
Share-based compensation		8,275		7,629		23,715
		10,623		9,573		27,010

XML

Basis of Presentation - Summary of Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2021
KamCan Products Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	KamCan Products Inc.
Principal activity	Inactive
Jurisdiction of incorporation	British Columbia, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Sundial Deutschland GmbH
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Sundial Deutschland GmbH
Principal activity	Inactive
Jurisdiction of incorporation	Germany
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
2657408 Ontario Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	2657408 Ontario Inc.
Principal activity	Operations
Jurisdiction of incorporation	Ontario, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
NGBA-BC Holdings Ltd
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	NGBA-BC Holdings Ltd.
Principal activity	Operations
Jurisdiction of incorporation	British Columbia, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Sundial Insurance (Bermuda) Ltd
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Sundial Insurance (Bermuda) Ltd.
Principal activity	Operations
Jurisdiction of incorporation	Bermuda
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Inner Spirit Holdings Ltd
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Inner Spirit Holdings Ltd.
Principal activity	Operations
Jurisdiction of incorporation	Alberta, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Spirit Leaf Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Spirit Leaf Inc.
Principal activity	Operations
Jurisdiction of incorporation	Alberta, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Spirit Leaf Corporate Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Spirit Leaf Corporate Inc.
Principal activity	Operations
Jurisdiction of incorporation	Alberta, Canada
Equity ownership	100.00%
Non-controlling interest ("NCI")	0.00%
Spirit Leaf Ontario Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Spirit Leaf Ontario Inc. (1)
Principal activity	Operations
Jurisdiction of incorporation	Ontario, Canada
Equity ownership	0.00%
Non-controlling interest ("NCI")	100.00%

XML

Significant Accounting Policies - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Significant Accounting Policies [Line Items]
Depreciation method, property, plant and equipment	straight-line method
Onerous contracts provision	$ 0	$ 0
Gain loss on conversion of financial liability reclassified to equity	0
Development costs capitalized	$ 0	$ 0
Sun 8 Holdings Inc
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	15 years
World Wide Proprietary Rights
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	12 years
Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturities period	90 days

XML

Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2021
Production Facilities
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	20 years
Equipment | Bottom of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	1 year
Equipment | Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	10 years
Right of Use Assets
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	Shorter of estimated useful life or lease term

XML

Business Acquisitions - Additional Information (Details)				5 Months Ended	7 Months Ended	12 Months Ended
	Aug. 04, 2021 CAD ($) shares	Jun. 20, 2021	May 05, 2021 CAD ($) shares	Dec. 31, 2021 CAD ($)	Jul. 19, 2021 CAD ($)	Dec. 31, 2021 CAD ($)	Dec. 31, 2020 CAD ($)	Dec. 31, 2019 CAD ($)	Jul. 20, 2021 CAD ($)	Dec. 31, 2018 CAD ($)
Disclosure Of Business Combinations [Line Items]
Cash consideration									$ 92,583,000
Issuance of common shares, value									26,216,000
Contingent consideration									$ 1,150,000
Convertible debenture settlement						$ 9,354,000	$ 0	$ 0
Equity component				$ 1,326,135,000		1,326,135,000	269,695,000	221,198,000		$ (7,908,000)
Liabilities component				98,127,000		98,127,000	25,176,000
Assets component				1,424,262,000		1,424,262,000	294,871,000
Issued Capital
Disclosure Of Business Combinations [Line Items]
Number of shares issued to settle convertible instruments, Shares | shares	2,500,000
Number of shares issued to settle convertible instruments, Value	$ 2,700,000
Convertible debenture settlement	$ 9,300,000
Equity component				2,035,704,000		2,035,704,000	$ 762,046,000	$ 509,654,000		$ 65,133,000
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Business combination, Transaction end date		Jul. 20, 2021
Description of acquiree			Inner Spirit is a retailer and franchisor of Spiritleaf recreational cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.
Cash consideration			$ 92,600,000
Cash transferred for each ordinary shares of acquire			$ 0.30
Issuance of common shares | shares			24,400,000
Issuance of common shares, value			$ 26,200,000
Number of instruments or interests issued or issuable for each ordinary shares of acquire | shares			0.0835
Equity component				1,800,000		1,800,000
Liabilities component				300,000		300,000
Assets component				900,000		900,000
Revenue				16,100,000
Net earnings				$ 1,100,000
Revenue increased amount					$ 20,400,000
Net loss increased amount					$ 7,400,000
Acquisition-related costs for business transaction						$ 1,900,000
Inner Spirit | Inner Spirit Warrants
Disclosure Of Business Combinations [Line Items]
Contingent consideration			$ 1,200,000

XML

Business Acquisitions - Summary of Purchase Price Allocated (Details) $ in Thousands	Jul. 20, 2021 CAD ($)
Disclosure Of Business Combinations [Abstract]
Cash	$ 92,583
Issuance of common shares	26,216
Contingent consideration	1,150
Total Purchase Price	$ 119,949

XML

Business Acquisitions - Summary of Fair Value of the Assets and Liabilities Acquired (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Jul. 20, 2021
Disclosure Of Business Combinations [Line Items]
Net investment in subleases	$ 26,562
Total Purchase Price		$ 119,949
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Cash		9,808
Accounts receivable		750
Prepaid expenses and deposits		853
Inventory		2,733
Property, plant and equipment		12,108
Net investment in subleases		23,751
Goodwill		114,537
Accounts payable and accrued liabilities		(2,678)
Convertible debentures		(12,025)
Lease liabilities		(29,481)
Financial guarantee liability		(407)
Total Purchase Price		$ 119,949

XML

Discontinued Operations - Summary Results of Discontinued Operations (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Disclosure of analysis of single amount of discontinued operations [line items]
Gross revenue		$ 67,279	$ 73,321		$ 66,927
Net revenue		56,128	60,918		63,562
Cost of sales		48,601	51,740		46,721
Gross margin before fair value adjustments		(9,451)	(36,735)		16,841
Change in fair value of biological assets		4,708	5,432		30,340
Gross margin		(6,990)	(49,869)		36,496
General and administrative		38,370	32,029		38,934
Sales and marketing		5,043	5,737		8,068
Depreciation and amortization		4,726	4,711		595
Share-based compensation		12,307	8,566		38,698
Loss from operations		(132,131)	(185,404)		(52,371)
Transaction costs		(17,566)	(3,587)		(8,481)
Finance costs, net		(3,756)	(3,819)		(24,216)
Gain on disposition of PP&E		235	488		8
Loss on disposition of Bridge Farm			(33,627)		(128,931)
Loss before income tax		(232,453)	(206,317)		(146,307)
Income tax recovery		2,271			3,609
Net loss		(230,182)	(239,944)		(271,629)
Bridge Farm
Disclosure of analysis of single amount of discontinued operations [line items]
Loss on disposition of Bridge Farm		$ (14,979)
Discontinued Operations | Bridge Farm
Disclosure of analysis of single amount of discontinued operations [line items]
Gross revenue			22,139	[1]	12,298	[2]
Net revenue			22,139	[1]	12,298	[2]
Cost of sales			15,633	[1]	9,426	[2]
Gross margin before fair value adjustments			6,506	[1]	2,872	[2]
Change in fair value of biological assets			1,064	[1]	386	[2]
Change in fair value realized through inventory	[1]		(1,122)
Gross margin			6,448	[1]	3,258	[2]
General and administrative			8,585	[1]	5,515	[2]
Sales and marketing			1,418	[1]	820	[2]
Depreciation and amortization			2,752	[1]	3,482	[2]
Foreign exchange			1,057	[1]	(1,779)	[2]
Share-based compensation			(826)	[1]	826	[2]
Goodwill impairment	[2]				100,305
Loss from operations			(6,538)	[1]	(105,911)	[2]
Transaction costs	[2]				(1,588)
Finance costs, net			(10,083)	[1]	(3,982)	[2]
Loss on contingent consideration			(2,252)	[1]	(18,645)	[2]
Gain on investment	[2]				165
Gain on disposition of PP&E	[2]				13
Loss on disposition of Bridge Farm	[1]		(14,979)
Loss before income tax			(33,852)	[1]	(129,948)	[2]
Income tax recovery			225	[1]	1,017	[2]
Net loss	[3]		$ (33,627)	[1]	$ (128,931)	[2]

[1] Period January 1, 2020, to June 5, 2020

[2] Period July 2, 2019, to December 31, 2019

[3] Net loss from the discontinued operations is attributable entirely to the owners of the Company.

XML

Discontinued Operations - Summary of Effect of Disposal on Financial Position (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of analysis of single amount of discontinued operations [line items]
Cash and cash equivalents	$ 558,251	$ 60,376	$ 45,337	$ 14,121
Accounts receivable	10,865	15,898
Biological assets	4,410	3,531	14,309
Inventory	29,503	25,613
Property, plant and equipment	63,189	116,928
Goodwill	114,537
Intangible assets	4,709	5,063
Accounts payable and accrued liabilities	(38,452)	(23,308)
Lease obligation	(27,769)	(1,031)
Accumulated other comprehensive income	(7,607)
Consideration received
Net loss from discontinued operations		$ (33,627)	$ (128,931)
Bridge Farm
Disclosure of analysis of single amount of discontinued operations [line items]
Cash and cash equivalents	2,963
Accounts receivable	15,641
Biological assets	2,831
Inventory	787
Property, plant and equipment	88,698
Goodwill	11,345
Intangible assets	23,884
Accounts payable and accrued liabilities	(22,792)
Lease obligation	(14,894)
Deferred tax liability	(3,115)
Accumulated other comprehensive income	(7,466)
Net assets and liabilities	97,882
Consideration received
Term Debt Facility	45,000
Contingent consideration liability	34,912
Cancellation of common shares	2,991
Total consideration	82,903
Net loss from discontinued operations	$ (14,979)

XML

Segment Information - Additional Information (Details) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2021 Segment	Dec. 31, 2021 CAD ($) Segment	Dec. 31, 2020 CAD ($) Segment	Dec. 31, 2019 CAD ($)
Disclosure Of Operating Segments [Line Items]
Number of reportable segments | Segment		2	3	1
Equity-accounted investees			$ 412,858
Share of profit of equity-accounted investees			32,913	$ 0	$ 0
Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Share of profit of equity-accounted investees			$ 32,913
Cannabis Segment [Member] | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues			Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada.
Share of profit of equity-accounted investees			$ 0
Retail | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues			Retail operations include the private sale of recreational cannabis through wholly owned and franchise retail cannabis stores.
Share of profit of equity-accounted investees	[1]		$ 0
Investments | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues			Investments include the deployment of capital to investment opportunities.
Share of profit of equity-accounted investees			$ 32,913

[1] Period July 20, 2021, to December 31, 2021

XML

Segment Information - Disclosure of Reportable Segments Explanatory (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Operating Segments [Line Items]
Total assets		$ 1,424,262	$ 294,871
Net revenue		56,128	60,918	$ 63,562
Gross margin		(6,990)	(49,869)	36,496
Share of profit of equity-accounted investees		32,913	0	0
Depreciation and amortization		4,726	4,711	595
Earnings (loss) before tax		(232,453)	$ (206,317)	$ (146,307)
Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Total assets		1,424,262
Net revenue		56,128
Gross margin		(6,990)
Interest and fee revenue		13,149
Loss on marketable securities		(44,501)
Share of profit of equity-accounted investees		32,913
Depreciation and amortization		4,726
Earnings (loss) before tax		(232,453)
Operating segments [member] | Cannabis Segment [Member]
Disclosure Of Operating Segments [Line Items]
Total assets		147,887
Net revenue		40,037
Gross margin		(15,499)
Interest and fee revenue		0
Loss on marketable securities		0
Share of profit of equity-accounted investees		0
Depreciation and amortization		3,108
Earnings (loss) before tax		(117,990)
Operating segments [member] | Retail
Disclosure Of Operating Segments [Line Items]
Total assets	[1]	153,624
Net revenue	[1]	16,091
Gross margin	[1]	8,509
Interest and fee revenue	[1]	0
Loss on marketable securities	[1]	0
Share of profit of equity-accounted investees	[1]	0
Depreciation and amortization	[1]	721
Earnings (loss) before tax	[1]	1,835
Operating segments [member] | Investments
Disclosure Of Operating Segments [Line Items]
Total assets		1,093,596
Net revenue		0
Gross margin		0
Interest and fee revenue		13,149
Loss on marketable securities		(44,501)
Share of profit of equity-accounted investees		32,913
Depreciation and amortization		0
Earnings (loss) before tax		(5,837)
Corporate
Disclosure Of Operating Segments [Line Items]
Total assets		29,155
Net revenue		0
Gross margin		0
Interest and fee revenue		0
Loss on marketable securities		0
Share of profit of equity-accounted investees		0
Depreciation and amortization		897
Earnings (loss) before tax		$ (110,461)

[1] Period July 20, 2021, to December 31, 2021

XML

Restricted Cash - Summary of Disclosure of Restricted Cash (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Restricted Cash [Abstract]
Letters of credit	$ 0	$ 5,333
Securities collateral	7,773	0
Captive insurance	19,240	0
Restricted cash and cash equivalents	$ 27,013	$ 5,333

XML

Restricted Cash - Additional Information (Details) $ in Millions	Dec. 31, 2021 CAD ($)
Restricted Cash [Line Items]
Cell account funded amount	$ 12.1
Sundial Insurance (Bermuda) Ltd [Member]
Restricted Cash [Line Items]
Additional coverage and funded amount to cell account	$ 7.1

XML

Marketable Securities - Disclosure of Marketable Securities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Marketable Securities Disclosure [Abstract]
Balance, beginning of year	$ 0	$ 0
Additions	158,101	0
Dispositions	(9,663)	0
Change in fair value recognized in profit or loss	(64,714)	0
Balance, end of period	$ 83,724	$ 0

XML

Marketable Securities - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 CAD ($)
Marketable Securities Disclosure [Abstract]
Proceeds from disposition of marketable securities	$ 29.9
Gain on disposition of marketable securities	$ 20.2

XML

Marketable Securities - Schedule of Components of Marketable Securities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components Of Marketable Securities [Abstract]
Equity securities	$ 83,802	$ 0
Put and call options	(78)	0
Financial Assets Marketable Securities Current	$ 83,724	$ 0	$ 0

XML

Accounts Receivable - Summary of Accounts Receivable (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Trade receivables	$ 10,865	$ 15,786
Other receivables		112
Accounts receivable	$ 10,865	$ 15,898

XML

Biological Assets - Summary of Change in Carrying Value of Biological Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Changes In Biological Assets [Abstract]
Balance, beginning of year	$ 3,531	$ 14,309
Increase in biological assets due to capitalized costs	25,880	39,957
Net change in fair value of biological assets	4,708	6,496
Transferred to inventory upon harvest	(29,709)	(54,388)
Disposition of Bridge Farm (note 6)	0	(2,831)
Foreign currency translation	0	(12)
Balance, end of year	$ 4,410	$ 3,531

XML

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 CAD ($) Quantity	Dec. 31, 2020 CAD ($) Quantity
Yield per Square Foot of Growing Space
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	$ 435	$ 347
Average Net Selling Price
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	1,014	1,022
After Harvest Cost to Complete and Sell
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	$ 249	$ 291
Weighted Average Input
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Yield per square foot of growing space | Quantity	49	45
Average net selling price | Quantity	4.49	5.13
After harvest cost to complete and sell | Quantity	1.06	1.32

XML

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2021
Changes In Biological Assets [Abstract]
Percentage of assumption of effect change	10.00%

XML

Biological Assets - Additional Information (Details) - kg	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Changes In Biological Assets [Abstract]
Estimated biological assets to be harvested	5,672	5,507
Harvested biological assets	22,784	27,972

XML

Inventory - Summary of Inventories (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Inventories [Line Items]
Inventory	$ 29,503	$ 25,613
Harvested Cannabis
Disclosure Of Inventories [Line Items]
Inventory	22,710	20,358
Cannabis Supplies and Consumables
Disclosure Of Inventories [Line Items]
Inventory	4,361	5,255
Retail
Disclosure Of Inventories [Line Items]
Inventory	2,397	0
Millwork
Disclosure Of Inventories [Line Items]
Inventory	$ 35	$ 0

XML

Inventory - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Classes Of Inventories [Abstract]
Inventories recognized as expense	$ 48.6	$ 51.7
Inventory write downs	17.5	56.9
Excess and obsolete inventory provision	17.0	45.9
Fair value component of excess and obsolete inventory provision	$ 0.5	$ 11.0

XML

Property Plant and Equipment - Schedule of Property Plant and Equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	$ 116,928
Net book value	63,189	$ 116,928
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	201,184	291,609
Acquisition (note 5)	12,108
Additions	4,356	8,189
Transfers from CIP	0	0
Reclass to assets held for sale		(2,998)
Dispositions	(1,111)	(2,527)
Disposition of Bridge Farm (note 6)		(92,301)
Foreign currency translation		(788)
Net book value	216,537	201,184
Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	84,256	9,625
Depreciation	9,249	12,209
Impairment	60,000	66,317
Dispositions	(157)	(257)
Disposition of Bridge Farm (note 6)		(3,603)
Foreign currency translation		(35)
Net book value	153,348	84,256
Right of Use Assets
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	1,323
Net book value	6,717	1,323
Right of Use Assets | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	1,894	16,509
Acquisition (note 5)	5,730
Additions	579	763
Transfers from CIP	0	0
Reclass to assets held for sale		0
Dispositions	(165)	(825)
Disposition of Bridge Farm (note 6)		(14,431)
Foreign currency translation		(122)
Net book value	8,038	1,894
Right of Use Assets | Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	571	363
Depreciation	897	638
Impairment	0	0
Dispositions	(147)	(176)
Disposition of Bridge Farm (note 6)		(251)
Foreign currency translation		(3)
Net book value	1,321	571
Land
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	8,640
Net book value	12,388	8,640
Land | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	8,640	26,606
Acquisition (note 5)	0
Additions	0	8
Transfers from CIP	3,748	509
Reclass to assets held for sale		(1,547)
Dispositions	0	(499)
Disposition of Bridge Farm (note 6)		(16,300)
Foreign currency translation		(137)
Net book value	12,388	8,640
Land | Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	0	3
Depreciation	0	475
Impairment	0	0
Dispositions	0	0
Disposition of Bridge Farm (note 6)		(473)
Foreign currency translation		(5)
Net book value	0	0
Production Facilities
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	83,573
Net book value	24,953	83,573
Production Facilities | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	152,937	166,442
Acquisition (note 5)	4,169
Additions	593	213
Transfers from CIP	0	8,212
Reclass to assets held for sale		0
Dispositions	(468)	(162)
Disposition of Bridge Farm (note 6)		(21,587)
Foreign currency translation		(181)
Net book value	157,231	152,937
Production Facilities | Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	69,364	5,400
Depreciation	2,914	6,249
Impairment	60,000	60,658
Dispositions	0	(37)
Disposition of Bridge Farm (note 6)		(2,879)
Foreign currency translation		(27)
Net book value	132,278	69,364
Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	20,394
Net book value	18,849	20,394
Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	28,894	24,021
Acquisition (note 5)	2,209
Additions	1,975	2,886
Transfers from CIP	0	2,287
Reclass to assets held for sale		0
Dispositions	(301)	(50)
Disposition of Bridge Farm (note 6)		(249)
Foreign currency translation		(1)
Net book value	32,777	28,894
Equipment | Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	8,500	3,697
Depreciation	5,438	4,847
Impairment	0	0
Dispositions	(10)	(44)
Disposition of Bridge Farm (note 6)		0
Foreign currency translation		0
Net book value	13,928	8,500
Construction in Progress
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	2,998
Net book value	282	2,998
Construction in Progress | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	8,819	58,031
Acquisition (note 5)	0
Additions	1,209	4,319
Transfers from CIP	(3,748)	(11,008)
Reclass to assets held for sale		(1,451)
Dispositions	(177)	(991)
Disposition of Bridge Farm (note 6)		(39,734)
Foreign currency translation		(347)
Net book value	6,103	8,819
Construction in Progress | Accumulated Amortization and impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	5,821	162
Depreciation	0	0
Impairment	0	5,659
Dispositions	0	0
Disposition of Bridge Farm (note 6)		0
Foreign currency translation		0
Net book value	$ 5,821	$ 5,821

XML

Property Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Dec. 28, 2020	Jun. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, capitalized to biological assets and inventory				$ 4,900	$ 6,900
Asset impairment				$ 60,000	79,191	$ 162
Merritt Facility | Kamloops Property
Disclosure of detailed information about property, plant and equipment [line items]
Investment in land and construction in progress					$ 10,000
Rocky View Facility | Non-Binding Purchase Agreement
Disclosure of detailed information about property, plant and equipment [line items]
Fair value less costs of disposal and impairment	$ 700
Investment of land and construction in progress in Merritt facility	5,000
Write down assets to recoverable amount	$ 5,000
Old Cash Generating Units
Disclosure of detailed information about property, plant and equipment [line items]
Impairment discount rate		25.00%
Estimated cash flow term		5 years
Asset impairment		$ 60,000
Increase impairment discount rate				1.00%
Increase of Impairment on Assets				$ 7,300
Alberta CGU
Disclosure of detailed information about property, plant and equipment [line items]
Impairment discount rate					25.00%
Estimated cash flow term					5 years
Asset impairment			$ 60,000
Estimated recoverable amount		$ 70,000	$ 154,000
B.C. Cash Generating Unit | Merritt Facility | Kamloops Property
Disclosure of detailed information about property, plant and equipment [line items]
Fair value less costs of disposal and impairment				5,700
Recoverable amount reduced due to receiving utility deposits				$ 2,900

XML

Net Investment In Subleases - Summary of Net Investment in Subleases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 CAD ($)
Disclosure Of Net Investment In Subleases [Abstract]
Acquisition (note 5)	$ 23,751
Additions	3,951
Finance income	573
Rents recovered (payments made directly to landlords)	(1,713)
Balance, end of year	26,562
Current portion	3,991
Long-term	$ 22,571

XML

Intangible Assets - Summary of Reconciliation of Changes in Intangible Assets and Goodwill (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	$ 5,063
Depreciation	4,726	$ 4,711	$ 595
Impairment		12,900
Ending Balance	4,709	5,063
Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Ending Balance	23,884
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	18,996	45,293
Additions		150
Disposition of Business		92,301
Foreign currency translation		(219)
Ending Balance	18,996	18,996	45,293
Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(26,228)
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	13,933	1,298
Depreciation	354	2,125
Impairment		12,874
Foreign currency translation		(20)
Ending Balance	14,287	13,933	1,298
Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(2,344)
Brands and Trademarks
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	5,063
Ending Balance	4,709	5,063
Brands and Trademarks | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	5,445	8,386
Additions		150
Foreign currency translation		(25)
Ending Balance	5,445	5,445	8,386
Brands and Trademarks | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(3,066)
Brands and Trademarks | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	382	131
Depreciation	354	441
Impairment		0
Foreign currency translation		0
Ending Balance	736	382	131
Brands and Trademarks | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(190)
Patents
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0
Ending Balance	0	0
Patents | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	13,551	13,551
Additions		0
Foreign currency translation		0
Ending Balance	13,551	13,551	13,551
Patents | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		0
Patents | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	13,551	0
Depreciation	0	677
Impairment		12,874
Foreign currency translation		0
Ending Balance	13,551	13,551	0
Patents | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		0
Customer Relationships
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0
Ending Balance	0	0
Customer Relationships | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0	19,578
Additions		0
Foreign currency translation		(163)
Ending Balance	0	0	19,578
Customer Relationships | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(19,415)
Customer Relationships | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0	976
Depreciation	0	842
Impairment		0
Foreign currency translation		(17)
Ending Balance	0	0	976
Customer Relationships | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(1,801)
Other
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0
Ending Balance	0	0
Other | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0	3,778
Additions		0
Foreign currency translation		(31)
Ending Balance	0	0	3,778
Other | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		(3,747)
Other | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	0	191
Depreciation	0	165
Impairment		0
Foreign currency translation		(3)
Ending Balance	$ 0	0	$ 191
Other | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition of Business		$ (353)

XML

Intangible Assets - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Intangible Assets [Line Items]
Impairment		$ 12.9
Pathway Rx Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	20 years
Other Intellectual Property
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	12 years
Sun 8 Holdings Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	15 years

XML

Investments - Investments Other Than Investments Accounted for Using Equity Method (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 73,563	$ 51,876
Investments	3,065	0
Long-term	70,498	51,876
Financial assets at amortized cost, category | At cost
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	24,987	0
Financial assets at fair value through profit or loss, category | At fair value
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 48,576	$ 51,876

XML

Investments - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions					2 Months Ended	12 Months Ended
	Oct. 04, 2021 CAD ($)	Apr. 26, 2021 CAD ($)	Feb. 23, 2021 CAD ($) shares	Feb. 16, 2021 shares	Dec. 31, 2020 shares	Dec. 31, 2021 CAD ($) Customer	Dec. 31, 2021 USD ($) Customer	Apr. 27, 2022 CAD ($)	Jul. 20, 2021 CAD ($)	Feb. 23, 2021 $ / shares
Disclosure Of Transactions Between Related Parties [Line Items]
Issuance Of Common Shares | shares					35,000,000.0
Proceeds from issue of ordinary shares						$ 855,200	$ 684.6
Cash consideration									$ 92,583
Spirit Leaf Franchise Partners | Promissory Notes
Disclosure Of Transactions Between Related Parties [Line Items]
Maturity period of investments						5 years	5 years
Spirit Leaf Franchise Partners | Promissory Notes | Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.						8.00%	8.00%
Spirit Leaf Franchise Partners | Promissory Notes | Bottom Of Range [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.						5.50%	5.50%
Zenabis
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.						14.00%	14.00%
Maturity date of investments						Mar. 31, 2025	Mar. 31, 2025
Cash consideration						$ 51,900
Number of royalty payable quarters | Customer						32	32
Number of days to file notice of appeal						30 days	30 days
Fair value of loan						$ 51,900
Adjusted fair value of senior loan						$ 3,300
Zenabis | Payments made in Respect of Senior Loan
Disclosure Of Transactions Between Related Parties [Line Items]
Monitoring fees payable per month								$ 100,000
Strategic Investment | Indiva Investment [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Issuance Of Common Shares | shares				22,000,000
Strategic Investment | Brokered Private Placement | Indiva Investment [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Issuance Of Common Shares | shares			25,000,000
Common Shares Issued Price Per Share | $ / shares										$ 0.44
Proceeds from issue of ordinary shares			$ 11,000
Term Loan | Brokered Private Placement | Amended Instrument
Disclosure Of Transactions Between Related Parties [Line Items]
Loans and receivables	$ 19,800
Term Loan | Strategic Investment | Brokered Private Placement
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.			9.00%
Maturity date of investments			Feb. 23, 2024
Interest receivable	$ 300
Term Loan | Strategic Investment | Brokered Private Placement | Amended Instrument
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.	15.00%
Maturity date of investments	Feb. 23, 2024
Cash Out Flow For Non Revolving Loan Issuance	$ 8,500
Term Loan | Strategic Investment | Brokered Private Placement | Indiva Investment [Member]
Disclosure Of Transactions Between Related Parties [Line Items]
Cash Out Flow For Non Revolving Loan Issuance			$ 11,000
Convertible Debenture | Private company
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.		9.00%
Maturity date of investments		Oct. 26, 2021
Debt instruments held		$ 3,000
Extended Maturity Date Of Investments		Apr. 26, 2022
Convertible Debenture | Private company | Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Rate of interest on investments.		12.00%

XML

Investments - Disclosure of Carrying Amount of Investments at Amortized Cost (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Carrying Amount of Investments at Amortized Cost [Line Items]
Carrying amount of investments at amortized cost	$ 73,563	$ 51,876
Financial assets at amortized cost, category | At cost
Disclosure of Carrying Amount of Investments at Amortized Cost [Line Items]
Carrying amount of investments at amortized cost	24,987	$ 0
Financial assets at amortized cost, category | At cost | Secured term loan
Disclosure of Carrying Amount of Investments at Amortized Cost [Line Items]
Carrying amount of investments at amortized cost	19,417
Financial assets at amortized cost, category | At cost | Convertible Debenture
Disclosure of Carrying Amount of Investments at Amortized Cost [Line Items]
Carrying amount of investments at amortized cost	3,065
Financial assets at amortized cost, category | At cost | Spirit Leaf Franchise Partners
Disclosure of Carrying Amount of Investments at Amortized Cost [Line Items]
Carrying amount of investments at amortized cost	$ 2,505

XML

Equity-Accounted Investees - Summary of Interest (Details) $ in Thousands	Dec. 31, 2021 CAD ($)
Investments Accounted For Using Equity Method [Abstract]
Interest in joint venture	$ 412,858
Interest in associate	0
Investments accounted for using equity method	$ 412,858

XML

Equity-Accounted Investees - Additional Information (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021 CAD ($)	Dec. 31, 2021 CAD ($) Warrant $ / shares	Dec. 31, 2020 CAD ($) $ / shares	Dec. 31, 2020 CAD ($) $ / shares	Dec. 31, 2019 CAD ($) $ / shares	Apr. 14, 2022 CAD ($)	Jul. 20, 2021 CAD ($)
Statements [Line Items]
Capital contributions		$ 395,600
Commitment To Contribute Capital Towards Joint Venture Monetary Instant Credit Definition		538,000
Interest in associate		0
Proportion of ownership interest in associate	50.00%
Percentage of decrease in equity interests	25.00%
Share of post-tax profit (loss) from discontinued operations of associates and joint ventures accounted for using equity method	$ 1,900		$ 0
Impairment of intangible assets			12,900
Non-controlling interests		229	(1,984)	$ (1,984)
Retained earnings		$ (788,510)	$ (558,128)	(558,128)
Basic and diluted | $ / shares		$ (0.12)	$ (1.07)		$ (3.17)
Income Loss From Continuing Operations Attributable To Owners Of Parent		$ (230,382)	$ (199,619)		$ (142,533)
Profit (loss) from continuing operations attributable to non-controlling interests		$ 200	(6,698)		$ (165)
Contingent consideration							$ 1,150
Number of instruments granted | Warrant		280,000
Exercise price of warrants | $ / shares		$ 1.81
Pathway Rx Inc [Member]
Statements [Line Items]
Contingent consideration		$ 2,300
Financial Effect Of Corrections Of Accounting Errors
Statements [Line Items]
Non-controlling interests			6,400	6,400
Retained earnings			6,400	$ 6,400
Basic and diluted | $ / shares				$ 0.03
Income Loss From Continuing Operations Attributable To Owners Of Parent			6,400
Profit (loss) from continuing operations attributable to non-controlling interests			6,400
Previously stated [member]
Statements [Line Items]
Non-controlling interests			4,400	$ 4,400
Retained earnings			564,500	$ 564,500
Basic and diluted | $ / shares				$ 1.10
Income Loss From Continuing Operations Attributable To Owners Of Parent			206,000
Profit (loss) from continuing operations attributable to non-controlling interests			300
Recast [Member]
Statements [Line Items]
Non-controlling interests			2,000	$ 2,000
Retained earnings			558,100	$ 558,100
Basic and diluted | $ / shares				$ 1.07
Income Loss From Continuing Operations Attributable To Owners Of Parent			199,600
Profit (loss) from continuing operations attributable to non-controlling interests			$ 6,700
SunStream [Member] | Subsequent Event [Member]
Statements [Line Items]
Interest in associate						$ 70,300

XML

Equity-Accounted Investees - Summary of Interest in Joint Venture (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of joint ventures [line items]
Capital contributions	$ 395,600
Distributions	10,481	$ 0	$ 0
Balance at December 31, 2021	412,858
Sun Stream Bancorp Inc. [Member]
Disclosure of joint ventures [line items]
Balance at December 31, 2020	0
Capital contributions	395,569
Share of net earnings	32,913
Share of other comprehensive income	9,878
Distributions	(25,502)
Balance at December 31, 2021	$ 412,858	$ 0

XML

Equity-Accounted Investees - Summary of Financial Information of SunStream (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents: $0.2 million)	$ 728,175	$ 118,371
Current liabilities	(65,853)	(24,145)
Profit from operations	(230,182)	(239,944)	$ (271,629)
Other comprehensive income	7,607	$ 600	$ 6,866
Sundial Growers Inc [Member]
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents: $0.2 million)	789
Non-current assets	407,860
Current liabilities	(1,596)
Non-current liabilities	0
Net assets (liabilities) (100%)	407,053
Revenue	36,203
Profit from operations	32,841
Other comprehensive income	9,878
Total comprehensive income	$ 42,747

XML

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Trade payables	$ 4,172	$ 4,849
Accrued and other liabilities	34,280	18,459
Accounts payable and accrued liabilities	$ 38,452	$ 23,308

XML

Derivative Warrants - Summary of Derivative Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Balance, beginning of year	$ 428	$ 0
Change in fair value recognized in profit or loss	(28,697)	12,995
Converted to common shares	(157,818)	(35,521)
Unrealized foreign exchange loss	0	22
Balance, end of year	21,700	428
2021 Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	62,680	0
2021 Additional Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	38,576	0
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	106,531	0
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	504
Secured Convertible Note Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	6,683
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	3,961
2020 Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	$ 0	$ 11,784

XML

Derivative Warrants - Summary of 2021 Series A And B Warrants - Additional Information (Detail) $ / shares in Units, $ in Millions, $ in Millions					2 Months Ended
	Feb. 22, 2021 USD ($) $ / shares shares	Feb. 10, 2021 USD ($) $ / shares shares	Feb. 04, 2021 USD ($) $ / shares shares	Feb. 02, 2021 USD ($) $ / shares shares	Dec. 31, 2020 CAD ($) shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised					35,000,000.0
Issuance of common shares					35,000,000.0
Gross proceeds from warrants | $					$ 8.0
January 2021 Units Offering
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Term of warrants				5 years
January 2021 Units Offering | Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised			33,300,000
January 2021 Units Offering | Series B Warrants | Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Price per unit | $ / shares				$ 0.0001
January 2021 Units Offering | Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price | $ / shares				$ 0.80
Warrants exercised	63,300,000	3,300,000
Issuance of common shares	63,300,000	3,300,000
Weighted average warrant exercise price | $ / shares	$ 0.80	$ 0.80
Gross proceeds from warrants | $	$ 50.7	$ 2.7
January 2021 Units Offering | Series B Units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Issuance of common shares			33,300,000
January 2021 Units Offering | Series A Units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of units issued				100,000,000.0
Description of offering units				series A units (the “Series A Units”), each consisting of one common share
Sale price per unit | $ / shares				$ 0.75
January 2021 Units Offering | Series B Units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of units issued				33,300,000
Description of offering units				series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “2021 Series B Warrants”) to purchase one common share
Sale price per unit | $ / shares				$ 0.75
January 2021 Units Offering | Series A and series B units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Gross proceeds from offering | $				$ 100.0
January 2021 Units Offering | Series A and series B units | Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Price per unit | $ / shares				$ 0.0001
February 2021 Units Offering
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Term of warrants			5 years
February 2021 Units Offering | Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Price per unit | $ / shares			$ 0.0001
Warrants exercised			14,000,000.0
February 2021 Units Offering | Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price | $ / shares			$ 1.10
Warrants exercised	35,000,000.0	2,300,000
Issuance of common shares	35,000,000.0	2,300,000
Weighted average warrant exercise price | $ / shares	$ 1.10	$ 1.10
Gross proceeds from warrants | $	$ 38.5	$ 2.5
February 2021 Units Offering | Series A Units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of units issued			60,500,000
Description of offering units			series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “2021 Additional Series A Warrants”) to purchase one common share
Sale price per unit | $ / shares			$ 1.00
February 2021 Units Offering | Series B Units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of units issued			14,000,000.0
Description of offering units			series B units (the “Additional Series B Units”), each consisting of one pre-funded additional series B warrant (the “2021 Additional Series B Warrants”) to purchase one common share and one-half 2021 Additional Series A Warrant to purchase one common share
Sale price per unit | $ / shares			$ 1.00
Issuance of common shares			14,000,000.0
February 2021 Units Offering | Series A and series B units
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Gross proceeds from offering | $			$ 74.5
February 2021 Units Offering | Series A and series B units | Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Price per unit | $ / shares			$ 0.0001

XML

Derivative Warrants - New Warrants - Additional Information (Details) $ / shares in Units, $ in Millions, $ in Millions				2 Months Ended
	Feb. 22, 2021 USD ($) $ / shares shares	Feb. 04, 2021	Feb. 02, 2021	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2021 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised				35,000,000.0
Issuance of common shares				35,000,000.0
Gross proceeds from warrants | $				$ 8.0
January 2021 Units Offering
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Term of warrants			5 years
January 2021 Units Offering | Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised	63,300,000
Weighted average warrant exercise price | $ / shares	$ 0.80
Issuance of common shares	63,300,000
Gross proceeds from warrants | $	$ 50.7
February 2021 Units Offering
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Term of warrants		5 years
February 2021 Units Offering | Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised	35,000,000.0
Weighted average warrant exercise price | $ / shares	$ 1.10
Issuance of common shares	35,000,000.0
Gross proceeds from warrants | $	$ 38.5
Registered Offerings | New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of warrants issued	98,300,000
Warrant exercise price | $ / shares	$ 1.50
Number of common stock shares issuable upon conversion of warrants	1
Term of warrants	42 months
Number of warrants outstanding					98,300,000

XML

Derivative Warrants - Agent Warrants - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions	2 Months Ended		12 Months Ended
	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2021 CAD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 $ / shares shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised	35,000,000.0
Weighted average exercise price of warrant | $ / shares		$ 0.1766
Issuance of common shares	35,000,000.0
Gross proceeds from exercise of warrants | $	$ 8,000
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Purchase warrants to acquire common shares					1,080,000.00
Initial exercise price of common share | $ / shares		$ 1.00			$ 1.00
Agent Warrants | Exercise of 540,000 Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised			1,080,000.00	1,080,000.00
Weighted average exercise price of warrant | $ / shares				$ 1.00
Issuance of common shares			356,949	356,949
Gross proceeds from exercise of warrants | $			$ 0
Agent Warrants | Exercise of Other Agents Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised			540,000	540,000
Weighted average exercise price of warrant | $ / shares				$ 1.00
Issuance of common shares			540,000	540,000
Gross proceeds from exercise of warrants | $				$ 0.5

XML

Derivative Warrants - Secured Convertible Note Warrants - Additional Information (Details) $ in Millions		2 Months Ended		12 Months Ended
	Jun. 05, 2020	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 CAD ($)	Dec. 31, 2020 $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price per warrant					$ 1.20
Warrants exercised | shares		35,000,000.0
Weighted average exercise price of warrant			$ 0.1766
Issuance of common shares | shares		35,000,000.0
Gross proceeds from exercise of warrants | $		$ 8.0
Secured Convertible Note Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance.
Common share purchase warrant holding period	36 months
Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Purchase warrants to acquire common shares amount | $				$ 17.5
Exercise price per warrant					$ 1.00

XML

Derivative Warrants - Unsecured Convertible Note Warrants - Additional Information (Details) $ in Millions		2 Months Ended		6 Months Ended		12 Months Ended
	Jun. 05, 2020 $ / shares	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 $ / shares shares	Dec. 31, 2021 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average exercise price of warrant | $ / shares			$ 0.1766
Warrants exercised		35,000,000.0
Issuance of common shares		35,000,000.0
Gross proceeds from exercise of warrants | $		$ 8.0
Warrants outstanding							99,333,334
Unsecured Convertible Notes
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants expiration period	42 months
Warrants description	The Unsecured Convertible Notes Warrants were issued on June 5, 2020, were immediately exercisable, and expire 42 months from the date that the underlying common shares become freely tradeable, which was July 16, 2020.
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average exercise price of warrant | $ / shares	$ 0.1766				$ 0.1766
Warrants exercised				14,000,000.0
Issuance of common shares				14,000,000.0
Gross proceeds from exercise of warrants | $				$ 3.2
Warrants outstanding							500,000
Unsecured Convertible Notes Warrants | Unsecured Convertible Notes
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Purchase warrants to acquire common shares						14,500,000
Initial exercise price of common share | $ / shares			$ 0.9338		$ 0.9338	$ 0.9338
Unsecured Convertible Notes Warrants | Bottom Of Range [Member]
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average price of common shares | $ / shares	$ 2.8014

XML

Derivative Warrants - Series A and Series B Warrants - Additional Information (Details) $ in Millions				2 Months Ended		4 Months Ended
	Aug. 20, 2020 shares	Aug. 19, 2020 shares	Aug. 18, 2020 $ / shares shares	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2020 $ / shares	Dec. 31, 2021 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants exercised				35,000,000.0
Weighted average exercise price of warrant | $ / shares					$ 0.1766
Issuance of common shares				35,000,000.0
Gross proceeds from exercise of warrants | $				$ 8.0
Warrants outstanding								99,333,334
2020 Series A and Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Term of warrants			5 years
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of warrants issued			40,100,000
Warrant exercise price | $ / shares			$ 0.75		$ 0.1766		$ 0.1766
Warrants exercised						39,600,000
Weighted average exercise price of warrant | $ / shares							$ 0.1766
Issuance of common shares						39,600,000
Gross proceeds from exercise of warrants | $						$ 9.1
Warrants outstanding								500,000
2020 Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of warrants issued			14,300,000
Warrant exercise price | $ / shares			$ 0.0001
Warrants exercised	5,100,000	9,200,000

XML

Derivative Warrants - Summary of Outstanding Derivative Warrants (Details)	12 Months Ended
	Dec. 31, 2021 shares $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	99,333,334
Weighted average contractual life	2 years 7 months 6 days
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 0.1766
Warrants outstanding	500,000
Weighted average contractual life	3 years 7 months 6 days
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 0.1766
Warrants outstanding	500,000
Weighted average contractual life	2 years
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1.50
Warrants outstanding	98,333,334
Weighted average contractual life	2 years 7 months 6 days

XML

Lease Obligations - Summary of Lease Obligations (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Lease Obligations [Line Items]
Acquisition (note 5)	$ 27,987		$ 47,007
Lease payments	(1,008)	$ (420)	(292)
Dispositions		(10,457)
Interest expense	776
Current portion	5,701	409
Long-term	27,769	1,031
IFRS 16
Disclosure Of Lease Obligations [Line Items]
Balance, beginning of year	1,440	16,949
Acquisition (note 5)	29,481
Liabilities incurred	4,514	763
Lease payments	(2,721)	(937)
Dispositions	(20)	(735)
Interest expense	776	416
Foreign currency translation	0	(122)
Balance, end of year	33,470	1,440	$ 16,949
Current portion	5,701	409
Long-term	27,769	1,031
Bridge Farm | IFRS 16
Disclosure Of Lease Obligations [Line Items]
Dispositions	$ 0	$ (14,894)

XML

Lease Obligations - Summary of Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2021 CAD ($)
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 38,505
Amounts representing finance charges	(5,035)
Net minimum lease payments	33,470
Less Than One Year
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	5,938
One to Three Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	10,514
Three to Five Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	8,424
Thereafter
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 13,629

XML

Other Liabilities - Schedule Of Other Liabilities (Detail) $ in Thousands	Dec. 31, 2021 CAD ($)
Disclosure Of Other Liabilities [Abstract]
Financial guarantee liability	$ 466
DSU liability	4,039
Total	$ 4,505

XML

Other Liabilities - Additional Information (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2021 CAD ($)
Disclosure Of Other Liabilities [Abstract]
Fair value of the deferred share units was reclassified from contributed surplus to accounts payable and accrued liabilities	$ 5.1

XML

Income Taxes - Summary of Income Tax Expense (Recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Abstract]
Loss before income tax	$ (232,453)	$ (206,317)	$ (146,307)
Statutory income tax rates	23.00%	24.00%	26.50%
Expected income tax recovery	$ (53,464)	$ (49,516)	$ (38,771)
Non-deductible share-based compensation	2,308	1,970	10,474
Non-deductible finance expense	2	2,130	15,981
Revaluation of the fair value of warrant liabilities	17,902	0	0
Non-deductible portion of capital losses	5,118	0	0
Other non-deductible expenses	610	348	2,621
Change in tax rates	0	1,528	3,305
Deferred tax benefits not recognized	25,253	43,540	2,781
Income tax (recovery) expense	$ (2,271)	$ 0	$ (3,609)

XML

Income Taxes - Summary of Deferred Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ 0	$ 0	$ 3,365
Inventory
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	20,472	8,388
Biological assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(9,509)	(8,388)
Net Investment in Subleases
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(6,109)	0
Lease Obligation
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(8,371)	0
Marketable Securities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	7,442	0
Equity Accounted Investee
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ (3,925)	$ 0

XML

Income Taxes - Summary of Unrecognized Deductible Temporary Differences (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Abstract]
Property, plant and equipment	$ 84,322	$ 36,782
Intangible assets	183	536
Share issue costs	23,835	11,112
Investments	3,300	0
Lease obligations	69,865	0
Financial obligations and other	4,100	1,054
Inventory and biological assets	0	34,781
Non-capital losses & SR&ED	219,165	171,205
Unrecognized deductible temporary differences	$ 404,770	$ 255,470

XML

Income Taxes - Summary of Movement in Deferred Income Tax Liability (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets And Liabilities [Line Items]
Balance, beginning of year	$ 0	$ 3,365
Recognized in profit and loss	(2,271)	0
Recognized in other comprehensive income	2,271	(25)
Recognized in discontinued operations (note 6)	0	(225)
Disposition of Bridge Farm (note 6)	0	(3,115)
Balance, end of year	0	0
Inner Spirit
Deferred Tax Assets And Liabilities [Line Items]
Acquisition of Inner Spirit	$ 0	$ 0

XML

Income Taxes - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Non-capital losses available for future periods	$ 218.5	$ 171.2
Uncertain tax losses that have not been recognized	$ 60.0

XML

Share Capital and Warrants - Summary of Issued and Outstanding (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Classes Of Share Capital [Line Items]
Share issuances, shares		796,300,000
Beginning balance		$ 269,695	$ 221,198	$ (7,908)
Share issuance costs		(16,371)	(5,593)	(12,770)
Business acquisitions		27,987		47,007
Convertible debt - conversions			63,002	117,025
Disposition of bridge farm			(10,457)
Derivative warrants exercised		277,136	55,912
Warrants exercised		0		17,950
Ending balance		$ 1,326,135	$ 269,695	$ 221,198
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Balance, beginning of year, shares		918,844,133	107,180,423
Share issuances, shares		956,806,648	337,696,867
Share issuance costs, shares		0	0
Business acquisitions, shares		24,431,278	0
Convertible debt - conversions, shares		2,488,754	373,371,318
Disposition of Bridge Farm, shares		0	(2,716,271)
Derivative warrants exercised, shares		152,146,950	102,836,429
Warrants exercised, shares		195,711	0
Employee awards exercised, shares	[1]	5,494,883	475,367
Balance, end of year, shares		2,060,408,357	918,844,133	107,180,423
Beginning balance		$ 762,046	$ 509,654	$ 65,133
Share issuances, carrying amount		977,425	176,931
Share issuance costs		(16,371)	(5,593)	(12,770)
Business acquisitions		26,216	0	39,849
Convertible debt - conversions		2,671	63,002	113,526
Disposition of bridge farm		0	(38,447)
Derivative warrants exercised		277,136	55,912
Warrants exercised		178	0	21,882
Employee awards exercised	[1]	6,403	587
Ending balance		$ 2,035,704	$ 762,046	$ 509,654

[1] Included in employee awards exercised are 875,000 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Excluded from employee awards exercised are 500,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

XML

Share Capital and Warrants - Summary of Issued and Outstanding (Parentheticals) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Share Units
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares vested	500,000	875,000

XML

Share Capital and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021 CAD ($) Warrant $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Capital And Warrants [Line Items]
Number of shares issued	796,300,000	796,300,000
Weighted average exercise price | $ / shares		$ 0.8597
Gross proceeds from offering of ATM program	$ 855.2	$ 684.6
Proceed from two offering allocated to share capital | $	$ 122.2
Inner Spirit Holdings Ltd
Share Capital And Warrants [Line Items]
Warrants Exercised	195,711	195,711
Net payment of warrants | $	$ 0.2
Sun 8 Holdings Inc
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares	$ 0.94
Warrants outstanding and exercisable, Number of warrants | Warrant	640,000
January 2021 Units Offering
Share Capital And Warrants [Line Items]
Number of shares issued	100,000,000.0	100,000,000.0
February 2021 Units Offering
Share Capital And Warrants [Line Items]
Number of shares issued	60,500,000	60,500,000

XML

Share Capital and Warrants - Summary of Common Share Purchase Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance	$ 269,695	$ 221,198
Ending balance	$ 1,326,135	$ 269,695
Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance, Number of Warrants	1,024,000	6,165,324
Acquisition (note 5)	2,097,828
Warrants issued, Number of Warrants	640,000	544,000
Warrants exercised, Number of Warrants	(195,711)
Warrants expired, Number of Warrants		(3,232,434)
Warrants cancelled, Number of Warrants		(2,452,890)
Ending balance, Number of Warrants	3,566,117	1,024,000
Beginning balance	$ 6,138	$ 27,831
Acquisition (note 5), Carrying Amount	1,771
Warrants Issued, Carrying Amount	361	306
Warrants exercised, Carrying Amount	(178)
Warrants expired, Carrying Amount		(5,908)
Warrants cancelled, Carrying Amount		(16,091)
Ending balance	$ 8,092	$ 6,138

XML

Share Capital And Warrants - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2021 Customer Warrant $ / shares
Sun 8 Holdings Inc
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Number of warrants | Warrant	640,000
Warrants
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 3.20
Warrants outstanding and exercisable, Number of warrants | Customer	3,566,117
Warrants outstanding and exercisable, Weighted average contractual life (years)	3 years 1 month 6 days
Warrants | Sun 8 Holdings Inc
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 0.94
Warrants outstanding and exercisable, Number of warrants | Customer	640,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	4 years
Warrants | Acquisition of Financial Obligation
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 15.94
Warrants outstanding and exercisable, Number of warrants | Customer	480,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	6 months
Warrants | Financial Services
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 4.60
Warrants outstanding and exercisable, Number of warrants | Customer	544,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 7 months 6 days
Warrants | Acquired From Inner Spirit [Member]
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 0.34	[1]
Warrants outstanding and exercisable, Number of warrants | Customer	1,902,117	[1]
Warrants outstanding and exercisable, Weighted average contractual life (years)	2 years 2 months 12 days	[1]

[1] Inner Spirit warrants are exchangeable for 0.0835 Sundial common shares in accordance with the Inner Spirit Transaction consideration (note 5) and have been presented based on the number of Sundial common shares that are issuable.

XML

Share Capital And Warrants - Summary of Outstanding Warrants (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2021 shares
Inner Spirit
Statements [Line Items]
Warrants are Exchangeable For Number Of Common Shares Accordance With The Transaction Consideration	0.0835

XML

Share-based Compensation - Components of Share-based Compensation Expense (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		$ 12,307	$ 8,566	$ 38,698
Simple Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		2,899	1,539	23,918
Performance Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		361	(42)	11,023
Stock Options | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		(14)	651	98
Restricted Share Units | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		6,789	4,069	220
Shares Issued For Services | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation				2,320
Deferred Share Units | Cash Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	[1]	$ 2,272	$ 2,349	$ 1,119

[1] Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each period end. Fluctuations in the fair value are recognized during the period in which they occur.

XML

Share-based Compensation - Black-Scholes Option Pricing Model to Estimate the Fair Value of Units Granted (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 CAD ($)	Dec. 31, 2021 $ / shares	Dec. 31, 2020 CAD ($)	Dec. 31, 2020 $ / shares	Dec. 31, 2019 CAD ($)	Dec. 31, 2019 $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate	0.45%
Expected life of units (years)	5 years		10 years
Expected annualized volatility	168.00%		143.00%
Expected dividend yield | $	$ 0		$ 0		$ 0
Weighted average Black-Scholes value of each unit		$ 0.56
Bottom Of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate			0.28%		1.41%
Expected life of units (years)					2 years
Expected annualized volatility					97.00%
Weighted average Black-Scholes value of each unit				$ 1.13		$ 0.67
Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate			0.29%		1.88%
Expected life of units (years)					10 years
Expected annualized volatility					116.00%
Weighted average Black-Scholes value of each unit				$ 1.17		$ 23.55

XML

Share-based Compensation - Additional Information (Details) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2022 shares	Sep. 30, 2021 CAD ($)	Dec. 31, 2021 CAD ($) shares	Dec. 31, 2020 shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Fair value of the deferred share units was reclassified from contributed surplus to accounts payable and accrued liabilities | $		$ 5.1
Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Fair value of the deferred share units was reclassified from contributed surplus to accounts payable and accrued liabilities | $			$ 5.1
Fair value of cash settled deferred share units | $			$ 4.0
Simple and Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period			3 years
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period			5 years
Stock Options | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period			3 years
Maturity period			10 years
Options granted			0	481,600
Restricted Share Units | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted			12,381,525	3,002,213
Restricted Share Units | Equity Settled Plan | Major Ordinary Share Transactions | Long-term Incentive Program
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	15,600,000
Deferred Share Units | Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted			2,489,173	3,265,503
Vesting term			DSUs are granted to directors and generally vest in equal instalments over one year.
Vesting period			1 year
Stock options, Exercisable			600,000

XML

Share-based Compensation - Summary of Changes in Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	3,424,600	9,815,000
Forfeited | shares	(668,800)	(6,390,400)
Exercised | shares	(120,000)
Expired | shares	(41,600)
Ending balance | shares	2,594,200	3,424,600
Weighted average exercise price, beginning balance	$ 4.41	$ 4.01
Weighted average exercise price, Forfeited	3.36	3.79
Weighted average exercise price, Exercised	0.94
Weighted average exercise price, Expired	3.45
Weighted average exercise price, ending balance	$ 4.86	$ 4.41
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	1,672,000	5,798,822
Forfeited | shares	(204,800)	(4,126,822)
Exercised | shares	(80,000)
Ending balance | shares	1,387,200	1,672,000
Weighted average exercise price, beginning balance	$ 4.19	$ 2.66
Weighted average exercise price, Forfeited	5.48	2.04
Weighted average exercise price, Exercised	1.09
Weighted average exercise price, Expired	0.00
Weighted average exercise price, ending balance	$ 4.18	$ 4.19

XML

Share-based Compensation - Summarizes Outstanding Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares	Dec. 31, 2019 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	2,594,200	3,424,600	9,815,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 4.86	$ 4.41	$ 4.01
Weighted average contractual life, Warrants outstanding (years)	3 years 8 months 4 days
Number of warrants, Warrants exercisable | shares	1,731,800
Weighted average exercise price, Warrants exercisable | $ / shares	$ 3.19
Weighted average contractual life, Warrants exercisable (years)	3 years 1 month 9 days
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	1,387,200	1,672,000	5,798,822
Weighted average exercise price, Warrants outstanding | $ / shares	$ 4.18	$ 4.19	$ 2.66
Number of warrants, Warrants exercisable | shares	1,182,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 2.04
$0.63 - $0.94 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	889,400
Weighted average exercise price, Warrants outstanding | $ / shares	$ 0.72
Weighted average contractual life, Warrants outstanding (years)	2 years 2 months 15 days
Number of warrants, Warrants exercisable | shares	889,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0.72
Weighted average contractual life, Warrants exercisable (years)	2 years 2 months 15 days
$0.63 - $0.94 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	458,667
Weighted average exercise price, Warrants outstanding | $ / shares	$ 0.68
Number of warrants, Warrants exercisable | shares	458,667
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0.68
$1.25 - $1.88 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	0
Weighted average exercise price, Warrants outstanding | $ / shares	$ 0
Weighted average contractual life, Warrants outstanding (years)	0 years
Number of warrants, Warrants exercisable | shares	0
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0
Weighted average contractual life, Warrants exercisable (years)	0 years
$1.25 - $1.88 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	189,333
Weighted average exercise price, Warrants outstanding | $ / shares	$ 1.51
Number of warrants, Warrants exercisable | shares	181,333
Weighted average exercise price, Warrants exercisable | $ / shares	$ 1.50
$2.97 - $4.53 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	351,200
Weighted average exercise price, Warrants outstanding | $ / shares	$ 3.09
Weighted average contractual life, Warrants outstanding (years)	3 years 1 month 2 days
Number of warrants, Warrants exercisable | shares	303,200
Weighted average exercise price, Warrants exercisable | $ / shares	$ 3.06
Weighted average contractual life, Warrants exercisable (years)	3 years 7 days
$2.97 - $4.53 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	504,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 3.16
Number of warrants, Warrants exercisable | shares	504,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 3.16
$6.25 - $9.38 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	1,219,200
Weighted average exercise price, Warrants outstanding | $ / shares	$ 6.29
Weighted average contractual life, Warrants outstanding (years)	4 years 8 months 19 days
Number of warrants, Warrants exercisable | shares	499,200
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.35
Weighted average contractual life, Warrants exercisable (years)	4 years 8 months 12 days
$6.25 - $9.38 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	144,533
Weighted average exercise price, Warrants outstanding | $ / shares	$ 7.23
Number of warrants, Warrants exercisable | shares	38,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.25
$12.50 - $37.50 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	134,400
Weighted average exercise price, Warrants outstanding | $ / shares	$ 23.91
Weighted average contractual life, Warrants outstanding (years)	5 years 6 months 7 days
Number of warrants, Warrants exercisable | shares	40,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 19.61
Weighted average contractual life, Warrants exercisable (years)	4 years 18 days
$12.50 - $37.50 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	90,667
Weighted average exercise price, Warrants outstanding | $ / shares	$ 28.24
Number of warrants, Warrants exercisable | shares	0
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0

XML

Share-based Compensation - Summary of Changes in Stock Options (Details) - Equity Settled Plan - Stock Options	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning Balance | shares	720,600	623,850
Granted | shares	0	481,600
Forfeited | shares	(275,000)	(384,850)
Expired | shares	(1,000)
Ending Balance | shares	444,600	720,600
Weighted average exercise price, beginning balance | $ / shares	$ 1.82	$ 4.33
Weighted average exercise price, Granted | $ / shares		1.16
Weighted average exercise price, Forfeited | $ / shares	2.60	4.96
Weighted average exercise price, Expired | $ / shares	3.15
Weighted average exercise price, ending balance | $ / shares	$ 1.33	$ 1.82

XML

Share-based Compensation - Summary of Outstanding Stock Options (Details) - Equity Settled Plan - Stock Options - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	444,600	720,600	623,850
Warrants outstanding and exercisable, Weighted average contractual life (years)	8 years 3 months
Number of options, Stock options exercisable	210,432
Weighted average contractual life, Stock options exercisable (years)	8 years 2 months 15 days
$1.15
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	325,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	8 years 4 months 28 days
Number of options, Stock options exercisable	108,332
Weighted average contractual life, Stock options exercisable (years)	8 years 4 months 28 days
$1.19
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	81,600
Warrants outstanding and exercisable, Weighted average contractual life (years)	8 years 5 months 26 days
Number of options, Stock options exercisable	81,600
Weighted average contractual life, Stock options exercisable (years)	8 years 5 months 26 days
$3.15
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	38,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	6 years 4 months 6 days
Number of options, Stock options exercisable	20,500
Weighted average contractual life, Stock options exercisable (years)	6 years 21 days

XML

Share-based Compensation - Summary of Changes in Restricted Share Units (Details) - Restricted Share Units - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercised	(500,000)	(875,000)
Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	1,656,916	48,883
Granted	12,381,525	3,002,213
Forfeited	(1,582,628)	(43,813)
Exercised	(4,919,883)	(1,350,367)
Ending balance	7,535,930	1,656,916

XML

Share-based Compensation - Summary of Changes in Deferred Share Units (Details) - Cash Settled Plan - Deferred Share Units - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	3,323,263	367,924
Granted	2,489,173	3,265,503
Exercised	(300,000)
Forfeited		(310,164)
Ending balance	5,512,436	3,323,263

XML

Gross Revenue - Disaggregation of Revenue from Contracts with Customers (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 67,279	$ 73,321	$ 66,927
Cannabis
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	51,188	73,321	66,927
Cannabis | Provincial Boards
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	41,338	55,315	13,386
Cannabis | Medical
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	8	32	24
Cannabis | Licensed Producers
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	9,842	$ 17,974	$ 53,517
Retail revenue [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	16,091
Retail revenue [Member] | Retail [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	10,207
Retail revenue [Member] | Franchise [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	4,251
Retail revenue [Member] | Other [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 1,633

XML

Gross Revenue - Disaggregation of Revenue from Contracts with Customers (Parenthetical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 CAD ($) Customer	Dec. 31, 2020 CAD ($) Customer	Dec. 31, 2019 CAD ($) Customer
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Sales	$ 67,279	$ 73,321	$ 66,927
Major Customer
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Number of major customers | Customer	3	4	4
Sales	$ 28,200	$ 43,900	$ 40,700

XML

Gross Revenue - Disaggregation of Revenue from Contracts with Customers by Form (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 67,279	$ 73,321	$ 66,927
Cannabis
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	51,188	73,321	66,927
Cannabis | Dried Flower
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	39,572	51,424	58,246
Cannabis | Vapes
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	4,743	18,447	504
Cannabis | Oil
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	1,665	3,145	$ 8,177
Cannabis | Edibles And Concentrates [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	2,555	$ 305
Cannabis | Services [Member]
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 2,653

XML

Gross Revenue - Summary of Receivables from Contracts with Customers (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue [Abstract]
Receivables, included in 'trade receivables' (note 10)	$ 10,865	$ 15,786	$ 20,281

XML

Gross Revenue - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue [Abstract]
Maximum period to settle receivables from contracts with customers	30 days
Impairment loss (reversal) on receivables from contracts with customers	$ 0.2	$ 0.5

XML

Investment Revenue - Summary of Interest and Fee Revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Investment Revenue [Abstract]
Interest revenue from investments at amortized cost	$ 1,654	$ 0	$ 0
Interest and fee revenue from investments at FVTPL	8,514	0	0
Interest revenue from cash	2,981	0	0
Interest and fee revenue	$ 13,149	$ 0	$ 0

XML

Investment Revenue - Summary of Investment Revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Investment Revenue [Abstract]
Realized gains	$ 20,213	$ 0	$ 0
Unrealized losses (note 9)	(64,714)	0	0
Investment revenue	$ (44,501)	$ 0	$ 0

XML

Other Operating Expenses - Summary of General and Administrative Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Expense By Nature [Abstract]
Salaries and wages	$ 18,675	$ 11,634	$ 15,262
Consulting fees	1,112	2,193	6,896
Office and general	7,560	9,843	9,533
Professional fees	6,530	4,658	3,559
Director fees	351	365	188
Other	4,142	3,336	3,496
General and administrative expense	$ 38,370	$ 32,029	$ 38,934

XML

Other Operating Expenses - Summary of Sales and Marketing Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Expense By Nature [Abstract]
Marketing	$ 3,671	$ 4,839	$ 3,093
Events	191	393	2,961
Research	43	57	199
Media	1,138	448	1,815
Sales and marketing expense	$ 5,043	$ 5,737	$ 8,068

XML

Government Subsidies - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy	$ 2,180	$ 4,128
Canadian Emergency Wage Subsidy
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy	$ 2,100	4,000
Canadian Emergency Rent Subsidy
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy		$ 100

XML

Finance Costs - Summary of Finance Costs (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash finance expense
Interest on Syndicated Credit Agreement		$ 4,546	$ 1,746
Interest on Term Debt Facility		2,936	3,478
Other finance costs	$ 40	286	9,202
Interest expense	40	7,768	14,426
Non-cash finance expense (income)
Change in fair value of investment at FVTPL	3,300
Interest on lease liabilities	776
Financial guarantee liability recovery	59
Accretion		1,622	5,511
Amortization of debt issue costs		1,782	1,586
Change in fair value of convertible notes		(7,141)
Other	154	3	3,973
Non-cash finance expense (income)	4,289	(3,734)	11,070
Interest income	(573)	(215)
Interest capitalized relating to CIP			(1,280)
Finance costs	$ 3,756	$ 3,819	$ 24,216

XML

Supplemental Cash Flow Disclosures - Summary of Changes in Non-cash Working Capital (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash provided by (used in):
Accounts receivable	$ 7,328	$ (2,037)	$ (19,625)
Biological assets	3,829	13,789	19,328
Inventory	(18,318)	(12,315)	(57,977)
Prepaid expenses and deposits	(3,922)	2,280	(7,213)
Investments	(402)
Property, plant and equipment	22
Accounts payable and accrued liabilities	9,665	(20,793)	27,819
Convertible notes			(152)
Changes in non cash working capital	(1,798)	(19,076)	(37,820)
Changes in non-cash working capital relating to:
Operating	(1,534)	(5,259)	(41,626)
Investing	(612)	(11,319)	1,659
Financing	348	(2,498)	2,147
Changes in non cash working capital	$ (1,798)	(19,076)	(37,820)
Cash interest paid		$ 6,094	$ 13,753

XML

Loss Per Share - Summary of Loss Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted average shares outstanding (000s)
Basic and dilutive	1,860,380	218,645	85,750
Continuing operations
Net loss attributable to Sundial Growers Inc.	$ (230,382)	$ (199,619)	$ (142,533)
Per share - basic and diluted	$ (0.12)	$ (0.92)	$ (1.67)
Discontinued operations
Net loss attributable to Sundial Growers Inc.		$ (33,627)	$ (128,931)
Per share - basic and diluted		$ (0.15)	$ (1.50)
Net loss attributable to Sundial Growers Inc.	$ (230,382)	$ (233,246)	$ (271,464)
Per share - basic and diluted	$ (0.12)	$ (1.07)	$ (3.17)

XML

Loss Per Share - Summary of Loss Per Share (Parenthetical) (Details) - CAD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Equity Classified warrants	3.6	1.0	6.2
Derivative warrants	99.3	1.0
Simple warrants	2.6	3.4	9.8
Performance warrants	1.4	1.7	5.8
Stock options	$ 0.4	$ 0.7	$ 0.6
RSUs Exercisable	$ 7.5	$ 1.7	$ 0.1

XML

Financial Instruments - Summary of Fair Value Measurements of Long-term Debt, Derivative Warrant Liabilities and Contingent Consideration (Details) - Recurring fair value measurement [member] - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	$ 83,724
Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	48,576	$ 51,876
Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	21,700	428
Level 1 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	83,724
Level 1 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	0	0
Level 1 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	0	0
Level 2 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	0
Level 2 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	0	0
Level 2 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	0	0
Level 3 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	0
Level 3 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets	48,576	51,876
Level 3 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	$ 21,700	$ 428

XML

Financial Instruments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 CAD ($)
Disclosure Of Financial Instruments [Line Items]
Percentage of change in material assumptions	10.00%
Marketable Securities
Disclosure Of Financial Instruments [Line Items]
Threshold Percentage of Change in Market Prices Would Effect Fair Value of Marketable Securities	10.00%
Change in Fair Value of Securities	$ 8.4
Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Change in fair value liabilities	$ 4.0

XML

Financial Instruments - Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Abstract]
Impairment loss (reversal) on trade receivables	$ 214	$ (506)
Impairment loss (reversal) on other receivables	798	(126)
Impairment loss (reversal) on accounts receivable	$ 1,012	$ (632)

XML

Financial Instruments - Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Abstract]
Balance, beginning of year	$ 120	$ 752
Net remeasurement of impairment loss allowance	1,012	(632)
Balance, end of year	$ 1,132	$ 120

XML

Financial Instruments - Risk Management Contracts Relating to Marketable Securities (Details) - Risk Management Contracts - Market Risk Management $ in Thousands	12 Months Ended
	Dec. 31, 2021 CAD ($) Quantity
Disclosure Of Risk Management Contracts Relating To Outstanding Marketable Securities [Line Items]
Quantity | Quantity	3,503
Proceeds	$ 99
Fair value	$ 78
Sold Put Options | February Eighteen Two Thousand and Twenty Two
Disclosure Of Risk Management Contracts Relating To Outstanding Marketable Securities [Line Items]
Quantity | Quantity	2,174
Expiry	Feb. 18, 2022
Proceeds	$ 34
Fair value	$ 27
Sold Put Options | March Eighteen Two Thousand and Twenty Two
Disclosure Of Risk Management Contracts Relating To Outstanding Marketable Securities [Line Items]
Quantity | Quantity	1,329
Expiry	Mar. 18, 2022
Proceeds	$ 65
Fair value	$ 51

XML

Financial Instruments - Timing of Expected Cash Outflows Relating to Financial Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	$ 38,452	$ 23,308
Liquidity Risk Management
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	38,452
Lease obligations	38,505
Financial guarantee liability	466
Balance, end of period	77,423
Liquidity Risk Management | Less Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	38,452
Lease obligations	5,938
Financial guarantee liability	0
Balance, end of period	44,390
Liquidity Risk Management | One to Three Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Lease obligations	10,514
Financial guarantee liability	466
Balance, end of period	10,980
Liquidity Risk Management | Three to Five Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Lease obligations	8,424
Financial guarantee liability	0
Balance, end of period	8,424
Liquidity Risk Management | Thereafter
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Lease obligations	13,629
Financial guarantee liability	0
Balance, end of period	$ 13,629

XML

Related Party Transactions - Additional Information (Details) - Employee Loan Agreement - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Transactions Between Related Parties [Line Items]
Loans and receivables available		$ 139
Repayment of loan balance	$ 139
Outstanding loan balance	$ 0

XML

Related Party Transactions - Summary of Related Party Transactions and Balances (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	$ 0	$ 3,606
Balance outstanding	0	(510)
Marketing, brand research and development services
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	0	1,144
Balance outstanding	0	0
Legal services
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	0	2,462
Balance outstanding	$ 0	$ (510)

XML

Related Party Transactions - Compensation of Key Management Personnel (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Abstract]
Salaries and short-term benefits	$ 2,348	$ 1,944	$ 3,295
Share-based compensation	8,275	7,629	23,715
Key management personnel compensation	$ 10,623	$ 9,573	$ 27,010

XML

Commitments and Contingencies - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Commitments And Contingencies [Abstract]
Accrued financial penalties payable	$ 2.5	$ 1.5
Unrecognized contingent asset	$ 2.0
Description of settlement agreement	A receivable for the $2 million will not be recognized until written confirmation of payment is received from the insurers.
Receivable to be recognized until written confirmation of payment is received from insurers	$ 2.0

XML

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Millions, $ in Millions				1 Months Ended	12 Months Ended
	Aug. 08, 2022 $ / shares	Feb. 08, 2022 $ / shares	Jan. 06, 2022 CAD ($) $ / shares shares	Jan. 31, 2022 USD ($) shares	Dec. 31, 2019 $ / shares shares	Dec. 31, 2021 shares	Oct. 07, 2021
SNDLSun8 Holdings Inc [Member] | SNDL Warrants [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrants to acquire common shares | shares					1,800,000
Common shares, exercise price per share | $ / shares					$ 0.94
Acquired brands and cultivars period					5 years
Warrants outstanding and exercisable, Number of warrants | shares						600,000
Major Ordinary Share Transactions
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of units issued | shares			320,600,000
Aggregate shares issued,value			$ 280.4
Major Ordinary Share Transactions | NASDAQ
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Minimum bid price per share | $ / shares	$ 1.00	$ 1.00
Minimum Bid requirement extension period		180 days
Regain compliance with listing qualifications initial period date		Feb. 07, 2022
Regain compliance with listing qualifications initial end date		Aug. 08, 2022
Minimum bid price consecutive days	10 days
Termination Of Agreement [Member] | SNDLSun8 Holdings Inc [Member] | SNDL Warrants [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Termination of Service and Sale Agreement Event Shares Issued | shares				3,700,000
Termination of service and sale agreement event value of shares issued				$ 2.9
Termination of service and sale agreement event cash payment made				$ 3.1
Cancellation of unvested share options | shares				1,200,000
Significant Investment [Member] | Promissory Note [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Notional amount				$ 5.0
Investments interest rate				15.00%
Investments maturity date				Feb. 09, 2025
Significant Investment [Member] | Purchase Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Notional amount				$ 10.0
Investments interest rate				10.00%
Investments maturity date				Mar. 30, 2025
Alcanna Inc [Member] | Major Ordinary Share Transactions
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Aggregate consideration			$ 54.3
Price per unit | $ / shares			$ 1.50
Common stock ,conversion price			8.85
Alcanna Inc [Member] | Nova Cannabis Inc. [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Percentage of equity interest							63.00%